

BlackRock Health Sciences Trust
Form N-CSRS
September 04, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

**CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT
COMPANIES**

Investment Company Act file number: 811-21702

Name of Fund: BlackRock Health Sciences Trust (BME)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Health Sciences Trust, 55 East 52nd Street, New York, NY 10055

Registrant's telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2018

Date of reporting period: 06/30/2018

Item 1 Report to Stockholders

SEMI-ANNUAL REPORT (UNAUDITED)

BlackRock Energy and Resources Trust (BGR)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

BlackRock Health Sciences Trust (BME)

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Trust (BST)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

**Not FDIC Insured May Lose Value No Bank
Guarantee**

The Markets in Review

Dear Shareholder,

In the 12 months ended June 30, 2018, the strongest corporate profits in seven years drove the equity market higher, while rising interest rates constrained bond returns. Though the market's appetite for risk remained healthy, risk taking was tempered somewhat, as shorter-term, higher-quality securities led the bond market, and U.S. equities outperformed most international stock markets.

Strong equity performance worldwide was driven by synchronized economic growth across the most influential economies. However, volatility in emerging market stocks rose, as U.S.-China trade relations and debt concerns weighed heavily on the Chinese stock market.

Short-term U.S. Treasury interest rates rose the fastest, while longer-term rates slightly increased, leading to a substantial flattening of the yield curve. The annual return for the three-month U.S. Treasury bill surpassed 1.0%, but remained well below the annual headline inflation rate of 2.9%. In contrast, the ten-year U.S. Treasury—a bellwether of the bond market—posted a negative return, as rising inflation expectations drove yields higher. Although the fundamentals in credit markets remained relatively solid, investment-grade bonds declined slightly, and high-yield bonds posted modest returns.

In response to rising growth and inflation, the U.S. Federal Reserve (the Fed) increased short-term interest rates three times during the reporting period. The Fed also announced plans to reduce its \$4.4 trillion balance sheet by \$420 billion in 2018, which began the process of gradually reversing its unprecedented stimulus measures after the financial crisis. Meanwhile, the European Central Bank announced that its bond-purchasing program would conclude at the end of the year, while also expressing an open-ended commitment to low interest rates. In contrast, the Bank of Japan continued to expand its balance sheet through bond purchasing while lowering its expectations for inflation.

The U.S. economy continued to gain momentum despite the Fed's modest reduction of economic stimulus; unemployment declined to 4.0%, wages increased, and the number of job openings reached a record high. Strong economic performance may justify a more rapid pace of rate hikes in 2018, as the headline inflation rate and investors' expectations for inflation have already surpassed the Fed's target of 2.0%.

While U.S. monetary policy is seeking to restrain economic growth and inflation, fiscal policy has produced new sources of growth that could nourish the economy for the next few years. Corporate tax cuts and repatriation of capital held abroad could encourage a virtuous cycle of business spending. Lower individual tax rates coupled with the robust job market may refresh consumer spending. Proposed infrastructure spending would deliver growth from the government sector, generate demand, and improve economic activity in other sectors.

We continue to believe the primary risks to economic expansion are trade protectionism, rapidly rising interest rates, and geopolitical tension. Given the deflationary forces of technology and globalization, a substantial increase in inflation is unlikely to materialize as long as the unemployment rate remains above 3.0%. However, we are closely monitoring trade protectionism and the rise of populism in Western nations. In particular, the outcome of trade negotiations between the United States and China is likely to influence the global growth trajectory and set the tone for free trade in many other nations.

In this environment, investors need to think globally, extend their scope across a broad array of asset classes, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit [blackrock.com](https://www.blackrock.com) for further insight about investing in today's markets.

Sincerely,

Rob Kapito

President, BlackRock Advisors, LLC

Rob Kapito

President, BlackRock Advisors, LLC

Total Returns as of June 30, 2018

	6-month	12-month
U.S. large cap equities (S&P 500® Index)	2.65%	14.37%
U.S. small cap equities (Russell 2000® Index)	7.66	17.57
International equities (MSCI Europe, Australasia, Far East Index)	(2.75)	6.84
Emerging market equities (MSCI Emerging Markets Index)	(6.66)	8.20
3-month Treasury bills (ICE BofAML 3-Month U.S. Treasury Bill Index)	0.81	1.36
U.S. Treasury securities (ICE BofAML 10-Year U.S. Treasury Index)	(2.68)	(2.69)
U.S. investment grade bonds (Bloomberg Barclays U.S. Aggregate Bond Index)	(1.62)	(0.40)
Tax-exempt municipal bonds (S&P Municipal Bond Index)	(0.02)	1.61
U.S. high yield bonds (Bloomberg Barclays U.S. Corporate High Yield 2% Issuer Capped Index)	0.16	2.62

Past performance is no guarantee of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.

Supplemental Information (unaudited)

Section 19(a) Notices

BlackRock Energy and Resources Trust s (BGR), BlackRock Enhanced Capital and Income Fund, Inc. s (CII), BlackRock Enhanced Equity Dividend Trust s (BDJ), BlackRock Enhanced Global Dividend Trust s (BOE), BlackRock Enhanced International Dividend Trust s (BGY), BlackRock Health Sciences Trust s (BME), BlackRock Resources & Commodities Strategy Trust s (BCX), BlackRock Science and Technology Trust s (BST) and BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (each, a Trust and collectively, the Trusts), amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust s investment experience during the fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

June 30, 2018

	Total Cumulative Distributions for the Fiscal Period				% Breakdown of the Total Cumulative Distributions for the Fiscal Period					
	Net Realized		Net Realized		Net Realized		Net Realized		Net Realized	
	Investment Income	Capital Gain Short-Term	Capital Gains Long-Term	Return of Capital	Total Per Share	Investment Income	Capital Gain Short-Term	Capital Gains Long-Term	Return of Capital	Total Per Share
BGR*	\$ 0.138969	\$	\$	\$ 0.326631	\$ 0.465600	30%	%	%	70%	100%
CII*	0.082050			0.414750	0.496800	17			83	100
BDJ	0.081478	0.008302	0.190420		0.280200	29	3	68		100
BOE	0.185780	0.097648		0.184572	0.468000	40	21		39	100
BGY*	0.113511		0.114489		0.228000	50		50		100
BME*	0.047943	0.009451	1.142607		1.200000	4	1	95		100
BCX*	0.108728			0.200872	0.309600	35			65	100
BST*			0.780000		0.780000	0		100		100
BUI	0.288398	0.047828	0.023475	0.366299	0.726000	40	7	3	50	100

* Certain Trusts estimate that they have distributed more than the amount of earned income and net realized gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. When distributions exceed total return performance, the difference will reduce the Trust s net asset value per share.

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at <http://www.blackrock.com>.

Section 19(b) Disclosure

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (SEC) exemptive order and with the approval of each Trust's Board of Trustees/Directors (the Board), each have adopted a plan, consistent with its investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the Plan). In accordance with the Plans, the Trusts distribute the following fixed amounts per share on a monthly basis as of June 30, 2018:

<i>Exchange Symbol</i>	<i>Amount Per Common Share</i>
BGR	\$ 0.0776
CII	0.0828
BDJ	0.0467
BOE	0.0780
BGY	0.0380
BME	0.2000
BCX	0.0516
BST	0.1300
BUI	0.1210

The fixed amounts distributed per share are subject to change at the discretion of each Trust's Board. Under its Plan, each Trust will distribute all available investment income to its shareholders, consistent with its primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the Code). If sufficient investment income is not available on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases or decreases to enable the Trusts to comply with the distribution requirements imposed by the Code.

Shareholders should not draw any conclusions about each Trust's investment performance from the amount of these distributions or from the terms of the Plan. Each Trust's total return performance on net asset value is presented in its financial highlights table.

The Board may amend, suspend or terminate a Trust's Plan at any time without prior notice to the Trust's shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust's stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BME's prospectus for a more complete description of its risks.

Table of Contents

	Page
<u>The Markets in Review</u>	2
<u>Section 19(a) Notices</u>	3
<u>Section 19(b) Disclosure</u>	3
<u>Semi-Annual Report:</u>	
<u>The Benefits and Risks of Option Over-Writing</u>	5
<u>Trust Summaries</u>	6
<u>Derivative Financial Instruments</u>	24
<u>Financial Statements:</u>	
<u>Schedules of Investments</u>	25
<u>Statements of Assets and Liabilities</u>	91
<u>Statements of Operations</u>	93
<u>Statements of Changes in Net Assets</u>	95
<u>Statements of Cash Flows</u>	100
<u>Financial Highlights</u>	102
<u>Notes to Financial Statements</u>	111
<u>Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements</u>	122
<u>Trustee and Officer Information</u>	127
<u>Additional Information</u>	128
<u>Glossary of Terms Used in this Report</u>	130

The Benefits and Risks of Option Over-Writing

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to enhance the Trusts distribution rate and total return performance. However, these objectives cannot be achieved in all market conditions.

The Trusts primarily write single stock covered call options, and may also from time to time write single stock put options. When writing (selling) a covered call option, the Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (strike price) within an agreed-upon time period. The Trusts receive cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trusts. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trusts realize gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by the Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Each Trust employs a plan to support a level distribution of income, capital gains and/or return of capital. The goal of the plan is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of the Trusts. Such distributions, under certain circumstances, may exceed a Trust s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust s total assets and net asset value per share (NAV) and, therefore, could have the effect of increasing the Trust s expense ratio and reducing the amount of assets, the Trust has available for long term investment. In order to make these distributions, a Trust may have to sell portfolio securities at less than opportune times.

The final tax characterization of distributions is determined after the fiscal year and is reported in the Trust s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. The Trust s taxable net investment income or net realized capital gains (taxable income) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital. Distributions that exceed a Trust s taxable income but do not exceed the Trust s current and accumulated earnings and profits, may be classified as ordinary income which are taxable to shareholders. Such distributions are reported as distributions in excess of net investment income.

A return of capital distribution does not necessarily reflect a Trust s investment performance and should not be confused with yield or income. A return of capital is a return of a portion of an investor s original investment. A return

of capital is not taxable, but it reduces a shareholder's tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital or as distributions in excess of net investment income for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at \$37.15 per share; (2) a three-month call option is written by a Trust with a strike price of \$40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives \$2.45, or 6.6% of the common stock's value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to \$34.70 per share), the option strategy would "break-even" from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of \$40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above \$40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust's downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call options to varying degrees depending upon market conditions. Please refer to each Trust's Schedule of Investments and the Notes to Financial Statements for details of written options.

Trust Information as of June 30, 2018

BlackRock Energy and Resources Trust**Investment Objective**

BlackRock Energy and Resources Trust s (BGR) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on New York Stock Exchange (NYSE)	BGR
Initial Offering Date	December 29, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$15.22) ^(a)	6.12%
Current Monthly Distribution per Common Share ^(b)	\$0.0776
Current Annualized Distribution per Common Share ^(b)	\$0.9312

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BGR ^{(a)(b)}	10.89%	4.49%
Lipper Natural Resources Funds ^(c)	(1.38)	(0.70)

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

(c) Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's absolute performance based on NAV:

What factors influenced performance?

Energy stocks experienced unusually high volatility in the first half of 2018. A strong advance in January gave way to a sharp sell-off in February, bringing the sector into negative territory for the year. After trading sideways for approximately two months, energy stocks staged a significant rally through April and early May. Although its performance cooled thereafter, energy nonetheless finished the second calendar quarter as the top performer among the stock market's eleven major sectors.

The Trust's position in the U.S. exploration and production (E&P) company ConocoPhillips made the largest positive contribution to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, boosting its stock price. The international E&P stock Anadarko Petroleum Corp. was also among the top contributors. Anadarko displayed capital discipline, and it reported robust growth stemming from higher production volume. The company further benefited from a more favorable backdrop in the liquified natural gas market. Other contributors of note include Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

On the negative side, the Trust's positions in E&Ps that emphasize natural gas generally lagged their more oil-focused peers. In this environment, Cabot Oil & Gas Corp. was a leading detractor from absolute performance. The energy distribution sub-sector also came under pressure as pipeline companies faced bottlenecks, leading to weakness in the Trust's position in TransCanada Corp. Other detractors of note include Cimarex Energy Co., Enbridge, Inc. and Halliburton Co.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

Describe recent portfolio activity.

The investment adviser shifted the Trust's positioning within the distribution subsector by initiating an investment in Williams Cos. and exiting its position in Enbridge, Inc. It also sold certain E&P stocks, including EOG Resources, Inc., Cimarex Energy Co., and Cabot Oil & Gas Corp., and initiated a new investment in the international E&P stock CNOOC Ltd.

Trust Information as of June 30, 2018 (continued)

BlackRock Energy and Resources Trust**Describe portfolio positioning at period end.**

The E&P sector represented the Trust's largest allocation, followed by the integrated, oil services, distribution, and refining & marketing industries, respectively. The investment adviser positioned the Trust with a higher-quality bias, focusing on companies with robust balance sheets and low costs of production.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 15.22	\$ 14.18	7.33%	\$ 15.63	\$ 12.85
Net Asset Value	15.97	15.79	1.14	16.54	14.24

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
Royal Dutch Shell PLC ADR	10%
Exxon Mobil Corp.	9
BP PLC	7
Chevron Corp.	6
TOTAL SA	5
Suncor Energy, Inc.	5
ConocoPhillips	5
Valero Energy Corp.	4
EOG Resources, Inc.	4
Pioneer Natural Resources Co.	3

* Excludes option positions and money market funds.

INDUSTRY ALLOCATION

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

<i>Industry</i>	<i>06/30/18</i>	<i>12/31/17</i>
Oil, Gas & Consumable Fuels	92%	90%
Energy Equipment & Services	8	10

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

7

Trust Information as of June 30, 2018

BlackRock Enhanced Capital and Income Fund, Inc.**Investment Objective**

BlackRock Enhanced Capital and Income Fund, Inc. s (CII) (the Trust) investment objective is to provide investors with a combination of current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment policy by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE	CII
Initial Offering Date	April 30, 2004
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$16.22) ^(a)	6.13%
Current Monthly Distribution per Common Share ^(b)	\$0.0828
Current Annualized Distribution per Common Share ^(b)	\$0.9936

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
CII ^{(a)(b)}	2.13%	1.76%
S&P 500 [®] Index	N/A	2.65

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

In the equity allocation of the Trust, the largest contributor to performance for the six-month period was stock selection in the health care sector. Specifically, selection decisions in the managed care industry provided strong relative returns. In financials, stock selection in capital markets and banks enhanced relative performance. Finally, an underweight allocation to as well as stock selection within industrials provided outperformance. In particular, selection among rail road operators contributed positively to return. At the stock level, the largest individual contributor was Urban Outfitters Inc., followed by a position in Humana Inc. and zero exposure to Johnson & Johnson.

In the equity allocation of the Trust, the largest detractor from relative performance for the six-month period was stock selection in the consumer discretionary sector. Most notably, positioning across homebuilders and underweight exposure to internet and direct marketing retail challenged relative performance. This was followed by positioning in information technology (IT) where electronic equipment and software holdings lagged. Finally, exposure to the tobacco industry hurt relative results in the consumer staples sector. Zero exposure to Amazon.com Inc. was the largest individual detractor, followed by a lack of exposure to Netflix Inc. and an overweight position to Altria Group Inc.

Describe recent portfolio activity.

During the six-month period, the Trust significantly boosted exposure to the IT sector. Holdings within industrials and health care also were increased. Conversely, the Trust significantly reduced exposure to the financials sector. The Trust also reduced exposure to consumer discretionary and materials stocks. The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

Describe portfolio positioning at period end.

At period end, the Trust's largest allocations were in the IT, health care and financials sectors. Relative to the benchmark, the Trust's largest overweight positions were in the IT, health care, financials and consumer discretionary sectors. Conversely, the Trust's largest relative underweights were in the telecommunication services, real estate, and utilities sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced Capital and Income Fund, Inc.**Market Price and Net Asset Value Per Share Summary**

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 16.22	\$ 16.38	(0.98)%	\$ 17.07	\$ 14.75
Net Asset Value	16.96	17.19	(1.34)	18.04	16.21

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
Apple, Inc.	6%
Alphabet, Inc.	5
Microsoft Corp.	5
JPMorgan Chase & Co.	3
Bank of America Corp.	3
Pfizer, Inc.	3
Cisco Systems, Inc.	3
Lowe's Cos., Inc.	3
Comcast Corp.	2
United Health Group, Inc.	2

* Excludes option positions and money market funds.

SECTOR ALLOCATION

<i>Sector</i>	<i>06/30/18</i>	<i>12/31/17</i>
Information Technology	28%	26%
Health Care	18	16
Financials	14	17
Consumer Discretionary	12	14
Industrials	8	7
Consumer Staples	6	6
Energy	6	6
Materials	5	5

Utilities

3 3

For Trust compliance purposes, the Trust's sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

TRUST INFORMATION

9

Trust Information as of June 30, 2018

BlackRock Enhanced Equity Dividend Trust**Investment Objective**

BlackRock Enhanced Equity Dividend Trust s (BDJ) (the Trust) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE	BDJ
Initial Offering Date	August 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.18) ^(a)	6.10%
Current Monthly Distribution per Common Share ^(b)	\$0.0467
Current Annualized Distribution per Common Share ^(b)	\$0.5604

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BDJ ^{(a)(b)}	2.59%	(0.38)%
Russell 1000 [®] Value Index	N/A	(1.69)

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

The largest contribution to performance for the six-month period came from stock selection in the consumer staples sector. Notably, selection decisions within the beverages industry boosted relative return. In health care, stock selection within pharmaceuticals and health care equipment & services, and an overweight in health care providers & services enhanced relative performance. Lastly, stock selection within energy and utilities contributed, as did a combination of stock selection and an underweight in industrials.

The largest detractor from relative performance derived from stock selection in the financials sector. In particular, a combination of stock selection within and overweight exposure to the banking and insurance industries weighed on relative performance. Additionally, stock selection in the capital markets industry represented a headwind. Within the consumer discretionary sector, issue selection within the media industry had a negative impact. Finally, a lack of exposure to real estate acted as a constraint on returns.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio's holdings. Premiums generated are recognized as current gains that are intended to enhance distributions payable to shareholders in the form of dividends. The use of options detracted modestly from relative performance.

Describe recent portfolio activity.

During the six-month period, the Trust increased exposure to the information technology sector. Holdings within health care and energy also were increased. Conversely, the Trust significantly lowered its exposure to industrials, and also reduced its positioning within financials and materials.

Describe portfolio positioning at period end.

The Trust's largest allocations were in the financials, health care and energy sectors. Relative to the benchmark, the Trust's largest overweight positions were in the health care, financials and energy sectors. Conversely, the Trust's largest relative underweights were in the real estate, consumer discretionary and materials sectors.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced Equity Dividend Trust**Market Price and Net Asset Value Per Share Summary**

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 9.18	\$ 9.23	(0.54)%	\$ 9.64	\$ 8.03
Net Asset Value	9.62	9.96	(3.41)	10.42	9.33

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
JPMorgan Chase & Co.	4%
Bank of America Corp.	4
Pfizer, Inc.	4
Citigroup, Inc.	4
Wells Fargo & Co.	3
Oracle Corp.	3
Anthem, Inc.	3
Microsoft Corp.	3
Suncor Energy, Inc.	2
Verizon Communications, Inc.	2

* Excludes option positions and money market funds.

SECTOR ALLOCATION

<i>Sector</i>	<i>06/30/18</i>	<i>12/31/17</i>
Financials	28%	29%
Health Care	20	19
Energy	13	12
Information Technology	11	10
Industrials	7	8
Consumer Staples	7	7
Utilities	5	5
Consumer Discretionary	4	4

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Telecommunication Services	3	3
Materials	2	3

For Trust compliance purposes, the Trust's sector classifications refer to any one or more of the sector sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

TRUST INFORMATION

11

Trust Information as of June 30, 2018

BlackRock Enhanced Global Dividend Trust**Investment Objective**

BlackRock Enhanced Global Dividend Trust's (BOE) (the Trust) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust's investment objectives will be achieved.

Trust Information

Symbol on NYSE	BOE
Initial Offering Date	May 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$11.12) ^(a)	8.42%
Current Monthly Distribution per Common Share ^(b)	\$0.0780
Current Annualized Distribution per Common Share ^(b)	\$0.9360

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The monthly distribution per Common Share, declared on July 2, 2018, was decreased to \$0.0630 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BOE ^{(a)(b)}	(7.44)%	(6.19)%
MSCI All Country World Index	N/A	(0.43)

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust's discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

Security selection within and overweight exposure to consumer staples represented the largest detractors from performance. Stock selection within industrials also weighed on returns. Two tobacco companies, British American Tobacco PLC and Altria Group, Inc., were among the top individual detractors. Tobacco stocks suffered due to a market rotation out of defensive sectors, coupled with the FDA's announcement that it would be looking to limit nicotine levels in traditional cigarettes, along with questions about Next Generation smoking products. In addition, the German postal and international courier company Deutsche Post AG detracted after the company lowered its earnings forecast as it launched a series of measures aimed at stemming a decline in profitability at its post, e-commerce and parcel division.

During the six-month period, the Trust's significant underweight to financials contributed to relative return as the sector was one of the worst-performing segments of the index. An underweight to real estate also contributed to performance. The Trust's position in the technology conglomerate Cisco Systems, Inc. was the top individual contributor after the company reported earnings that exceeded expectations and also announced a share buyback. Additionally, the British pharmaceutical firm GlaxoSmithKline PLC was among the top contributors to returns after Novartis AG announced that they will be selling their stake in a consumer health care joint venture to GlaxoSmithKline. Holdings of Chinese sportswear company Anta Sports Products Ltd. also helped performance with positive sentiment driven by the company's continued strong retail sales.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust's options writing strategy contributed to Trust performance.

Describe recent portfolio activity.

The Trust's allocation to tobacco stocks was reduced in May, with the proceeds reinvested in high quality, dividend-paying names in which the investment adviser has high conviction. These included health care, consumer staples and industrials stocks.

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced Global Dividend Trust**Describe portfolio positioning at period end.**

At period end, the Trust's largest sector overweight positions were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweights were to information technology and financials. The Trust had no exposure to real estate, utilities or energy at the end of the period. From a regional perspective, a majority of portfolio assets was invested either within the United States or Europe, with significant exposure in the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 11.12	\$ 12.51	(11.11)%	\$ 13.08	\$ 10.96
Net Asset Value	11.91	13.22	(9.91)	13.71	11.78

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
Johnson & Johnson	4%
TELUS Corp.	4
Altria Group, Inc.	3
Sanofi	3
Novartis AG, Registered Shares	3
Coca-Cola Co.	3
Rogers Communications, Inc., Class B	3
Cisco Systems, Inc.	3
Nestle SA	3
Unilever PLC	3

* Excludes option positions and money market funds.

GEOGRAPHIC ALLOCATION

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

<i>Country</i>	<i>06/30/18</i>	<i>12/31/17</i>
United States	43%	42%
United Kingdom	17	16
Australia	6	4
Switzerland	6	10
France	4	3
India	4	(a)
Singapore	3	
Taiwan	3	3
Netherlands	3	
Germany	3	2
Canada	3	6
Japan	2	2
Belgium	1	2
Denmark	1	
Finland	1	2
China	(a)	(a)
Sweden	(a)	(a)
Ireland	(a)	
Other ^(b)		5

(a) Representing less than 1% of the Trust's total investments.

(b) Other includes a 1% holding or less in each of the following countries: Denmark, Hong Kong, India, Italy, Netherlands and Spain.

Trust Information as of June 30, 2018

BlackRock Enhanced International Dividend Trust**Investment Objective**

BlackRock Enhanced International Dividend Trust s (BGY) (the Trust) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and utilizing an option writing (selling) strategy to seek total return performance and enhance distributions. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE	BGY
Initial Offering Date	May 30, 2007
Current Distribution Rate on Closing Market Price as of as of June 30, 2018 (\$5.74) ^(a)	7.94%
Current Monthly Distribution per Common Share ^(b)	\$0.0380
Current Annualized Distribution per Common Share ^(b)	\$0.4560

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BGY ^{(a)(b)}	(8.61)%	(6.49)%
MSCI All Country World Index ex-USA	N/A	(3.77)

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

Security selection within and an overweight to consumer staples were the largest detractors from performance. Additionally, selection within industrials detracted, including positions in international courier companies Deutsche Post AG (Germany) and bpost SA (Belgium). The Trust's lack of holdings in energy stocks also subtracted from returns.

The leading contributor to relative performance during the period was the Trust's overweight to the health care sector. Additionally, an underweight to financials contributed to performance. Lastly, stock selection within consumer discretionary added to returns, in particular from holdings in the Chinese sportswear company Anta Sports Products Ltd. and the Macau-based resort firm Sands China Ltd.

During the period, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust's options writing strategy contributed to relative return.

Describe recent portfolio activity.

The Trust reduced its exposure to tobacco stocks over the period, while retaining an overweight in the industry. The Trust also increased exposure to financials by purchasing two Singapore bank stocks.

Describe portfolio positioning at period end.

At period end, the Trust's largest sector overweights were in the consumer staples and health care sectors, with an emphasis on the tobacco and pharmaceuticals industries, respectively. The largest underweight exposure was to financials, particularly banks. The Trust had no exposure to real estate, utilities or energy. In regional terms, the majority of portfolio assets was invested in European equities, with significant exposure to the United Kingdom and Switzerland.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Enhanced International Dividend Trust**Market Price and Net Asset Value Per Share Summary**

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 5.74	\$ 6.52	(11.96)%	\$ 6.85	\$ 5.64
Net Asset Value	6.36	7.06	(9.92)	7.32	6.27

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
TELUS Corp.	6%
Sanofi	5
Novartis AG, Registered Shares	5
Rogers Communications, Inc., Class B	5
Nestle SA	5
Amcor	5
Imperial Brands PLC	5
Unilever PLC	5
British American Tobacco PLC	4
Deutsche Post AG, Registered Shares	4

* Excludes option positions and money market funds.

GEOGRAPHIC ALLOCATION

<i>Country</i>	<i>06/30/18</i>	<i>12/31/17</i>
United Kingdom	24%	19%
Switzerland	13	12
Canada	11	7
Australia	9	5
France	7	6
United States	5	6
Germany	4	3
Netherlands	4	6

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Taiwan	4	3
Finland	4	2
Singapore	3	
China	2	5
Sweden	2	2
Belgium	2	3
India	2	2
Japan	2	5
Denmark	2	(a)
Hong Kong		2
South Korea		2
South Africa		2
Other		2 ^(b)

(a) Representing less than 1% of the Trust's total investments.

(b) Other includes a 1% holding or less in each of the following countries: Ireland and Portugal.

Trust Information as of June 30, 2018

BlackRock Health Sciences Trust**Investment Objective**

BlackRock Health Sciences Trust's (BME) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust's investment objective will be achieved.

Trust Information

Symbol on NYSE	BME
Initial Offering Date	March 31, 2005
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$38.58) ^(a)	6.22%
Current Monthly Distribution per Common Share ^(b)	\$0.2000
Current Annualized Distribution per Common Share ^(b)	\$2.4000

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BME ^{(a)(b)}	9.33%	5.90%
Russell 3000 [®] Healthcare Index	N/A	4.15

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust's premium to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

The Trust added value through its effective individual stock selection. An out-of-benchmark position in Sarepta Therapeutics, Inc., a biotechnology company focused on orphan drugs, was among the largest contributors to relative performance. Sarepta presented preliminary data for its experimental treatment for patients with Duchenne muscular dystrophy, sparking a rally in its shares.

Merger-and-acquisition activity was also a key driver of the Trust's performance. Avexis, Inc., a clinical-stage gene therapy biotechnology company, announced that it would be acquired at a substantial premium by the Swiss pharmaceutical giant Novartis AG. Toward the end of the period, shares of Boston Scientific Corp. rallied on the rumor that the company had received a takeover bid from Stryker Corp.

Other contributors of note included overweight positions in the health care services companies Humana, Inc, and Teladoc, Inc. The Trust's overweight position in the biotechnology stock Alnylam Pharmaceuticals, Inc. was among the largest detractors from returns, as the company came under pressure after Pfizer, Inc. released positive data on a competing drug.

A zero weighting in Align Technology, Inc. was among the largest detractors from relative performance in the medical devices & supplies sub-sector. The stock rallied following an analyst event that dispelled concerns about rising competition and outlined a strong growth outlook.

Other detractors of note included overweight positions in Cigna Corp., Novo Nordisk A/S and Inmed, Inc.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. This strategy detracted from performance in the period.

Describe recent portfolio activity.

The Trust increased its allocation to the medical devices & supplies subsector and slightly reduced its weightings in the healthcare providers & services area. Its allocation to biotechnology decreased, while its weighting in pharmaceuticals was largely unchanged.

Trust Information as of June 30, 2018 (continued)

BlackRock Health Sciences Trust**Describe portfolio positioning at period end.**

The Trust continued to employ a bottom-up, fundamental investment process in an effort to construct a balanced, diversified portfolio of health care stocks. The portfolio continues to reflect two broad themes: innovation and value-based health care.

Innovation in medical technology remains a secular growth driver for the health care sector as companies continue to develop new therapies or products that are either fulfilling an unmet medical need or are an improvement over current treatments. This encompasses not only the biotechnology industry, but also the pharmaceuticals and medical devices & supplies sub-sectors.

With respect to value-based health care, the Trust has an above-benchmark weighting in the health care providers & services sub-sector largely due to its sizeable overweight in the managed care industry. The investment adviser continues to find a number of companies in this area that it believes are well positioned to leverage their scale and analytical capabilities to reduce health care costs. Additionally, select holdings in the health care services industry feature business models that are benefiting from the shift to lower-cost options such as home health care.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 38.58	\$ 36.50	5.70%	\$ 39.83	\$ 32.89
Net Asset Value	36.54	35.69	2.38	38.56	34.33

Market Price and Net Asset Value History For the Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

	<i>06/30/18</i>
<i>Security</i>	
UnitedHealth Group, Inc.	9%
Pfizer, Inc.	5
Medtronic PLC	4

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Abbott Laboratories	4
Stryker Corp.	3
Boston Scientific Corp.	4
Quest Diagnostics, Inc.	3
Anthem, Inc.	3
Humana, Inc.	2
Baxter International, Inc.	2

* Excludes option positions and money market funds.

INDUSTRY ALLOCATION

<i>Industry</i>	<i>06/30/18</i>	<i>12/31/17</i>
Health Care Equipment & Supplies	28%	23%
Health Care Providers & Services	25	25
Biotechnology	20	25
Pharmaceuticals	22	24
Life Sciences Tools & Services	3	2
Diversified Consumer Services	1	1
Health Care Technology	1	

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

17

Trust Information as of June 30, 2018

BlackRock Resources & Commodities Strategy Trust**Investment Objective**

BlackRock Resources & Commodities Strategy Trust s (BCX) (the Trust) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option overwriting strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objectives will be achieved.

Trust Information

Symbol on NYSE	BCX
Initial Offering Date	March 30, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$9.29) ^(a)	6.67%
Current Monthly Distribution per Common Share ^(b)	\$0.0516
Current Annualized Distribution per Common Share ^(b)	\$0.6192

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BCX ^{(a)(b)}	(1.71)%	0.07%
Lipper Natural Resources Funds ^(c)	(1.38)	(0.70)

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust s discount to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

^(c)

Average return. Returns reflect investment of dividends and/or distributions at NAV on the ex-dividend as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's absolute performance based on NAV:

What factors influenced performance?

The Trust's allocation to energy stocks made a positive contribution to its six-month results. Oil prices rallied behind the combination of tighter supplies and higher-than-expected demand, leading to strong returns for the energy sector. In this environment, the U.S. exploration and production company ConocoPhillips was among the largest contributors to performance. Upstream producers, in general, maintained capital discipline and prioritized shareholder returns over growth. ConocoPhillips participated in this trend by announcing a 7.5% dividend increase and a 33% expansion of its share buyback program, which boosted its stock price. Other contributors of note within energy included Royal Dutch Shell PLC, Suncor Energy, Inc. and BP PLC.

The mining stock Nevsun Resources Ltd., which was bid for by a competitor in May, was also a large contributor to returns.

After performing strongly in 2017, the battery materials industry came under pressure in early 2018 as lithium prices retreated. The downturn stemmed from supply concerns that arose after the lithium miner Sociedad Química y Minera de Chile SA reached an agreement with the Chilean government that would allow it to significantly increase production. The Trust's position in Neo Lithium Corp. detracted from performance as a result. The investment adviser retained the position on the belief that the long-term demand for lithium from electric vehicle sales is likely to outweigh the available supply.

The Brazil-based food producer BRF SA also detracted. The Brazilian Federal Police announced it was investigating the company for manipulating food/meat sample tests that are required to meet export regulatory standards. The company's former chief executive officer was arrested, along with ten other employees. This news introduced significant risk into the BRF investment case, prompting the Trust to sell the position. Other detractors of note included Glencore PLC, Nutrien Ltd. and ArcelorMittal.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy detracted from results.

Describe recent portfolio activity.

The Trust exited three of its positions in the agriculture industry, including Monsanto Co. The investment adviser believed the stock had limited upside since its price was close to the level at which the company was bid for by Bayer AG. The Trust also sold BRF and AGCO Corp., and initiated a position in the agricultural supply-chain company Archer Daniels Midland Co. on the expectation that the company's restructuring effort will lead to higher earnings growth.

Trust Information as of June 30, 2018 (continued)

BlackRock Resources & Commodities Strategy Trust

The investment adviser rotated some of the portfolio's positions in the mining industry based on relative valuations. In addition, the Trust's allocation to the industry was increased through additions to BHP Billiton Ltd. and Glencore.

Describe portfolio positioning at period end.

The mining industry represented the largest allocation following the Trust's purchases in this area. Energy and agriculture were the second- and third-largest weightings, respectively.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	06/30/18	12/31/17	Change	High	Low
Market Price	\$ 9.29	\$ 9.77	(4.91)%	\$ 10.49	\$ 8.69
Net Asset Value	10.30	10.64	(3.20)	11.05	9.68

Market Price and Net Asset Value History For Past Five Years**Overview of the Trust's Total Investments*****TEN LARGEST HOLDINGS**

<i>Security</i>	06/30/18
Nutrien LTD	6%
Royal Dutch Shell PLC ADR	6
Glencore PLC	5
BP PLC ADR	5
BHP Billiton PLC	5
TOTAL SA	5
Rio Tinto PLC ADR	4
Suncor Energy, Inc.	4
Vale SA ADR	4
Archer-Daniels-Midland Co.	3

* Excludes option positions and money market funds.

INDUSTRY ALLOCATION

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

<i>Industry</i>	<i>06/30/18</i>	<i>12/31/17</i>
Metals & Mining	36%	34%
Oil, Gas & Consumable Fuels	34	34
Chemicals	12	13
Food Products	8	11
Containers & Packaging	5	3
Energy Equipment & Services	2	3
Paper & Forest Products	1	1
Machinery	1	1
Electronic Equipment, Instruments & Components	1	

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Trust Information as of June 30, 2018

BlackRock Science and Technology Trust**Investment Objective**

BlackRock Science and Technology Trust s (BST) (the Trust) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of science and technology companies. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and utilizing an option over-writing strategy in an effort to seek total return performance and enhance distributions.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE	BST
Initial Offering Date	October 30, 2014
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$33.65) ^(a)	4.64%
Current Monthly Distribution per Common Share ^(b)	\$0.1300
Current Annualized Distribution per Common Share ^(b)	\$1.5600

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The monthly distribution per Common Share, declared on July 2, 2018, was increased to \$0.1500 per share. The current distribution rate on closing market price, current monthly distribution per Common Share and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2018 were as follows:

	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
BST ^{(a)(b)}	29.37%	15.46%
MSCI World Information Technology Index	N/A	9.44

^(a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

^(b) The Trust moved from a discount to NAV to a premium to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.

N/A Not applicable as the index does not have a market price.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's relative performance based on the index cited above:

What factors influenced performance?

Global markets were flat during the period, as the MSCI World Index returned 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risk.

The Trust's non-benchmark position in Amazon.com, Inc. was the largest contributor to relative performance, as strong e-commerce sales helped Amazon surpass first quarter earnings expectations, boosting the company's share price. Holdings in Netflix, Inc. represented the second largest contributor, as the company beat expectations for growth in subscribers. A non-benchmark position in the mobile payment company Square Inc. was also additive. Square has benefited from an improving macroeconomic backdrop as well as significant growth in mobile payment utilization rates.

The largest detractors from relative performance were the Trust's underweight positions in Facebook, Inc. and Apple, Inc. Facebook shares rallied after strong earnings helped ease fears surrounding the possible impact of user privacy concerns on Facebook's business model. Elsewhere, a non-benchmark position in Linx, a Brazilian management software company, was among the largest detractors from performance as recent political unrest in Brazil weighed on the company's share price.

Also, the Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The Trust's options writing strategy detracted from returns.

Describe recent portfolio activity.

During the six-month period, the Trust took profits on a position in a semiconductor company that had performed particularly well. Proceeds from the sale were rotated into a value opportunity within the internet software & services sub-industry.

Describe portfolio positioning at period end.

At period end, the Trust held its largest allocation within the software & services industry group, with a focus on idiosyncratic opportunities within the internet software & services and application software sub-industries. Regionally, the Trust maintained most of its exposure in North America, with smaller allocations to the emerging markets and Europe.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Trust Information as of June 30, 2018 (continued)

BlackRock Science and Technology Trust**Market Price and Net Asset Value Per Share Summary**

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 33.65	\$ 26.69	26.08%	\$ 35.71	\$ 26.00
Net Asset Value	31.20	27.73	12.51	32.73	27.48

Market Price and Net Asset Value History Since Inception

(a) Commencement of operations.

Overview of the Trust's Total Investments***TEN LARGEST HOLDINGS**

<i>Security</i>	<i>06/30/18</i>
Amazon.com, Inc.	6%
Microsoft Corp.	5
Tencent Holdings Ltd.	5
Alphabet Inc.	5
Apple, Inc.	4
Alibaba Group Holding LTD. ADR.	3
Mastercard, Inc.	3
Square, Inc.	2
Visa, Inc.	2
salesforce.com, Inc.	2

* Excludes option positions and money market funds.

INDUSTRY ALLOCATION

<i>Industry</i>	<i>06/30/18</i>	<i>12/31/17</i>
Software	30%	22%
Internet Software & Services	28	28
Semiconductors & Semiconductor Equipment	13	18
IT Services	12	10
Internet & Direct Marketing Retail	8	6

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Technology Hardware, Storage & Peripherals	4	7
Electronic Equipment, Instruments & Components	1	2
Media	1	1
Other	3 ^(a)	6 ^(a)

^(a) Other includes a 1% holding or less in each of the following industries: Automobiles, Chemicals, Consumer Finance, Household Durables, Health Care Technology, Professional Services and Diversified Consumer Services.

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

TRUST INFORMATION

21

Trust Information as of June 30, 2018

BlackRock Utilities, Infrastructure & Power Opportunities Trust**Investment Objective**

BlackRock Utilities, Infrastructure & Power Opportunities Trust s (BUI) (the Trust) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing primarily in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by utilizing an option writing (selling) strategy in an effort to seek total return performance and enhance distributions. The Trust considers the Utilities business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the Infrastructure business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the Power Opportunities business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust s investment objective will be achieved.

Trust Information

Symbol on NYSE	BUI
Initial Offering Date	November 25, 2011
Current Distribution Rate on Closing Market Price as of June 30, 2018 (\$20.01) ^(a)	7.26%
Current Monthly Distribution per Common Share ^(b)	\$0.1210
Current Annualized Distribution per Common Share ^(b)	\$1.4520

^(a) Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate consists of income, net realized gains and/or a return of capital. See the Financial Highlights for the actual sources and character of distributions. Past performance does not guarantee future results.

^(b) The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

Performance and Portfolio Management Commentary

Returns for the six-months ended June 30, 2018:

BUI ^{(a)(b)}	Returns Based On	
	<i>Market Price</i>	<i>Net Asset Value</i>
	(4.06)%	(0.56)%

Lipper Utility Funds ^(c)	(4.84)	(2.54)
-------------------------------------	--------	--------

- (a) All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.
- (b) The Trust moved from a premium to NAV to a discount to NAV during the period, which accounts for the difference between performance based on market price and performance based on NAV.
- (c) Average return. Returns reflect reinvestment of dividends and/or distributions at NAV on the ex-dividend date as calculated by Lipper.

Past performance is not indicative of future results. Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust's absolute performance based on NAV:

What factors influenced performance?

Markets were essentially flat during the period, as the MSCI World Index returning 0.43%. However, this masked considerable volatility driven by rising trade tensions and broader geopolitical risks.

A position in Spanish renewable energy company EDP Renovaveis was the largest contributor to the Trust's performance during the six-month period. The company's shares rose on speculation that one or more companies were looking to acquire all or part of the business. Another renewable energy holding, China Longyuan, was among the leading contributors for the period. China is introducing a national emissions trading scheme for carbon dioxide that will incentivize the move to cleaner technologies, boosting the company's shares in the period. Other contributors of note included clean energy company NextEra Energy Inc., Macquarie Infrastructure Corp. and electric utility FirstEnergy Corp.

Exposure to multinational automotive supplier Valeo was the largest detractor from the Trust's absolute performance during the period. Despite a stronger-than-expected order book, the company reported lower year-on-year profits for 2017, especially in the autonomous driving and electric vehicle segments, while lowering forward guidance for organic growth. The Trust has maintained the position on a positive view of both the company and the broader vehicle electrification theme, particularly given the regulatory support emerging from many countries. Elsewhere within the automotive space, temporary disruption related to the move to real world driving testing standards negatively impacted our positions in component manufacturers Continental AG and Osram Licht AG. Other detractors of note included European energy company Enel SpA and Denmark-based wind energy manufacturer Vestas Wind Systems A/S.

The Trust made use of options, principally written call options on individual stocks, in order to seek enhanced income returns while continuing to participate in the performance of the underlying equities. The option overlay strategy had a negative impact on results.

Trust Information as of June 30, 2018 (continued) **BlackRock Utilities, Infrastructure & Power Opportunities Trust**

Describe recent portfolio activity.

During the period, the Trust reduced exposure to midstream energy companies, exiting Shell Midstream Partners and Plains All American Pipeline in the process. Capital was rotated into the electric vehicle exposed companies, such as semiconductor manufacturer Infineon Technologies AG and Continental AG.

Describe portfolio positioning at period end.

At period end, the utilities sector accounted for approximately 63.5% of the Trust's assets, with holdings concentrated in U.S. electric and multi-utilities. Approximately 16% of the portfolio was invested in the industrials sector, with roughly another 12% in the energy sector. The remainder was invested in other infrastructure- and power-related sectors.

Against a backdrop of historically low interest rates, the demand for equity yield has led to valuations for U.S. utilities that are high relative to their historical levels, placing even greater importance on stock selection. As such, the Trust was focused on owning companies with strong management teams that offer the potential for above-sector growth in earnings and dividends. The Trust had a preference for regulated utilities over their non-regulated counterparts given their existing barriers to entry, strong balance sheets, and lower sensitivity to commodity prices.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

Market Price and Net Asset Value Per Share Summary

	<i>06/30/18</i>	<i>12/31/17</i>	<i>Change</i>	<i>High</i>	<i>Low</i>
Market Price	\$ 20.01	\$ 21.62	(7.45)%	\$ 21.73	\$ 19.09
Net Asset Value	20.26	21.12	(4.07)	21.27	19.69

Market Price and Net Asset Value History For the Past Five Years

Overview of the Trust's Total Investments*

TEN LARGEST HOLDINGS

<i>Security</i>	<i>06/30/18</i>
NextEra Energy, Inc.	11%
Enel SpA	5
EDP Renovaveis SA	5

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

National Grid PLC	4
Public Service Enterprise Group	4
Duke Energy Corp.	4
Dominion Energy, Inc.	3
Atlantia SpA	3
Exelon Corp.	3
TransCanada Corp.	3

* Excludes option positions and money market funds.

INDUSTRY ALLOCATION

<i>Industry</i>	<i>06/30/18</i>	<i>12/31/17</i>
Electric Utilities	36%	33%
Multi-Utilities	20	20
Oil, Gas & Consumable Fuels	12	12
Transportation Infrastructure	11	15
Independent Power and Renewable Electricity Producers	8	8
Electrical Equipment	4	3
Chemicals	4	3
Water Utilities	1	1
Construction & Engineering		3
Gas Utilities		1
Auto Components	2	
Other	2 ^(a)	1 ^(a)

^(a) Other includes a 1% holding or less in each of the following industries: Building Products and Semiconductors & Semiconductor Equipment.

For Trust compliance purposes, the Trust's industry classifications refer to any one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. The Trusts' successful use of a derivative financial instrument depends on the investment adviser's ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts' investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

Schedule of Investments (unaudited)

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 99.8%		
Energy Equipment & Services 7.6%		
Baker Hughes a GE Co. ^(a)	255,700	\$ 8,445,771
Halliburton Co. ^(a)	306,900	13,828,914
Patterson-UTI Energy, Inc. ^(a)	192,557	3,466,026
Schlumberger Ltd. ^(a)	156,674	10,501,858
		36,242,569
Oil, Gas & Consumable Fuels 92.2%		
Anadarko Petroleum Corp. ^(a)	165,033	12,088,667
Andeavor ^(a)	103,050	13,518,099
BP PLC	4,427,650	33,687,851
Cairn Energy PLC ^(b)	1,747,695	5,738,664
Canadian Natural Resources Ltd.	418,540	15,106,472
Chevron Corp. ^{(a)(c)}	242,585	30,670,022
Cimarex Energy Co. ^(a)	65,550	6,669,057
CNOOC Ltd.	4,423,000	7,579,007
Concho Resources, Inc. ^{(a)(b)}	26,750	3,700,862
ConocoPhillips ^(a)	314,800	21,916,376
Devon Energy Corp. ^(a)	339,050	14,904,638
Encana Corp.	849,530	11,095,295
EOG Resources, Inc. ^(a)	142,700	17,756,161
EQT Corp.	180,450	9,957,231
Exxon Mobil Corp. ^{(a)(c)}	487,002	40,289,675
Galp Energia SGPS SA	14,335	273,455
Kosmos Energy Ltd. ^(b)	720,108	5,955,293
Marathon Oil Corp. ^(a)	191,748	3,999,863
Noble Energy, Inc. ^(a)	303,842	10,719,546
Oil Search Ltd.	911,863	5,990,891
Pioneer Natural Resources Co. ^(a)	82,876	15,683,454
Royal Dutch Shell PLC ADR, Class A ^(a)	713,800	49,416,374
Royal Dutch Shell PLC, Class A	273,248	9,456,815
Suncor Energy, Inc.	548,400	22,317,271
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Oil, Gas & Consumable Fuels (continued)		
TOTAL SA	425,553	\$ 25,842,019
TransCanada Corp.	306,250	13,250,295
Valero Energy Corp. ^(a)	168,800	18,708,104
Williams Cos., Inc. ^(a)	482,900	13,091,419
		439,382,876
		475,625,445

Total Long-Term Investments	99.8%		
(Cost \$404,613,943)			
Short-Term Securities	1.0%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(d)(e)}		4,599,459	4,599,459
Total Short-Term Securities	1.0%		
(Cost \$4,599,459)			4,599,459
Total Investments Before Options Written	100.8%		
(Cost \$409,213,402)			480,224,904
Options Written	(0.7)%		
(Premiums Received \$3,574,813)			(3,538,539)
Total Investments, Net of Options Written	100.1%		
(Cost \$405,638,589)			476,686,365
Liabilities in Excess of Other Assets	(0.1)%		(381,317)
Net Assets	100.0%		\$ 476,305,048

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) Non-income producing security.
- (c) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (d) Annualized 7-day yield as of period end.
- (e) During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at 12/31/17	Net Activity	Shares Held at 06/30/18	Value at 06/30/18	Income	Change in Net Unrealized Appreciation (Loss)
BlackRock Liquidity Funds, T-Fund, Institutional Class	3,870,844	728,615	4,599,459	\$ 4,599,459	\$ 28,875	\$

(a) Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust's industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End**Exchange-Traded Options Written**

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Chevron Corp.	154	07/06/18	USD 128.00	USD 1,947	\$ (9,086)
ConocoPhillips	164	07/06/18	USD 70.00	USD 1,142	(11,890)
Devon Energy Corp.	114	07/06/18	USD 43.50	USD 501	(11,856)
Devon Energy Corp.	130	07/06/18	USD 41.00	USD 571	(39,975)
EOG Resources, Inc.	89	07/06/18	USD 119.00	USD 1,107	(53,400)
Halliburton Co.	290	07/06/18	USD 51.50	USD 1,307	(870)
Williams Cos., Inc.	460	07/06/18	USD 27.50	USD 1,247	(5,750)
Anadarko Petroleum Corp.	70	07/13/18	USD 72.00	USD 513	(16,450)

SCHEDULES OF INVESTMENTS

25

Schedule of Investments (unaudited) (continued)

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Chevron Corp.	154	07/13/18	USD 129.00	USD 1,947	\$ (13,013)
ConocoPhillips	202	07/13/18	USD 70.00	USD 1,406	(24,139)
EOG Resources, Inc.	38	07/13/18	USD 120.00	USD 473	(20,900)
Exxon Mobil Corp.	356	07/13/18	USD 83.00	USD 2,945	(36,312)
Pioneer Natural Resources Co.	111	07/13/18	USD 197.50	USD 2,101	(15,817)
Royal Dutch Shell PLC ADR, Class A	205	07/13/18	USD 71.00	USD 1,419	(7,175)
Valero Energy Corp.	60	07/13/18	USD 116.00	USD 665	(4,080)
Williams Cos., Inc.	576	07/13/18	USD 27.00	USD 1,562	(29,088)
Anadarko Petroleum Corp.	259	07/20/18	USD 72.50	USD 1,897	(63,196)
Andeavor	104	07/20/18	USD 145.00	USD 1,364	(4,160)
Baker Hughes a GE Co.	287	07/20/18	USD 39.00	USD 948	(2,870)
Baker Hughes a GE Co.	233	07/20/18	USD 36.00	USD 770	(5,825)
Canadian Natural Resources Ltd.	165	07/20/18	CAD 48.00	CAD 783	(10,605)
Chevron Corp.	353	07/20/18	USD 130.00	USD 4,463	(33,712)
Cimarex Energy Co.	74	07/20/18	USD 90.00	USD 753	(92,130)
Concho Resources, Inc.	38	07/20/18	USD 152.75	USD 526	(2,011)
ConocoPhillips	227	07/20/18	USD 72.50	USD 1,580	(13,393)
ConocoPhillips	164	07/20/18	USD 70.50	USD 1,142	(20,582)
Devon Energy Corp.	152	07/20/18	USD 38.00	USD 668	(93,860)
Devon Energy Corp.	70	07/20/18	USD 44.00	USD 308	(10,465)
Devon Energy Corp.	92	07/20/18	USD 46.00	USD 404	(6,348)
EOG Resources, Inc.	116	07/20/18	USD 125.00	USD 1,443	(33,756)
Encana Corp.	1,255	07/20/18	CAD 17.00	CAD 2,155	(69,210)
Noble Energy, Inc.	492	07/20/18	USD 37.50	USD 1,736	(17,220)
Royal Dutch Shell PLC ADR, Class A	289	07/20/18	USD 70.00	USD 2,001	(26,733)
Royal Dutch Shell PLC ADR, Class A	405	07/20/18	USD 75.00	USD 2,804	(3,037)
Schlumberger Ltd.	326	07/20/18	USD 73.45	USD 2,185	(3,376)
Suncor Energy, Inc.	982	07/20/18	CAD 54.00	CAD 5,254	(61,625)
Andeavor	131	07/27/18	USD 152.50	USD 1,718	(2,882)
Chevron Corp.	65	07/27/18	USD 130.00	USD 822	(9,782)
ConocoPhillips	108	07/27/18	USD 69.00	USD 752	(25,326)
Devon Energy Corp.	1	07/27/18	USD 44.00	USD 4	(175)
Devon Energy Corp.	92	07/27/18	USD 45.50	USD 404	(9,982)
Devon Energy Corp.	141	07/27/18	USD 45.00	USD 620	(18,118)
EOG Resources, Inc.	91	07/27/18	USD 119.00	USD 1,132	(65,748)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Exxon Mobil Corp.	410	07/27/18	USD	85.00	USD	3,392	(32,800)
Halliburton Co.	392	07/27/18	USD	49.50	USD	1,766	(11,172)
Pioneer Natural Resources Co.	52	07/27/18	USD	202.50	USD	984	(9,880)
Royal Dutch Shell PLC ADR, Class A	296	07/27/18	USD	71.00	USD	2,049	(23,680)
Royal Dutch Shell PLC ADR, Class A	405	07/27/18	USD	69.50	USD	2,804	(57,713)
Williams Cos., Inc.	139	07/27/18	USD	28.50	USD	377	(2,363)
Williams Cos., Inc.	257	07/27/18	USD	28.00	USD	697	(7,453)
Concho Resources, Inc.	55	07/30/18	USD	128.25	USD	761	(67,595)
Chevron Corp.	58	08/03/18	USD	130.00	USD	733	(10,498)
Devon Energy Corp.	71	08/03/18	USD	43.50	USD	312	(17,821)
Exxon Mobil Corp.	471	08/03/18	USD	83.00	USD	3,897	(92,081)
Pioneer Natural Resources Co.	31	08/03/18	USD	190.00	USD	587	(21,855)
Pioneer Natural Resources Co.	64	08/03/18	USD	200.00	USD	1,211	(20,320)
Valero Energy Corp.	197	08/03/18	USD	116.00	USD	2,183	(41,567)
Chevron Corp.	65	08/10/18	USD	128.00	USD	822	(19,370)
Devon Energy Corp.	141	08/10/18	USD	46.00	USD	620	(21,925)
EOG Resources, Inc.	165	08/10/18	USD	129.00	USD	2,053	(48,180)
Valero Energy Corp.	128	08/10/18	USD	115.00	USD	1,419	(32,832)
Anadarko Petroleum Corp.	248	08/17/18	USD	72.50	USD	1,817	(97,340)
Andeavor	90	08/17/18	USD	140.00	USD	1,181	(15,390)
Canadian Natural Resources Ltd.	670	08/17/18	CAD	44.00	CAD	3,179	(214,049)
Cimarex Energy Co.	167	08/17/18	USD	100.00	USD	1,699	(105,210)
ConocoPhillips	236	08/17/18	USD	70.00	USD	1,643	(60,298)
Devon Energy Corp.	90	08/17/18	USD	42.00	USD	396	(33,525)
Devon Energy Corp.	92	08/17/18	USD	46.00	USD	404	(15,778)
Encana Corp.	2,268	08/17/18	CAD	17.00	CAD	3,894	(187,181)
Exxon Mobil Corp.	467	08/17/18	USD	82.50	USD	3,863	(113,481)

Schedule of Investments (unaudited) (continued)

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Halliburton Co.	392	08/17/18	USD 50.00	USD 1,766	\$ (20,580)
Patterson-UTI Energy, Inc.	210	08/17/18	USD 19.00	USD 378	(15,750)
Pioneer Natural Resources Co.	32	08/17/18	USD 185.00	USD 606	(38,240)
Royal Dutch Shell PLC ADR, Class A	206	08/17/18	USD 72.50	USD 1,426	(14,420)
Schlumberger Ltd.	187	08/17/18	USD 67.50	USD 1,253	(42,169)
Suncor Energy, Inc.	937	08/17/18	CAD 54.00	CAD 5,013	(103,347)
TransCanada Corp.	1,071	08/17/18	CAD 58.00	CAD 6,092	(68,839)
Valero Energy Corp.	205	08/17/18	USD 115.00	USD 2,272	(59,245)
Williams Cos., Inc.	258	08/17/18	USD 28.00	USD 699	(13,674)
					\$ (2,763,549)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
Noble Energy, Inc.	Bank of America N.A.	59,000	07/09/18	USD 35.40	USD 2,082	\$ (42,265)
BP PLC Oil Search Ltd.	Goldman Sachs International Morgan Stanley & Co. International PLC	311,600 157,000	07/10/18 07/10/18	GBP 5.83 AUD 8.81	GBP 1,798 AUD 1,394	(23,239) (21,568)
Patterson-UTI Energy, Inc.	UBS AG	35,300	07/10/18	USD 23.63	USD 635	
TOTAL SA	Credit Suisse International	10,700	07/11/18	EUR 53.41	EUR 556	(2,456)
TOTAL SA Canadian Natural Resources Ltd.	UBS AG Credit Suisse International	18,600 67,900	07/11/18 07/16/18	EUR 54.88 CAD 46.25	EUR 967 CAD 3,222	(524) (91,397)
BP PLC	Barclays Bank PLC	262,800	07/18/18	GBP 5.85	GBP 1,516	(25,083)
CNOOC Ltd.	Goldman Sachs International	207,000	07/18/18	HKD 14.07	HKD 2,782	(3,447)
TOTAL SA	Goldman Sachs International	26,500	07/25/18	EUR 53.15	EUR 1,378	(13,724)
BP PLC	Citibank N.A.	230,000	07/26/18	GBP 5.96	GBP 1,327	(15,927)
CNOOC Ltd.	JPMorgan Chase Bank N.A.	261,000	07/26/18	HKD 14.07	HKD 3,508	(6,498)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Royal Dutch Shell PLC, Class A	Goldman Sachs International	95,700	07/26/18	GBP	25.93	GBP	2,509	(94,603)
TOTAL SA	Citibank N.A.	47,000	07/26/18	EUR	53.63	EUR	2,444	(19,103)
BP PLC	Barclays Bank PLC	213,300	07/27/18	GBP	5.86	GBP	1,231	(26,684)
BP PLC	Citibank N.A.	221,000	07/27/18	GBP	5.70	GBP	1,275	(50,760)
CNOOC Ltd.	Societe Generale	300,000	08/01/18	HKD	12.78	HKD	4,032	(32,136)
TOTAL SA	UBS AG	30,000	08/01/18	EUR	53.87	EUR	1,560	(16,207)
Patterson-UTI Energy, Inc.	UBS AG	11,000	08/06/18	USD	20.20	USD	198	(3,321)
Royal Dutch Shell PLC ADR, Class A	Citibank N.A.	34,600	08/06/18	USD	70.97	USD	2,395	(39,852)
Oil Search Ltd.	Citibank N.A.	190,000	08/07/18	AUD	8.35	AUD	1,687	(86,874)
BP PLC	Goldman Sachs International	311,000	08/08/18	GBP	5.85	GBP	1,794	(55,006)
TOTAL SA	Goldman Sachs International	16,100	08/08/18	EUR	52.17	EUR	837	(21,605)
Baker Hughes a GE Co.	Citibank N.A.	31,300	08/13/18	USD	33.93	USD	1,034	(39,343)
Royal Dutch Shell PLC ADR, Class A	Citibank N.A.	34,600	08/20/18	USD	70.97	USD	2,395	(43,368)
								\$ (774,990)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premiums Paid</i>	<i>Swap Premiums Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 966,746	\$ (930,472)	\$ (3,538,539)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written at value	\$	\$	\$ 3,538,539	\$	\$	\$	\$ 3,538,539

SCHEDULES OF INVESTMENTS

Schedule of Investments (unaudited) (continued)

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

For the six months ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity</i>	<i>Credit</i>	<i>Foreign</i>	<i>Equity</i>	<i>Exchange</i>	<i>Interest</i>	<i>Other</i>	<i>Total</i>
	<i>Contract</i>	<i>Contracts</i>	<i>Contract</i>	<i>Contract</i>	<i>Contract</i>	<i>Contract</i>	<i>Contracts</i>	
Net Realized Gain (Loss) from:								
Options purchased ^(a)	\$	\$	\$ (841)	\$	\$	\$	\$	\$ (841)
Options written			(14,337,904)					(14,337,904)
	\$	\$	\$ (14,338,745)	\$	\$	\$	\$	\$ (14,338,745)

^(a)Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation (Depreciation) on:

Options written	\$	\$	\$ 4,386,198	\$	\$	\$	\$	\$ 4,386,198
-----------------	----	----	--------------	----	----	----	----	--------------

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased	\$	(a)
Average value of option contracts written	\$	3,136,477

^(a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments – Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) are as follows:

Assets *Liabilities*

Derivative Financial Instruments:

Options	\$	\$ 3,538,539
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,763,549)
Total derivative assets and liabilities subject to an MNA	\$	\$ 774,990

The following table presents the Trust's derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Bank of America N.A.	\$ 42,265	\$	\$	\$	\$ 42,265
Barclays Bank PLC	51,767		(51,767)		
Citibank N.A.	295,227		(295,227)		
Credit Suisse International	93,853		(93,240)		613
Goldman Sachs International	211,624		(211,624)		
JPMorgan Chase Bank N.A.	6,498				6,498
Morgan Stanley & Co. International PLC	21,568				21,568
Societe Generale	32,136				32,136
UBS AG	20,052		(20,052)		
	\$ 774,990	\$	\$ (671,910)	\$	\$ 103,080

^(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

^(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Schedule of Investments (unaudited) (continued)

BlackRock Energy and Resources Trust (BGR)

June 30, 2018

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Energy Equipment & Services	\$ 36,242,569	\$	\$	\$ 36,242,569
Oil, Gas & Consumable Fuels	350,814,174	88,568,702		439,382,876
Short-Term Securities	4,599,459			4,599,459
	\$ 391,656,202	\$ 88,568,702	\$	\$ 480,224,904
Derivative Financial Instruments ^(a)				
Liabilities:				
Equity contracts	\$ (2,690,567)	\$ (847,972)	\$	\$ (3,538,539)

^(a) Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 100.3%		
Airlines 1.4%		
Delta Air Lines, Inc.	204,085	\$ 10,110,371
Banks 10.4%		
Bank of America Corp. ^{(a)(b)}	710,271	20,022,540
JPMorgan Chase & Co. ^(b)	239,356	24,940,895
Regions Financial Corp.	327,605	5,824,817
SunTrust Banks, Inc.	205,255	13,550,935
U.S. Bancorp	263,202	13,165,364
		77,504,551
Biotechnology 3.5%		
Biogen, Inc. ^(c)	55,904	16,225,577
Gilead Sciences, Inc.	138,969	9,844,564
		26,070,141
Capital Markets 1.2%		
E*Trade Financial Corp. ^(c)	150,986	9,234,304
Chemicals 2.1%		
DowDuPont, Inc.	243,080	16,023,834
Commercial Services & Supplies 1.1%		
KAR Auction Services, Inc.	154,771	8,481,451
Communications Equipment 2.7%		
Cisco Systems, Inc.	474,074	20,399,404
Consumer Finance 1.6%		
Ally Financial, Inc.	213,891	5,618,916
SLM Corp. ^(c)	537,693	6,156,585
		11,775,501
Containers & Packaging 1.2%		
Packaging Corp. of America	82,529	9,225,917
Electric Utilities 2.9%		
FirstEnergy Corp.	363,947	13,069,337
PG&E Corp.	206,492	8,788,299
		21,857,636
Electronic Equipment, Instruments & Components 2.5%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

CDW Corp.	154,847	12,510,089
Flex Ltd. ^(c)	443,330	6,255,386
		18,765,475
Food & Staples Retailing 2.2%		
Walmart, Inc.	191,513	16,403,088
Food Products 1.3%		
J.M. Smucker Co.	89,440	9,613,011
Health Care Equipment & Supplies 1.5%		
Baxter International, Inc.	150,208	11,091,359
Health Care Providers & Services 9.1%		
Centene Corp. ^(c)	79,887	9,842,877
CVS Health Corp. ^(a)	124,485	8,010,610
Humana, Inc.	57,029	16,973,541
Laboratory Corp. of America Holdings ^(c)	81,168	14,572,091
UnitedHealth Group, Inc.	77,355	18,978,276
		68,377,395
Hotels, Restaurants & Leisure 1.1%		
Carnival Corp.	147,293	8,441,362
Household Durables 2.9%		
D.R. Horton, Inc.	337,430	13,834,630
Lennar Corp., Class A	90,366	4,744,215
NVR, Inc. ^(c)	1,081	3,210,948
		21,789,793
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Household Products 0.2%		
Energizer Holdings, Inc.	22,475	\$ 1,415,026
Industrial Conglomerates 0.9%		
General Electric Co.	481,941	6,559,217
Insurance 1.4%		
Assured Guaranty Ltd.	105,887	3,783,343
Hartford Financial Services Group, Inc.	135,210	6,913,287
		10,696,630
Internet Software & Services 5.0%		
Alphabet, Inc., Class A ^(c)	33,203	37,492,496
IT Services 3.0%		
Amdocs Ltd.	83,760	5,544,075
Cognizant Technology Solutions Corp., Class A	209,862	16,576,999
		22,121,074
Machinery 2.3%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Allison Transmission Holdings, Inc.	142,313	5,762,253
Fortive Corp.	150,060	11,571,127
		17,333,380
Media 2.5%		
Comcast Corp., Class A ^(a)	565,618	18,557,927
Metals & Mining 1.5%		
Freeport-McMoRan, Inc.	433,357	7,479,742
Rio Tinto PLC ADR	59,686	3,311,379
		10,791,121
Oil, Gas & Consumable Fuels 6.6%		
BP PLC ADR	202,348	9,239,210
Chevron Corp.	134,226	16,970,193
Marathon Oil Corp.	239,650	4,999,099
Suncor Energy, Inc.	404,193	16,442,571
TOTAL SA ADR	32,322	1,957,420
		49,608,493
Pharmaceuticals 4.1%		
Novo Nordisk A/S ADR	188,798	8,707,364
Pfizer, Inc.	608,765	22,085,994
		30,793,358
Road & Rail 2.1%		
Norfolk Southern Corp.	102,299	15,433,850
Software 8.7%		
Dell Technologies, Inc., Class V ^(c)	122,393	10,352,000
Microsoft Corp. ^(a)	395,647	39,014,751
Oracle Corp.	351,281	15,477,441
		64,844,192
Specialty Retail 5.2%		
Home Depot, Inc.	45,995	8,973,625
Lowe's Cos., Inc. ^(a)	204,067	19,502,683
Urban Outfitters, Inc. ^(c)	233,622	10,407,860
		38,884,168
Technology Hardware, Storage & Peripherals 5.9%		
Apple, Inc. ^(b)	237,136	43,896,245
Tobacco 2.2%		
Altria Group, Inc. ^(a)	288,708	16,395,726
Total Long-Term Investments 100.3% (Cost \$584,059,977)		749,987,496

Schedule of Investments (unaudited) (continued) **BlackRock Enhanced Capital and Income Fund, Inc. (CII)**

June 30, 2018 **(Percentages shown are based on Net Assets)**

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Short-Term Securities 0.6%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(d)(e)}	4,630,300	\$ 4,630,300
Total Short-Term Securities 0.6% (Cost \$4,630,300)		4,630,300
Options Purchased 0.0% (Cost \$1,360)		1,605
Total Investments Before Options Written 100.9% (Cost \$588,691,637)		754,619,401
Options Written (0.9)% (Premiums Received \$8,067,614)		(6,477,238)
Total Investments, Net of Options Written 100.0% (Cost \$580,624,023)		748,142,163
Liabilities in Excess of Other Assets (0.0)%		(18,462)
Net Assets 100.0%		\$ 748,123,701

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) All or a portion of security has been pledged as collateral in connection with OTC derivatives.

(c) Non-income producing security.

(d) Annualized 7-day yield as of period end.

(e) During the six months ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Change in NetUnrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	3,142,974	1,487,326	4,630,300	\$ 4,630,300	\$ 29,997	\$

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

(a) Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust's industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Purchased

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call General Electric Co.	321	07/13/18	USD 14.50	USD 437	\$ 1,605

Exchange-Traded Options Written

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call Bank of America Corp.	188	07/02/18	USD 31.35	USD 530	\$
Pfizer, Inc.	38	07/02/18	USD 36.25	USD 138	(755)
General Electric Co.	414	07/05/18	USD 14.75	USD 563	(213)
Bank of America Corp.	669	07/06/18	USD 30.50	USD 1,886	(1,003)
Baxter International, Inc.	37	07/06/18	USD 73.50	USD 273	(3,108)
CVS Health Corp.	278	07/06/18	USD 66.00	USD 1,789	(8,479)
Carnival Corp.	285	07/06/18	USD 64.00	USD 1,633	(1,425)
Chevron Corp.	104	07/06/18	USD 128.00	USD 1,315	(6,136)
Cisco Systems, Inc.	610	07/06/18	USD 44.50	USD 2,625	(1,525)
Cognizant Technology Solutions Corp., Class A	337	07/06/18	USD 77.00	USD 2,662	(75,825)
Comcast Corp., Class A	368	07/06/18	USD 32.00	USD 1,207	(35,880)
D.R. Horton, Inc.	114	07/06/18	USD 43.50	USD 467	(627)
Delta Air Lines, Inc.	284	07/06/18	USD 56.00	USD 1,407	(852)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>		<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)						
DowDuPont, Inc.	54	07/06/18	USD	67.50	USD 356	\$ (1,026)
Flex Ltd.	372	07/06/18	USD	14.00	USD 525	(9,300)
General Electric Co.	82	07/06/18	USD	15.25	USD 112	(12)
General Electric Co.	146	07/06/18	USD	14.50	USD 199	(292)
Gilead Sciences, Inc.	82	07/06/18	USD	69.50	USD 581	(13,489)
Hartford Financial Services Group, Inc.	178	07/06/18	USD	54.00	USD 910	(712)
Humana, Inc.	43	07/06/18	USD	297.50	USD 1,280	(14,513)
Microsoft Corp.	327	07/06/18	USD	101.00	USD 3,225	(7,357)
Norfolk Southern Corp.	135	07/06/18	USD	160.00	USD 2,037	(1,350)
Oracle Corp.	123	07/06/18	USD	48.00	USD 542	(246)
Pfizer, Inc.	78	07/06/18	USD	36.00	USD 283	(3,471)
Pfizer, Inc.	103	07/06/18	USD	36.50	USD 374	(1,339)
Pfizer, Inc.	39	07/06/18	USD	37.00	USD 141	(175)
Suncor Energy, Inc.	256	07/06/18	USD	40.00	USD 1,041	(23,936)
U.S. Bancorp	154	07/06/18	USD	52.50	USD 770	(308)
U.S. Bancorp	43	07/06/18	USD	53.00	USD 215	(430)
UnitedHealth Group, Inc.	57	07/06/18	USD	245.00	USD 1,398	(14,421)
Urban Outfitters, Inc.	278	07/06/18	USD	42.50	USD 1,238	(56,295)
Novo Nordisk A/S ADR	124	07/09/18	USD	50.00	USD 572	(46)
Suncor Energy, Inc.	8	07/09/18	USD	38.40	USD 33	(1,920)
FirstEnergy Corp.	442	07/11/18	USD	34.01	USD 1,587	(87,636)
Alphabet, Inc., Class A	18	07/13/18	USD	1,145.00	USD 2,033	(19,980)
Altria Group, Inc.	383	07/13/18	USD	57.50	USD 2,175	(21,257)
Apple, Inc.	129	07/13/18	USD	192.50	USD 2,388	(5,160)
Apple, Inc.	101	07/13/18	USD	187.50	USD 1,870	(18,685)
BP PLC ADR	133	07/13/18	USD	46.00	USD 607	(7,315)
Bank of America Corp.	318	07/13/18	USD	30.50	USD 896	(1,431)
Bank of America Corp.	161	07/13/18	USD	31.00	USD 454	(563)
Biogen, Inc.	28	07/13/18	USD	295.00	USD 813	(9,660)
Carnival Corp.	70	07/13/18	USD	65.00	USD 401	(350)
Carnival Corp.	70	07/13/18	USD	66.50	USD 401	(350)
Chevron Corp.	104	07/13/18	USD	129.00	USD 1,315	(8,788)
Cisco Systems, Inc.	81	07/13/18	USD	45.00	USD 349	(486)
D.R. Horton, Inc.	114	07/13/18	USD	44.00	USD 467	(1,425)
DowDuPont, Inc.	189	07/13/18	USD	67.00	USD 1,246	(13,136)
DowDuPont, Inc.	126	07/13/18	USD	69.00	USD 831	(2,331)
FirstEnergy Corp.	154	07/13/18	USD	34.50	USD 553	(24,476)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Flex Ltd.	378	07/13/18	USD	14.50	USD	533	(5,103)
Hartford Financial Services Group, Inc.	152	07/13/18	USD	54.00	USD	777	(1,216)
Humana, Inc.	88	07/13/18	USD	307.50	USD	2,619	(9,020)
JPMorgan Chase & Co.	128	07/13/18	USD	111.00	USD	1,334	(2,560)
Microsoft Corp.	71	07/13/18	USD	103.00	USD	700	(1,704)
Microsoft Corp.	260	07/13/18	USD	102.00	USD	2,564	(10,400)
Oracle Corp.	45	07/13/18	USD	49.00	USD	198	(90)
Oracle Corp.	303	07/13/18	USD	48.00	USD	1,335	(1,212)
PG&E Corp.	522	07/13/18	USD	42.50	USD	2,222	(126,585)
Pfizer, Inc.	155	07/13/18	USD	36.50	USD	562	(4,417)
Pfizer, Inc.	38	07/13/18	USD	37.00	USD	138	(418)
SunTrust Banks, Inc.	389	07/13/18	USD	70.00	USD	2,568	(5,815)
U.S. Bancorp	360	07/13/18	USD	50.50	USD	1,801	(17,460)
U.S. Bancorp	43	07/13/18	USD	52.50	USD	215	(236)
U.S. Bancorp	129	07/13/18	USD	51.00	USD	645	(3,805)
U.S. Bancorp	65	07/13/18	USD	51.50	USD	325	(1,105)
Urban Outfitters, Inc.	165	07/13/18	USD	43.00	USD	735	(36,713)
Walmart Inc.	374	07/13/18	USD	85.00	USD	3,203	(55,726)
SunTrust Banks, Inc.	97	07/18/18	USD	70.50	USD	640	(1,880)
Allison Transmission Holdings, Inc.	200	07/20/18	USD	42.51	USD	810	(5,899)
Ally Financial, Inc.	348	07/20/18	USD	27.00	USD	914	(12,180)
Ally Financial, Inc.	120	07/20/18	USD	26.00	USD	315	(9,600)
Alphabet, Inc., Class A	34	07/20/18	USD	1,100.00	USD	3,839	(146,030)
Alphabet, Inc., Class A	7	07/20/18	USD	1,190.00	USD	790	(3,185)
Altria Group, Inc.	470	07/20/18	USD	57.50	USD	2,669	(38,540)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Apple, Inc.	520	07/20/18	USD 190.00	USD 9,626	\$ (68,380)
Assured Guaranty Ltd.	200	07/20/18	USD 37.00	USD 715	(4,400)
Assured Guaranty Ltd.	200	07/20/18	USD 39.00	USD 715	(600)
BP PLC ADR	357	07/20/18	USD 47.00	USD 1,630	(12,138)
Bank of America Corp.	297	07/20/18	USD 32.00	USD 837	(1,336)
Bank of America Corp.	274	07/20/18	USD 31.00	USD 772	(1,781)
Baxter International, Inc.	121	07/20/18	USD 72.50	USD 893	(25,592)
Biogen, Inc.	58	07/20/18	USD 280.00	USD 1,683	(80,040)
CDW Corp.	645	07/20/18	USD 80.00	USD 5,211	(158,025)
CVS Health Corp.	283	07/20/18	USD 72.50	USD 1,821	(4,103)
Carnival Corp.	154	07/20/18	USD 64.50	USD 883	(770)
Centene Corp.	211	07/20/18	USD 125.00	USD 2,600	(41,145)
Chevron Corp.	310	07/20/18	USD 130.00	USD 3,919	(29,605)
Cisco Systems, Inc.	344	07/20/18	USD 45.00	USD 1,480	(4,816)
Cisco Systems, Inc.	240	07/20/18	USD 44.00	USD 1,033	(8,040)
Cognizant Technology Solutions Corp., Class A	239	07/20/18	USD 80.00	USD 1,888	(23,900)
Comcast Corp., Class A	141	07/20/18	USD 33.01	USD 463	(12,455)
Comcast Corp., Class A	389	07/20/18	USD 32.50	USD 1,276	(43,374)
D.R. Horton, Inc.	114	07/20/18	USD 45.00	USD 467	(1,482)
Dell Technologies, Inc., Class V	434	07/20/18	USD 90.00	USD 3,671	(77,035)
DowDuPont, Inc.	231	07/20/18	USD 70.00	USD 1,523	(4,504)
DowDuPont, Inc.	94	07/20/18	USD 67.50	USD 620	(7,332)
E*Trade Financial Corp.	113	07/20/18	USD 65.00	USD 691	(5,819)
Energizer Holdings, Inc.	150	07/20/18	USD 60.00	USD 944	(53,250)
FirstEnergy Corp.	242	07/20/18	USD 35.00	USD 869	(29,645)
Flex Ltd.	372	07/20/18	USD 14.00	USD 525	(15,066)
Fortive Corp.	464	07/20/18	USD 80.00	USD 3,578	(25,520)
Freeport-McMoRan, Inc.	414	07/20/18	USD 16.00	USD 715	(62,100)
Freeport-McMoRan, Inc.	213	07/20/18	USD 16.50	USD 368	(23,856)
Freeport-McMoRan, Inc.	267	07/20/18	USD 17.50	USD 461	(14,819)
General Electric Co.	113	07/20/18	USD 15.00	USD 154	(734)
General Electric Co.	52	07/20/18	USD 13.50	USD 71	(2,600)
Gilead Sciences, Inc.	167	07/20/18	USD 67.50	USD 1,183	(64,713)
Hartford Financial Services Group, Inc.	135	07/20/18	USD 55.00	USD 690	(1,080)
J.M. Smucker Co.	227	07/20/18	USD 115.00	USD 2,440	(13,052)
JPMorgan Chase & Co.	103	07/20/18	USD 113.85	USD 1,073	(1,060)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

JPMorgan Chase & Co.	79	07/20/18	USD	110.00	USD	823	(4,108)
KAR Auction Services, Inc.	272	07/20/18	USD	55.00	USD	1,491	(23,120)
Laboratory Corp. of America Holdings	15	07/20/18	USD	195.00	USD	269	(450)
Lennar Corp., Class A	188	07/20/18	USD	57.50	USD	987	(3,478)
Lennar Corp., Class A	128	07/20/18	USD	52.50	USD	672	(18,304)
Lowe's Cos., Inc.	281	07/20/18	USD	86.20	USD	2,686	(287,158)
Marathon Oil Corp.	83	07/20/18	USD	21.00	USD	173	(5,893)
Marathon Oil Corp.	125	07/20/18	USD	22.00	USD	261	(4,312)
Microsoft Corp.	200	07/20/18	USD	100.00	USD	1,972	(40,400)
Norfolk Southern Corp.	223	07/20/18	USD	155.00	USD	3,364	(31,778)
Novo Nordisk A/S ADR	295	07/20/18	USD	48.90	USD	1,361	(5,578)
Oracle Corp.	301	07/20/18	USD	48.00	USD	1,326	(903)
Packaging Corp. of America	128	07/20/18	USD	125.00	USD	1,431	(1,280)
Pfizer, Inc.	2	07/20/18	USD	36.00	USD	7	(137)
Pfizer, Inc.	105	07/20/18	USD	35.00	USD	381	(15,540)
Pfizer, Inc.	159	07/20/18	USD	37.00	USD	577	(3,100)
Regions Financial Corp.	348	07/20/18	USD	19.00	USD	619	(6,090)
Rio Tinto PLC ADR	47	07/20/18	USD	60.00	USD	261	(705)
SLM Corp.	863	07/20/18	USD	11.55	USD	988	(24,351)
SunTrust Banks, Inc.	177	07/20/18	USD	70.00	USD	1,169	(5,133)
Suncor Energy, Inc.	34	07/20/18	USD	40.00	USD	138	(4,658)
TOTAL SA ADR	75	07/20/18	USD	60.00	USD	454	(11,250)
TOTAL SA ADR	60	07/20/18	USD	62.50	USD	363	(2,100)
U.S. Bancorp	130	07/20/18	USD	51.50	USD	650	(4,810)
Walmart Inc.	77	07/20/18	USD	87.50	USD	660	(4,889)
FirstEnergy Corp.	154	07/24/18	USD	34.75	USD	553	(24,317)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
CDW Corp.	219	07/25/18	USD 79.65	USD 1,769	\$ (63,069)
Alphabet, Inc., Class A	18	07/27/18	USD 1,160.00	USD 2,033	(42,750)
Apple, Inc.	101	07/27/18	USD 190.00	USD 1,870	(22,523)
Apple, Inc.	101	07/27/18	USD 187.50	USD 1,870	(28,028)
BP PLC ADR	133	07/27/18	USD 47.00	USD 607	(6,450)
BP PLC ADR	82	07/27/18	USD 46.00	USD 374	(7,257)
Bank of America Corp.	275	07/27/18	USD 31.00	USD 775	(2,612)
Baxter International, Inc.	121	07/27/18	USD 76.00	USD 893	(11,313)
Biogen, Inc.	57	07/27/18	USD 310.00	USD 1,654	(18,668)
Carnival Corp.	154	07/27/18	USD 64.50	USD 883	(1,540)
Chevron Corp.	39	07/27/18	USD 130.00	USD 493	(5,869)
Cisco Systems, Inc.	163	07/27/18	USD 45.00	USD 701	(3,423)
Cognizant Technology Solutions Corp., Class A	167	07/27/18	USD 80.00	USD 1,319	(20,875)
Comcast Corp., Class A	96	07/27/18	USD 33.00	USD 315	(11,088)
D.R. Horton, Inc.	137	07/27/18	USD 45.00	USD 562	(4,589)
Delta Air Lines, Inc.	169	07/27/18	USD 52.00	USD 837	(11,745)
DowDuPont, Inc.	117	07/27/18	USD 72.00	USD 771	(1,345)
DowDuPont, Inc.	139	07/27/18	USD 67.50	USD 916	(13,831)
DowDuPont, Inc.	35	07/27/18	USD 66.50	USD 231	(5,040)
E*Trade Financial Corp.	372	07/27/18	USD 65.50	USD 2,275	(55,428)
Flex Ltd.	380	07/27/18	USD 14.50	USD 536	(19,190)
Freeport-McMoRan, Inc.	400	07/27/18	USD 18.00	USD 690	(22,000)
Freeport-McMoRan, Inc.	213	07/27/18	USD 17.00	USD 368	(21,407)
General Electric Co.	578	07/27/18	USD 14.50	USD 787	(9,826)
General Electric Co.	52	07/27/18	USD 14.00	USD 71	(1,664)
Gilead Sciences, Inc.	317	07/27/18	USD 72.00	USD 2,246	(58,487)
Hartford Financial Services Group, Inc.	152	07/27/18	USD 54.00	USD 777	(5,320)
JPMorgan Chase & Co.	149	07/27/18	USD 112.00	USD 1,553	(6,034)
Lowe's Cos., Inc.	199	07/27/18	USD 101.00	USD 1,902	(9,552)
Marathon Oil Corp.	125	07/27/18	USD 22.00	USD 261	(5,875)
Marathon Oil Corp.	121	07/27/18	USD 21.00	USD 252	(10,406)
Microsoft Corp.	71	07/27/18	USD 103.00	USD 700	(8,023)
Microsoft Corp.	133	07/27/18	USD 101.00	USD 1,312	(24,273)
Oracle Corp.	179	07/27/18	USD 49.00	USD 789	(895)
Pfizer, Inc.	324	07/27/18	USD 37.00	USD 1,175	(8,748)
Pfizer, Inc.	60	07/27/18	USD 36.50	USD 218	(2,910)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Suncor Energy, Inc.	393	07/27/18	USD	40.00	USD	1,599	(63,666)
U.S. Bancorp	138	07/27/18	USD	52.00	USD	690	(4,554)
UnitedHealth Group, Inc.	155	07/27/18	USD	255.00	USD	3,803	(38,053)
Urban Outfitters, Inc.	340	07/27/18	USD	46.50	USD	1,515	(33,150)
Walmart Inc.	75	07/27/18	USD	86.50	USD	642	(9,262)
Walmart Inc.	153	07/27/18	USD	86.00	USD	1,310	(22,568)
Pfizer, Inc.	59	07/30/18	USD	36.75	USD	214	(2,580)
Pfizer, Inc.	385	07/30/18	USD	36.50	USD	1,397	(18,691)
Bank of America Corp.	88	07/31/18	USD	30.25	USD	248	(1,845)
Cisco Systems, Inc.	240	07/31/18	USD	44.60	USD	1,033	(8,113)
FirstEnergy Corp.	302	07/31/18	USD	34.75	USD	1,084	(50,824)
Altria Group, Inc.	266	08/03/18	USD	58.50	USD	1,511	(24,738)
BP PLC ADR	164	08/03/18	USD	46.00	USD	749	(19,106)
Bank of America Corp.	146	08/03/18	USD	30.00	USD	412	(3,723)
Bank of America Corp.	90	08/03/18	USD	29.00	USD	254	(5,040)
Baxter International, Inc.	82	08/03/18	USD	75.00	USD	605	(10,619)
Baxter International, Inc.	43	08/03/18	USD	73.50	USD	318	(8,772)
Biogen, Inc.	19	08/03/18	USD	300.00	USD	551	(13,205)
Chevron Corp.	92	08/03/18	USD	130.00	USD	1,163	(16,652)
Comcast Corp., Class A	141	08/03/18	USD	34.00	USD	463	(11,844)
D.R. Horton, Inc.	291	08/03/18	USD	42.50	USD	1,193	(32,738)
Delta Air Lines, Inc.	500	08/03/18	USD	55.00	USD	2,477	(13,250)
E*Trade Financial Corp.	128	08/03/18	USD	66.00	USD	783	(7,680)
Freeport-McMoRan, Inc.	267	08/03/18	USD	17.50	USD	461	(22,695)
General Electric Co.	205	08/03/18	USD	13.50	USD	279	(12,300)
General Electric Co.	295	08/03/18	USD	15.00	USD	401	(3,392)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>		<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)						
JPMorgan Chase & Co.	35	08/03/18	USD	110.00	USD 365	\$ (3,045)
JPMorgan Chase & Co.	79	08/03/18	USD	111.00	USD 823	(5,411)
Lowe's Cos., Inc.	245	08/03/18	USD	99.00	USD 2,341	(27,563)
Marathon Oil Corp.	245	08/03/18	USD	21.50	USD 511	(20,213)
Microsoft Corp.	133	08/03/18	USD	102.00	USD 1,312	(22,145)
Oracle Corp.	155	08/03/18	USD	44.00	USD 683	(15,810)
Pfizer, Inc.	100	08/03/18	USD	36.50	USD 363	(6,050)
Suncor Energy, Inc.	7	08/03/18	USD	41.00	USD 28	(850)
Urban Outfitters, Inc.	250	08/03/18	USD	47.50	USD 1,114	(20,625)
Novo Nordisk A/S ADR	567	08/06/18	USD	45.01	USD 2,615	(111,182)
SunTrust Banks, Inc.	368	08/06/18	USD	68.30	USD 2,430	(40,062)
UnitedHealth Group, Inc.	107	08/09/18	USD	255.00	USD 2,625	(38,690)
Bank of America Corp.	516	08/10/18	USD	30.10	USD 1,455	(15,495)
Bank of America Corp.	305	08/10/18	USD	29.01	USD 860	(18,629)
Chevron Corp.	39	08/10/18	USD	128.00	USD 493	(11,622)
Comcast Corp., Class A	344	08/10/18	USD	33.50	USD 1,129	(39,904)
DowDuPont, Inc.	247	08/10/18	USD	66.00	USD 1,628	(57,428)
FirstEnergy Corp.	301	08/10/18	USD	33.75	USD 1,081	(71,285)
Flex Ltd.	379	08/10/18	USD	14.50	USD 535	(18,950)
General Electric Co.	118	08/10/18	USD	14.00	USD 161	(4,838)
Hartford Financial Services Group, Inc.	63	08/10/18	USD	52.00	USD 322	(7,497)
JPMorgan Chase & Co.	60	08/10/18	USD	108.25	USD 625	(9,219)
Lowe's Cos., Inc.	116	08/10/18	USD	98.50	USD 1,109	(17,284)
Marathon Oil Corp.	121	08/10/18	USD	21.50	USD 252	(11,192)
Microsoft Corp.	133	08/10/18	USD	102.00	USD 1,312	(24,871)
Oracle Corp.	551	08/10/18	USD	45.10	USD 2,428	(35,791)
PG&E Corp.	200	08/10/18	USD	44.00	USD 851	(52,000)
Pfizer, Inc.	385	08/10/18	USD	36.50	USD 1,397	(25,025)
U.S. Bancorp	191	08/10/18	USD	50.00	USD 955	(26,072)
Urban Outfitters, Inc.	251	08/10/18	USD	47.50	USD 1,118	(26,983)
Ally Financial, Inc.	348	08/17/18	USD	27.00	USD 914	(24,360)
Ally Financial, Inc.	120	08/17/18	USD	26.00	USD 315	(14,400)
Alphabet, Inc., Class A	39	08/17/18	USD	1,105.00	USD 4,404	(234,585)
Altria Group, Inc.	468	08/17/18	USD	59.20	USD 2,658	(48,271)
Apple, Inc.	352	08/17/18	USD	190.00	USD 6,516	(147,840)
BP PLC ADR	161	08/17/18	USD	46.00	USD 735	(19,964)
BP PLC ADR	82	08/17/18	USD	47.00	USD 374	(6,724)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Bank of America Corp.	274	08/17/18	USD	31.00	USD	772	(5,343)
Bank of America Corp.	305	08/17/18	USD	29.00	USD	860	(20,893)
Baxter International, Inc.	121	08/17/18	USD	72.50	USD	893	(36,300)
Biogen, Inc.	33	08/17/18	USD	300.00	USD	958	(28,875)
CVS Health Corp.	128	08/17/18	USD	72.50	USD	824	(5,952)
Chevron Corp.	50	08/17/18	USD	130.00	USD	632	(11,625)
Comcast Corp., Class A	501	08/17/18	USD	35.00	USD	1,644	(34,820)
D.R. Horton, Inc.	137	08/17/18	USD	43.00	USD	562	(14,454)
D.R. Horton, Inc.	274	08/17/18	USD	41.00	USD	1,123	(55,896)
Delta Air Lines, Inc.	169	08/17/18	USD	52.50	USD	837	(15,126)
DowDuPont, Inc.	34	08/17/18	USD	70.00	USD	224	(2,958)
DowDuPont, Inc.	70	08/17/18	USD	67.50	USD	461	(12,145)
E*Trade Financial Corp.	217	08/17/18	USD	63.75	USD	1,327	(29,719)
Flex Ltd.	557	08/17/18	USD	15.00	USD	786	(19,774)
Fortive Corp.	61	08/17/18	USD	76.01	USD	470	(23,071)
Freeport-McMoRan, Inc.	210	08/17/18	USD	17.00	USD	362	(25,935)
Freeport-McMoRan, Inc.	400	08/17/18	USD	18.00	USD	690	(31,800)
General Electric Co.	175	08/17/18	USD	15.00	USD	238	(2,887)
Gilead Sciences, Inc.	217	08/17/18	USD	75.00	USD	1,537	(29,512)
Hartford Financial Services Group, Inc.	63	08/17/18	USD	53.05	USD	322	(6,152)
Home Depot, Inc.	274	08/17/18	USD	200.00	USD	5,346	(104,120)
Humana, Inc.	68	08/17/18	USD	300.00	USD	2,024	(63,580)
J.M. Smucker Co.	264	08/17/18	USD	110.00	USD	2,837	(76,560)
JPMorgan Chase & Co.	204	08/17/18	USD	115.00	USD	2,126	(9,792)
KAR Auction Services, Inc.	269	08/17/18	USD	55.00	USD	1,474	(45,730)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Lowe's Cos., Inc.	281	08/17/18	USD 97.50	USD 2,686	\$ (59,572)
Marathon Oil Corp.	373	08/17/18	USD 22.00	USD 778	(30,027)
Marathon Oil Corp.	125	08/17/18	USD 23.00	USD 261	(6,437)
Microsoft Corp.	56	08/17/18	USD 105.00	USD 552	(6,272)
Oracle Corp.	275	08/17/18	USD 44.00	USD 1,212	(34,513)
Packaging Corp. of America	160	08/17/18	USD 120.00	USD 1,789	(20,800)
Pfizer, Inc.	100	08/17/18	USD 37.00	USD 363	(4,600)
SunTrust Banks, Inc.	97	08/17/18	USD 72.50	USD 640	(3,492)
Suncor Energy, Inc.	35	08/17/18	USD 41.00	USD 142	(5,075)
TOTAL SA ADR	42	08/17/18	USD 62.50	USD 254	(4,095)
U.S. Bancorp	194	08/17/18	USD 52.50	USD 970	(9,118)
Walmart Inc.	374	08/17/18	USD 85.00	USD 3,203	(108,460)
UnitedHealth Group, Inc.	107	08/20/18	USD 255.00	USD 2,625	(47,841)
					\$ (5,814,712)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
Allison Transmission Holdings, Inc.	Credit Suisse International	20,300	07/06/18	USD 43.10	USD 822	\$ (358)
SLM Corp.	Citibank N.A.	30,400	07/09/18	USD 11.42	USD 348	(7,273)
Suncor Energy, Inc.	Citibank N.A.	68,100	07/09/18	USD 38.95	USD 2,770	(128,037)
Amdocs Ltd. Laboratory Corp. of America Holdings	JPMorgan Chase Bank N.A.	23,500	07/10/18	USD 66.43	USD 1,555	(17,802)
Ally Financial, Inc.	UBS AG	21,000	07/10/18	USD 177.00	USD 3,770	(87,241)
	Citibank N.A.	24,000	07/11/18	USD 27.24	USD 630	(3,578)
	UBS AG	21,000	07/19/18	USD 177.00	USD 3,770	(107,192)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Laboratory Corp. of America Holdings Centene Corp.	Citibank N.A.	22,800	07/23/18	USD	118.90	USD	2,809	(146,941)
Regions Financial Corp.	Morgan Stanley & Co. International PLC	75,000	07/24/18	USD	19.58	USD	1,334	(8,423)
SLM Corp.	UBS AG	81,500	07/24/18	USD	12.01	USD	933	(12,623)
Novo Nordisk A/S ADR	Barclays Bank PLC	5,200	07/26/18	USD	45.41	USD	240	(7,887)
Rio Tinto PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/03/18	USD	58.75	USD	1,171	(12,758)
SLM Corp.	Morgan Stanley & Co. International PLC	97,500	08/07/18	USD	12.15	USD	1,116	(19,150)
Assured Guaranty Ltd.	Citibank N.A.	18,200	08/13/18	USD	36.51	USD	650	(11,926)
Amdocs Ltd.	JPMorgan Chase Bank N.A.	22,500	08/16/18	USD	67.10	USD	1,489	(27,933)
Regions Financial Corp.	JPMorgan Chase Bank N.A.	35,200	08/16/18	USD	19.45	USD	626	(7,458)
Rio Tinto PLC ADR	Morgan Stanley & Co. International PLC	21,100	08/20/18	USD	58.75	USD	1,171	(12,288)
Regions Financial Corp.	Morgan Stanley & Co. International PLC	35,100	08/27/18	USD	18.81	USD	624	(14,867)
FirstEnergy Corp.	JPMorgan Chase Bank N.A.	40,600	08/29/18	USD	36.65	USD	1,458	(28,791)
								\$ (662,526)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 2,911,349	\$ (1,320,973)	\$ (6,477,238)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Assets Derivative Financial Instruments							
Options purchased							
Investments at value unaffiliated ^(a)	\$	\$	\$ 1,605	\$	\$	\$	\$ 1,605
Liabilities Derivative Financial Instruments							
Options written							
Options written at value	\$	\$	\$ 6,477,238	\$	\$	\$	\$ 6,477,238

^(a) Includes options purchased at value as reported in the schedule of Investments.

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (2,570)	\$	\$	\$	\$ (2,570)
Options written			(4,323,450)				(4,323,450)
	\$	\$	\$ (4,326,020)	\$	\$	\$	\$ (4,326,020)

^(a) Options purchased are included in net realized gain (loss) from investments.

**Net Change in Unrealized Appreciation
(Depreciation) on:**

Options purchased	\$	\$	\$ 245	\$	\$	\$	\$ 245
Options written			3,616,469				3,616,469
	\$	\$	\$3,616,714	\$	\$	\$	\$3,616,714

(a) Options purchased are included in net change in unrealized appreciation (depreciation) from investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased	\$	803
Average value of option contracts written	\$	5,340,856

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments:		
Options	\$ 1,605 ^(a)	\$ 6,477,238
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(1,605)	(5,814,712)
Total derivative assets and liabilities subject to an MNA	\$	\$ 662,526

(a) Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

June 30, 2018

The following table presents the Trust's derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Barclays Bank PLC	\$ 7,887	\$	\$	\$	\$ 7,887
Citibank N.A.	297,755		(297,755)		
Credit Suisse International	358				358
JPMorgan Chase Bank N.A.	81,984				81,984
Morgan Stanley & Co. International PLC	67,486				67,486
UBS AG	207,056		(207,056)		
	\$ 662,526	\$	\$ (504,811)	\$	\$ 157,715

(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Long-Term Investments:				
Common Stocks ^(a)	\$ 749,987,496	\$	\$	\$ 749,987,496
Short-Term Securities	4,630,300			4,630,300
Options Purchased:				
Equity Contracts	1,605			1,605

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

	\$ 754,619,401	\$	\$	\$ 754,619,401
Derivative Financial Instruments ^(b)				
Liabilities:				
Equity contracts	\$ (4,690,612)	\$ (1,786,626)	\$	\$ (6,477,238)

^(a) See above Schedule of Investments for values in each industry.

^(b) Derivative financial instruments are options written, which are shown at value.

During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 100.2%		
Aerospace & Defense 1.1%		
Lockheed Martin Corp. ^(a)	20,920	\$ 6,180,396
Northrop Grumman Corp. ^(a)	46,090	14,181,893
		20,362,289
Banks 17.8%		
Bank of America Corp. ^{(a)(b)}	2,540,170	71,607,392
Citigroup, Inc. ^{(a)(b)}	983,479	65,814,415
JPMorgan Chase & Co. ^{(a)(b)}	696,148	72,538,622
KeyCorp ^(a)	501,280	9,795,011
SunTrust Banks, Inc. ^(a)	293,049	19,347,095
U.S. Bancorp ^(a)	479,743	23,996,745
Wells Fargo & Co. ^(a)	1,033,491	57,296,741
		320,396,021
Beverages 2.2%		
Diageo PLC	507,609	18,236,314
Dr. Pepper Snapple Group, Inc. ^(a)	84,850	10,351,700
PepsiCo, Inc. ^(a)	110,300	12,008,361
		40,596,375
Capital Markets 3.4%		
Charles Schwab Corp. ^(a)	170,420	8,708,462
Goldman Sachs Group, Inc. ^(a)	106,920	23,583,344
Morgan Stanley ^(a)	621,970	29,481,378
		61,773,184
Chemicals 1.2%		
DowDuPont, Inc. ^(a)	315,265	20,782,269
Communications Equipment 1.7%		
Cisco Systems, Inc. ^(a)	236,610	10,181,328
Motorola Solutions, Inc. ^(a)	171,600	19,969,092
		30,150,420
Construction Materials 0.8%		
CRH PLC	387,800	13,602,955
Containers & Packaging 0.4%		
International Paper Co. ^(a)	135,700	7,067,256
Diversified Financial Services 0.3%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

AXA Equitable Holdings, Inc. ^{(a)(c)}	273,200	5,630,652
Diversified Telecommunication Services 2.9%		
AT&T, Inc.	37,469	1,203,130
BCE, Inc. ^(a)	122,500	4,960,025
Verizon Communications, Inc. ^(a)	911,410	45,853,037
		52,016,192
Electric Utilities 3.8%		
Edison International ^(a)	80,393	5,086,465
FirstEnergy Corp. ^(a)	673,530	24,186,462
NextEra Energy, Inc. ^(a)	115,512	19,293,969
PG&E Corp. ^(a)	481,290	20,483,703
		69,050,599
Electrical Equipment 0.1%		
nVent Electric PLC ^(c)	109,190	2,740,669
Electronic Equipment, Instruments & Components 0.7%		
CDW Corp. ^(a)	161,890	13,079,093
Food & Staples Retailing 0.7%		
Kroger Co. ^(a)	436,290	12,412,451
Food Products 1.4%		
Danone SA	58,500	4,271,230
General Mills, Inc. ^(a)	193,760	8,575,817
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Food Products (continued)		
Kellogg Co. ^(a)	165,540	\$ 11,566,280
		24,413,327
Health Care Equipment & Supplies 3.1%		
Koninklijke Philips NV	716,440	30,354,090
Medtronic PLC ^(a)	301,650	25,824,257
		56,178,347
Health Care Providers & Services 8.7%		
Aetna, Inc. ^(a)	167,946	30,818,091
Anthem, Inc. ^(a)	205,890	49,007,997
Cardinal Health, Inc. ^(a)	169,200	8,262,036
CVS Health Corp. ^(a)	206,260	13,272,831
Humana, Inc. ^(a)	27,590	8,211,612
McKesson Corp. ^(a)	120,390	16,060,026
Quest Diagnostics, Inc. ^(a)	75,810	8,334,551
UnitedHealth Group, Inc. ^(a)	90,460	22,193,456
		156,160,600
Household Products 0.9%		
Procter & Gamble Co. ^(a)	209,320	16,339,519

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Industrial Conglomerates 3.0%		
3M Co. ^(a)	44,990	8,850,433
General Electric Co. ^(a)	1,710,590	23,281,130
Honeywell International, Inc. ^(a)	152,390	21,951,779
		54,083,342
Insurance 6.2%		
American International Group, Inc. ^(a)	681,330	36,124,116
Arthur J Gallagher & Co.	23,433	1,529,706
Brighthouse Financial, Inc. ^{(a)(c)}	44,511	1,783,556
Lincoln National Corp. ^(a)	46,320	2,883,420
Marsh & McLennan Cos., Inc. ^(a)	183,800	15,066,086
MetLife, Inc. ^(a)	798,253	34,803,831
Travelers Cos., Inc. ^(a)	165,150	20,204,451
		112,395,166
IT Services 0.4%		
Cognizant Technology Solutions Corp., Class A ^(a)	82,580	6,522,994
Leisure Products 0.5%		
Mattel, Inc. ^{(a)(d)}	586,956	9,637,818
Machinery 0.3%		
Pentair PLC ^(a)	109,190	4,594,715
Media 2.1%		
Comcast Corp., Class A ^(a)	895,110	29,368,559
Interpublic Group of Cos., Inc. ^(a)	397,970	9,328,417
		38,696,976
Multi-Utilities 1.3%		
Public Service Enterprise Group, Inc. ^(a)	437,430	23,682,460
Multiline Retail 0.3%		
Dollar General Corp. ^(a)	54,587	5,382,278
Oil, Gas & Consumable Fuels 13.0%		
Anadarko Petroleum Corp. ^(a)	51,700	3,787,025
BP PLC	5,057,210	38,477,869
Chevron Corp. ^(a)	118,260	14,951,612
Devon Energy Corp. ^(a)	536,160	23,569,594
Enterprise Products Partners LP ^(a)	758,400	20,984,928
Hess Corp. ^(a)	411,110	27,499,148
Marathon Oil Corp. ^(a)	169,820	3,542,445
Marathon Petroleum Corp. ^(a)	201,459	14,134,364
ONEOK, Inc. ^(a)	138,180	9,649,109
Royal Dutch Shell PLC ADR, Class A ^(a)	156,710	10,849,033
Suncor Energy, Inc. ^(a)	1,141,580	46,439,474

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Oil, Gas & Consumable Fuels (continued)		
TOTAL SA ADR ⁽¹⁾	211,897	\$ 12,832,482
Williams Cos., Inc. ^(a)	259,552	7,036,455
		233,753,538
Personal Products 0.8%		
Unilever NV NY Share ⁽³⁾	255,590	14,241,475
Pharmaceuticals 8.5%		
AstraZeneca PLC	480,846	33,258,762
Bayer AG, Registered Shares	107,845	11,843,916
Merck & Co., Inc. ^(a)	413,570	25,103,699
Novo Nordisk A/S ADR ⁽¹⁾	298,910	13,785,729
Pfizer, Inc. ^{(a)(b)}	1,911,740	69,357,927
		153,350,033
Professional Services 1.3%		
Experian PLC	530,780	13,093,606
Nielsen Holdings PLC ^(a)	343,020	10,609,609
		23,703,215
Road & Rail 0.7%		
Union Pacific Corp. ^(a)	83,780	11,869,950
Semiconductors & Semiconductor Equipment 1.8%		
QUALCOMM, Inc. ^(a)	418,240	23,471,629
Taiwan Semiconductor Manufacturing Co. Ltd. ADR ⁽¹⁾	237,560	8,685,193
		32,156,822
Software 5.9%		
Constellation Software, Inc.	14,240	11,043,542
Microsoft Corp. ^(a)	476,210	46,959,068
Oracle Corp. ^(a)	1,118,660	49,288,159
		107,290,769
Specialty Retail 0.7%		
Lowe's Cos., Inc. ^(a)	137,050	13,097,869
Technology Hardware, Storage & Peripherals 0.8%		
Lenovo Group Ltd.	13,220,000	7,115,799
Samsung Electronics Co. Ltd. GDR	7,819	8,109,582
		15,225,381
<i>Security</i>	<i>Shares</i>	<i>Value</i>

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Tobacco 1.4%			
Altria Group, Inc. ^(a)		340,020	\$ 19,309,736
Philip Morris International, Inc. ^(a)		69,830	5,638,074
			24,947,810
Total Long-Term Investments 100.2%			
(Cost \$1,400,287,297)			1,807,384,829
Short-Term Securities 0.8%			
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(e)(g)}		13,793,172	13,793,172
SL Liquidity Series, LLC, Money Market Series, 2.16% ^{(e)(f)(g)}		12,294	12,294
Total Short-Term Securities 0.8%			
(Cost \$13,805,466)			13,805,466
Options Purchased 0.0%			
(Cost \$3,195)			3,770
Total Investments Before Options Written 101.0%			
(Cost \$1,414,095,958)			1,821,194,065
Options Written (0.9)%			
(Premiums Received \$17,508,135)			(15,288,978)
Total Investments, Net of Options Written 100.1%			
(Cost \$1,396,587,823)			1,805,905,087
Liabilities in Excess of Other Assets (0.1)%			(1,936,617)
Net Assets 100.0%			\$ 1,803,968,470

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.

(c) Non-income producing security.

(d) Security, or a portion of the security, is on loan.

(e) Annualized 7-day yield as of period end.

(f) Security was purchased with the cash collateral from loaned securities.

(g) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Net Change Realized in Gain (Loss) Unrealized</i>
------------------	--------------------------------	---------------------	--------------------------------	--------------------------	---------------	--

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

						<i>Appreciation (Depreciation)</i>	
BlackRock Liquidity Funds, T-Fund, Institutional Class SL Liquidity Series, LLC, Money Market Series	4,967,189	8,825,983	13,793,172	\$ 13,793,172	\$ 67,095	\$	\$
		12,294	12,294	12,294	7 ^(b)		
				\$ 13,805,466	\$ 67,102	\$	\$

^(a) Includes net capital gain distributions, if applicable.

^(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust's industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Derivative Financial Instruments Outstanding as of Period End**Exchange-Traded Options Purchased**

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call General Electric Co.	754	07/13/18	USD 14.50	USD 1,026	\$ 3,770

Exchange-Traded Options Written

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call Bank of America Corp.	722	07/02/18	USD 31.35	USD 2,035	\$
Pfizer, Inc.	253	07/02/18	USD 36.25	USD 918	(5,028)
General Electric Co.	992	07/05/18	USD 14.75	USD 1,350	(511)
Aetna, Inc.	131	07/06/18	USD 232.50	USD 3,118	(84,168)
Bank of America Corp.	2,146	07/06/18	USD 30.50	USD 6,050	(3,219)
CVS Health Corp.	279	07/06/18	USD 66.00	USD 1,795	(8,509)
Charles Schwab Corp.	205	07/06/18	USD 59.00	USD 1,048	(1,025)
Citigroup, Inc.	351	07/06/18	USD 69.50	USD 2,349	(4,036)
Comcast Corp., Class A	224	07/06/18	USD 32.00	USD 735	(21,840)
Devon Energy Corp.	64	07/06/18	USD 43.50	USD 281	(6,656)
Devon Energy Corp.	72	07/06/18	USD 41.00	USD 317	(22,140)
DowDuPont, Inc.	56	07/06/18	USD 67.50	USD 369	(1,064)
General Electric Co.	177	07/06/18	USD 15.25	USD 241	(25)
General Electric Co.	339	07/06/18	USD 14.50	USD 461	(678)
Goldman Sachs Group, Inc.	162	07/06/18	USD 235.00	USD 3,573	(1,053)
Hess Corp.	655	07/06/18	USD 62.00	USD 4,381	(324,225)
Honeywell International, Inc.	113	07/06/18	USD 152.50	USD 1,628	(452)
Humana, Inc.	27	07/06/18	USD 297.50	USD 804	(9,112)
Marathon Oil Corp.	181	07/06/18	USD 82.00	USD 1,270	(5,792)
McKesson Corp.	108	07/06/18	USD 146.00	USD 1,441	(1,620)
MetLife, Inc.	570	07/06/18	USD 48.00	USD 2,485	(6,270)
Microsoft Corp.	492	07/06/18	USD 101.00	USD 4,852	(11,070)
Morgan Stanley	206	07/06/18	USD 54.00	USD 976	(1,648)
Morgan Stanley	136	07/06/18	USD 52.00	USD 645	(816)
Oracle Corp.	475	07/06/18	USD 48.00	USD 2,093	(950)
Pfizer, Inc.	514	07/06/18	USD 36.00	USD 1,865	(22,873)
Pfizer, Inc.	470	07/06/18	USD 36.50	USD 1,705	(6,110)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Pfizer, Inc.	176	07/06/18	USD	37.00	USD	639	(792)
QUALCOMM, Inc.	440	07/06/18	USD	60.00	USD	2,469	(3,740)
QUALCOMM, Inc.	605	07/06/18	USD	62.00	USD	3,395	(4,840)
Suncor Energy, Inc.	215	07/06/18	USD	40.00	USD	875	(20,102)
U.S. Bancorp	338	07/06/18	USD	52.50	USD	1,691	(676)
U.S. Bancorp	69	07/06/18	USD	53.00	USD	345	(690)
Union Pacific Corp.	188	07/06/18	USD	147.00	USD	2,664	(1,786)
Verizon Communications, Inc.	495	07/06/18	USD	49.00	USD	2,490	(72,270)
Wells Fargo & Co.	470	07/06/18	USD	55.50	USD	2,606	(28,905)
Wells Fargo & Co.	873	07/06/18	USD	55.00	USD	4,840	(79,007)
Williams Cos., Inc.	224	07/06/18	USD	27.50	USD	607	(2,800)
BCE, Inc.	251	07/09/18	USD	42.45	USD	1,016	(264)
Interpublic Group of Cos., Inc.	450	07/09/18	USD	23.20	USD	1,055	(25,440)
Novo Nordisk A/S ADR	451	07/09/18	USD	50.00	USD	2,080	(168)
Suncor Energy, Inc.	366	07/09/18	USD	38.40	USD	1,489	(87,819)
Pentair PLC	545	07/10/18	USD	46.51	USD	2,293	(96)
FirstEnergy Corp.	368	07/11/18	USD	34.01	USD	1,321	(72,964)
Altria Group, Inc.	253	07/13/18	USD	57.50	USD	1,437	(14,041)
American International Group, Inc.	719	07/13/18	USD	54.00	USD	3,812	(26,603)
Anthem, Inc.	217	07/13/18	USD	235.00	USD	5,165	(124,233)
Bank of America Corp.	987	07/13/18	USD	30.50	USD	2,782	(4,441)
Bank of America Corp.	484	07/13/18	USD	31.00	USD	1,364	(1,694)
Cisco Systems, Inc.	108	07/13/18	USD	45.00	USD	465	(648)
Citigroup, Inc.	186	07/13/18	USD	70.50	USD	1,245	(5,301)
Dollar General Corp.	354	07/13/18	USD	97.50	USD	3,490	(79,650)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
DowDuPont, Inc.	220	07/13/18	USD 67.00	USD 1,450	\$ (15,290)
DowDuPont, Inc.	136	07/13/18	USD 69.00	USD 897	(2,516)
FirstEnergy Corp.	239	07/13/18	USD 34.50	USD 858	(37,985)
Goldman Sachs Group, Inc.	93	07/13/18	USD 237.50	USD 2,051	(1,953)
JPMorgan Chase & Co.	679	07/13/18	USD 111.00	USD 7,075	(13,580)
KeyCorp	270	07/13/18	USD 20.50	USD 528	(2,160)
Kroger Co.	823	07/13/18	USD 25.00	USD 2,341	(288,050)
Marathon Petroleum Corp.	136	07/13/18	USD 78.00	USD 954	(1,020)
McKesson Corp.	65	07/13/18	USD 148.00	USD 867	(975)
Medtronic PLC	146	07/13/18	USD 88.50	USD 1,250	(1,606)
Microsoft Corp.	201	07/13/18	USD 103.00	USD 1,982	(4,824)
Microsoft Corp.	369	07/13/18	USD 102.00	USD 3,639	(14,760)
Morgan Stanley	225	07/13/18	USD 53.00	USD 1,067	(900)
Morgan Stanley	257	07/13/18	USD 54.00	USD 1,218	(5,654)
ONEOK, Inc.	138	07/13/18	USD 69.50	USD 964	(18,285)
Oracle Corp.	141	07/13/18	USD 49.00	USD 621	(282)
Oracle Corp.	961	07/13/18	USD 48.00	USD 4,234	(3,844)
PG&E Corp.	1,334	07/13/18	USD 42.50	USD 5,678	(323,495)
PepsiCo, Inc.	191	07/13/18	USD 102.00	USD 2,079	(137,520)
Pfizer, Inc.	704	07/13/18	USD 36.50	USD 2,554	(20,064)
Pfizer, Inc.	176	07/13/18	USD 37.00	USD 639	(1,936)
Procter & Gamble Co.	226	07/13/18	USD 74.00	USD 1,764	(97,745)
SunTrust Banks, Inc.	466	07/13/18	USD 70.00	USD 3,077	(6,966)
U.S. Bancorp	640	07/13/18	USD 50.50	USD 3,201	(31,040)
U.S. Bancorp	69	07/13/18	USD 52.50	USD 345	(379)
U.S. Bancorp	189	07/13/18	USD 51.00	USD 945	(5,575)
U.S. Bancorp	94	07/13/18	USD 51.50	USD 470	(1,598)
Wells Fargo & Co.	539	07/13/18	USD 56.50	USD 2,988	(36,113)
Williams Cos., Inc.	224	07/13/18	USD 27.00	USD 607	(11,312)
SunTrust Banks, Inc.	118	07/18/18	USD 70.50	USD 779	(2,287)
Wells Fargo & Co.	873	07/19/18	USD 56.25	USD 4,840	(83,303)
3M Co.	105	07/20/18	USD 200.00	USD 2,066	(23,258)
AXA Equitable Holdings, Inc.	437	07/20/18	USD 22.50	USD 901	(4,370)
Aetna, Inc.	218	07/20/18	USD 180.00	USD 4,000	(116,085)
Aetna, Inc.	415	07/20/18	USD 195.00	USD 7,615	(25,730)
Altria Group, Inc.	391	07/20/18	USD 57.50	USD 2,220	(32,062)
Anadarko Petroleum Corp.	129	07/20/18	USD 72.50	USD 945	(31,476)
Anthem, Inc.	144	07/20/18	USD 240.00	USD 3,428	(57,600)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Anthem, Inc.	262	07/20/18	USD	245.00	USD	6,236	(55,675)
Bank of America Corp.	1,190	07/20/18	USD	32.00	USD	3,355	(5,355)
Bank of America Corp.	822	07/20/18	USD	31.00	USD	2,317	(5,343)
Brighthouse Financial, Inc.	155	07/20/18	USD	50.00	USD	621	(1,550)
CDW Corp.	445	07/20/18	USD	80.00	USD	3,595	(109,025)
CVS Health Corp.	349	07/20/18	USD	72.50	USD	2,246	(5,060)
Charles Schwab Corp.	205	07/20/18	USD	60.00	USD	1,048	(1,025)
Chevron Corp.	425	07/20/18	USD	130.00	USD	5,373	(40,588)
Cisco Systems, Inc.	404	07/20/18	USD	45.00	USD	1,738	(5,656)
Cisco Systems, Inc.	336	07/20/18	USD	44.00	USD	1,446	(11,256)
Citigroup, Inc.	757	07/20/18	USD	72.50	USD	5,066	(12,490)
Cognizant Technology Solutions Corp., Class A	103	07/20/18	USD	77.50	USD	814	(25,235)
Cognizant Technology Solutions Corp., Class A	103	07/20/18	USD	80.00	USD	814	(10,300)
Comcast Corp., Class A	254	07/20/18	USD	33.01	USD	833	(22,436)
Comcast Corp., Class A	568	07/20/18	USD	32.50	USD	1,864	(63,332)
Devon Energy Corp.	182	07/20/18	USD	38.00	USD	800	(112,385)
Devon Energy Corp.	153	07/20/18	USD	44.00	USD	673	(22,874)
Devon Energy Corp.	99	07/20/18	USD	46.00	USD	435	(6,831)
DowDuPont, Inc.	244	07/20/18	USD	70.00	USD	1,608	(4,758)
DowDuPont, Inc.	108	07/20/18	USD	67.50	USD	712	(8,424)
Enterprise Products Partners LP	1,264	07/20/18	USD	29.00	USD	3,497	(12,640)
FirstEnergy Corp.	311	07/20/18	USD	35.00	USD	1,117	(38,098)
General Electric Co.	244	07/20/18	USD	15.00	USD	332	(1,586)
General Electric Co.	120	07/20/18	USD	13.50	USD	163	(6,000)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
General Mills, Inc.	301	07/20/18	USD 45.00	USD 1,332	\$ (14,147)
General Mills, Inc.	667	07/20/18	USD 47.50	USD 2,952	(6,336)
Goldman Sachs Group, Inc.	279	07/20/18	USD 240.00	USD 6,154	(14,508)
Hess Corp.	485	07/20/18	USD 65.00	USD 3,244	(155,200)
Honeywell International, Inc.	75	07/20/18	USD 149.00	USD 1,080	(7,275)
International Paper Co.	176	07/20/18	USD 57.50	USD 917	(1,056)
Interpublic Group of Cos., Inc.	770	07/20/18	USD 24.00	USD 1,805	(28,875)
JPMorgan Chase & Co.	516	07/20/18	USD 113.85	USD 5,377	(5,310)
JPMorgan Chase & Co.	218	07/20/18	USD 110.00	USD 2,272	(11,336)
Kellogg Co.	349	07/20/18	USD 65.00	USD 2,438	(184,970)
KeyCorp	387	07/20/18	USD 21.00	USD 756	(3,483)
Kroger Co.	1,005	07/20/18	USD 26.00	USD 2,859	(260,798)
Lincoln National Corp.	116	07/20/18	USD 72.50	USD 722	(812)
Lincoln National Corp.	115	07/20/18	USD 67.50	USD 716	(1,610)
Lowe's Cos., Inc.	46	07/20/18	USD 86.20	USD 440	(47,008)
Marathon Oil Corp.	419	07/20/18	USD 77.50	USD 2,940	(7,961)
Marathon Oil Corp.	269	07/20/18	USD 22.00	USD 561	(9,280)
Marsh & McLennan Cos., Inc.	596	07/20/18	USD 83.50	USD 4,885	(30,611)
Mattel, Inc.	144	07/20/18	USD 16.00	USD 236	(12,600)
Medtronic PLC	138	07/20/18	USD 87.50	USD 1,181	(6,141)
Medtronic PLC	147	07/20/18	USD 90.00	USD 1,258	(1,323)
Merck & Co., Inc.	339	07/20/18	USD 60.00	USD 2,058	(51,698)
Merck & Co., Inc.	537	07/20/18	USD 62.50	USD 3,260	(20,675)
MetLife, Inc.	248	07/20/18	USD 50.00	USD 1,081	(3,720)
Microsoft Corp.	238	07/20/18	USD 100.00	USD 2,347	(48,076)
Morgan Stanley	284	07/20/18	USD 53.15	USD 1,346	(2,317)
Motorola Solutions, Inc.	214	07/20/18	USD 110.00	USD 2,490	(150,335)
Motorola Solutions, Inc.	429	07/20/18	USD 115.00	USD 4,992	(126,555)
NextEra Energy, Inc.	247	07/20/18	USD 166.25	USD 4,126	(71,079)
NextEra Energy, Inc.	83	07/20/18	USD 165.00	USD 1,386	(29,880)
Nielsen Holdings PLC	570	07/20/18	USD 32.00	USD 1,763	(12,825)
Northrop Grumman Corp.	73	07/20/18	USD 340.00	USD 2,246	(1,460)
Novo Nordisk A/S ADR	352	07/20/18	USD 48.90	USD 1,623	(6,655)
ONEOK, Inc.	138	07/20/18	USD 70.00	USD 964	(17,940)
Oracle Corp.	818	07/20/18	USD 48.00	USD 3,604	(2,454)
Pepsico, Inc.	112	07/20/18	USD 102.95	USD 1,219	(69,128)
Pfizer, Inc.	821	07/20/18	USD 36.00	USD 2,979	(56,239)
Pfizer, Inc.	894	07/20/18	USD 35.00	USD 3,243	(132,312)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Pfizer, Inc.	736	07/20/18	USD	37.00	USD	2,670	(14,352)
Philip Morris International, Inc.	349	07/20/18	USD	85.00	USD	2,818	(22,685)
Procter & Gamble Co.	220	07/20/18	USD	76.00	USD	1,717	(55,000)
QUALCOMM, Inc.	605	07/20/18	USD	62.50	USD	3,395	(11,495)
Quest Diagnostics, Inc.	216	07/20/18	USD	106.90	USD	2,375	(81,583)
SunTrust Banks, Inc.	235	07/20/18	USD	70.00	USD	1,551	(6,815)
Suncor Energy, Inc.	534	07/20/18	USD	40.00	USD	2,172	(73,158)
TOTAL SA ADR	530	07/20/18	USD	62.50	USD	3,210	(18,550)
Taiwan Semiconductor Manufacturing Co. Ltd. ADR	1,030	07/20/18	USD	41.00	USD	3,766	(10,300)
Travelers Cos., Inc.	272	07/20/18	USD	135.00	USD	3,328	(2,720)
Travelers Cos., Inc.	276	07/20/18	USD	130.00	USD	3,377	(11,730)
U.S. Bancorp	189	07/20/18	USD	51.50	USD	945	(6,993)
Unilever NV NY Shares	639	07/20/18	USD	57.50	USD	3,561	(19,170)
Union Pacific Corp.	120	07/20/18	USD	150.00	USD	1,700	(7,500)
Verizon Communications, Inc.	477	07/20/18	USD	50.00	USD	2,400	(38,160)
Wells Fargo & Co.	540	07/20/18	USD	55.00	USD	2,994	(85,320)
Williams Cos., Inc.	369	07/20/18	USD	28.00	USD	1,000	(7,933)
FirstEnergy Corp.	238	07/24/18	USD	34.75	USD	855	(37,581)
Public Service Enterprise Group, Inc.	514	07/24/18	USD	52.01	USD	2,783	(119,901)
CDW Corp.	366	07/25/18	USD	79.65	USD	2,957	(105,402)
Nextera Energy, Inc.	247	07/25/18	USD	156.00	USD	4,126	(280,248)
Aetna, Inc.	150	07/27/18	USD	185.00	USD	2,753	(41,625)
American International Group, Inc.	289	07/27/18	USD	56.00	USD	1,532	(5,057)
Anthem, Inc.	131	07/27/18	USD	235.00	USD	3,118	(108,730)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Bank of America Corp.	823	07/27/18	USD 31.00	USD 2,320	\$ (7,818)
Cardinal Health, Inc.	303	07/27/18	USD 55.00	USD 1,480	(6,817)
Charles Schwab Corp.	196	07/27/18	USD 58.00	USD 1,002	(1,960)
Chevron Corp.	177	07/27/18	USD 127.00	USD 2,238	(49,560)
Cisco Systems, Inc.	215	07/27/18	USD 45.00	USD 925	(4,515)
Citigroup, Inc.	538	07/27/18	USD 70.00	USD 3,600	(37,391)
Citigroup, Inc.	139	07/27/18	USD 67.50	USD 930	(22,171)
Comcast Corp., Class A	241	07/27/18	USD 33.00	USD 791	(27,836)
Devon Energy Corp.	455	07/27/18	USD 44.00	USD 2,000	(79,625)
Devon Energy Corp.	99	07/27/18	USD 45.50	USD 435	(10,741)
Devon Energy Corp.	353	07/27/18	USD 45.00	USD 1,552	(45,361)
DowDuPont, Inc.	144	07/27/18	USD 72.00	USD 949	(1,656)
DowDuPont, Inc.	204	07/27/18	USD 67.50	USD 1,345	(20,298)
DowDuPont, Inc.	51	07/27/18	USD 66.50	USD 336	(7,344)
Enterprise Products Partners LP	1,264	07/27/18	USD 29.00	USD 3,497	(15,800)
General Electric Co.	1,316	07/27/18	USD 14.50	USD 1,791	(22,372)
General Electric Co.	122	07/27/18	USD 14.00	USD 166	(3,904)
Honeywell International, Inc.	460	07/27/18	USD 152.50	USD 6,626	(22,540)
International Paper Co.	149	07/27/18	USD 59.00	USD 776	(1,341)
JPMorgan Chase & Co.	473	07/27/18	USD 112.00	USD 4,929	(19,156)
KeyCorp	855	07/27/18	USD 21.50	USD 1,671	(11,970)
Lockheed Martin Corp.	52	07/27/18	USD 310.00	USD 1,536	(15,470)
Lowe's Cos., Inc.	150	07/27/18	USD 101.00	USD 1,434	(7,200)
Marathon Oil Corp.	269	07/27/18	USD 22.00	USD 561	(12,643)
Marsh & McLennan Cos., Inc.	598	07/27/18	USD 82.60	USD 4,902	(57,753)
Mattel, Inc.	1,479	07/27/18	USD 19.00	USD 2,429	(162,690)
Medtronic PLC	170	07/27/18	USD 86.50	USD 1,455	(16,830)
Merck & Co., Inc.	537	07/27/18	USD 63.50	USD 3,260	(25,239)
MetLife, Inc.	1,274	07/27/18	USD 48.00	USD 5,555	(14,014)
Microsoft Corp.	201	07/27/18	USD 103.00	USD 1,982	(22,713)
Microsoft Corp.	180	07/27/18	USD 101.00	USD 1,775	(32,850)
Morgan Stanley	731	07/27/18	USD 53.00	USD 3,465	(8,772)
Motorola Solutions, Inc.	215	07/27/18	USD 112.00	USD 2,502	(123,124)
ONEOK, Inc.	276	07/27/18	USD 70.00	USD 1,927	(42,780)
Oracle Corp.	278	07/27/18	USD 49.00	USD 1,225	(1,390)
PepsiCo, Inc.	248	07/27/18	USD 106.00	USD 2,700	(101,680)
Pfizer, Inc.	1,535	07/27/18	USD 37.00	USD 5,569	(41,445)
Pfizer, Inc.	299	07/27/18	USD 36.50	USD 1,085	(14,501)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Royal Dutch Shell PLC ADR, Class A	783	07/27/18	USD	71.00	USD	5,421	(62,640)
Suncor Energy, Inc.	2,098	07/27/18	USD	40.00	USD	8,535	(339,876)
U.S. Bancorp	241	07/27/18	USD	52.00	USD	1,205	(7,953)
Union Pacific Corp.	126	07/27/18	USD	146.00	USD	1,785	(24,759)
UnitedHealth Group, Inc.	173	07/27/18	USD	255.00	USD	4,244	(42,472)
Verizon Communications, Inc.	157	07/27/18	USD	50.00	USD	790	(16,720)
Verizon Communications, Inc.	675	07/27/18	USD	49.00	USD	3,396	(113,738)
Wells Fargo & Co.	245	07/27/18	USD	56.50	USD	1,358	(24,255)
Williams Cos., Inc.	251	07/27/18	USD	28.00	USD	680	(7,279)
Pfizer, Inc.	295	07/30/18	USD	36.75	USD	1,070	(12,902)
Pfizer, Inc.	591	07/30/18	USD	36.50	USD	2,144	(28,692)
Travelers Cos., Inc.	277	07/30/18	USD	133.00	USD	3,389	(10,994)
Bank of America Corp.	244	07/31/18	USD	30.25	USD	688	(5,115)
Cisco Systems, Inc.	337	07/31/18	USD	44.60	USD	1,450	(11,393)
FirstEnergy Corp.	366	07/31/18	USD	34.75	USD	1,314	(61,595)
Kellogg Co.	362	07/31/18	USD	67.00	USD	2,529	(150,416)
Altria Group, Inc.	423	08/03/18	USD	58.50	USD	2,402	(39,339)
Anthem, Inc.	144	08/03/18	USD	242.50	USD	3,428	(74,520)
Bank of America Corp.	912	08/03/18	USD	30.00	USD	2,571	(23,256)
Bank of America Corp.	274	08/03/18	USD	29.00	USD	772	(15,344)
Citigroup, Inc.	1,162	08/03/18	USD	68.50	USD	7,776	(165,585)
Comcast Corp., Class A	254	08/03/18	USD	34.00	USD	833	(21,336)
Devon Energy Corp.	507	08/03/18	USD	43.50	USD	2,229	(127,257)
General Electric Co.	461	08/03/18	USD	13.50	USD	627	(27,660)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
General Electric Co.	663	08/03/18	USD 15.00	USD 902	\$ (7,624)
International Paper Co.	176	08/03/18	USD 54.50	USD 917	(14,256)
JPMorgan Chase & Co.	305	08/03/18	USD 110.00	USD 3,178	(26,535)
JPMorgan Chase & Co.	217	08/03/18	USD 111.00	USD 2,261	(14,864)
Lowe's Cos., Inc.	139	08/03/18	USD 99.00	USD 1,328	(15,637)
Medtronic PLC	361	08/03/18	USD 86.50	USD 3,091	(43,140)
Microsoft Corp.	360	08/03/18	USD 102.00	USD 3,550	(59,940)
Morgan Stanley	161	08/03/18	USD 52.00	USD 763	(4,186)
Northrop Grumman Corp.	73	08/03/18	USD 317.50	USD 2,246	(43,070)
Oracle Corp.	493	08/03/18	USD 44.00	USD 2,172	(50,286)
Pfizer, Inc.	751	08/03/18	USD 36.50	USD 2,725	(45,436)
Procter & Gamble Co.	190	08/03/18	USD 78.50	USD 1,483	(26,125)
Suncor Energy, Inc.	727	08/03/18	USD 41.00	USD 2,957	(88,331)
Verizon Communications, Inc.	1,181	08/03/18	USD 50.00	USD 5,942	(137,587)
Wells Fargo & Co.	572	08/03/18	USD 55.00	USD 3,171	(103,246)
Novo Nordisk A/S ADR	339	08/06/18	USD 45.01	USD 1,563	(66,474)
SunTrust Banks, Inc.	528	08/06/18	USD 68.30	USD 3,486	(57,480)
UnitedHealth Group, Inc.	140	08/09/18	USD 255.00	USD 3,435	(50,622)
American International Group, Inc.	145	08/10/18	USD 55.00	USD 769	(12,832)
Anadarko Petroleum Corp.	129	08/10/18	USD 76.50	USD 945	(24,188)
Bank of America Corp.	989	08/10/18	USD 30.10	USD 2,788	(29,699)
Bank of America Corp.	1,142	08/10/18	USD 29.01	USD 3,219	(69,751)
CVS Health Corp.	283	08/10/18	USD 66.50	USD 1,821	(47,120)
Comcast Corp., Class A	587	08/10/18	USD 33.50	USD 1,926	(68,092)
Devon Energy Corp.	353	08/10/18	USD 46.00	USD 1,552	(54,892)
DowDuPont, Inc.	260	08/10/18	USD 66.00	USD 1,714	(60,450)
FirstEnergy Corp.	367	08/10/18	USD 33.75	USD 1,318	(86,915)
General Electric Co.	265	08/10/18	USD 14.00	USD 361	(10,865)
Hess Corp.	915	08/10/18	USD 70.50	USD 6,120	(161,955)
JPMorgan Chase & Co.	386	08/10/18	USD 108.25	USD 4,022	(59,311)
Mattel, Inc.	287	08/10/18	USD 17.00	USD 471	(25,113)
McKesson Corp.	124	08/10/18	USD 138.00	USD 1,654	(47,120)
Medtronic PLC	361	08/10/18	USD 87.00	USD 3,091	(42,598)
MetLife, Inc.	1,448	08/10/18	USD 44.00	USD 6,313	(187,516)
Microsoft Corp.	181	08/10/18	USD 102.00	USD 1,785	(33,847)
Morgan Stanley	806	08/10/18	USD 50.00	USD 3,820	(55,614)
Oracle Corp.	1,550	08/10/18	USD 45.10	USD 6,829	(100,682)
PG&E Corp.	350	08/10/18	USD 44.00	USD 1,490	(91,000)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Pfizer, Inc.	592	08/10/18	USD	36.50	USD	2,148	(38,480)
QUALCOMM, Inc.	441	08/10/18	USD	58.00	USD	2,475	(78,498)
U.S. Bancorp	1,006	08/10/18	USD	50.00	USD	5,032	(137,319)
Union Pacific Corp.	110	08/10/18	USD	142.00	USD	1,558	(47,300)
Verizon Communications, Inc.	620	08/10/18	USD	52.00	USD	3,119	(31,620)
Wells Fargo & Co.	483	08/10/18	USD	58.00	USD	2,678	(31,154)
3M Co.	119	08/17/18	USD	210.00	USD	2,341	(21,658)
AXA Equitable Holdings, Inc.	465	08/17/18	USD	22.50	USD	958	(11,625)
Altria Group, Inc.	633	08/17/18	USD	59.20	USD	3,595	(65,290)
American International Group, Inc.	1,231	08/17/18	USD	57.50	USD	6,527	(32,622)
Bank of America Corp.	823	08/17/18	USD	31.00	USD	2,320	(16,048)
Bank of America Corp.	1,142	08/17/18	USD	29.00	USD	3,219	(78,227)
CVS Health Corp.	120	08/17/18	USD	72.50	USD	772	(5,580)
Cardinal Health, Inc.	289	08/17/18	USD	55.00	USD	1,411	(17,340)
Charles Schwab Corp.	32	08/17/18	USD	55.00	USD	164	(2,160)
Chevron Corp.	166	08/17/18	USD	130.00	USD	2,099	(38,595)
Cisco Systems, Inc.	137	08/17/18	USD	44.00	USD	590	(14,248)
Citigroup, Inc.	309	08/17/18	USD	67.50	USD	2,068	(61,800)
Cognizant Technology Solutions Corp., Class A	206	08/17/18	USD	80.00	USD	1,627	(48,410)
Comcast Corp., Class A	1,004	08/17/18	USD	35.00	USD	3,294	(69,778)
Devon Energy Corp.	244	08/17/18	USD	42.00	USD	1,073	(90,890)
Devon Energy Corp.	99	08/17/18	USD	46.00	USD	435	(16,978)
DowDuPont, Inc.	51	08/17/18	USD	70.00	USD	336	(4,437)
DowDuPont, Inc.	102	08/17/18	USD	67.50	USD	672	(17,697)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Dr. Pepper Snapple Group, Inc.	424	08/17/18	USD 120.00	USD 5,173	\$ (125,080)
Enterprise Products Partners LP	1,264	08/17/18	USD 29.00	USD 3,497	(25,280)
FirstEnergy Corp.	468	08/17/18	USD 36.00	USD 1,681	(43,290)
General Electric Co.	406	08/17/18	USD 15.00	USD 553	(6,699)
Honeywell International, Inc.	113	08/17/18	USD 148.75	USD 1,628	(21,857)
Humana, Inc.	41	08/17/18	USD 300.00	USD 1,220	(38,335)
Humana, Inc.	69	08/17/18	USD 305.00	USD 2,054	(48,645)
International Paper Co.	177	08/17/18	USD 55.00	USD 922	(14,425)
Interpublic Group of Cos., Inc.	769	08/17/18	USD 24.00	USD 1,803	(61,520)
JPMorgan Chase & Co.	686	08/17/18	USD 115.00	USD 7,148	(32,928)
Kellogg Co.	116	08/17/18	USD 68.75	USD 810	(38,802)
KeyCorp	994	08/17/18	USD 20.45	USD 1,942	(36,752)
Kroger Co.	353	08/17/18	USD 30.00	USD 1,004	(16,414)
Lockheed Martin Corp.	52	08/17/18	USD 315.00	USD 1,536	(17,420)
Lowe's Cos., Inc.	144	08/17/18	USD 97.50	USD 1,376	(30,528)
Marathon Oil Corp.	42	08/17/18	USD 22.00	USD 88	(3,381)
Marathon Oil Corp.	269	08/17/18	USD 23.00	USD 561	(13,853)
Marathon Petroleum Corp.	271	08/17/18	USD 72.50	USD 1,901	(59,620)
Mattel, Inc.	144	08/17/18	USD 18.00	USD 236	(8,280)
McKesson Corp.	124	08/17/18	USD 140.00	USD 1,654	(38,750)
Medtronic PLC	186	08/17/18	USD 87.50	USD 1,592	(21,111)
Merck & Co., Inc.	335	08/17/18	USD 62.50	USD 2,033	(38,358)
Merck & Co., Inc.	537	08/17/18	USD 65.00	USD 3,260	(24,434)
MetLife, Inc.	451	08/17/18	USD 47.50	USD 1,966	(12,177)
Microsoft Corp.	159	08/17/18	USD 105.00	USD 1,568	(17,808)
Morgan Stanley	303	08/17/18	USD 51.75	USD 1,436	(12,875)
Northrop Grumman Corp.	84	08/17/18	USD 335.00	USD 2,585	(20,370)
ONEOK, Inc.	138	08/17/18	USD 70.00	USD 964	(27,255)
Oracle Corp.	877	08/17/18	USD 44.00	USD 3,864	(110,064)
Pfizer, Inc.	751	08/17/18	USD 37.00	USD 2,725	(34,546)
Procter & Gamble Co.	410	08/17/18	USD 77.50	USD 3,200	(87,535)
Quest Diagnostics, Inc.	216	08/17/18	USD 106.90	USD 2,375	(107,635)
SunTrust Banks, Inc.	118	08/17/18	USD 72.50	USD 779	(4,248)
Suncor Energy, Inc.	534	08/17/18	USD 41.00	USD 2,172	(77,430)
TOTAL SA ADR	530	08/17/18	USD 62.50	USD 3,210	(51,675)
Taiwan Semiconductor Manufacturing Co. Ltd. ADR	514	08/17/18	USD 39.50	USD 1,879	(20,770)
U.S. Bancorp	283	08/17/18	USD 52.50	USD 1,416	(13,301)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Unilever NV NY Shares	638	08/17/18	USD	55.00	USD	3,555	(108,460)
Verizon Communications, Inc.	952	08/17/18	USD	49.00	USD	4,790	(187,068)
Wells Fargo & Co.	572	08/17/18	USD	55.00	USD	3,171	(113,828)
Williams Cos., Inc.	251	08/17/18	USD	28.00	USD	680	(13,303)
UnitedHealth Group, Inc.	140	08/20/18	USD	255.00	USD	3,435	(62,596)
Public Service Enterprise Group, Inc.	421	08/22/18	USD	54.05	USD	2,279	(65,209)
Edison International	281	08/27/18	USD	63.25	USD	1,778	(59,496)

\$ (13,659,306)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
Suncor Energy, Inc.	Citibank N.A.	123,300	07/09/18	USD 38.95	USD 5,016	\$(231,820)
BP PLC	Goldman Sachs International	88,400	07/10/18	GBP 5.83	GBP 510	(6,593)
Bayer AG, Registered Shares	Credit Suisse International	19,917	07/10/18	EUR 102.39	EUR 1,873	(572)
Constellation Software, Inc.	Citibank N.A.	7,700	07/10/18	CAD 981.42	CAD 7,850	(240,823)
Diageo PLC	Goldman Sachs International	28,400	07/10/18	GBP 26.86	GBP 773	(22,641)
AstraZeneca PLC	Morgan Stanley & Co. International PLC	99,800	07/11/18	GBP 54.55	GBP 5,231	(14,525)
CRH PLC	UBS AG	72,500	07/11/18	GBP 28.27	GBP 1,927	(911)
Experian PLC	Credit Suisse International	121,000	07/11/18	GBP 19.04	GBP 2,261	(20,653)
Koninklijke Philips N.V.	Morgan Stanley & Co. International PLC	222,400	07/12/18	EUR 37.12	EUR 8,069	(62,386)
Lenovo Group Ltd.	UBS AG	3,306,000	07/12/18	HKD 3.96	HKD 13,951	(111,388)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>		<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued) Public Service Enterprise Group, Inc.	Bank of America N.A.	125,200	07/16/18	USD	53.44	USD 6,778	\$ (137,595)
BCE, Inc.	Barclays Bank PLC	36,100	07/17/18	USD	41.90	USD 1,462	(3,955)
AstraZeneca PLC	Goldman Sachs International	33,000	07/18/18	GBP	54.00	GBP 1,730	(14,138)
CRH PLC	Morgan Stanley & Co. International PLC	25,500	07/18/18	GBP	28.61	GBP 678	(577)
Danone SA	Credit Suisse International	29,300	07/18/18	EUR	65.87	EUR 1,832	(2,155)
Diageo PLC	Goldman Sachs International	56,350	07/18/18	GBP	27.45	GBP 1,534	(27,917)
Experian PLC	Goldman Sachs International	181,000	07/18/18	GBP	19.09	GBP 3,383	(40,311)
Diageo PLC	Goldman Sachs International	44,600	07/25/18	GBP	27.90	GBP 1,214	(14,539)
BP PLC	Citibank N.A.	1,175,000	07/26/18	GBP	5.96	GBP 6,780	(81,367)
CRH PLC	Citibank N.A.	36,000	07/26/18	GBP	29.14	GBP 957	(637)
Koninklijke Philips N.V.	Goldman Sachs International	135,800	07/26/18	EUR	37.04	EUR 4,927	(74,385)
Novo Nordisk A/S ADR	Barclays Bank PLC	35,200	07/26/18	USD	45.41	USD 1,623	(53,392)
BP PLC	Barclays Bank PLC	1,176,000	07/27/18	GBP	5.86	GBP 6,786	(147,117)
Bayer AG, Registered Shares	UBS AG	30,500	07/27/18	EUR	103.22	EUR 2,868	(7,642)
TOTAL SA ADR	Barclays Bank PLC	31,700	07/31/18	USD	61.39	USD 1,920	(35,273)
Samsung Electronics Co. Ltd. GDR	UBS AG	5,000	08/02/18	USD	1,158.42	USD 5,186	(34,431)
AstraZeneca PLC	Goldman Sachs International	35,500	08/08/18	GBP	52.35	GBP 1,861	(64,406)
BP PLC	Goldman Sachs International	89,200	08/08/18	GBP	5.85	GBP 515	(15,777)
Diageo PLC	Morgan Stanley & Co. International PLC	124,500	08/08/18	GBP	27.03	GBP 3,389	(136,100)
CRH PLC	UBS AG	59,900	08/09/18	GBP	28.20	GBP 1,592	(12,848)
Charles Schwab	Citibank N.A.	46,900	08/14/18	USD	57.40	USD 2,397	(12,798)

Corp.

\$ (1,629,672)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 6,136,175	\$ (3,917,018)	\$ (15,288,978)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Foreign Equity Contracts</i>	<i>Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Assets Derivative Financial Instruments							
Options purchased							
Investments at value unaffiliated ^(a)	\$	\$	\$ 3,770	\$	\$	\$	\$ 3,770
Liabilities Derivative Financial Instruments							
Options written							
Options written, at value	\$	\$	\$ 15,288,978	\$	\$	\$	\$ 15,288,978

^(a) Includes options purchased at value as reported in the Schedule of Investments.

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Foreign Equity Contracts</i>	<i>Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (10,020)	\$	\$	\$	\$ (10,020)
Options written			(9,659,803)				(9,659,803)

\$ \$ \$ (9,669,823) \$ \$ \$ \$ (9,669,823)

(a) Options purchased are included in net realized gain (loss) from investments.

SCHEDULES OF INVESTMENTS

47

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Foreign Equity Contracts</i>	<i>Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Change in Unrealized Appreciation on:							
Options purchased ^(a)	\$	\$	\$ 575	\$	\$	\$	\$ 575
Options written			6,323,305				6,323,305
	\$	\$	\$ 6,323,880	\$	\$	\$	\$ 6,323,880

^(a) Options purchased are included in net change in unrealized appreciation (depreciation) from investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased	\$ 3,218
Average value of option contracts written	\$ 13,467,680

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments – Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) were as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments:		
Options	\$ 3,770 ^(a)	\$ 15,288,978
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)	(3,770)	(13,659,306)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,629,672

^(a) Includes options purchased at value which is included in Investments at value unaffiliated in the Statements of Assets and Liabilities and reported in the Schedule of Investments.

The following table presents the Trust's derivative assets and liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral received and pledged by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Bank of America N.A.	\$ 137,595	\$	\$	\$	\$ 137,595
Barclays Bank PLC	239,737		(239,737)		
Citibank N.A.	567,445		(567,445)		
Credit Suisse International	23,380		(23,380)		
Goldman Sachs International	280,707		(242,630)		38,077
Morgan Stanley & Co. International PLC	213,588		(213,588)		
UBS AG	167,220		(167,220)		
	\$ 1,629,672	\$	\$ (1,454,000)	\$	\$ 175,672

^(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

^(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Equity Dividend Trust (BDJ)

June 30, 2018

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Aerospace & Defense	\$ 20,362,289	\$	\$	\$ 20,362,289
Banks	320,396,021			320,396,021
Beverages	22,360,061	18,236,314		40,596,375
Capital Markets	61,773,184			61,773,184
Chemicals	20,782,269			20,782,269
Communications Equipment	30,150,420			30,150,420
Construction Materials		13,602,955		13,602,955
Containers & Packaging	7,067,256			7,067,256
Diversified Financial Services	5,630,652			5,630,652
Diversified Telecommunication Services	52,016,192			52,016,192
Electric Utilities	69,050,599			69,050,599
Electrical Equipment	2,740,669			2,740,669
Electronic Equipment, Instruments & Components	13,079,093			13,079,093
Food & Staples Retailing	12,412,451			12,412,451
Food Products	20,142,097	4,271,230		24,413,327
Health Care Equipment & Supplies	25,824,257	30,354,090		56,178,347
Health Care Providers & Services	156,160,600			156,160,600
Household Products	16,339,519			16,339,519
IT Services	6,522,994			6,522,994
Industrial Conglomerates	54,083,342			54,083,342
Insurance	112,395,166			112,395,166
Leisure Products	9,637,818			9,637,818
Machinery	4,594,715			4,594,715
Media	38,696,976			38,696,976
Multi-Utilities	23,682,460			23,682,460
Multiline Retail	5,382,278			5,382,278
Oil, Gas & Consumable Fuels	195,275,669	38,477,869		233,753,538
Personal Products	14,241,475			14,241,475
Pharmaceuticals	108,247,355	45,102,678		153,350,033

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Professional Services	10,609,609	13,093,606		23,703,215
Road & Rail	11,869,950			11,869,950
Semiconductors & Semiconductor Equipment	32,156,822			32,156,822
Software	107,290,769			107,290,769
Specialty Retail	13,097,869			13,097,869
Technology Hardware, Storage & Peripherals		15,225,381		15,225,381
Tobacco	24,947,810			24,947,810
Short-Term Securities	13,793,172			13,793,172
Options Purchased: Equity Contracts	3,770			3,770
	\$ 1,642,817,648	\$ 178,364,123	\$	\$ 1,821,181,771
Investments Valued at NAV ^(a)				12,294
				\$ 1,821,194,065
Derivative Financial Instruments ^(b) Liabilities:				
Equity contracts	\$ (10,982,991)	\$ (4,305,987)	\$	\$ (15,288,978)

^(a) As of June 30, 2018, certain of the Trust's Investments were fair valued using net asset value (NAV) per share and have been excluded from the fair value hierarchy.

^(b) Derivative financial instruments are options written, which are shown at value. During the six months ended June 30, 2018, there were no transfers between levels.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 98.9%		
Australia 5.4%		
Ancor Ltd.	2,166,058	\$ 23,078,661
Ansell Ltd.	476,285	9,569,000
Ensogo Ltd. ^{(a)(b)}	418,198	3
Sonic Healthcare Ltd.	666,385	12,088,268
		44,735,932
Belgium 1.5%		
Anheuser-Busch InBev SA	60,431	6,095,366
bpost SA	373,254	5,897,538
		11,992,904
Canada 6.7%		
Rogers Communications, Inc., Class B	541,683	25,727,522
TELUS Corp.	815,027	28,952,011
		54,679,533
China 1.0%		
ANTA Sports Products Ltd.	1,514,000	7,983,785
Denmark 1.0%		
Novo Nordisk A/S, Class B	186,453	8,612,368
Finland 2.3%		
Kone OYJ, Class B	368,057	18,714,053
France 4.4%		
Sanofi	334,985	26,885,729
Schneider Electric SE	111,650	9,285,566
		36,171,295
Germany 2.2%		
Deutsche Post AG, Registered Shares	545,851	17,734,889
India 1.0%		
Hero MotoCorp Ltd.	167,596	8,497,945
Ireland 1.5%		
Medtronic PLC ^(c)	143,502	12,285,206
Japan 1.0%		
Japan Tobacco, Inc.	310,500	8,677,361

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Netherlands 2.6%		
Heineken NV	111,338	11,154,782
Koninklijke Philips NV	237,749	10,072,937
		21,227,719
Singapore 2.7%		
DBS Group Holdings Ltd.	575,568	11,193,081
United Overseas Bank Ltd.	557,900	10,934,131
		22,127,212
Sweden 1.3%		
Svenska Handelsbanken AB, Class A	937,035	10,378,079
Switzerland 7.8%		
Nestle SA, Registered Shares	305,978	23,713,541
Novartis AG, Registered Shares	347,751	26,342,460
SGS SA, Registered Shares	5,218	13,865,236
		63,921,237
Taiwan 2.4%		
Far EastTone Telecommunications Co. Ltd.	2,705,000	6,987,454
Taiwan Semiconductor Manufacturing Co. Ltd.	1,796,000	12,753,528
		19,740,982
United Kingdom 14.4%		
AstraZeneca PLC	241,470	16,701,799
British American Tobacco PLC	447,851	22,559,764
Diageo PLC	384,545	13,815,128
<i>Security</i>	<i>Shares</i>	<i>Value</i>
United Kingdom (continued)		
GlaxoSmithKline PLC	910,852	\$ 18,363,626
Imperial Brands PLC	626,898	23,281,806
Unilever PLC	427,866	23,635,512
		118,357,635
United States 39.7%		
3M Co. ^(c)	75,958	14,942,458
AbbVie, Inc. ^(c)	95,833	8,878,927
Altria Group, Inc. ^{(c)(d)}	491,905	27,935,285
Cisco Systems, Inc. ^{(c)(d)}	573,725	24,687,387
Citizens Financial Group, Inc. ^(c)	167,555	6,517,889
Coca-Cola Co. ^(c)	589,989	25,876,943
FirstSun Capital Bancorp, (Acquired 3/10/14, cost \$5,461,692) ^{(a)(e)}	120,312	4,411,841
Genuine Parts Co. ^(c)	242,320	22,242,553
International Paper Co. ^(c)	303,694	15,816,384
Johnson & Johnson ^{(c)(d)}	250,145	30,352,594
M&T Bank Corp. ^(c)	69,614	11,844,822
Microsoft Corp. ^(c)	84,489	8,331,460
PepsiCo, Inc. ^(c)	199,047	21,670,247
Pfizer, Inc. ^{(c)(d)}	463,707	16,823,290

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Philip Morris International, Inc. ^{(c)(d)}	219,915	17,755,937
Procter & Gamble Co. ^(c)	220,742	17,231,121
U.S. Bancorp ^(c)	249,836	12,496,797
United Parcel Service, Inc., Class B ^(c)	76,232	8,098,125
United Technologies Corp. ^(c)	138,181	17,276,770
Wells Fargo & Co. ^(c)	228,446	12,665,046
		325,855,876
Total Common Stocks 98.9% (Cost \$840,788,043)		811,694,011
Preferred Stocks 1.0%		
India 0.1%		
Jasper Infotech Private Ltd., Series F, (Acquired 05/07/14, cost 1,895,230), 0.00% ^{(a)(b)(e)}	266	465,324
Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost 741,913), 0.00% ^{(a)(b)(e)}	88	187,962
		653,286
United States 0.9%		
Palantir Technologies, Inc., Series I (Acquired 3/27/14, cost \$3,118,944), 0.00% ^{(a)(b)(e)}	508,800	2,940,864
Uber Technologies, Inc., Series D (Acquired 06/01/14, cost \$1,611,693), 0.00% ^{(a)(b)(e)}	103,893	4,155,720
		7,096,584
Total Preferred Stocks 1.0% (Cost \$7,367,781)		7,749,870
Total Long-Term Investments 99.9% (Cost \$848,155,824)		819,443,881
Total Investments Before Options Written 99.9% (Cost \$848,155,824)		819,443,881
Options Written (0.8)% (Premiums Received \$6,227,625)		(6,213,872)
Total Investments, Net of Options Written 99.1% (Cost \$841,928,199)		813,230,009
Other Assets Less Liabilities 0.9%		7,377,581
Net Assets 100.0%		\$ 820,607,590

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

- (a) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (b) Non-income producing security.
- (c) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (d) All or a portion of security has been pledged as collateral in connection with outstanding OTC derivatives.
- (e) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$12,167,736 and an original cost of \$7,367,780, which was 1.5% of its net assets.

During the year ended December 31, 2017, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

Affiliate	Shares Held at 12/31/17	Net Activity	Shares Held		Value at 06/30/18	Income Gain (Loss)	Change in Net Unrealized Appreciation (Depreciation)	
			at 06/30/18	at 06/30/18				
BlackRock Liquidity Funds, T-Fund, Institutional Class ^(a)	13,118,524	(13,118,524)			\$	\$ 56,205	\$	\$

(a) No longer held by the Trust.

(b) Includes net capital gain distributions, if applicable.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Description	Number of Contracts	Expiration Date	Exercise Price	Notional Amount (000)	Value
Call					
Pfizer, Inc.	18	07/02/18	USD 36.25	USD 65	\$ (358)
Cisco Systems, Inc.	314	07/06/18	USD 44.50	USD 1,351	(785)
Coca-Cola Co.	556	07/06/18	USD 44.00	USD 2,439	(12,788)
Genuine Parts Co.	151	07/06/18	USD 93.00	USD 1,386	(5,285)
International Paper Co.	181	07/06/18	USD 55.00	USD 943	(1,267)
International Paper Co.	93	07/06/18	USD 56.00	USD 484	(372)
Johnson & Johnson	344	07/06/18	USD 122.00	USD 4,174	(24,252)
Pfizer, Inc.	19	07/06/18	USD 36.00	USD 69	(845)
Pfizer, Inc.	104	07/06/18	USD 36.50	USD 377	(1,352)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Pfizer, Inc.	38	07/06/18	USD	37.00	USD	138	(171)
U.S. Bancorp	245	07/06/18	USD	52.50	USD	1,225	(490)
U.S. Bancorp	34	07/06/18	USD	53.00	USD	170	(340)
United Technologies Corp.	245	07/06/18	USD	128.00	USD	3,063	(3,675)
Wells Fargo & Co.	103	07/06/18	USD	55.50	USD	571	(6,334)
Wells Fargo & Co.	175	07/06/18	USD	55.00	USD	970	(15,838)
Altria Group, Inc.	478	07/13/18	USD	57.50	USD	2,715	(26,529)
Cisco Systems, Inc.	598	07/13/18	USD	45.00	USD	2,573	(3,588)
Coca-Cola Co.	158	07/13/18	USD	44.00	USD	693	(6,320)
Genuine Parts Co.	180	07/13/18	USD	92.00	USD	1,652	(23,400)
Genuine Parts Co.	163	07/13/18	USD	95.50	USD	1,496	(2,852)
International Paper Co.	181	07/13/18	USD	55.50	USD	943	(1,900)
Medtronic PLC	110	07/13/18	USD	88.50	USD	942	(1,210)
Microsoft Corp.	76	07/13/18	USD	103.00	USD	749	(1,824)
Microsoft Corp.	82	07/13/18	USD	102.00	USD	809	(3,280)
PepsiCo, Inc.	6	07/13/18	USD	102.00	USD	65	(4,320)
Pfizer, Inc.	156	07/13/18	USD	36.50	USD	566	(4,446)
Pfizer, Inc.	39	07/13/18	USD	37.00	USD	141	(429)
Procter & Gamble Co.	306	07/13/18	USD	74.00	USD	2,389	(132,345)
U.S. Bancorp	101	07/13/18	USD	50.50	USD	505	(4,898)
U.S. Bancorp	34	07/13/18	USD	52.50	USD	170	(187)
U.S. Bancorp	147	07/13/18	USD	51.00	USD	735	(4,336)
U.S. Bancorp	73	07/13/18	USD	51.50	USD	365	(1,241)
Wells Fargo & Co.	93	07/13/18	USD	56.50	USD	516	(6,231)
Wells Fargo & Co.	175	07/19/18	USD	56.25	USD	970	(16,699)
3M Co.	234	07/20/18	USD	200.00	USD	4,603	(51,831)
AbbVie, Inc.	67	07/20/18	USD	100.00	USD	621	(1,440)
Altria Group, Inc.	620	07/20/18	USD	57.50	USD	3,521	(50,840)
Cisco Systems, Inc.	811	07/20/18	USD	45.00	USD	3,490	(11,354)
Cisco Systems, Inc.	361	07/20/18	USD	44.00	USD	1,553	(12,094)
Citizens Financial Group, Inc.	507	07/20/18	USD	42.95	USD	1,972	(3,791)
Coca-Cola Co.	557	07/20/18	USD	44.00	USD	2,443	(28,686)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Genuine Parts Co.	151	07/20/18	USD 92.50	USD 1,386	\$ (26,803)
Genuine Parts Co.	163	07/20/18	USD 97.50	USD 1,496	(4,482)
International Paper Co.	153	07/20/18	USD 57.50	USD 797	(918)
Johnson & Johnson	286	07/20/18	USD 125.00	USD 3,470	(24,310)
M&T Bank Corp.	164	07/20/18	USD 190.00	USD 2,790	(2,460)
M&T Bank Corp.	163	07/20/18	USD 180.00	USD 2,773	(11,410)
Medtronic PLC	167	07/20/18	USD 87.50	USD 1,430	(7,432)
Microsoft Corp.	88	07/20/18	USD 100.00	USD 868	(17,776)
PepsiCo, Inc.	225	07/20/18	USD 102.95	USD 2,450	(138,873)
Pfizer, Inc.	612	07/20/18	USD 36.00	USD 2,220	(41,922)
Pfizer, Inc.	253	07/20/18	USD 35.00	USD 918	(37,444)
Pfizer, Inc.	158	07/20/18	USD 37.00	USD 573	(3,081)
Philip Morris International, Inc.	316	07/20/18	USD 85.00	USD 2,551	(20,540)
Procter & Gamble Co.	57	07/20/18	USD 76.00	USD 445	(14,250)
Rogers Communications, Inc., Class B	247	07/20/18	CAD 62.00	CAD 1,542	(21,794)
TELUS Corp.	127	07/20/18	CAD 46.00	CAD 584	(9,322)
U.S. Bancorp	146	07/20/18	USD 51.50	USD 730	(5,402)
United Parcel Service, Inc.	57	07/20/18	USD 120.00	USD 606	(256)
Wells Fargo & Co.	93	07/20/18	USD 55.00	USD 516	(14,694)
3M Co.	34	07/27/18	USD 200.00	USD 669	(12,835)
AbbVie, Inc.	158	07/27/18	USD 102.00	USD 1,464	(4,582)
Cisco Systems, Inc.	998	07/27/18	USD 45.00	USD 4,294	(20,958)
Coca-Cola Co.	751	07/27/18	USD 44.50	USD 3,294	(39,803)
International Paper Co.	66	07/27/18	USD 59.00	USD 344	(594)
Medtronic PLC	177	07/27/18	USD 86.50	USD 1,515	(17,523)
Microsoft Corp.	76	07/27/18	USD 103.00	USD 749	(8,588)
Microsoft Corp.	55	07/27/18	USD 101.00	USD 542	(10,038)
PepsiCo, Inc.	223	07/27/18	USD 106.00	USD 2,428	(91,430)
Pfizer, Inc.	320	07/27/18	USD 37.00	USD 1,161	(8,640)
Pfizer, Inc.	26	07/27/18	USD 36.50	USD 94	(1,261)
U.S. Bancorp	77	07/27/18	USD 52.00	USD 385	(2,541)
United Parcel Service, Inc., Class B	301	07/27/18	USD 118.00	USD 3,198	(7,374)
United Technologies Corp.	112	07/27/18	USD 128.00	USD 1,400	(16,800)
Wells Fargo & Co.	42	07/27/18	USD 56.50	USD 233	(4,158)
Pfizer, Inc.	25	07/30/18	USD 36.75	USD 91	(1,093)
Pfizer, Inc.	54	07/30/18	USD 36.50	USD 196	(2,622)
Cisco Systems, Inc.	360	07/31/18	USD 44.60	USD 1,549	(12,170)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

AbbVie, Inc.	67	08/03/18	USD	95.50	USD	621	(12,596)
Altria Group, Inc.	3	08/03/18	USD	58.50	USD	17	(279)
International Paper Co.	400	08/03/18	USD	54.50	USD	2,083	(32,400)
Johnson & Johnson	122	08/03/18	USD	126.00	USD	1,480	(12,566)
Medtronic PLC	110	08/03/18	USD	86.50	USD	942	(13,145)
Microsoft Corp.	45	08/03/18	USD	102.00	USD	444	(7,493)
Pfizer, Inc.	151	08/03/18	USD	36.50	USD	548	(9,136)
Procter & Gamble Co.	216	08/03/18	USD	78.50	USD	1,686	(29,700)
Wells Fargo & Co.	150	08/03/18	USD	55.00	USD	832	(27,075)
Genuine Parts Co.	152	08/10/18	USD	93.00	USD	1,395	(25,840)
Medtronic PLC	110	08/10/18	USD	87.00	USD	942	(12,980)
Microsoft Corp.	55	08/10/18	USD	102.00	USD	542	(10,285)
Pfizer, Inc.	54	08/10/18	USD	36.50	USD	196	(3,510)
U.S. Bancorp	97	08/10/18	USD	50.00	USD	485	(13,241)
Wells Fargo & Co.	92	08/10/18	USD	58.00	USD	510	(5,934)
3M Co.	89	08/17/18	USD	210.00	USD	1,751	(16,198)
AbbVie, Inc.	158	08/17/18	USD	105.00	USD	1,464	(8,058)
Altria Group, Inc.	620	08/17/18	USD	59.20	USD	3,521	(63,949)
Coca-Cola Co.	750	08/17/18	USD	45.00	USD	3,290	(38,250)
Genuine Parts Co.	178	08/17/18	USD	95.00	USD	1,634	(28,035)
International Paper Co.	353	08/17/18	USD	55.00	USD	1,838	(28,770)
Johnson & Johnson	123	08/17/18	USD	125.00	USD	1,492	(22,017)
Microsoft Corp.	29	08/17/18	USD	105.00	USD	286	(3,248)
PepsiCo, Inc.	481	08/17/18	USD	105.00	USD	5,237	(263,348)
Pfizer, Inc.	152	08/17/18	USD	37.00	USD	551	(6,992)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Philip Morris International, Inc.	534	08/17/18	USD 82.50	USD 4,312	\$ (113,742)
Procter & Gamble Co.	458	08/17/18	USD 77.50	USD 3,575	(97,783)
Rogers Communications, Inc., Class B	750	08/17/18	CAD 64.00	CAD 4,683	(38,794)
TELUS Corp.	666	08/17/18	CAD 46.00	CAD 3,110	(65,605)
U.S. Bancorp	220	08/17/18	USD 52.50	USD 1,100	(10,340)
United Technologies Corp.	126	08/17/18	USD 125.00	USD 1,575	(46,305)
Wells Fargo & Co.	150	08/17/18	USD 55.00	USD 832	(29,850)
					\$ (2,243,866)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
TELUS Corp.	Goldman Sachs International	7,641	07/09/18	CAD 46.27	CAD 357	\$ (3,616)
BS Group Holdings Ltd.	Deutsche Bank AG	68,000	07/10/18	SGD 29.99	SGD 1,802	(42,000)
BS Group Holdings Ltd.	Deutsche Bank AG	67,000	07/10/18	SGD 29.91	SGD 1,776	(49,000)
Diageo PLC	Goldman Sachs International	12,800	07/10/18	GBP 26.86	GBP 348	(10,204)
Car EasTone Telecommunications Co. Ltd.	Goldman Sachs International	136,000	07/10/18	USD 75.75	USD 10,711	(13,329)
Heineken NV	UBS AG	24,000	07/10/18	EUR 86.63	EUR 2,059	(18,269)
GS SA, Registered Shares	Goldman Sachs International	1,300	07/10/18	CHF 2,577.54	CHF 3,421	(92,472)
Schneider Electric	UBS AG	22,000	07/10/18	EUR 79.66	EUR 1,567	(131,000)
Post SA	Credit Suisse International	15,800	07/10/18	EUR 17.43	EUR 214	(9,000)
AstraZeneca PLC	UBS AG	69,200	07/11/18	GBP 55.20	GBP 3,627	(4,820)
Deutsche Post AG, Registered Shares	Goldman Sachs International	128,000	07/11/18	EUR 33.57	EUR 3,561	(37,000)
Car EasTone Telecommunications	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD 77.89	USD 17,170	(8,820)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

o. Ltd.								
oninklijke Philips	Morgan Stanley & Co. International PLC	112,000	07/11/18	EUR	36.27	EUR	4,063	(73,730)
V								
ovo Nordisk A/S,	Goldman Sachs International	26,100	07/11/18	DKK	306.74	DKK	7,691	(3,329)
lass B								
ogers								
ommunications,								
nc., Class B	Morgan Stanley & Co. International PLC	44,000	07/11/18	CAD	63.00	CAD	2,747	(15,666)
nsell Ltd.	JPMorgan Chase Bank N.A.	24,200	07/12/18	AUD	26.93	AUD	657	(8,916)
ritish American								
obacco PLC	Citibank N.A.	210,900	07/12/18	GBP	39.09	GBP	8,050	(97,123)
pan Tobacco, Inc.	Goldman Sachs International	41,200	07/12/18	JPY	3,040.60	JPY	127,477	(30,331)
one OYJ, Class B	UBS AG	38,800	07/12/18	EUR	43.39	EUR	1,689	(38,679)
ELUS Corp.	Citibank N.A.	32,400	07/13/18	CAD	46.34	CAD	1,513	(16,442)
ncor Ltd.	Goldman Sachs International	256,000	07/18/18	AUD	13.88	AUD	3,686	(109,795)
nheuser-Busch								
Bev SA	Morgan Stanley & Co. International PLC	28,500	07/18/18	EUR	83.88	EUR	2,462	(101,994)
nsell Ltd.	Goldman Sachs International	27,000	07/18/18	AUD	26.80	AUD	733	(12,577)
eutsche Post AG,								
egistered Shares	Credit Suisse International	64,000	07/18/18	EUR	33.48	EUR	1,780	(614)
ar EasTone								
elecommunications								
o. Ltd.	Goldman Sachs International	370,000	07/18/18	USD	77.13	USD	29,141	(22,892)
perial Brands PLC	HSBC Bank PLC	65,400	07/18/18	GBP	26.85	GBP	1,840	(126,258)
one OYJ, Class B	Credit Suisse International	46,000	07/18/18	EUR	43.47	EUR	2,003	(51,419)
anofi	Morgan Stanley & Co. International PLC	28,150	07/18/18	EUR	65.82	EUR	1,935	(108,851)
chneider Electric								
E	Barclays Bank PLC	8,500	07/18/18	EUR	76.74	EUR	605	(699)
ELUS Corp.	Citibank N.A.	16,700	07/18/18	CAD	45.85	CAD	780	(13,682)
nited Overseas								
ank Ltd.	JPMorgan Chase Bank N.A.	139,000	07/18/18	SGD	28.67	SGD	3,711	(4,316)
ost SA	Credit Suisse International	42,000	07/18/18	EUR	15.21	EUR	568	(748)
NTA Sports								
roducts Ltd.	Goldman Sachs International	206,000	07/19/18	HKD	44.78	HKD	8,522	(16,373)
ovartis AG,								
egistered Shares	Morgan Stanley & Co. International PLC	106,400	07/19/18	CHF	76.10	CHF	7,982	(79,253)
onic Healthcare								
td.	UBS AG	68,700	07/24/18	AUD	23.80	AUD	1,684	(45,937)
nited Overseas								
ank Ltd.	UBS AG	123,300	07/24/18	SGD	29.32	SGD	3,292	(2,207)
NTA Sports								
roducts Ltd.	UBS AG	295,000	07/25/18	HKD	49.34	HKD	12,204	(6,819)
nsell Ltd.	Morgan Stanley & Co. International PLC	33,500	07/25/18	AUD	26.66	AUD	910	(20,674)
iageo PLC	Goldman Sachs International	68,800	07/25/18	GBP	27.90	GBP	1,873	(22,428)
laxoSmithKline								
LC	Citibank N.A.	99,900	07/25/18	GBP	15.50	GBP	1,526	(23,619)
eineken NV	Deutsche Bank AG	28,300	07/25/18	EUR	87.76	EUR	2,428	(24,416)
one OYJ, Class B	UBS AG	12,000	07/25/18	EUR	42.77	EUR	522	(20,691)
estle SA,								
egistered Shares	Morgan Stanley & Co. International PLC	73,000	07/25/18	CHF	76.40	CHF	5,603	(96,268)
	UBS AG	61,600	07/25/18	DKK	308.50	DKK	18,153	(17,246)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Novo Nordisk A/S, Class B Anofi	UBS AG	58,100	07/25/18	EUR	67.27	EUR	3,993	(153,582)
Genomic Healthcare Ltd.	UBS AG	60,300	07/25/18	AUD	24.52	AUD	1,478	(21,816)
Svenska Handelsbanken AB, Class A	UBS AG	206,500	07/25/18	SEK	101.02	SEK	20,485	(35,170)

SCHEDULES OF INVESTMENTS

53

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

OTC Options Written (continued)

Description	Counterparty	Number of Expiration		Exercise Price	Notional Amount (000)	Valuation
		Contracts	Date			
LL (continued)						
ELUS Corp.	Citibank N.A.	29,200	07/25/18	CAD 46.49	CAD 1,364	\$ (15,35)
Microchip Technology Inc.	UBS AG	844,000	07/25/18	USD 228.60	USD 182,726	(29,47)
Post SA	Deutsche Bank AG	24,200	07/25/18	EUR 16.07	EUR 327	(44)
ANTA Sports						
Products Ltd.	JPMorgan Chase Bank N.A.	192,000	07/26/18	HKD 50.34	HKD 7,943	(2,94)
Incubor Ltd.	UBS AG	398,100	07/26/18	AUD 14.13	AUD 5,733	(126,21)
Resell Ltd.	Morgan Stanley & Co. International PLC	31,200	07/26/18	AUD 27.05	AUD 847	(13,32)
Eastone						
Telecommunications						
Resell Ltd.	Citibank N.A.	297,000	07/26/18	USD 78.15	USD 23,392	(13,29)
Eastone						
Telecommunications						
Resell Ltd.	Goldman Sachs International	250,000	07/26/18	USD 78.76	USD 19,690	(8,65)
Novartis AG,						
Registered Shares	Morgan Stanley & Co. International PLC	18,250	07/26/18	CHF 75.85	CHF 1,369	(18,18)
Pilever PLC	Citibank N.A.	141,100	07/26/18	GBP 41.71	GBP 5,906	(174,67)
ELUS Corp.	Goldman Sachs International	24,300	07/27/18	CAD 46.23	CAD 1,135	(16,40)
ELUS Corp.	Goldman Sachs International	24,300	07/31/18	CAD 46.46	CAD 1,135	(14,33)
Resell Ltd.	Citibank N.A.	32,000	08/01/18	AUD 26.57	AUD 869	(24,55)
Deutsche Post AG,						
Registered Shares	HSBC Bank PLC	64,500	08/01/18	EUR 28.30	EUR 1,794	(46,69)
One OYJ, Class B	Credit Suisse International	46,000	08/01/18	EUR 43.47	EUR 2,003	(60,57)
Pharmaceutical Healthcare						
Resell Ltd.	Morgan Stanley & Co. International PLC	95,000	08/01/18	AUD 24.40	AUD 2,328	(38,38)
ELUS Corp.	Citibank N.A.	29,200	08/01/18	CAD 46.49	CAD 1,364	(18,65)
Post SA	Credit Suisse International	59,400	08/01/18	EUR 15.15	EUR 804	(4,24)
Telecommunications						
Resell Ltd., Class B	Morgan Stanley & Co. International PLC	55,400	08/02/18	CAD 62.10	CAD 3,459	(55,61)
ELUS Corp.	Goldman Sachs International	33,800	08/03/18	CAD 47.00	CAD 1,578	(10,60)
Post SA, Registered						
Shares	UBS AG	1,100	08/07/18	CHF 2,574.49	CHF 2,895	(101,34)
Resell Ltd.	Citibank N.A.	32,000	08/08/18	AUD 26.57	AUD 869	(26,60)
Zeneca PLC	Goldman Sachs International	44,300	08/08/18	GBP 52.35	GBP 2,322	(80,37)
	UBS AG	135,000	08/08/18	SGD 27.16	SGD 3,578	(47,79)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

BS Group Holdings

Ageo PLC	Morgan Stanley & Co. International PLC	99,500	08/08/18	GBP	27.03	GBP	2,708	(108,77)
axoSmithKline								
C	Morgan Stanley & Co. International PLC	328,200	08/08/18	GBP	15.25	GBP	5,015	(164,19)
perial Brands PLC	UBS AG	155,000	08/08/18	GBP	27.66	GBP	4,362	(219,95)
an Tobacco, Inc.	Goldman Sachs International	71,700	08/08/18	JPY	3,078.48	JPY	221,846	(57,42)
ne OYJ, Class B	Credit Suisse International	30,100	08/08/18	EUR	43.32	EUR	1,311	(45,58)
nofi	Morgan Stanley & Co. International PLC	71,100	08/08/18	EUR	69.52	EUR	4,887	(100,39)
hneider Electric								
	Morgan Stanley & Co. International PLC	22,000	08/08/18	EUR	71.59	EUR	1,567	(48,91)
nic Healthcare								
	JPMorgan Chase Bank N.A.	89,300	08/08/18	AUD	25.08	AUD	2,189	(20,59)
enska								
ndelsbanken AB,								
ass A	JPMorgan Chase Bank N.A.	234,000	08/08/18	SEK	98.45	SEK	23,213	(72,72)
ilever PLC	Goldman Sachs International	60,000	08/08/18	GBP	41.88	GBP	2,512	(61,67)
ELUS Corp.	Citibank N.A.	16,600	08/09/18	CAD	45.90	CAD	775	(16,22)
NTA Sports								
oducts Ltd.	Goldman Sachs International	215,000	08/10/18	HKD	41.32	HKD	8,895	(75,47)
sell Ltd.	Citibank N.A.	31,200	08/14/18	AUD	26.94	AUD	847	(21,10)
ovartis AG,								
gistered Shares	Morgan Stanley & Co. International PLC	38,800	08/14/18	CHF	73.40	CHF	2,911	(113,21)
astle SA,								
gistered Shares	Morgan Stanley & Co. International PLC	70,800	08/15/18	CHF	77.24	CHF	5,434	(92,45)
ELUS Corp.	Royal Bank of Canada	30,600	08/15/18	CAD	47.24	CAD	1,429	(14,75)
ncor Ltd.	JPMorgan Chase Bank N.A.	364,000	08/16/18	AUD	14.52	AUD	5,242	(82,60)
izens Financial								
roup, Inc.	Morgan Stanley & Co. International PLC	28,000	08/20/18	USD	41.84	USD	1,089	(15,17)
sell Ltd.	Morgan Stanley & Co. International PLC	12,800	08/22/18	AUD	27.62	AUD	348	(4,79)
gers								
mmunications,								
, Class B	Citibank N.A.	55,400	08/28/18	CAD	62.50	CAD	3,459	(64,02)
ELUS Corp.	Royal Bank of Canada	59,000	08/29/18	CAD	46.70	CAD	2,755	(44,83)

\$ (3,970,00)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 1,779,580	\$ (1,765,827)	\$ (6,213,872)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written at value	\$	\$	\$ 6,213,872	\$	\$	\$	\$ 6,213,872

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (687)	\$	\$	\$	\$ (687)
Options written			2,305,969				2,305,969
	\$	\$	\$ 2,305,282	\$	\$	\$	\$ 2,305,282

^(a) Options purchased are included in net realized gain (loss) from investments.

**Net Change in Unrealized
Appreciation on:**

Options written	\$	\$	\$ (63,217)	\$	\$	\$	\$ (63,217)
-----------------	----	----	-------------	----	----	----	-------------

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased							\$ (a)
---	--	--	--	--	--	--	--------

Average value of option contracts written \$ 5,532,778

(a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments – Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments:		
Options	\$	\$ 6,213,872
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,243,866)
Total derivative assets and liabilities subject to an MNA	\$	\$ 3,970,006

The following table presents the Trust's derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

	<i>Derivative Liabilities</i>	<i>Derivatives Subject to an MNA by Counterparty</i>	<i>Available for Offset</i>	<i>Non-cash Collateral Pledged ^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities ^(b)</i>
<i>Counterparty</i>						
Barclays Bank PLC	\$	699	\$	\$ (699)	\$	\$
Citibank N.A.		525,371		(525,371)		
Credit Suisse International		163,196		(163,196)		
Deutsche Bank AG		24,952		(24,952)		
Goldman Sachs International		662,326		(662,326)		
HSBC Bank PLC		172,956				172,956
JPMorgan Chase Bank N.A.		192,104		(138,470)	(53,634)	
Morgan Stanley & Co. International PLC		1,278,672		(1,278,672)		

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

Counterparty	Derivative Liabilities		Non-cash Collateral Pledged ^(a)	Cash Collateral Pledged	Net Amount of Derivative Liabilities ^(b)
	Subject to an MNA by Counterparty	Available for Offset			
Royal Bank of Canada	\$ 59,582	\$	\$	\$	\$ 59,582
UBS AG	890,148		(890,148)		
	\$ 3,970,006	\$	\$ (3,683,834)	\$ (53,634)	\$ 232,538

(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 44,735,932	\$	\$ 44,735,932
Belgium	5,897,538	6,095,366		11,992,904
Canada	54,679,533			54,679,533
China		7,983,785		7,983,785
Denmark		8,612,368		8,612,368
Finland		18,714,053		18,714,053
France		36,171,295		36,171,295
Germany		17,734,889		17,734,889
India		8,497,945		8,497,945
Ireland	12,285,206			12,285,206
Japan		8,677,361		8,677,361
Netherlands		21,227,719		21,227,719
Singapore		22,127,212		22,127,212
Sweden		10,378,079		10,378,079
Switzerland		63,921,237		63,921,237

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Taiwan		19,740,982		19,740,982
United Kingdom		118,357,635		118,357,635
United States	321,444,035		4,411,841	325,855,876
Preferred Stocks			7,749,870	7,749,870
	\$ 394,306,312	\$ 412,975,858	\$ 12,161,711	\$ 819,443,881
Derivative Financial Instruments ^(a)				
Liabilities:				
Equity contracts	\$ (1,994,988)	\$ (4,218,884)	\$	\$ (6,213,872)

^(a) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1^(a)</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2^(a)</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$ 11,359,711	\$ 19,072,931	\$ 19,072,931	\$ 11,359,711

^(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced Global Dividend Trust (BOE)

June 30, 2018

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	<i>Common Stocks</i>	<i>Preferred Stocks</i>	<i>Total</i>
Assets:			
Opening Balance, as of December 31, 2017	\$ 4,411,841	\$ 11,646,491	\$ 16,058,332
Transfers into Level 3			
Transfers out of Level 3			
Accrued discounts/premiums			
Net realized gain (loss)		2,510,578	2,510,578
Net change in unrealized appreciation (depreciation) ^{(a)(b)}		(1,662,515)	(1,662,515)
Purchases			
Sales		(4,744,684)	(4,744,684)
Closing Balance, as of June 30, 2018	\$ 4,411,841	\$ 7,749,870	\$ 12,161,711
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2018 ^(b)	\$	\$ (1,662,515)	\$ (1,662,515)

(a) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust's Level 3 investments as of period end.

	<i>Value</i>	<i>Valuation Approach</i>	<i>Unobservable Inputs</i>	<i>Range of Inputs Utilized</i>	<i>Weighted Average of Unobservable Inputs</i>
Assets:					
Common Stocks	\$ 4,411,841	Market	Tangible Book Value Multiple ^(a)	1.90x	
Preferred Stocks	7,749,870	Market	Revenue Multiple ^(a)	7.50x 14.50x	13.23x

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Time to Exit ^(b)	2.5 years
Volatility ^(b)	35%
Recent Transactions ^(a)	

\$ 12,161,711

^(a) Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

^(b) Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 98.7%		
Australia 8.7%		
Ancor Ltd.	3,033,685	\$ 32,322,952
Ansell Ltd.	657,064	13,201,015
Sonic Healthcare Ltd.	816,976	14,819,998
		60,343,965
Belgium 2.3%		
Anheuser-Busch InBev SA	82,168	8,287,867
bpost SA	506,122	7,996,897
		16,284,764
Canada 10.6%		
Rogers Communications, Inc., Class B	743,612	35,318,247
TELUS Corp.	1,076,118	38,226,684
		73,544,931
China 1.8%		
ANTA Sports Products Ltd.	2,377,600	12,537,812
Denmark 1.7%		
Novo Nordisk A/S, Class B	252,763	11,675,264
Finland 3.8%		
Kone OYJ, Class B	521,612	26,521,638
France 7.3%		
Sanofi	459,696	36,894,971
Schneider Electric SE	164,273	13,662,050
		50,557,021
Germany 4.3%		
Deutsche Post AG, Registered Shares	928,368	30,162,999
India 1.7%		
Hero MotoCorp Ltd.	225,738	11,446,031
Japan 1.7%		
Japan Tobacco, Inc.	421,300	11,773,823
Netherlands 4.3%		
Heineken NV	149,488	14,976,972
Koninklijke Philips NV	347,780	14,734,724

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

			29,711,696
Singapore 2.9%			
DBS Group Holdings Ltd.	511,300		9,943,260
United Overseas Bank Ltd.	507,200		9,940,475
			19,883,735
Sweden 2.3%			
Svenska Handelsbanken AB, Class A	1,471,323		16,295,557
Switzerland 13.0%			
Nestle SA, Registered Shares	430,668		33,377,116
Novartis AG, Registered Shares	486,345		36,841,085
SGS SA, Registered Shares	7,522		19,987,410
			90,205,611
Taiwan 4.3%			
Far EastTone Telecommunications Co. Ltd.	3,663,000		9,462,123
Taiwan Semiconductor Manufacturing Co. Ltd.	2,845,000		20,202,554
			29,664,677
United Kingdom 23.4%			
AstraZeneca PLC	310,495		21,476,063
British American Tobacco PLC	608,013		30,627,664
Diageo PLC	596,483		21,429,193
GlaxoSmithKline PLC	1,291,186		26,031,515
Imperial Brands PLC	850,881		31,600,110
Unilever PLC	562,299		31,061,652
			162,226,197
<i>Security</i>		<i>Shares</i>	<i>Value</i>
United States 4.6%			
3M Co. ^(a)	102,009	\$	20,067,210
Microsoft Corp. ^(a)	116,534		11,491,418
			31,558,628
Total Common Stocks 98.7%			
(Cost \$715,814,039)			684,394,349
Preferred Stocks 0.7%			
China 0.6%			
Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 7/28/15, cost \$2,106,332), 0.00% ^{(b)(c)(d)}	76,800		3,911,424
India 0.1%			
Jasper Infotech Private Ltd., Series F, (Acquired 5/7/14, cost \$2,835,730), 0.00% ^{(b)(c)(d)}	398		696,237

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Jasper Infotech Private Ltd., Series G, (Acquired 10/29/14, cost \$1,112,870), 0.00% ^{(b)(c)(d)}	132	281,943
		978,180
Total Preferred Stocks 0.7% (Cost \$6,054,932)		4,889,604
Total Long-Term Investments 99.4% (Cost \$721,868,971)		689,283,953
Short-Term Securities 0.1% BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(e)(f)}	943,659	943,659
Total Short-Term Securities 0.1% (Cost \$943,659)		943,659
Total Investments Before Options Written 99.5% (Cost \$722,812,630)		690,227,612
Options Written (0.8)% (Premiums Received \$5,304,238)		(5,608,380)
Total Investments, Net of Options Written 98.7% (Cost \$717,508,392)		684,619,232
Other Assets Less Liabilities 1.3%		8,816,866
Net Assets 100.0%		\$ 693,436,098

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(c) Non-income producing security.

(d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$4,889,604 and an original cost of \$6,054,935, which was 0.7% of its net assets.

(e) Annualized 7-day yield as of period end.

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

(e) During the period ended June 30, 2018, investments in issuers considered to be an affiliate of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Realized Gain (Loss)</i>	<i>Change in Unrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	5,073,700	(4,130,041)	943,659	\$ 943,659	\$ 53,789	\$	\$

(a) Includes net capital gain distributions, if applicable.

For Trust compliance purposes, the Trust's sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Microsoft Corp.	100	07/06/18	USD 101.00	USD 986	\$ (2,250)
Microsoft Corp.	71	07/13/18	USD 103.00	USD 700	(1,704)
Microsoft Corp.	80	07/13/18	USD 102.00	USD 789	(3,200)
3M Co.	268	07/20/18	USD 200.00	USD 5,272	(59,362)
Rogers Communications, Inc., Class B	819	07/20/18	CAD 62.00	CAD 5,114	(72,266)
TELUS Corp.	265	07/20/18	CAD 46.00	CAD 1,238	(19,452)
3M Co.	60	07/27/18	USD 210.00	USD 1,180	(5,940)
3M Co.	34	07/27/18	USD 200.00	USD 669	(12,835)
Microsoft Corp.	71	07/27/18	USD 103.00	USD 700	(8,023)
Microsoft Corp.	299	08/03/18	USD 102.00	USD 2,948	(49,783)
3M Co.	117	08/17/18	USD 210.00	USD 2,302	(21,294)
Microsoft Corp.	57	08/17/18	USD 105.00	USD 562	(6,384)
Rogers Communications, Inc., Class B	970	08/17/18	CAD 64.00	CAD 6,057	(50,173)
TELUS Corp.	947	08/17/18	CAD 46.00	CAD 4,422	(93,285)

\$ (405,951)

OTC Options Written

	Counterparty	Number of Expiration		Exercise	Notional
		Contracts	Date		
Corp.	Goldman Sachs International	15,959	07/09/18	CAD 46.27	CAD 745
Corp Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD 29.99	SGD 1,590
Corp Holdings Ltd.	Deutsche Bank AG	60,000	07/10/18	SGD 29.91	SGD 1,590
Corp	Goldman Sachs International	77,900	07/10/18	GBP 26.86	GBP 2,120
Telecommunications Co. Ltd.	Goldman Sachs International	109,000	07/10/18	USD 75.75	USD 8,585
NV	UBS AG	45,000	07/10/18	EUR 86.63	EUR 3,861
Registered Shares	Goldman Sachs International	1,300	07/10/18	CHF 2,577.54	CHF 3,421
Electric SE	UBS AG	29,500	07/10/18	EUR 79.66	EUR 2,101
	Credit Suisse International	34,200	07/10/18	EUR 17.43	EUR 463
ca PLC	UBS AG	129,800	07/11/18	GBP 55.20	GBP 6,803
Post AG, Registered Shares	Goldman Sachs International	143,000	07/11/18	EUR 33.57	EUR 3,978
Telecommunications Co. Ltd.	Morgan Stanley & Co. International PLC	218,000	07/11/18	USD 77.89	USD 17,170
Philips NV	Morgan Stanley & Co. International PLC	163,000	07/11/18	EUR 36.27	EUR 5,914
Bank A/S, Class B	Goldman Sachs International	74,100	07/11/18	DKK 306.74	DKK 21,837
Communications, Inc., Class B	Morgan Stanley & Co. International PLC	25,900	07/11/18	CAD 63.00	CAD 1,617
	JPMorgan Chase Bank N.A.	32,000	07/12/18	AUD 26.93	AUD 869
American Tobacco PLC	Citibank N.A.	296,800	07/12/18	GBP 39.09	GBP 11,329
Brands PLC	UBS AG	113,000	07/12/18	GBP 29.02	GBP 3,180
acco, Inc.	Goldman Sachs International	44,000	07/12/18	JPY 3,040.60	JPY 136,140
, Class B	UBS AG	34,600	07/12/18	EUR 43.39	EUR 1,506
	Morgan Stanley & Co. International PLC	60,000	07/12/18	EUR 66.89	EUR 4,124
semiconductor Manufacturing Co.	Goldman Sachs International	350,000	07/12/18	USD 237.08	USD 75,775
Corp.	Citibank N.A.	33,400	07/13/18	CAD 46.34	CAD 1,560

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>		<i>Exercise Price</i>		<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)								
Amcor Ltd.	Goldman Sachs International	624,700	07/18/18	AUD	13.88	AUD	8,996	\$ (267,926)
Anheuser-Busch InBev SA	Morgan Stanley & Co. International PLC	22,000	07/18/18	EUR	83.88	EUR	1,900	(78,733)
Ansell Ltd.	Goldman Sachs International	52,600	07/18/18	AUD	26.80	AUD	1,428	(24,501)
Deutsche Post AG, Registered Shares	Morgan Stanley & Co. International PLC	110,000	07/18/18	EUR	33.57	EUR	3,060	(959)
Diageo PLC	Goldman Sachs International	88,950	07/18/18	GBP	27.45	GBP	2,421	(44,068)
Far EasTone Telecommunications Co. Ltd.	Goldman Sachs International	544,000	07/18/18	USD	77.13	USD	42,845	(33,657)
Imperial Brands PLC	HSBC Bank PLC	17,000	07/18/18	GBP	26.85	GBP	478	(32,820)
Kone OYJ, Class B	Credit Suisse International	52,000	07/18/18	EUR	43.47	EUR	2,264	(58,126)
Sanofi	Morgan Stanley & Co. International PLC	20,850	07/18/18	EUR	65.82	EUR	1,433	(80,623)
Schneider Electric SE	Barclays Bank PLC	18,500	07/18/18	EUR	76.74	EUR	1,318	(1,521)
TELUS Corp.	Citibank N.A.	46,000	07/18/18	CAD	45.85	CAD	2,148	(37,687)
United Overseas Bank Ltd.	JPMorgan Chase Bank N.A.	126,500	07/18/18	SGD	28.67	SGD	3,378	(3,928)
Opport SA	Credit Suisse International	57,000	07/18/18	EUR	15.21	EUR	771	(1,014)
ANTA Sports Products Ltd.	Goldman Sachs International	550,000	07/19/18	HKD	44.78	HKD	22,754	(43,714)
Novartis AG, Registered Shares	Morgan Stanley & Co. International PLC	97,900	07/19/18	CHF	76.10	CHF	7,344	(72,921)
Unilever PLC	Morgan Stanley & Co. International PLC	96,700	07/19/18	GBP	42.83	GBP	4,048	(37,595)
Sonic Healthcare Ltd.	UBS AG	62,300	07/24/18	AUD	23.80	AUD	1,527	(41,658)
United Overseas Bank Ltd.	UBS AG	111,900	07/24/18	SGD	29.32	SGD	2,988	(2,003)
ANTA Sports Products Ltd.	UBS AG	309,000	07/25/18	HKD	49.34	HKD	12,783	(7,142)
Anheuser-Busch InBev SA	UBS AG	16,700	07/25/18	EUR	84.29	EUR	1,442	(57,527)
Ansell Ltd.	Morgan Stanley & Co. International PLC	32,000	07/25/18	AUD	26.66	AUD	869	(19,748)
Diageo PLC	Goldman Sachs International	5,000	07/25/18	GBP	27.90	GBP	136	(1,630)
GlaxoSmithKline PLC	Citibank N.A.	572,700	07/25/18	GBP	15.50	GBP	8,751	(135,399)
Heineken NV	Deutsche Bank AG	25,300	07/25/18	EUR	87.76	EUR	2,170	(21,828)
Kone OYJ, Class B	UBS AG	83,000	07/25/18	EUR	42.77	EUR	3,614	(143,110)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Nestle S.A., Registered Shares	Morgan Stanley & Co. International PLC	68,000	07/25/18	CHF	76.40	CHF	5,219	(89,674)
Novo Nordisk A/S, Class B	UBS AG	44,700	07/25/18	DKK	308.50	DKK	13,173	(12,515)
Sanofi	UBS AG	71,300	07/25/18	EUR	67.27	EUR	4,900	(188,475)
Sonic Healthcare Ltd.	UBS AG	133,900	07/25/18	AUD	24.52	AUD	3,282	(48,443)
Svenska Handelsbanken AB, Class A	UBS AG	270,500	07/25/18	SEK	101.02	SEK	26,834	(46,070)
TELUS Corp. Taiwan Semiconductor Manufacturing Co. Ltd.	Citibank N.A.	28,500	07/25/18	CAD	46.49	CAD	1,331	(14,982)
Deutsche Post SA	UBS AG	987,000	07/25/18	USD	228.60	USD	213,686	(34,466)
ANTA Sports Products Ltd.	Deutsche Bank AG	28,800	07/25/18	EUR	16.07	EUR	390	(529)
Ancor Ltd.	JPMorgan Chase Bank N.A.	258,000	07/26/18	HKD	50.34	HKD	10,673	(3,960)
Ansell Ltd.	UBS AG	317,300	07/26/18	AUD	14.13	AUD	4,569	(100,596)
Far EasTone Telecommunications Co. Ltd.	Morgan Stanley & Co. International PLC	54,800	07/26/18	AUD	27.05	AUD	1,488	(23,397)
Far EasTone Telecommunications Co. Ltd.	Citibank N.A.	401,000	07/26/18	USD	78.15	USD	31,583	(17,953)
Japan Tobacco, Inc.	Goldman Sachs International	450,000	07/26/18	USD	78.76	USD	35,442	(15,575)
Novartis AG, Registered Shares	Citibank N.A.	38,800	07/26/18	JPY	3,114.06	JPY	120,051	(15,119)
Unilever PLC	Morgan Stanley & Co. International PLC	6,750	07/26/18	CHF	75.85	CHF	506	(6,725)
TELUS Corp.	Citibank N.A.	123,300	07/26/18	GBP	41.71	GBP	5,161	(152,640)
TELUS Corp.	Goldman Sachs International	24,600	07/27/18	CAD	46.23	CAD	1,149	(16,605)
TELUS Corp.	Goldman Sachs International	24,600	07/31/18	CAD	46.46	CAD	1,149	(14,516)
Ansell Ltd.	Citibank N.A.	35,000	08/01/18	AUD	26.57	AUD	950	(26,861)
Deutsche Post AG, Registered Shares	HSBC Bank PLC	183,500	08/01/18	EUR	28.30	EUR	5,105	(132,854)
Diageo PLC	Citibank N.A.	26,200	08/01/18	GBP	27.89	GBP	713	(11,797)
Kone OYJ, Class B	Credit Suisse International	52,000	08/01/18	EUR	43.47	EUR	2,264	(68,480)
Sonic Healthcare Ltd.	Morgan Stanley & Co. International PLC	78,800	08/01/18	AUD	24.40	AUD	1,931	(31,841)
TELUS Corp.	Citibank N.A.	28,500	08/01/18	CAD	46.49	CAD	1,331	(18,211)
Deutsche Post SA	Credit Suisse International	76,800	08/01/18	EUR	15.15	EUR	1,039	(5,483)
Rogers Communications, Inc., Class B	Morgan Stanley & Co. International PLC	72,300	08/02/18	CAD	62.10	CAD	4,514	(72,581)
TELUS Corp.	Goldman Sachs International	32,400	08/03/18	CAD	47.00	CAD	1,513	(10,165)
SGS SA, Registered Shares	UBS AG	1,700	08/07/18	CHF	2,574.49	CHF	4,473	(156,618)
Ansell Ltd.	Citibank N.A.	35,000	08/08/18	AUD	26.57	AUD	950	(29,095)
AstraZeneca PLC	Goldman Sachs International	16,200	08/08/18	GBP	52.35	GBP	849	(29,391)
DBS Group Holdings Ltd.	UBS AG	120,000	08/08/18	SGD	27.16	SGD	3,180	(42,486)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

GlaxoSmithKline PLC	Morgan Stanley & Co. International PLC	34,100	08/08/18	GBP	15.25	GBP	521	(17,060)
Imperial Brands PLC	UBS AG	165,000	08/08/18	GBP	27.66	GBP	4,643	(234,149)
Japan Tobacco, Inc.	Goldman Sachs International	64,700	08/08/18	JPY	3,078.48	JPY	200,188	(51,819)
Kone OYJ, Class B	Credit Suisse International	23,600	08/08/18	EUR	43.32	EUR	1,028	(35,744)
Sanofi	Morgan Stanley & Co. International PLC	63,900	08/08/18	EUR	69.52	EUR	4,392	(90,225)
Schneider Electric SE	Morgan Stanley & Co. International PLC	29,300	08/08/18	EUR	71.59	EUR	2,087	(65,142)

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)						
Sonic Healthcare Ltd.	JPMorgan Chase Bank N.A.	109,000	08/08/18	AUD 25.08	AUD 2,672	\$ (25,136)
Svenska Handelsbanken AB, Class A	JPMorgan Chase Bank N.A.	421,000	08/08/18	SEK 98.45	SEK 41,763	(130,843)
Unilever PLC	Goldman Sachs International	72,000	08/08/18	GBP 41.88	GBP 3,014	(74,014)
TELUS Corp.	Citibank N.A.	46,100	08/09/18	CAD 45.90	CAD 2,153	(45,062)
ANTA Sports Products Ltd.	Goldman Sachs International	310,000	08/10/18	HKD 41.32	HKD 12,825	(108,817)
Diageo PLC	Deutsche Bank AG	82,300	08/10/18	GBP 27.66	GBP 2,240	(41,224)
Ansell Ltd.	Citibank N.A.	28,800	08/14/18	AUD 26.94	AUD 782	(19,485)
Novartis AG, Registered Shares	Morgan Stanley & Co. International PLC	124,000	08/14/18	CHF 73.40	CHF 9,302	(361,833)
Nestle S.A., Registered Shares	Morgan Stanley & Co. International PLC	134,500	08/15/18	CHF 77.24	CHF 10,323	(175,636)
TELUS Corp.	Royal Bank of Canada	63,500	08/15/18	CAD 47.24	CAD 2,965	(30,610)
Amcor Ltd.	JPMorgan Chase Bank N.A.	483,800	08/16/18	AUD 14.52	AUD 6,967	(109,795)
Ansell Ltd.	Morgan Stanley & Co. International PLC	38,600	08/22/18	AUD 27.62	AUD 1,048	(14,459)
Rogers Communications, Inc., Class B	Citibank N.A.	72,300	08/28/18	CAD 62.50	CAD 4,514	(83,559)
TELUS Corp.	Royal Bank of Canada	41,000	08/29/18	CAD 46.70	CAD 1,915	(31,154)
						\$ (5,202,429)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 1,388,709	\$ (1,692,850)	\$ (5,608,380)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written at value	\$	\$	\$ 5,608,380	\$	\$	\$	\$ 5,608,380

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss) from:							
Options written	\$	\$	\$ 3,505,781	\$	\$	\$	\$ 3,505,781
Net Change in Unrealized Appreciation (Depreciation) on:							
Options written	\$	\$	\$ (1,888,476)	\$	\$	\$	\$ (1,888,476)

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts written \$ 4,967,544

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Schedule of Investments (unaudited) (continued) **BlackRock Enhanced International Dividend Trust (BGY)**

June 30, 2018

Derivative Financial Instruments Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Options	\$	\$ 5,608,380
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(405,951)
Total derivative assets and liabilities subject to an MNA	\$	\$ 5,202,429

The following table presents the Trust's derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to Derivatives an MNA by Counterparty</i>		<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
	<i>Available for Offset</i>				
Barclays Bank PLC	\$ 1,521	\$	\$	\$	\$ 1,521
Citibank N.A.	761,481		(761,481)		
Credit Suisse International	168,867		(168,867)		
Deutsche Bank AG	63,662		(63,662)		
Goldman Sachs International	951,424		(951,424)		
HSBC Bank PLC	165,674				165,674
JPMorgan Chase Bank N.A.	285,452			(285,452)	
Morgan Stanley & Co. International PLC	1,517,647		(1,517,647)		
Royal Bank of Canada	61,764				61,764
UBS AG	1,224,937		(1,224,937)		
	\$ 5,202,429	\$	\$ (4,688,018)	\$ (285,452)	\$ 228,869

(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Australia	\$	\$ 60,343,965	\$	\$ 60,343,965
Belgium	7,996,897	8,287,867		16,284,764
Canada	73,544,931			73,544,931
China		12,537,812		12,537,812
Denmark		11,675,264		11,675,264
Finland		26,521,638		26,521,638
France		50,557,021		50,557,021
Germany		30,162,999		30,162,999
India		11,446,031		11,446,031
Japan		11,773,823		11,773,823
Netherlands		29,711,696		29,711,696
Singapore		19,883,735		19,883,735
Sweden		16,295,557		16,295,557
Switzerland		90,205,611		90,205,611
Taiwan		29,664,677		29,664,677
United Kingdom		162,226,197		162,226,197
United States	31,558,628			31,558,628
Preferred Stocks			4,889,604	4,889,604
Short-Term Securities	943,659			943,659
	\$ 114,044,115	\$ 571,293,893	\$ 4,889,604	\$ 690,227,612

Schedule of Investments (unaudited) (continued)

BlackRock Enhanced International Dividend Trust (BGY)

June 30, 2018

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Derivative Financial Instruments ^(a)				
Liabilities:				
Equity contracts	\$ (386,499)	\$ (5,221,881)	\$	\$ (5,608,380)

^(a) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1^(a)</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2^(a)</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$ 12,033,525	\$ 17,468,213	\$ 17,468,213	\$ 12,033,525

^(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Health Sciences Trust (BME)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 98.3%		
Biotechnology 19.7%		
ACADIA Pharmaceuticals, Inc. ^{(a)(b)}	37,400	\$ 571,098
Acceleron Pharma, Inc. ^{(a)(b)}	35,700	1,732,164
Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402) ^{(c)(d)}	17,146,440	1,839,813
Agios Pharmaceuticals, Inc. ^{(a)(b)}	15,700	1,322,411
Alexion Pharmaceuticals, Inc. ^{(a)(b)}	28,400	3,525,860
Alnylam Pharmaceuticals, Inc. ^{(a)(b)}	15,000	1,477,350
Amgen, Inc. ^(b)	28,160	5,198,054
Amicus Therapeutics, Inc. ^{(a)(b)}	22,430	350,357
AnaptysBio, Inc. ^(a)	1,500	106,560
Apellis Pharmaceuticals, Inc. ^(a)	14,547	320,034
Arena Pharmaceuticals, Inc. ^{(a)(b)}	25,144	1,096,278
Argenx SE, ADR ^(a)	4,536	375,853
Biogen, Inc. ^{(a)(b)}	25,248	7,327,979
Biohaven Pharmaceutical Holding Co. Ltd. ^{(a)(b)}	7,050	278,616
BioMarin Pharmaceutical, Inc. ^{(a)(b)}	32,400	3,052,080
Bluebird Bio, Inc. ^{(a)(b)}	2,200	345,290
Blueprint Medicines Corp. ^{(a)(b)}	3,500	222,180
Cellectis SA, ADR ^(a)	15,095	427,038
Cytokinetics, Inc. ^{(a)(b)}	11,300	93,790
Eidos Therapeutics, Inc. ^(a)	4,486	91,245
Galapagos NV, ADR ^{(a)(b)}	5,700	525,426
Gilead Sciences, Inc. ^(b)	85,600	6,063,904
Global Blood Therapeutics, Inc. ^{(a)(b)}	5,388	243,538
Halozyme Therapeutics, Inc. ^{(a)(b)}	41,600	701,792
HUA Medicine, Series D (Acquired 03/13/18, cost \$82,789) ^(d)	7,449	82,789
HUA Medicine, Series E (Acquired 03/13/18, cost \$260,147) ^(d)	19,558	260,147
Incyte Corp. ^{(a)(b)}	22,900	1,534,300
InflaRx NV, (Acquired 11/08/17, cost \$253,349) ^(d)	19,488	628,488
InflaRx NV ^(a)	29,508	951,633
Insmed, Inc. ^(a)	67,286	1,591,314
Intercept Pharmaceuticals, Inc. ^{(a)(b)}	2,600	218,166
Madrigal Pharmaceuticals, Inc. ^(a)	2,100	587,349
Myovant Sciences Ltd. ^(a)	16,236	371,317
Neurocrine Biosciences, Inc. ^{(a)(b)}	9,300	913,632
Ovid therapeutics, Inc. ^(a)	42,053	328,013
Regeneron Pharmaceuticals, Inc. ^{(a)(b)}	4,958	1,710,460
Sage Therapeutics, Inc. ^{(a)(b)}	13,552	2,121,295
Sarepta Therapeutics, Inc. ^{(a)(b)}	38,650	5,108,757
Seattle Genetics, Inc. ^{(a)(b)}	50,467	3,350,504
Spark Therapeutics, Inc. ^{(a)(b)}	9,010	745,668
Spectrum Pharmaceuticals, Inc. ^{(a)(b)}	55,600	1,165,376

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Syndax Pharmaceuticals, Inc. ^{(a)(b)}	15,784	110,804
TESARO, Inc. ^(a)	17,831	792,945
Ultragenyx Pharmaceutical, Inc. ^{(a)(b)}	21,300	1,637,331
Vertex Pharmaceuticals, Inc. ^{(a)(b)}	34,005	5,779,490
		67,278,488
Diversified Consumer Services 0.6%		
Service Corp. International ^(b)	59,800	2,140,242
Health Care Equipment & Supplies 28.0%		
Abbott Laboratories ^(b)	239,600	14,613,204
Baxter International, Inc. ^(b)	108,800	8,033,792
Becton Dickinson & Co. ^(b)	27,633	6,619,761
Boston Scientific Corp. ^{(a)(b)}	415,484	13,586,327
Cooper Cos., Inc. ^(b)	4,915	1,157,237
Edwards Lifesciences Corp. ^{(a)(b)}	31,500	4,585,455
Globus Medical, Inc., Class A ^{(a)(b)}	24,500	1,236,270
Intuitive Surgical, Inc. ^{(a)(b)}	12,100	5,789,608
iRhythm Technologies, Inc. ^{(a)(b)}	15,083	1,223,684
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Health Care Equipment & Supplies (continued)		
Masimo Corp. ^{(a)(b)}	38,600	\$ 3,769,290
Medtronic PLC ^(b)	169,100	14,476,651
Nevro Corp. ^{(a)(b)}	24,600	1,964,310
ResMed, Inc. ^(b)	31,900	3,304,202
Stryker Corp. ^(b)	69,200	11,685,112
Teleflex, Inc. ^(b)	8,400	2,252,964
Varian Medical Systems, Inc. ^{(a)(b)}	14,900	1,694,428
		95,992,295
Health Care Providers & Services 24.1%		
Amedisys, Inc. ^{(a)(b)}	39,760	3,397,890
AmerisourceBergen Corp. ^(b)	16,300	1,389,901
Anthem, Inc.	35,800	8,521,474
Centene Corp. ^(a)	42,800	5,273,388
Cigna Corp. ^(b)	39,500	6,713,025
DaVita, Inc. ^{(a)(b)}	55,694	3,867,391
HCA Healthcare, Inc. ^(b)	18,094	1,856,444
HealthEquity, Inc. ^{(a)(b)}	12,400	931,240
Humana, Inc. ^(b)	27,600	8,214,588
Molina Healthcare, Inc. ^{(a)(b)}	11,300	1,106,722
Quest Diagnostics, Inc. ^(b)	80,100	8,806,194
UnitedHealth Group, Inc.	118,302	29,024,213
Universal Health Services, Inc., Class B ^(b)	16,800	1,872,192
WellCare Health Plans, Inc. ^{(a)(b)}	6,400	1,575,936
		82,550,598
Health Care Technology 0.6%		
Teladoc, Inc. ^{(a)(b)}	37,100	2,153,655
Life Sciences Tools & Services 3.4%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Agilent Technologies, Inc. ^(b)	32,200	1,991,248
Charles River Laboratories International, Inc. ^{(a)(b)}	7,771	872,372
QIAGEN NV ^(a)	48,300	1,746,528
Thermo Fisher Scientific, Inc. ^(b)	27,300	5,654,922
Wuxi Biologics Cayman, Inc. ^{(a)(e)}	120,500	1,336,723
		11,601,793
Pharmaceuticals 21.9%		
Allergan PLC ^(b)	34,985	5,832,699
Assembly Biosciences, Inc. ^(a)	2,200	86,262
AstraZeneca PLC	69,576	4,812,376
AstraZeneca PLC ADR [®]	63,100	2,215,441
Bristol-Myers Squibb Co. ^(b)	104,762	5,797,529
Chugai Pharmaceutical Co. Ltd.	15,900	832,532
Eli Lilly & Co. ^(b)	65,800	5,614,714
Jazz Pharmaceuticals PLC ^{(a)(b)}	10,400	1,791,920
Johnson & Johnson ^(b)	41,970	5,092,640
Medicines Co. ^{(a)(b)}	18,600	682,620
Merck & Co., Inc. ^(b)	109,579	6,651,445
Merck KGaA	28,300	2,754,930
Nektar Therapeutics ^{(a)(b)}	7,400	361,342
Novartis AG, ADR ^(b)	33,900	2,560,806
Novo Nordisk A/S ADR [®]	74,300	3,426,716
Pfizer, Inc. ^(b)	465,298	16,881,012
Reata Pharmaceuticals, Inc., Class A ^{(a)(b)}	5,860	204,924
Sanofi	20,400	1,637,294
Sanofi ADR [®]	50,200	2,008,502
Teva Pharmaceutical Industries Ltd. ADR	35,500	863,360
Theravance Biopharma, Inc. ^{(a)(b)}	4,700	106,596
Tricida, Inc. ^(a)	9,249	276,545
Zoetis, Inc. ^(b)	54,500	4,642,855
		75,135,060
Total Common Stocks 98.3% (Cost \$226,041,590)		336,852,131

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Other Interests^(f) 0.0%		
Pharmaceuticals 0.0%		
Afferent Pharmaceuticals, Inc., Series C, (Acquired 09/30/15, Cost \$0) ^{(c)(d)}	190 \$	115,997
Total Other Interests 0.0% (Cost \$)		115,997
Preferred Stock		
Biotechnology 0.2%		
Rubius Therapeutics, Inc., (Acquired 2/23/18, cost \$505,410), 0.00% ^{(a)(c)(d)}	39,516	505,410
Total Preferred Stocks 0.2% (Cost \$505,410)		505,410
Rights 0.0%		
Health Care Technology 0.0%		
Dyax Corp., CVR (Expires 12/31/19) ^(c)	61,727	141,355
Total Rights 0.0% (Cost \$25,848)		141,355
Total Long-Term Investments 98.5% (Cost \$226,572,848)		337,614,893
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Short-Term Securities 2.1%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(g)(h)}	7,272,162 \$	7,272,162
Total Short-Term Securities 2.1% (Cost \$7,272,162)		7,272,162
Total Investments Before Options Written 100.6% (Cost \$233,845,010)		344,887,055
Options Written (0.8)% (Premiums Received \$2,899,524)		(2,688,836)
Total Investments, Net of Options Written 99.8% (Cost \$230,945,486)		342,198,219

Other Assets Less Liabilities	0.2%	531,212
Net Assets	100.0%	\$ 342,729,431

- (a) Non-income producing security.
- (b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (c) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$3,432,644 and an original cost of \$2,088,097, which was 0.8% of its net assets.
- (e) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (f) Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
- (g) Annualized 7-day yield as of period end.
- (h) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income Gain (Loss)</i>	<i>Realized Gain (Loss)</i>	<i>Change in Unrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	14,301,421	(7,029,259)	7,272,162	\$ 7,272,162	\$ 83,489	\$	\$
SL Liquidity Series, LLC, Money Market Series	120,903	(120,903)			1,241 ^(b)	13	7
				\$ 7,272,162	\$ 84,730	\$ 13	\$ 7

(a) Includes net capital gain distributions, if applicable.

(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust's sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Pfizer, Inc.	30	07/02/18	USD 36.25	USD 109	\$ (596)
Allergan PLC	63	07/06/18	USD 157.50	USD 1,050	(61,583)
Amgen, Inc.	7	07/06/18	USD 187.50	USD 129	(420)
AstraZeneca PLC	247	07/06/18	USD 37.50	USD 867	(1,235)
Baxter International, Inc.	45	07/06/18	USD 73.50	USD 332	(3,780)

SCHEDULES OF INVESTMENTS

65

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Gilead Sciences, Inc.	65	07/06/18	USD 69.50	USD 460	\$ (10,693)
Humana, Inc.	67	07/06/18	USD 297.50	USD 1,994	(22,613)
Pfizer, Inc.	101	07/06/18	USD 36.00	USD 366	(4,494)
Pfizer, Inc.	101	07/06/18	USD 36.50	USD 366	(1,313)
Pfizer, Inc.	38	07/06/18	USD 37.00	USD 138	(171)
Zoetis, Inc.	148	07/06/18	USD 85.50	USD 1,261	(9,620)
Novo Nordisk A/S ADR	229	07/09/18	USD 50.00	USD 1,056	(85)
AmerisourceBergen Corp.	44	07/13/18	USD 87.00	USD 375	(5,500)
Amgen, Inc.	72	07/13/18	USD 182.50	USD 1,329	(29,160)
Becton Dickinson & Co.	61	07/13/18	USD 232.50	USD 1,461	(53,070)
Biogen, Inc.	26	07/13/18	USD 295.00	USD 755	(8,970)
Humana, Inc.	22	07/13/18	USD 307.50	USD 655	(2,255)
Medtronic PLC	37	07/13/18	USD 88.50	USD 317	(407)
Pfizer, Inc.	152	07/13/18	USD 36.50	USD 551	(4,332)
Pfizer, Inc.	38	07/13/18	USD 37.00	USD 138	(418)
Vertex Pharmaceuticals, Inc.	109	07/13/18	USD 157.50	USD 1,853	(148,240)
ACADIA Pharmaceuticals, Inc.	149	07/20/18	USD 18.00	USD 228	(4,097)
Acceleron Pharma, Inc.	142	07/20/18	USD 40.00	USD 689	(129,220)
Agilent Technologies, Inc.	40	07/20/18	USD 67.50	USD 247	(180)
Agios Pharmaceuticals, Inc.	62	07/20/18	USD 105.00	USD 522	(1,240)
Alexion Pharmaceuticals, Inc.	56	07/20/18	USD 125.00	USD 695	(19,600)
Allergan PLC	76	07/20/18	USD 180.00	USD 1,267	(4,902)
Alnylam Pharmaceuticals, Inc.	60	07/20/18	USD 120.00	USD 591	(2,400)
Amedisys, Inc.	102	07/20/18	USD 80.00	USD 872	(55,845)
Amedisys, Inc.	58	07/20/18	USD 85.00	USD 496	(16,066)
Arena Pharmaceuticals, Inc.	16	07/20/18	USD 50.00	USD 70	(704)
Baxter International, Inc.	69	07/20/18	USD 72.50	USD 509	(14,594)
BioMarin Pharmaceutical, Inc.	56	07/20/18	USD 95.00	USD 528	(17,500)
BioMarin Pharmaceutical, Inc.	73	07/20/18	USD 100.00	USD 688	(11,498)
Biogen, Inc.	24	07/20/18	USD 280.00	USD 697	(33,120)
Biohaven Pharmaceutical Holding Co. Ltd.	28	07/20/18	USD 40.00	USD 111	(6,300)
Bluebird Bio, Inc.	8	07/20/18	USD 195.00	USD 126	(620)
Blueprint Medicines Corp.	14	07/20/18	USD 85.00	USD 89	(1,260)
Boston Scientific Corp.	658	07/20/18	USD 31.00	USD 2,152	(135,548)
Bristol-Myers Squibb Co.	142	07/20/18	USD 55.00	USD 786	(16,046)
Cooper Cos., Inc.	19	07/20/18	USD 230.00	USD 447	(15,580)
Cytokinetics, Inc.	45	07/20/18	USD 10.00	USD 37	(450)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

DaVita, Inc.	125	07/20/18	USD	70.00	USD	868	(19,375)
Edwards Lifesciences Corp.	33	07/20/18	USD	145.00	USD	480	(11,385)
Galapagos NV, ADR	22	07/20/18	USD	105.00	USD	203	(10,780)
Gilead Sciences, Inc.	156	07/20/18	USD	67.50	USD	1,105	(60,450)
Global Blood Therapeutics, Inc.	21	07/20/18	USD	50.00	USD	95	(3,202)
Globus Medical, Inc., Class A	88	07/20/18	USD	57.50	USD	444	(1,760)
HCA Healthcare, Inc.	41	07/20/18	USD	105.00	USD	421	(3,997)
Halozyne Therapeutics, Inc.	170	07/20/18	USD	20.00	USD	287	(1,700)
HealthEquity, Inc.	49	07/20/18	USD	85.00	USD	368	(980)
Incyte Corp.	82	07/20/18	USD	75.00	USD	549	(2,665)
Jazz Pharmaceuticals PLC	40	07/20/18	USD	180.00	USD	689	(7,300)
Johnson & Johnson	102	07/20/18	USD	125.00	USD	1,238	(8,670)
Masimo Corp.	151	07/20/18	USD	100.00	USD	1,475	(18,875)
Medicines Co.	74	07/20/18	USD	39.00	USD	272	(5,180)
Medtronic PLC	5	07/20/18	USD	87.50	USD	43	(222)
Medtronic PLC	21	07/20/18	USD	90.00	USD	180	(189)
Merck & Co., Inc.	25	07/20/18	USD	60.00	USD	152	(3,812)
Merck & Co., Inc.	106	07/20/18	USD	62.50	USD	643	(4,081)
Molina Healthcare, Inc.	45	07/20/18	USD	100.00	USD	441	(8,100)
Nektar Therapeutics	29	07/20/18	USD	65.00	USD	142	(1,087)
Neurocrine Biosciences, Inc.	36	07/20/18	USD	94.25	USD	354	(22,744)
Nevro Corp.	98	07/20/18	USD	85.00	USD	783	(8,330)
Novartis AG, ADR	86	07/20/18	USD	80.00	USD	650	(1,075)
Novo Nordisk A/S ADR	58	07/20/18	USD	48.90	USD	267	(1,097)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Pfizer, Inc.	137	07/20/18	USD 36.00	USD 497	\$ (9,385)
Pfizer, Inc.	169	07/20/18	USD 35.00	USD 613	(25,012)
Pfizer, Inc.	139	07/20/18	USD 37.00	USD 504	(2,710)
Quest Diagnostics, Inc.	83	07/20/18	USD 106.90	USD 913	(31,349)
Regeneron Pharmaceuticals, Inc.	8	07/20/18	USD 320.00	USD 276	(22,200)
Resmed, Inc.	130	07/20/18	USD 106.95	USD 1,347	(9,808)
Sage Therapeutics, Inc.	39	07/20/18	USD 185.00	USD 610	(1,755)
Sanofi ADR	200	07/20/18	USD 40.00	USD 800	(13,000)
Seattle Genetics, Inc.	201	07/20/18	USD 75.00	USD 1,334	(4,522)
Spark Therapeutics, Inc.	36	07/20/18	USD 79.00	USD 298	(23,431)
Stryker Corp.	280	07/20/18	USD 175.00	USD 4,728	(36,400)
Syndax Pharmaceuticals, Inc.	63	07/20/18	USD 10.00	USD 44	(1,260)
Teladoc, Inc.	148	07/20/18	USD 60.00	USD 859	(26,270)
Theravance Biopharma, Inc.	18	07/20/18	USD 25.00	USD 41	(585)
Thermo Fisher Scientific, Inc.	109	07/20/18	USD 220.00	USD 2,258	(2,725)
Universal Health Services, Inc., Class B	34	07/20/18	USD 120.00	USD 379	(1,020)
Varian Medical Systems, Inc.	59	07/20/18	USD 125.00	USD 671	(885)
Vertex Pharmaceuticals, Inc.	27	07/20/18	USD 160.00	USD 459	(33,345)
WellCare Health Plans, Inc.	25	07/20/18	USD 240.00	USD 616	(23,250)
iRhythm Technologies, Inc.	57	07/20/18	USD 85.00	USD 462	(8,408)
Universal Health Services, Inc., Class B	33	07/23/18	USD 116.50	USD 368	(2,189)
Novartis AG, ADR	66	07/25/18	USD 76.45	USD 499	(7,301)
Abbott Laboratories	486	07/27/18	USD 63.00	USD 2,964	(25,029)
Baxter International, Inc.	71	07/27/18	USD 76.00	USD 524	(6,638)
Biogen, Inc.	8	07/27/18	USD 310.00	USD 232	(2,620)
Boston Scientific Corp.	181	07/27/18	USD 31.50	USD 592	(38,553)
Boston Scientific Corp.	186	07/27/18	USD 33.50	USD 608	(18,600)
Bristol-Myers Squibb Co.	73	07/27/18	USD 55.00	USD 404	(11,826)
Cigna Corp.	158	07/27/18	USD 180.00	USD 2,685	(16,432)
Edwards Lifesciences Corp.	60	07/27/18	USD 155.00	USD 873	(16,650)
Gilead Sciences, Inc.	63	07/27/18	USD 72.00	USD 446	(11,624)
Intercept Pharmaceuticals, Inc.	10	07/27/18	USD 85.00	USD 84	(4,600)
Medtronic PLC	61	07/27/18	USD 88.50	USD 522	(2,318)
Medtronic PLC	85	07/27/18	USD 86.50	USD 728	(8,415)
Merck & Co., Inc.	106	07/27/18	USD 63.50	USD 643	(4,982)
Pfizer, Inc.	255	07/27/18	USD 37.00	USD 925	(6,885)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Pfizer, Inc.	73	07/27/18	USD	36.50	USD	265	(3,540)
Sage Therapeutics, Inc.	15	07/27/18	USD	165.00	USD	235	(8,025)
Pfizer, Inc.	71	07/30/18	USD	36.75	USD	258	(3,105)
Pfizer, Inc.	121	07/30/18	USD	36.50	USD	439	(5,874)
Amicus Therapeutics, Inc.	89	08/03/18	USD	16.00	USD	139	(8,455)
Baxter International, Inc.	136	08/03/18	USD	75.00	USD	1,004	(17,612)
Baxter International, Inc.	45	08/03/18	USD	73.50	USD	332	(9,180)
Biogen, Inc.	3	08/03/18	USD	300.00	USD	87	(2,085)
Bristol-Myers Squibb Co.	175	08/03/18	USD	56.00	USD	968	(22,838)
Johnson & Johnson	33	08/03/18	USD	126.00	USD	400	(3,399)
Medtronic PLC	74	08/03/18	USD	86.50	USD	634	(8,843)
Pfizer, Inc.	157	08/03/18	USD	36.50	USD	570	(9,499)
Novo Nordisk A/S ADR	33	08/06/18	USD	45.01	USD	152	(6,471)
Abbott Laboratories	251	08/09/18	USD	62.50	USD	1,531	(22,009)
AmerisourceBergen Corp.	21	08/10/18	USD	88.00	USD	179	(5,512)
Boston Scientific Corp.	318	08/10/18	USD	32.50	USD	1,040	(50,403)
Edwards Lifesciences Corp.	33	08/10/18	USD	149.00	USD	480	(18,645)
Eli Lilly & Co.	133	08/10/18	USD	86.00	USD	1,135	(25,337)
HCA Healthcare, Inc.	31	08/10/18	USD	106.00	USD	318	(5,425)
Intuitive Surgical, Inc.	48	08/10/18	USD	495.00	USD	2,297	(58,800)
Medtronic PLC	74	08/10/18	USD	87.00	USD	634	(8,732)
Pfizer, Inc.	121	08/10/18	USD	36.50	USD	439	(7,865)
Zoetis, Inc.	70	08/10/18	USD	87.50	USD	596	(11,375)
Abbott Laboratories	221	08/17/18	USD	62.82	USD	1,348	(20,353)
Agilent Technologies, Inc.	88	08/17/18	USD	62.50	USD	544	(18,480)
Alexion Pharmaceuticals, Inc.	57	08/17/18	USD	125.00	USD	708	(35,625)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Amgen, Inc.	33	08/17/18	USD 190.00	USD 609	\$ (11,715)
Baxter International, Inc.	69	08/17/18	USD 72.50	USD 509	(20,700)
Becton Dickinson & Co.	49	08/17/18	USD 240.00	USD 1,174	(37,485)
Biogen, Inc.	39	08/17/18	USD 300.00	USD 1,132	(34,125)
Boston Scientific Corp.	318	08/17/18	USD 33.00	USD 1,040	(46,746)
Charles River Laboratories International, Inc.	36	08/17/18	USD 115.00	USD 404	(10,980)
Eli Lilly & Co.	130	08/17/18	USD 87.50	USD 1,109	(18,720)
Gilead Sciences, Inc.	37	08/17/18	USD 75.00	USD 262	(5,032)
Humana, Inc.	21	08/17/18	USD 305.00	USD 625	(14,805)
Johnson & Johnson	32	08/17/18	USD 125.00	USD 388	(5,728)
Medtronic PLC	319	08/17/18	USD 87.50	USD 2,731	(36,207)
Merck & Co., Inc.	95	08/17/18	USD 62.50	USD 577	(10,878)
Merck & Co., Inc.	106	08/17/18	USD 65.00	USD 643	(4,823)
Pfizer, Inc.	158	08/17/18	USD 37.00	USD 573	(7,268)
Quest Diagnostics, Inc.	83	08/17/18	USD 106.90	USD 913	(41,360)
Quest Diagnostics, Inc.	154	08/17/18	USD 110.00	USD 1,693	(49,280)
Reata Pharmaceuticals, Inc., Class A	23	08/17/18	USD 40.00	USD 80	(4,197)
Regeneron Pharmaceuticals, Inc., Class A	11	08/17/18	USD 340.00	USD 379	(23,100)
Sarepta Therapeutics, Inc., Class A	154	08/17/18	USD 145.00	USD 2,036	(107,415)
Spectrum Pharmaceuticals, Inc., Class A	222	08/17/18	USD 20.00	USD 465	(61,605)
Teleflex, Inc , Class A	33	08/17/18	USD 290.00	USD 885	(16,500)
Teva Pharmaceutical Industries Ltd. ADR, Class A	124	08/17/18	USD 25.00	USD 302	(15,810)
Ultragenyx Pharmaceutical, Inc., Class A	85	08/17/18	USD 80.00	USD 653	(36,125)
Service Corp. International, Class A	53	08/20/18	USD 36.75	USD 190	(5,977)
					\$ (2,548,831)

OTC Options Written

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
InflaRx NV	UBS AG	11,800	07/02/18	USD 39.00	USD 381	\$
Insmmed, Inc.	Barclays Bank PLC	13,500	07/09/18	USD 27.50	USD 319	(897)
DaVita, Inc.	UBS AG	9,700	07/10/18	USD 70.46	USD 674	(8,289)
Myovant Sciences Ltd.	Bank of America N.A.	7,100	07/11/18	USD 24.98	USD 162	(1,492)
Merck & Co., Inc. Service Corp.	Morgan Stanley & Co. International PLC	11,300	07/19/18	EUR 89.51	EUR 942	(1,907)
International Wuxi Biologics	Barclays Bank PLC	18,600	07/24/18	USD 35.48	USD 666	(18,247)
Cayman, Inc.	JPMorgan Chase Bank N.A.	48,000	07/24/18	HKD 89.71	HKD 4,177	(22,519)
Insmmed, Inc.	Barclays Bank PLC	13,500	07/25/18	USD 27.50	USD 319	(5,098)
Sanofi Novo Nordisk A/S	UBS AG	8,100	07/25/18	EUR 67.27	EUR 557	(21,412)
ADR	Barclays Bank PLC	6,400	07/26/18	USD 45.41	USD 295	(9,708)
AstraZeneca PLC	Goldman Sachs International	27,800	08/08/18	GBP 52.35	GBP 1,457	(50,436)
						\$ (140,005)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 893,309	\$ (682,621)	\$ (2,688,836)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written, at value	\$	\$	\$ 2,688,836	\$	\$	\$	\$ 2,688,836

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (360)	\$	\$	\$	\$ (360)
Options written			(2,080,545)				(2,080,545)
	\$	\$	\$ (2,080,905)	\$	\$	\$	\$ (2,080,905)

^(a) Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation on:

Options written	\$	\$	\$ 6,401	\$	\$	\$	\$ 6,401
-----------------	----	----	----------	----	----	----	----------

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts written	\$	(a)
Average value of option contracts written	\$	2,243,250

(a) Derivative not held at quarter-end. The amount shown in the Statements of Operation reflect the results of activity during the period.

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End:

The Trust's derivative assets and liabilities (by type) were as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments:		
Options	\$	\$ 2,688,836
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,548,831)
Total derivative assets and liabilities subject to an MNA	\$	\$ 140,005

The following table presents the Trust's derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities (a)</i>
Bank of America N.A.	\$ 1,492	\$	\$	\$	\$ 1,492
Barclays Bank PLC	33,950				33,950
Goldman Sachs International	50,436				50,436
JPMorgan Chase Bank N.A.	22,519				22,519
Morgan Stanley & Co. International PLC	1,907				1,907
UBS AG	29,701				29,701
	\$ 140,005	\$	\$	\$	\$ 140,005

(a) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

June 30, 2018

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Biotechnology	\$ 64,467,251	\$ 628,488	\$ 2,182,749	\$ 67,278,488
Diversified Consumer Services	2,140,242			2,140,242
Health Care Equipment & Supplies	95,992,295			95,992,295
Health Care Providers & Services	82,550,598			82,550,598
Health Care Technology	2,153,655			2,153,655
Life Sciences Tools & Services	10,265,070	1,336,723		11,601,793
Pharmaceuticals	65,097,928	10,037,132		75,135,060
Other Interests			115,997	115,997
Preferred Stock			505,410	505,410
Rights			141,355	141,355
Short-Term Securities	7,272,162			7,272,162
	\$ 329,939,201	\$ 12,002,343	\$ 2,945,511	\$ 344,887,055
Derivative Financial Instruments ^(a)				
Liabilities:				
Equity contracts	\$ (2,345,082)	\$ (343,754)	\$	\$ (2,688,836)

^(a) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 548,148	\$ 548,148	\$

- (a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	<i>Common Stocks</i>	<i>Preferred Stocks</i>	<i>Other Interests</i>	<i>Rights</i>	<i>Total</i>
Assets:					
Opening Balance, as of December 31, 2017	\$ 1,916,972	\$	\$ 387,926	\$ 141,355	\$ 2,446,253
Transfers into Level 3					
Transfers out of Level 3					
Accrued discounts/premiums					
Net realized gain (loss)					
Net change in unrealized appreciation (depreciation) ^{(a)(b)}	(77,160)		(271,928)		(349,088)
Purchases	342,936	505,410			848,346
Sales					
Closing Balance, as of June 30, 2018	\$ 2,182,748	\$ 505,410	\$ 115,998	\$ 141,355	\$ 2,945,511
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2018 ^(b)	\$ (77,159)	\$	\$ (271,929)	\$	\$ (349,088)

(a) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 98.4%		
Chemicals 11.9%		
Albemarle Corp. ^(a)	91,502	\$ 8,631,384
CF Industries Holdings, Inc. ^(a)	144,743	6,426,589
FMC Corp. ^(a)	196,837	17,559,829
Nufarm Ltd.	1,447,185	9,485,131
Nutrien Ltd. ^(a)	1,094,186	59,501,835
Umicore SA	132,428	7,559,973
Yara International ASA	210,760	8,719,600
		117,884,341
Containers & Packaging 4.6%		
International Paper Co. ^(a)	138,669	7,221,881
Packaging Corp. of America ^(a)	177,059	19,793,426
Smurfit Kappa Group PLC	464,673	18,759,400
		45,774,707
Electronic Equipment, Instruments & Components 0.7%		
Trimble, Inc. ^{(a)(b)}	201,408	6,614,239
Energy Equipment & Services 1.7%		
Baker Hughes a GE Co. ^(a)	212,620	7,022,839
Halliburton Co. ^(a)	221,372	9,975,022
		16,997,861
Food Products 7.7%		
Archer-Daniels-Midland Co. ^(a)	680,887	31,205,051
Bunge Ltd. ^(a)	96,788	6,747,091
Glanbia PLC	628,916	11,677,725
Hormel Foods Corp. ^(a)	426,641	15,875,312
Origin Enterprises PLC	583,252	4,202,521
Tyson Foods, Inc., Class A ^(a)	83,491	5,748,355
		75,456,055
Machinery 1.3%		
Deere & Co. ^(a)	88,995	12,441,501
Metals & Mining 34.9%		
ArcelorMittal	776,992	22,669,328
BHP Billiton PLC	2,264,226	50,814,714
First Quantum Minerals Ltd.	1,023,945	15,086,764
Franco-Nevada Corp.	110,278	8,048,662
Fresnillo PLC	564,708	8,509,983

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Glencore PLC ^(b)	11,099,845	52,699,723
Lundin Mining Corp.	1,509,300	8,392,335
Neo Lithium Corp. ^(b)	5,022,674	5,004,908
Nevsun Resources Ltd.	3,527,285	12,261,585
Newcrest Mining Ltd.	1,174,528	19,070,967
OZ Minerals Ltd.	1,292,966	9,016,014
Polyus PJSC	128,648	4,220,500
Rio Tinto PLC ADR ^(b)	767,833	42,599,375
Stelco Holdings, Inc.	1,079,971	20,824,756
Teck Resources Ltd., Class B ^(a)	725,386	18,461,074
Vale SA ADR ^(b)	2,713,425	34,786,108
Wheaton Precious Metals Corp.	571,192	12,600,496

345,067,292

Oil, Gas & Consumable Fuels 34.1%

BP PLC ADR ^(b)	1,143,873	52,229,241
Cairn Energy PLC ^(b)	1,965,097	6,452,517
Canadian Natural Resources Ltd.	407,563	14,710,276
Chevron Corp. ^(a)	129,953	16,429,958
CNOOC Ltd.	6,962,000	11,929,696
ConocoPhillips ^(a)	212,222	14,774,896
Devon Energy Corp. ^(a)	231,866	10,192,829
Encana Corp.	374,738	4,894,270
EQT Corp.	115,770	6,388,189
Exxon Mobil Corp. ^(a)	337,908	27,955,129

Security

Shares

Value

Oil, Gas & Consumable Fuels (continued)

Kosmos Energy Ltd. ^(b)	600,090	\$ 4,962,744
Pioneer Natural Resources Co. ^(a)	61,744	11,684,435
Royal Dutch Shell PLC ADR, Class A ^(a)	833,537	57,705,766
Suncor Energy, Inc.	913,331	37,168,226
TOTAL SA	757,330	45,989,421
Valero Energy Corp.	121,400	13,454,762

336,922,355

Paper & Forest Products 1.5%

Mondi PLC	538,826	14,536,491
Precious Woods Holding AG ^(b)	20,000	153,489
Quintis Ltd. ^{(b)(c)(d)}	7,903,565	67

14,690,047

Total Common Stocks 98.4%
(Cost \$805,565,896)

971,848,398

Par
(000)

Corporate Bonds 1.6%

Metals & Mining 1.6%

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Beadell Resources LTD, 6.00%, 06/30/23 ^(c)	USD	1,800	1,799,820
Pilgangoora Operations Pty Ltd, 12.00%, 06/21/22		9,000	10,077,705
Osisko Gold Royalties, Ltd., 4.00%, 12/31/22	CAD	5,652	4,299,243
			16,176,768
Total Corporate Bonds 1.6%			
(Cost \$15,311,494)			16,176,768
Total Long-Term Investments 100.0%			
(Cost \$820,877,390)			988,025,166
		<i>Shares</i>	
Short-Term Securities 0.8%			
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(e)(g)}		7,893,261	7,893,261
SL Liquidity Series, LLC, Money Market Series, 2.16% ^{(e)(f)(g)}		30,670	30,673
Total Short-Term Securities 0.8%			
(Cost \$7,923,928)			7,923,934
Total Investments Before Options Written 100.8%			
(Cost \$828,801,318)			\$ 995,949,100
Options Written (0.7)%			
(Premiums Received \$9,065,805)			(7,080,083)
Total Investments, Net of Options Written 100.1%			
(Cost \$819,735,513)			988,869,017
Liabilities in Excess of Other Assets (0.1)%			(693,588)
Net Assets Applicable to Common Shares 100.0%			\$ 988,175,429

(a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) Non-income producing security.

(c) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d) Security, or a portion of the security, is on loan.

(e) Annualized 7-day yield as of period end.

(f) Security was purchased with the cash collateral from loaned securities.

Schedule of Investments (unaudited) (continued) **BlackRock Resources & Commodities Strategy Trust (BCX)**

June 30, 2018

(g) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Realized Gain (Loss)</i>	<i>Unrealized Appreciation (Depreciation)</i>	<i>Change in Net Unrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class SL Liquidity Series, LLC, Money Market Series	16,156,750	(8,263,489)	7,893,261	\$ 7,893,261	\$ 73,740	\$	\$	
	488,032	(457,362)	30,670	30,673	2,510 ^(b)	2	45	
				\$ 7,923,934	\$ 76,250	\$ 2	\$ 45	

(a) Includes net capital gain distributions, if applicable.

(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust's sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End**Exchange-Traded Options Written**

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Archer-Daniels-Midland Co.	501	07/06/18	USD 45.00	USD 2,296	\$ (51,854)
Chevron Corp.	151	07/06/18	USD 128.00	USD 1,909	(8,909)
ConocoPhillips	236	07/06/18	USD 70.00	USD 1,643	(17,110)
Deere & Co.	66	07/06/18	USD 165.00	USD 923	(924)
Devon Energy Corp.	114	07/06/18	USD 43.50	USD 501	(11,856)
Devon Energy Corp.	129	07/06/18	USD 41.00	USD 567	(39,668)
Halliburton Co.	143	07/06/18	USD 51.50	USD 644	(429)
Hormel Foods Corp.	240	07/06/18	USD 36.50	USD 893	(20,400)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

International Paper Co.	134	07/06/18	USD	55.00	USD	698	(938)
International Paper Co.	70	07/06/18	USD	56.00	USD	365	(280)
Tyson Foods, Inc., Class A	84	07/06/18	USD	73.00	USD	578	(840)
Tyson Foods, Inc., Class A	96	07/06/18	USD	72.00	USD	661	(1,440)
Vale SA ADR	852	07/06/18	USD	15.00	USD	1,092	(1,704)
Archer-Daniels-Midland Co.	330	07/13/18	USD	44.00	USD	1,512	(68,475)
BP PLC ADR	534	07/13/18	USD	46.00	USD	2,438	(29,370)
Chevron Corp.	150	07/13/18	USD	129.00	USD	1,896	(12,675)
ConocoPhillips	278	07/13/18	USD	70.00	USD	1,935	(33,221)
Exxon Mobil Corp.	251	07/13/18	USD	83.00	USD	2,077	(25,602)
Hormel Foods Corp.	215	07/13/18	USD	36.00	USD	800	(29,563)
Hormel Foods Corp.	215	07/13/18	USD	36.50	USD	800	(22,037)
International Paper Co.	134	07/13/18	USD	55.50	USD	698	(1,407)
Pioneer Natural Resources Co.	87	07/13/18	USD	197.50	USD	1,646	(12,397)
Royal Dutch Shell PLC ADR, Class A	157	07/13/18	USD	71.00	USD	1,087	(5,495)
Teck Resources Ltd., Class B	619	07/13/18	USD	31.50	USD	1,575	(103,992)
Tyson Foods, Inc., Class A	332	07/13/18	USD	69.00	USD	2,286	(35,690)
Vale SA ADR	590	07/13/18	USD	14.00	USD	756	(3,835)
Vale SA ADR	752	07/13/18	USD	14.50	USD	964	(2,632)
Albemarle Corp.	370	07/20/18	USD	95.00	USD	3,490	(81,400)
Archer-Daniels-Midland Co.	410	07/20/18	USD	45.00	USD	1,879	(54,120)
BP PLC ADR	1,498	07/20/18	USD	47.00	USD	6,840	(50,932)
Baker Hughes a GE Co.	233	07/20/18	USD	39.00	USD	770	(2,330)
Baker Hughes a GE Co.	311	07/20/18	USD	36.00	USD	1,027	(7,775)
Bunge Ltd.	116	07/20/18	USD	72.50	USD	809	(11,020)
CF Industries Holdings, Inc.	110	07/20/18	USD	42.50	USD	488	(29,095)
Canadian Natural Resources Ltd.	195	07/20/18	CAD	48.00	CAD	925	(12,534)
Chevron Corp.	149	07/20/18	USD	130.00	USD	1,884	(14,229)
ConocoPhillips	30	07/20/18	USD	72.50	USD	209	(1,770)
ConocoPhillips	236	07/20/18	USD	70.50	USD	1,643	(29,618)
Deere & Co.	80	07/20/18	USD	165.00	USD	1,118	(1,360)
Devon Energy Corp.	150	07/20/18	USD	38.00	USD	659	(92,625)

Schedule of Investments (unaudited) (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Devon Energy Corp.	69	07/20/18	USD 44.00	USD 303	\$ (10,315)
Devon Energy Corp.	82	07/20/18	USD 46.00	USD 360	(5,658)
Encana Corp.	860	07/20/18	CAD 17.00	CAD 1,477	(47,427)
FMC Corp.	304	07/20/18	USD 92.50	USD 2,712	(25,840)
First Quantum Minerals Ltd.	1,000	07/20/18	CAD 18.00	CAD 1,937	(140,342)
First Quantum Minerals Ltd.	391	07/20/18	CAD 23.00	CAD 757	(3,272)
First Quantum Minerals Ltd.	1,299	07/20/18	CAD 22.00	CAD 2,516	(18,280)
Franco-Nevada Corp.	299	07/20/18	CAD 94.00	CAD 2,869	(65,616)
Hormel Foods Corp.	139	07/20/18	USD 36.25	USD 517	(17,337)
International Paper Co.	19	07/20/18	USD 57.50	USD 99	(114)
Lundin Mining Corp.	633	07/20/18	CAD 9.00	CAD 463	(1,926)
Nutrien Ltd.	250	07/20/18	USD 51.55	USD 1,360	(80,311)
Nutrien Ltd.	800	07/20/18	USD 55.00	USD 4,350	(72,000)
Packaging Corp. of America	480	07/20/18	USD 125.00	USD 5,366	(4,800)
Rio Tinto PLC ADR	373	07/20/18	USD 62.50	USD 2,069	(3,730)
Rio Tinto PLC ADR	249	07/20/18	USD 60.00	USD 1,381	(3,735)
Royal Dutch Shell PLC ADR, Class A	558	07/20/18	USD 70.00	USD 3,863	(51,615)
Royal Dutch Shell PLC ADR, Class A	579	07/20/18	USD 75.00	USD 4,008	(4,342)
Suncor Energy, Inc.	2,088	07/20/18	CAD 54.00	CAD 11,171	(131,031)
Teck Resources Ltd., Class B	264	07/20/18	USD 29.00	USD 672	(2,376)
Trimble, Inc.	148	07/20/18	USD 35.00	USD 486	(1,850)
Vale SA ADR	1,325	07/20/18	USD 15.00	USD 1,699	(4,637)
Archer-Daniels-Midland Co.	254	07/27/18	USD 46.00	USD 1,164	(21,082)
Archer-Daniels-Midland Co.	264	07/27/18	USD 47.00	USD 1,210	(10,824)
BP PLC ADR	535	07/27/18	USD 47.00	USD 2,443	(25,948)
BP PLC ADR	338	07/27/18	USD 46.00	USD 1,543	(29,913)
CF Industries Holdings, Inc.	361	07/27/18	USD 45.50	USD 1,603	(41,335)
Chevron Corp.	56	07/27/18	USD 130.00	USD 708	(8,428)
ConocoPhillips	1	07/27/18	USD 69.00	USD 7	(234)
Deere & Co.	130	07/27/18	USD 147.00	USD 1,817	(25,025)
Devon Energy Corp.	82	07/27/18	USD 45.50	USD 360	(8,897)
Devon Energy Corp.	31	07/27/18	USD 45.00	USD 136	(3,983)
Exxon Mobil Corp.	820	07/27/18	USD 85.00	USD 6,784	(65,600)
Halliburton Co.	374	07/27/18	USD 49.50	USD 1,685	(10,659)
International Paper Co.	18	07/27/18	USD 59.00	USD 94	(162)
Nutrien Ltd.	735	07/27/18	USD 52.50	USD 3,997	(191,100)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Nutrien Ltd.	500	07/27/18	USD	55.00	USD	2,719	(56,250)
Pioneer Natural Resources Co.	75	07/27/18	USD	202.50	USD	1,419	(14,250)
Royal Dutch Shell PLC ADR, Class A	186	07/27/18	USD	71.00	USD	1,288	(14,880)
Royal Dutch Shell PLC ADR, Class A	579	07/27/18	USD	69.50	USD	4,008	(82,508)
Teck Resources Ltd., Class B	410	07/27/18	USD	29.50	USD	1,043	(20,090)
Vale SA ADR	398	07/27/18	USD	14.50	USD	510	(3,980)
Vale SA ADR	1,030	07/27/18	USD	13.50	USD	1,320	(28,840)
Bunge Ltd.	85	08/02/18	USD	72.01	USD	593	(13,504)
Archer-Daniels-Midland Co.	264	08/03/18	USD	47.00	USD	1,210	(20,460)
BP PLC ADR	686	08/03/18	USD	46.00	USD	3,132	(79,919)
Devon Energy Corp.	69	08/03/18	USD	43.50	USD	303	(17,319)
Exxon Mobil Corp.	137	08/03/18	USD	83.00	USD	1,133	(26,784)
International Paper Co.	105	08/03/18	USD	54.50	USD	547	(8,505)
Pioneer Natural Resources Co.	22	08/03/18	USD	190.00	USD	416	(15,510)
Pioneer Natural Resources Co.	41	08/03/18	USD	200.00	USD	776	(13,017)
Teck Resources Ltd., Class B	210	08/03/18	USD	27.00	USD	534	(13,650)
Vale SA ADR	1,545	08/03/18	USD	13.50	USD	1,981	(50,985)
Archer-Daniels-Midland Co.	350	08/10/18	USD	46.00	USD	1,604	(46,725)
CF Industries Holdings, Inc.	107	08/10/18	USD	46.00	USD	475	(16,157)
Chevron Corp.	13	08/10/18	USD	128.00	USD	164	(3,874)
Devon Energy Corp.	31	08/10/18	USD	46.00	USD	136	(4,820)
Hormel Foods Corp.	367	08/10/18	USD	37.50	USD	1,366	(37,618)
Teck Resources Ltd., Class B	800	08/10/18	USD	26.00	USD	2,036	(94,400)
Valero Energy Corp.	480	08/10/18	USD	115.00	USD	5,320	(123,120)
Archer-Daniels-Midland Co.	350	08/17/18	USD	46.00	USD	1,604	(48,125)
BP PLC ADR	671	08/17/18	USD	46.00	USD	3,064	(83,204)

Schedule of Investments (unaudited) (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
BP PLC ADR	338	08/17/18	USD 47.00	USD 1,543	\$ (27,716)
Bunge Ltd.	101	08/17/18	USD 72.50	USD 704	(23,987)
Canadian Natural Resources Ltd.	778	08/17/18	CAD 44.00	CAD 3,692	(248,553)
ConocoPhillips	72	08/17/18	USD 70.00	USD 501	(18,396)
Deere & Co.	79	08/17/18	USD 150.00	USD 1,104	(22,712)
Devon Energy Corp.	89	08/17/18	USD 42.00	USD 391	(33,153)
Devon Energy Corp.	82	08/17/18	USD 46.00	USD 360	(14,063)
Encana Corp.	1,995	08/17/18	CAD 17.00	CAD 3,425	(164,650)
Exxon Mobil Corp.	143	08/17/18	USD 82.50	USD 1,183	(34,749)
Halliburton Co.	374	08/17/18	USD 50.00	USD 1,685	(19,635)
International Paper Co.	74	08/17/18	USD 55.00	USD 385	(6,031)
Nutrien Ltd.	735	08/17/18	USD 55.00	USD 3,997	(132,300)
Packaging Corp. of America	228	08/17/18	USD 120.00	USD 2,549	(29,640)
Pioneer Natural Resources Co.	21	08/17/18	USD 185.00	USD 397	(25,095)
Royal Dutch Shell PLC ADR, Class A	139	08/17/18	USD 72.50	USD 962	(9,730)
Suncor Energy, Inc.	1,565	08/17/18	CAD 54.00	CAD 8,373	(172,612)
Teck Resources Ltd., Class B	600	08/17/18	USD 30.00	USD 1,527	(17,100)
Trimble, Inc.	220	08/17/18	USD 35.00	USD 722	(14,300)
Vale SA ADR	1,775	08/17/18	USD 15.00	USD 2,276	(20,412)
Vale SA ADR	437	08/17/18	USD 14.00	USD 560	(12,673)
Vale SA ADR	2,150	09/21/18	USD 13.00	USD 2,756	(178,450)
					\$ (4,235,746)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
FMC Corp.	Citibank N.A.	35,000	07/09/18	USD 90.75	USD 3,122	\$ (29,217)
First Quantum Minerals Ltd.	Goldman Sachs International	142,800	07/09/18	CAD 20.76	CAD 2,766	(21,334)
Nutrien Ltd.	Citibank N.A.	50,000	07/09/18	USD 47.93	USD 2,719	(326,789)
Stelco Holdings, Inc.	Goldman Sachs International	36,300	07/09/18	CAD 27.21	CAD 920	(1,356)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Glanbia PLC	Goldman Sachs International	79,700	07/10/18	EUR	14.45	EUR	1,267	(135,048)
Rio Tinto PLC ADR	Citibank N.A.	53,400	07/10/18	USD	55.85	USD	2,963	(47,448)
BHP Billiton PLC	HSBC Bank PLC	232,700	07/11/18	GBP	17.65	GBP	3,958	(42,220)
TOTAL SA	UBS AG	81,800	07/11/18	EUR	54.88	EUR	4,254	(2,306)
Glencore PLC	Morgan Stanley & Co. International PLC	1,038,000	07/12/18	GBP	3.94	GBP	3,737	(17,051)
Lundin Mining Corp.	Credit Suisse International	126,600	07/12/18	CAD	8.70	CAD	925	(1,830)
Nufarm Ltd.	Morgan Stanley & Co. International PLC	96,000	07/12/18	AUD	9.69	AUD	851	(51)
Smurfit Kappa Group PLC	Goldman Sachs International	58,000	07/12/18	EUR	35.54	EUR	2,005	(12,710)
Stelco Holdings, Inc.	Goldman Sachs International	50,000	07/12/18	CAD	26.52	CAD	1,268	(7,079)
Umicore SA Canadian Natural	Morgan Stanley & Co. International PLC	26,700	07/12/18	EUR	50.02	EUR	1,305	(18,255)
Resources Ltd.	Credit Suisse International	77,900	07/16/18	CAD	46.25	CAD	3,696	(104,857)
CNOOC Ltd.	Goldman Sachs International	810,000	07/18/18	HKD	14.07	HKD	10,886	(13,486)
Fresnillo PLC	Morgan Stanley & Co. International PLC	40,000	07/18/18	GBP	13.52	GBP	457	(21)
Glanbia PLC	Morgan Stanley & Co. International PLC	93,500	07/18/18	EUR	15.94	EUR	1,487	(24,510)
Glencore PLC	Credit Suisse International	1,453,000	07/18/18	GBP	4.20	GBP	5,231	(8,564)
Oz Minerals Ltd.	Societe Generale	520,000	07/18/18	AUD	10.59	AUD	4,898	(1,725)
Stelco Holdings, Inc.	Goldman Sachs International	27,600	07/18/18	CAD	25.20	CAD	700	(16,399)
Umicore SA	HSBC Bank PLC	26,500	07/18/18	EUR	51.37	EUR	1,295	(11,853)
ArcelorMittal	UBS AG	24,700	07/19/18	EUR	28.16	EUR	617	(1,856)
Franco-Nevada Corp.	Goldman Sachs International	14,400	07/19/18	CAD	96.00	CAD	1,382	(17,191)
Hormel Foods Corp.	Bank of America N.A.	24,000	07/19/18	USD	36.13	USD	893	(31,580)
Mondi PLC	Morgan Stanley & Co. International PLC	77,400	07/19/18	GBP	20.91	GBP	1,582	(14,984)
Trimble, Inc.	Citibank N.A.	22,200	07/23/18	USD	35.83	USD	729	(1,491)
Fresnillo PLC	Goldman Sachs International	123,400	07/24/18	GBP	13.55	GBP	1,409	(1,166)
Stelco Holdings, Inc.	Goldman Sachs International	27,600	07/24/18	CAD	25.20	CAD	700	(18,567)
Lundin Mining Corp.	Morgan Stanley & Co. International PLC	158,000	07/25/18	CAD	9.07	CAD	1,155	(5,066)
Newcrest Mining Ltd.	UBS AG	25,000	07/25/18	AUD	21.18	AUD	549	(18,860)
Rio Tinto PLC ADR	Citibank N.A.	36,000	07/25/18	USD	61.02	USD	1,997	(4,324)
Smurfit Kappa Group PLC	Goldman Sachs International	17,900	07/25/18	EUR	34.31	EUR	619	(18,875)

Schedule of Investments (unaudited) (continued)

BlackRock Resources & Commodities Strategy Trust (BCX)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)						
Smurfit						
Kappa Group						
PLC	UBS AG	40,000	07/25/18	EUR 34.54	EUR 1,383	\$ (37,215)
TOTAL SA	UBS AG	38,000	07/25/18	EUR 53.09	EUR 1,976	(22,957)
ArcelorMittal	Morgan Stanley & Co. International PLC	100,800	07/26/18	EUR 30.11	EUR 2,518	(2,786)
ArcelorMittal	Morgan Stanley & Co. International PLC	116,000	07/26/18	EUR 29.61	EUR 2,898	(5,046)
BHP Billiton						
PLC	UBS AG	340,200	07/26/18	GBP 17.26	GBP 5,787	(187,686)
CNOOC Ltd.	JPMorgan Chase Bank N.A.	800,000	07/26/18	HKD 14.07	HKD 10,752	(19,916)
Fresnillo						
PLC	Goldman Sachs International	63,800	07/26/18	GBP 12.45	GBP 729	(2,707)
Glencore						
PLC	Goldman Sachs International	704,100	07/26/18	GBP 3.97	GBP 2,535	(32,086)
Mondi PLC	Morgan Stanley & Co. International PLC	139,206	07/26/18	GBP 21.47	GBP 2,845	(13,802)
Nufarm Ltd.	Morgan Stanley & Co. International PLC	214,000	07/26/18	AUD 9.04	AUD 1,896	(21,436)
TOTAL SA	Citibank N.A.	70,500	07/26/18	EUR 53.63	EUR 3,666	(28,655)
Yara						
International						
ASA	UBS AG	84,700	07/26/18	NOK 360.37	NOK 28,540	(32,354)
Rio Tinto						
PLC ADR	Citibank N.A.	54,000	07/30/18	USD 58.98	USD 2,996	(25,136)
Hormel						
Foods Corp.	Morgan Stanley & Co. International PLC	29,000	07/31/18	USD 36.26	USD 1,079	(39,135)
Lundin						
Mining Corp.	Royal Bank of Canada	196,000	07/31/18	CAD 9.03	CAD 1,433	(10,439)
Stelco						
Holdings,						
Inc.	Credit Suisse International	30,000	07/31/18	CAD 26.30	CAD 761	(12,226)
CNOOC Ltd.	Societe Generale	193,000	08/01/18	HKD 12.78	HKD 2,594	(20,674)
FMC Corp.	Morgan Stanley & Co. International PLC	13,700	08/01/18	USD 88.40	USD 1,222	(45,696)
Stelco						
Holdings,						
Inc.	Goldman Sachs International	25,000	08/01/18	CAD 25.85	CAD 634	(13,517)
TOTAL SA	UBS AG	44,000	08/01/18	EUR 53.87	EUR 2,288	(23,770)
BHP Billiton						
PLC	Morgan Stanley & Co. International PLC	179,000	08/02/18	GBP 18.01	GBP 3,045	(48,551)
Rio Tinto						
PLC ADR	Morgan Stanley & Co. International PLC	51,600	08/03/18	USD 58.75	USD 2,863	(31,200)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Royal Dutch Shell PLC ADR, Class A	Citibank N.A.	56,800	08/06/18	USD	70.97	USD	3,932	(65,421)
Glencore PLC Lundin Mining Corp.	Goldman Sachs International	1,184,511	08/07/18	GBP	3.88	GBP	4,264	(108,761)
Nufarm Ltd.	Citibank N.A.	63,200	08/07/18	CAD	8.31	CAD	462	(4,324)
Nutrien Ltd.	UBS AG	272,000	08/07/18	AUD	9.58	AUD	2,410	(8,852)
ArcelorMittal BHP Billiton PLC	Barclays Bank PLC	63,000	08/07/18	USD	51.10	USD	3,426	(249,604)
Glanbia PLC	Goldman Sachs International	65,073	08/08/18	EUR	26.10	EUR	1,626	(51,290)
Smurfit Kappa Group PLC	JPMorgan Chase Bank N.A.	158,700	08/08/18	GBP	16.62	GBP	2,699	(176,037)
Stelco Holdings, Inc.	Morgan Stanley & Co. International PLC	74,978	08/08/18	EUR	15.91	EUR	1,192	(30,090)
TOTAL SA Baker Hughes a GE Co.	Goldman Sachs International	67,372	08/08/18	EUR	35.40	EUR	2,329	(45,227)
Stelco Holdings, Inc.	Goldman Sachs International	25,000	08/08/18	CAD	25.85	CAD	634	(15,287)
Nutrien Ltd.	Goldman Sachs International	70,200	08/08/18	EUR	52.17	EUR	3,650	(94,205)
Bunge Ltd. Stelco Holdings, Inc.	Citibank N.A.	31,100	08/13/18	USD	33.93	USD	1,027	(39,092)
Rio Tinto PLC ADR	Credit Suisse International	30,000	08/13/18	CAD	26.88	CAD	761	(11,779)
Royal Dutch Shell PLC ADR, Class A	JPMorgan Chase Bank N.A.	25,000	08/14/18	USD	53.95	USD	1,360	(53,272)
Stelco Holdings, Inc.	Barclays Bank PLC	8,500	08/16/18	USD	70.73	USD	593	(26,455)
Stelco Holdings, Inc.	Goldman Sachs International	35,500	08/16/18	CAD	27.00	CAD	900	(13,937)
Stelco Holdings, Inc.	Morgan Stanley & Co. International PLC	51,600	08/20/18	USD	58.75	USD	2,863	(30,049)
Stelco Holdings, Inc.	Citibank N.A.	56,800	08/20/18	USD	70.97	USD	3,932	(71,193)
Stelco Holdings, Inc.	Goldman Sachs International	17,300	08/22/18	CAD	26.50	CAD	439	(9,584)
Stelco Holdings, Inc.	Goldman Sachs International	18,200	08/22/18	CAD	25.83	CAD	461	(13,530)
Stelco Holdings, Inc.	Credit Suisse International	32,200	08/29/18	CAD	26.00	CAD	816	(24,082)
Stelco Holdings, Inc.	Credit Suisse International	32,200	09/07/18	CAD	26.00	CAD	816	(26,277)
	Goldman Sachs International	22,500	09/12/18	CAD	25.76	CAD	570	(20,930)

Stelco
Holdings,
Inc.

\$ (2,844,337)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 3,795,486	\$ (1,809,764)	\$ (7,080,083)

SCHEDULES OF INVESTMENTS

75

Schedule of Investments (unaudited) (continued) **BlackRock Resources & Commodities Strategy Trust (BCX)**

June 30, 2018

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written, at value	\$	\$	\$ 7,080,083	\$	\$	\$	\$ 7,080,083

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Net Realized Gain (Loss)							
from:							
Options purchased ^(a)	\$	\$	\$ (5,226)	\$	\$	\$	\$ (5,226)
Options written			(19,278,563)				(19,278,563)
	\$	\$	\$ (19,283,789)	\$	\$	\$	\$ (19,283,789)

^(a) Includes net capital gain distributions, if applicable.

**Net Change in Unrealized
Appreciation (Depreciation) on:**

Options written	\$	\$	\$ 10,195,573	\$	\$	\$	\$ 10,195,573
-----------------	----	----	---------------	----	----	----	---------------

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased							\$ 2,190
---	--	--	--	--	--	--	----------

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Average value of option contracts written \$ 6,199,199

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust's derivative asset and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments		
Options	\$	\$ 7,080,083
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(4,235,746)
Total derivative assets and liabilities subject to an MNA	\$	\$ 2,844,337

The following table presents the Trust's derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral and pledged by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Bank of America N.A.	\$ 31,580	\$	\$ (31,580)	\$	\$
Barclays Bank PLC	276,059		(276,059)		
Citibank N.A.	643,090		(643,090)		
Credit Suisse International	189,615		(189,615)		
Goldman Sachs International	684,272		(684,272)		
HSBC Bank PLC	54,073				54,073
JPMorgan Chase Bank N.A.	249,225		(48,722)		200,503
Morgan Stanley & Co. International PLC	347,729		(347,729)		
Royal Bank of Canada	10,439				10,439

Schedule of Investments (unaudited) (continued) **BlackRock Resources & Commodities Strategy Trust (BCX)**

June 30, 2018

Counterparty	Derivative Liabilities		Non-cash Collateral Pledged ^(a)	Cash Collateral Pledged	Net Amount of Derivative Liabilities ^(b)
	Subject to an MNA by Counterparty	Derivatives Available for Offset			
Societe Generale	\$ 22,399	\$	\$	\$	\$ 22,399
UBS AG	335,856		(335,856)		
	\$ 2,844,337	\$	\$ (2,556,923)	\$	\$ 287,414

(a) Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	Level 1	Level 2	Level 3	Total
Assets:				
Investments:				
Common Stocks:				
Chemicals	\$ 92,119,637	\$ 25,764,704	\$	\$ 117,884,341
Containers & Packaging	27,015,307	18,759,400		45,774,707
Electronic Equipment, Instruments & Components	6,614,239			6,614,239
Energy Equipment & Services	16,997,861			16,997,861
Food Products	75,456,055			75,456,055
Machinery	12,441,501			12,441,501
Metals & Mining	178,066,063	165,201,409	1,799,820	345,067,292
Oil, Gas & Consumable Fuels	272,550,721	64,371,634		336,922,355
Paper & Forest Products		14,689,980	67	14,690,047
Corporate Bonds		16,176,768		16,176,768
Short-Term Securities	7,893,261			7,893,261
Subtotal	\$ 689,154,645	\$ 304,963,895	\$ 1,799,887	\$ 995,918,427

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Investments Valued at NAV ^(a)				30,673
				\$ 995,949,100
Derivative Financial Instruments ^(b)				
Liabilities:				
Equity contracts	\$ (4,124,595)	\$ (2,955,488)	\$	\$ (7,080,083)

(a) As of June 30, 2018, certain of the Trust's Investments were fair valued using net asset value (NAV) per share and have been excluded from the fair value hierarchy.

(b) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 5,523,874	\$ 5,523,874	\$

(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Schedule of Investments (unaudited)

BlackRock Science and Technology Trust (BST)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 97.6%		
Automobiles 0.8%		
Tesla, Inc. ^{(a)(b)}	16,500	\$ 5,658,675
Consumer Finance 0.2%		
I3 Verticals, Inc., Class A ^(a)	65,175	991,964
Diversified Consumer Services 0.2%		
Sunlands Online Education Group ADR ^(c)	177,787	1,584,082
Electronic Equipment, Instruments & Components 1.4%		
Hangzhou Hikvision Digital Technology Co., Ltd.	516,990	2,885,697
Isra Vision AG	42,725	2,611,108
Sunny Optical Technology Group Co. Ltd.	230,800	4,280,730
		9,777,535
Health Care Technology 0.5%		
Pingan Healthcare and Tech Placing (Acquired 04/27/18, Cost \$4,108,447) ^(d)	582,478	3,583,014
Household Durables 0.6%		
Roku, Inc. ^{(a)(b)}	101,197	4,313,016
Internet & Direct Marketing Retail 7.6%		
Amazon.com, Inc. ^{(a)(b)}	22,960	39,027,409
Ensogo Ltd. ^{(a)(e)}	173,282	
Netflix, Inc. ^{(a)(b)}	36,530	14,298,938
		53,326,347
Internet Software & Services 25.9%		
58.com, Inc. ADR ^(b)	52,400	3,633,416
Alibaba Group Holding Ltd. ADR ^(b)	123,740	22,957,482
Alphabet, Inc., Class A ^{(a)(b)}	28,186	31,827,349
Baidu, Inc. ADR ^(b)	35,500	8,626,500
Bandwidth, Inc., Class A ^(a)	93,150	3,537,837
Delivery Hero AG ^{(a)(f)}	93,637	4,963,227
DocuSign, Inc. ^{(a)(b)}	79,740	4,222,233
Facebook, Inc., Class A ^{(a)(b)}	71,900	13,971,608
IAC/InterActiveCorp ^{(a)(b)}	23,100	3,522,519
MercadoLibre, Inc. ^(b)	14,700	4,394,271
Mercari, Inc. ^(a)	93,400	3,825,760
MongoDB, Inc. ^{(a)(b)}	33,811	1,678,040
Okta, Inc. ^{(a)(b)}	99,850	5,029,444
SendGrid, Inc. ^{(a)(b)}	152,159	4,035,257

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Shopify, Inc., Class A ^{(a)(b)}	33,800	4,931,082
Spotify Technology SA ^{(a)(b)}	20,709	3,484,082
Tencent Holdings Ltd.	654,600	32,870,983
Twilio, Inc., Class A ^(a)	83,700	4,688,874
Uxin, Ltd., ADR ^(a)	486,264	4,395,827
Wix.com Ltd. ^{(a)(b)}	56,100	5,626,830
Yandex NV, Class A ^{(a)(b)}	250,480	8,992,232
		181,214,853
IT Services 12.0%		
Adyen NV ^{(a)(f)}	10,362	5,708,526
GMO Payment Gateway, Inc.	38,300	4,409,488
InterXion Holding NV ^{(a)(b)}	76,600	4,781,372
Mastercard, Inc., Class A ^(b)	93,300	18,335,316
Pagseguro Digital Ltd., Class A ^{(a)(b)}	286,408	7,947,822
PayPal Holdings, Inc. ^{(a)(b)}	97,800	8,143,806
Square, Inc., Class A ^{(a)(b)}	279,700	17,240,708
Visa, Inc., Class A ^(b)	128,100	16,966,845
		83,533,883
Media 1.2%		
Naspers Ltd., Class N	33,100	8,345,959
Professional Services 0.5%		
UT Group Co., Ltd. ^(a)	90,200	3,368,913
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Semiconductors & Semiconductor Equipment 13.4%		
Advanced Micro Devices, Inc. ^{(a)(b)}	294,700	\$ 4,417,553
Aixtron SE ^(a)	210,100	2,703,808
ams AG	44,830	3,324,598
ASML Holding NV	67,100	13,278,066
Broadcom, Inc. ^(b)	51,696	12,543,517
Cree, Inc. ^{(a)(b)}	76,400	3,175,948
Lam Research Corp. ^(b)	43,301	7,484,578
NVIDIA Corp. ^(b)	37,900	8,978,510
ON Semiconductor Corp. ^{(a)(b)}	200,000	4,447,000
Qorvo, Inc. ^{(a)(b)}	54,400	4,361,248
Silicon Laboratories, Inc. ^{(a)(b)}	34,100	3,396,360
Skyworks Solutions, Inc.	43,700	4,223,605
SOITEC ^(a)	89,625	7,515,486
STMicroelectronics NV	245,900	5,459,789
Taiwan Semiconductor Manufacturing Co. Ltd.	1,200,000	8,521,288
		93,831,354
Software 29.5%		
Activision Blizzard, Inc. ^(b)	143,400	10,944,288
Adobe Systems, Inc. ^{(a)(b)}	55,900	13,628,979
Altair Engineering, Inc., Class A ^(a)	154,413	5,277,836
Altium Ltd.	207,900	3,455,363
Autodesk, Inc. ^{(a)(b)}	70,100	9,189,409

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Avalara, Inc. ^(a)	112,941	6,027,661
Bilibili, Inc. ADR ^(b)	179,800	2,515,402
Carbon Black, Inc. ^(a)	48,040	1,249,040
Electronic Arts, Inc. ^{(a)(b)}	45,500	6,416,410
FireEye, Inc. ^{(a)(b)}	207,752	3,197,303
ForeScout Technologies, Inc. ^{(a)(b)}	88,655	3,037,320
Guidewire Software, Inc. ^{(a)(b)}	42,500	3,773,150
Kingdee International Software Group Co., Ltd.	3,724,000	3,793,000
Linx SA	636,166	2,905,280
Microsoft Corp. ^(b)	370,380	36,523,172
Pivotal Software, Inc., Class A ^{(a)(b)}	161,575	3,921,425
Pluralsight, Inc. ^(a)	190,185	4,650,023
Proofpoint, Inc. ^{(a)(b)}	46,900	5,408,039
PTC, Inc. ^{(a)(b)}	55,300	5,187,693
RIB Software SE	149,200	3,457,046
SailPoint Technologies Holding, Inc. ^{(a)(b)}	198,822	4,879,092
salesforce.com, Inc. ^{(a)(b)}	120,000	16,368,000
ServiceNow, Inc. ^{(a)(b)}	38,210	6,590,079
Smartsheet, Inc., Class A ^(a)	40,591	1,054,148
Take-Two Interactive Software, Inc. ^{(a)(b)}	79,700	9,433,292
Ubisoft Entertainment SA ^(a)	77,447	8,465,593
Xero Ltd. ^(a)	120,100	3,994,889
Zendesk, Inc. ^{(a)(b)}	93,900	5,116,611
Zuora, Inc., 6 mo. (Acquired 04/11/18, Cost \$3,894,522), ^(d)	512,531	13,545,852
Zuora, Inc., Class A ^{(a)(b)}	88,129	2,397,109
		206,402,504
Technology Hardware, Storage & Peripherals 3.8%		
Apple, Inc. ^(b)	141,896	26,266,369
Total Common Stocks 97.6% (Cost \$346,208,121)		682,198,468
Preferred Securities		
Preferred Stocks 2.3%		
Internet & Direct Marketing Retail 0.1%		
Jasper Infotech Private Ltd., Series I, (Acquired 08/08/15, Cost 1,998,435), 0.00% ^{(d)(e)}	1,054	520,676
Internet Software & Services 2.2%		
Uber Technologies, Inc., Series E, (Acquired 12/04/14, cost \$3,000,048), 0.00% ^{(d)(e)}	90,044	3,601,760

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Internet Software & Services (continued)		
Xiaoju Kuaizhi, Inc., Series A-17 (Acquired 07/28/15, cost \$3,016,964), 0.00% ^{(d)(e)}	110,003	\$ 5,602,453
Ant International Co., Ltd., (Acquired 06/06/18, cost \$6,492,863), 0.00% ^{(d)(e)}	1,157,373	6,492,862
		15,697,075
Total Preferred Stocks 2.3% (Cost \$14,508,310)		16,217,751
Total Long-Term Investments 99.9% (Cost \$360,716,431)		698,416,219
Short-Term Securities 0.9%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(g)(i)}	5,803,333	5,803,333
SL Liquidity Series, LLC, Money Market Series, 2.16% ^{(g)(h)(i)}	276,979	277,007
Total Short-Term Securities 0.9% (Cost \$6,080,330)		6,080,340
Total Investments Before Options Written 100.8% (Cost \$366,796,761)		704,496,559
Options Written (0.9)% (Premiums Received \$7,916,075)		(6,462,316)
Total Investments, Net of Options Written 99.9% (Cost \$358,880,686)		698,034,243
Other Assets Less Liabilities 0.1%		764,977
Net Assets 100.0%		\$ 698,799,220

(a) Non-income producing security.

(b) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(c) Security, or a portion of the security, is on loan.

(d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$33,346,617 and an original cost of \$22,511,279, which was 4.8% of its net assets.

(e) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

- (f) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (g) Annualized 7-day yield as of period end.
- (h) Security was purchased with the cash collateral from loaned securities.
- (i) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Gain (Loss)</i>	<i>Change in Net Unrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	4,696,297	1,107,036	5,803,333	\$ 5,803,333	\$ 32,717	\$	\$
SL Liquidity Series, LLC, Money Market Series	3,497,053	(3,220,074)	276,979	277,007	123,932 ^(b)	(464)	179
				\$ 6,080,340	\$ 156,649	\$ (464)	\$ 179

(a) Includes net capital gain distributions, if applicable.

(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust's sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Activision Blizzard, Inc.	166	07/06/18	USD 73.00	USD 1,267	\$(58,930)
Adobe Systems, Inc.	77	07/06/18	USD 257.50	USD 1,877	(808)
Advanced Micro Devices, Inc.	527	07/06/18	USD 13.50	USD 790	(79,577)
Alibaba Group Holding Ltd. ADR	144	07/06/18	USD 205.00	USD 2,672	(720)
Amazon.com, Inc.	7	07/06/18	USD 1,660.00	USD 1,190	(34,178)

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Facebook, Inc., Class A	61	07/06/18	USD 202.50	USD 1,185	\$ (1,464)
Microsoft Corp.	195	07/06/18	USD 101.00	USD 1,923	(4,387)
Netflix, Inc.	25	07/06/18	USD 360.00	USD 979	(82,063)
PayPal Holdings, Inc.	70	07/06/18	USD 83.50	USD 583	(6,580)
ServiceNow, Inc.	66	07/06/18	USD 187.50	USD 1,138	(660)
Square, Inc., Class A	362	07/06/18	USD 65.00	USD 2,231	(9,593)
Yandex NV, Class A	27	07/06/18	USD 36.50	USD 97	(945)
salesforce.com, Inc.	86	07/06/18	USD 134.00	USD 1,173	(28,595)
Alibaba Group Holding Ltd. ADR	82	07/13/18	USD 205.00	USD 1,521	(2,378)
Alphabet, Inc., Class A	5	07/13/18	USD 1,145.00	USD 565	(5,550)
Amazon.com, Inc.	8	07/13/18	USD 1,657.50	USD 1,360	(47,600)
Apple, Inc.	17	07/13/18	USD 187.50	USD 315	(3,145)
Autodesk, Inc.	62	07/13/18	USD 135.00	USD 813	(8,773)
Broadcom Inc.	40	07/13/18	USD 255.00	USD 971	(3,300)
FireEye, Inc.	100	07/13/18	USD 18.00	USD 154	(250)
Mastercard, Inc., Class A	175	07/13/18	USD 205.00	USD 3,439	(7,175)
Microsoft Corp.	71	07/13/18	USD 103.00	USD 700	(1,704)
Microsoft Corp.	155	07/13/18	USD 102.00	USD 1,528	(6,200)
Netflix, Inc.	25	07/13/18	USD 365.00	USD 979	(75,563)
Spotify Technology SA	16	07/13/18	USD 165.00	USD 269	(11,600)
salesforce.com, Inc.	55	07/13/18	USD 133.00	USD 750	(26,537)
SailPoint Technologies Holding, Inc.	360	07/18/18	USD 27.01	USD 883	(9,939)
58.com, Inc. ADR	183	07/20/18	USD 85.00	USD 1,269	(1,830)
Activision Blizzard, Inc.	104	07/20/18	USD 80.00	USD 794	(6,552)
Advanced Micro Devices, Inc.	531	07/20/18	USD 13.00	USD 796	(111,245)
Alphabet, Inc., Class A	8	07/20/18	USD 1,100.00	USD 903	(34,360)
Alphabet, Inc., Class A	9	07/20/18	USD 1,190.00	USD 1,016	(4,095)
Apple, Inc.	164	07/20/18	USD 190.00	USD 3,036	(21,566)
Autodesk, Inc.	21	07/20/18	USD 145.00	USD 275	(630)
Bilibili, Inc. ADR	629	07/20/18	USD 15.00	USD 880	(59,755)
Broadcom, Inc.	38	07/20/18	USD 270.00	USD 922	(760)
DocuSign, Inc.	148	07/20/18	USD 65.00	USD 784	(6,660)
DocuSign, Inc.	148	07/20/18	USD 70.00	USD 784	(2,960)
Electronic Arts, Inc.	58	07/20/18	USD 135.00	USD 818	(44,660)
Facebook, Inc., Class A	24	07/20/18	USD 190.00	USD 466	(17,940)
FireEye, Inc.	92	07/20/18	USD 17.00	USD 142	(1,150)
ForeScout Technologies, Inc.	310	07/20/18	USD 40.00	USD 1,062	(4,650)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Guidewire Software, Inc.	233	07/20/18	USD	95.00	USD	2,069	(8,737)
IAC/InterActiveCorp.	80	07/20/18	USD	165.00	USD	1,220	(6,200)
InterXion Holding NV	92	07/20/18	USD	65.00	USD	574	(3,680)
Lam Research Corp.	65	07/20/18	USD	185.00	USD	1,124	(10,075)
MercadoLibre, Inc.	40	07/20/18	USD	310.00	USD	1,196	(29,000)
Microsoft Corp.	324	07/20/18	USD	100.00	USD	3,195	(65,448)
MongoDB, Inc.	118	07/20/18	USD	65.00	USD	586	(885)
NVIDIA Corp.	62	07/20/18	USD	255.00	USD	1,469	(10,230)
Netflix, Inc.	33	07/20/18	USD	350.00	USD	1,292	(164,835)
ON Semiconductor Corp.	217	07/20/18	USD	28.00	USD	483	(2,170)
Okta, Inc.	275	07/20/18	USD	55.00	USD	1,385	(24,062)
PTC, Inc.	193	07/20/18	USD	95.00	USD	1,811	(57,900)
Pagseguro Digital Ltd., Class A	813	07/20/18	USD	40.00	USD	2,256	(4,065)
PayPal Holdings, Inc.	57	07/20/18	USD	85.25	USD	475	(6,981)
Pivotal Software, Inc., Class A	192	07/20/18	USD	20.00	USD	466	(87,360)
Proofpoint, Inc.	164	07/20/18	USD	130.00	USD	1,891	(2,870)
Roku, Inc.	194	07/20/18	USD	35.00	USD	827	(152,290)
SailPoint Technologies Holding, Inc.	168	07/20/18	USD	25.00	USD	412	(15,120)
SendGrid, Inc.	328	07/20/18	USD	30.00	USD	870	(14,760)
Silicon Laboratories, Inc.	187	07/20/18	USD	110.00	USD	1,863	(9,350)
Spotify Technology SA	40	07/20/18	USD	175.00	USD	673	(17,200)
Square, Inc., Class A	362	07/20/18	USD	50.00	USD	2,231	(432,590)
Take-Two Interactive Software, Inc.	95	07/20/18	USD	117.00	USD	1,124	(42,275)
Tesla, Inc.	18	07/20/18	USD	350.00	USD	617	(27,630)
Twilio, Inc., Class A	174	07/20/18	USD	60.00	USD	975	(17,487)

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Visa, Inc., Class A	112	07/20/18	USD 135.00	USD 1,483	\$ (15,176)
Yandex NV, Class A	145	07/20/18	USD 36.00	USD 521	(18,125)
Zendesk, Inc.	328	07/20/18	USD 60.00	USD 1,787	(13,120)
Zuora, Inc., Class A	104	07/20/18	USD 22.50	USD 283	(57,720)
Zuora, Inc., Class A	93	07/20/18	USD 35.00	USD 253	(4,650)
Alibaba Group Holding Ltd. ADR	67	07/27/18	USD 192.50	USD 1,243	(24,790)
Alphabet, Inc., Class A	24	07/27/18	USD 1,160.00	USD 2,710	(57,000)
Amazon.com, Inc.	25	07/27/18	USD 1,725.00	USD 4,250	(138,938)
Apple, Inc.	18	07/27/18	USD 190.00	USD 333	(4,014)
Apple, Inc.	18	07/27/18	USD 187.50	USD 333	(4,995)
Baidu, Inc. ADR	75	07/27/18	USD 270.00	USD 1,823	(16,050)
Cree, Inc.	107	07/27/18	USD 51.00	USD 445	(1,712)
Facebook, Inc., Class A	27	07/27/18	USD 192.50	USD 525	(20,925)
Microsoft Corp.	71	07/27/18	USD 103.00	USD 700	(8,023)
Microsoft Corp.	174	07/27/18	USD 101.00	USD 1,716	(31,755)
PayPal Holdings, Inc.	57	07/27/18	USD 86.00	USD 475	(10,374)
Roku, Inc.	130	07/27/18	USD 48.00	USD 554	(12,025)
ServiceNow, Inc.	67	07/27/18	USD 187.50	USD 1,156	(12,562)
Shopify, Inc., Class A	68	07/27/18	USD 167.50	USD 992	(6,970)
Spotify Technology SA	16	07/27/18	USD 180.00	USD 269	(8,960)
Take-Two Interactive Software, Inc.	95	07/27/18	USD 118.00	USD 1,124	(45,125)
Tesla, Inc.	39	07/27/18	USD 330.00	USD 1,338	(114,173)
Visa, Inc., Class A	163	07/27/18	USD 137.00	USD 2,159	(26,487)
salesforce.com, Inc.	93	07/27/18	USD 137.00	USD 1,269	(36,270)
Okta, Inc.	275	07/31/18	USD 55.00	USD 1,385	(38,639)
Activision Blizzard, Inc.	119	08/03/18	USD 76.50	USD 908	(38,675)
Adobe Systems, Inc.	50	08/03/18	USD 250.00	USD 1,219	(26,875)
Alibaba Group Holding Ltd. ADR	82	08/03/18	USD 205.00	USD 1,521	(12,628)
Autodesk, Inc.	57	08/03/18	USD 138.00	USD 747	(12,682)
Baidu, Inc. ADR	49	08/03/18	USD 245.00	USD 1,191	(53,410)
Facebook, Inc., Class A	18	08/03/18	USD 202.50	USD 350	(8,460)
Facebook, Inc., Class A	61	08/03/18	USD 205.00	USD 1,185	(23,942)
Microsoft Corp.	78	08/03/18	USD 102.00	USD 769	(12,987)
NVIDIA Corp.	75	08/03/18	USD 250.00	USD 1,777	(36,000)
Roku, Inc.	130	08/03/18	USD 42.50	USD 554	(39,975)
Take-Two Interactive Software, Inc.	91	08/03/18	USD 122.00	USD 1,077	(41,860)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Visa, Inc., Class A	111	08/03/18	USD	135.00	USD	1,470	(29,526)
Yandex NV, Class A	174	08/03/18	USD	36.50	USD	625	(32,625)
Amazon.com, Inc.	15	08/10/18	USD	1,710.00	USD	2,550	(112,838)
Cree, Inc.	80	08/10/18	USD	44.00	USD	333	(8,040)
FireEye, Inc.	50	08/10/18	USD	16.00	USD	77	(4,300)
Microsoft Corp.	174	08/10/18	USD	102.00	USD	1,716	(32,538)
PayPal Holdings, Inc.	79	08/10/18	USD	85.00	USD	658	(23,344)
Square, Inc., Class A	460	08/10/18	USD	62.00	USD	2,835	(192,050)
salesforce.com, Inc.	92	08/10/18	USD	138.00	USD	1,255	(40,710)
Activision Blizzard, Inc.	119	08/17/18	USD	77.50	USD	908	(39,865)
Adobe Systems, Inc.	70	08/17/18	USD	250.00	USD	1,707	(47,250)
Advanced Micro Devices, Inc.	562	08/17/18	USD	16.00	USD	842	(49,456)
Alibaba Group Holding Ltd. ADR	76	08/17/18	USD	210.00	USD	1,410	(16,986)
Alphabet, Inc., Class A	13	08/17/18	USD	1,105.00	USD	1,468	(78,195)
Amazon.com, Inc.	25	08/17/18	USD	1,760.00	USD	4,250	(139,000)
Apple, Inc.	68	08/17/18	USD	190.00	USD	1,259	(28,560)
Broadcom Inc.	106	08/17/18	USD	280.00	USD	2,572	(5,830)
Cree, Inc.	80	08/17/18	USD	49.00	USD	333	(5,200)
Electronic Arts, Inc.	101	08/17/18	USD	145.00	USD	1,424	(54,793)
Facebook, Inc., Class A	60	08/17/18	USD	190.00	USD	1,166	(70,350)
FireEye, Inc.	101	08/17/18	USD	18.00	USD	155	(2,676)
FireEye, Inc.	76	08/17/18	USD	17.00	USD	117	(3,458)
Lam Research Corp.	21	08/17/18	USD	180.00	USD	363	(14,175)
Mastercard, Inc., Class A	151	08/17/18	USD	200.00	USD	2,967	(80,785)
Microsoft Corp.	56	08/17/18	USD	105.00	USD	552	(6,272)
NVIDIA Corp.	73	08/17/18	USD	265.00	USD	1,729	(32,668)

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)					
Netflix, Inc.	47	08/17/18	USD 405.00	USD 1,840	\$ (109,275)
ON Semiconductor Corp.	218	08/17/18	USD 23.00	USD 485	(22,345)
PageSeguro Digital Ltd., Class A	815	08/17/18	USD 30.00	USD 2,262	(142,625)
PayPal Holdings, Inc.	79	08/17/18	USD 87.50	USD 658	(17,459)
Pivotal Software, Inc., Class A	192	08/17/18	USD 26.00	USD 466	(33,600)
Qorvo, Inc.	190	08/17/18	USD 82.50	USD 1,523	(74,100)
Roku, Inc.	102	08/17/18	USD 44.00	USD 435	(37,740)
SailPoint Technologies Holding, Inc.	167	08/17/18	USD 25.00	USD 410	(26,720)
Shopify, Inc., Class A	120	08/17/18	USD 175.00	USD 1,751	(28,800)
Skyworks Solutions, Inc.	154	08/17/18	USD 105.00	USD 1,488	(23,100)
Square, Inc., Class A	361	08/17/18	USD 65.00	USD 2,225	(117,325)
Visa, Inc., Class A	62	08/17/18	USD 135.00	USD 821	(19,840)
Wix.com Ltd.	196	08/17/18	USD 100.00	USD 1,966	(159,740)
Yandex NV, Class A	142	08/17/18	USD 37.00	USD 510	(28,045)
Zuora, Inc., Class A	111	08/17/18	USD 35.00	USD 302	(17,482)
salesforce.com, Inc.	94	08/17/18	USD 140.00	USD 1,282	(37,365)
MercadoLibre, Inc.	40	09/21/18	USD 310.00	USD 1,196	(93,400)
Pivotal Software, Inc., Class A	191	09/21/18	USD 30.00	USD 464	(30,083)
					\$ (5,256,833)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
Aixtron SE	Morgan Stanley & Co. International PLC	42,000	07/10/18	EUR 14.29	EUR 463	\$ (24)
Delivery Hero AG	Morgan Stanley & Co. International PLC	15,100	07/10/18	EUR 41.61	EUR 685	(67,235)
SOITEC	UBS AG	14,200	07/10/18	EUR 81.37	EUR 1,020	(3,595)
STMicroelectronics						
NV	Morgan Stanley & Co. International PLC	25,300	07/10/18	EUR 21.04	EUR 481	(1,222)
SendGrid, Inc.	Barclays Bank PLC	20,400	07/10/18	USD 27.40	USD 541	(16,684)
UbiSoft						
Entertainment SA	Morgan Stanley & Co. International PLC	15,700	07/10/18	EUR 87.10	EUR 1,470	(127,596)
	Barclays Bank PLC	7,900	07/11/18	USD 37.54	USD 300	(10,424)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Bandwidth, Inc., Class A								
Bandwidth, Inc., Class A	Citibank N.A.	7,800	07/11/18	USD	35.00	USD	296	(24,656)
Isra Vision AG	Goldman Sachs International	7,800	07/11/18	EUR	50.93	EUR	408	(23,300)
Linx SA	Morgan Stanley & Co. International PLC	30,600	07/11/18	USD	20.20	USD	542	(37)
Naspers Ltd., Class N	Goldman Sachs International	6,600	07/11/18	ZAR	3,386.25	ZAR	22,828	(53,807)
RIB Software SE	Morgan Stanley & Co. International PLC	41,000	07/11/18	EUR	21.22	EUR	813	(10,343)
Tencent Holdings Ltd.	Goldman Sachs International	120,200	07/11/18	HKD	421.00	HKD	47,355	(12,707)
Altair Engineering, Inc.	Barclays Bank PLC	26,000	07/12/18	USD	38.45	USD	889	(902)
Sunny Optical Technology Group Co. Ltd.	UBS AG	90,400	07/12/18	HKD	156.89	HKD	13,155	(14,979)
Taiwan Semiconductor Manufacturing Co. Ltd.	Goldman Sachs International	325,000	07/12/18	USD	237.08	USD	70,363	(306)
ASML Holding NV	HSBC Bank PLC	11,500	07/18/18	EUR	184.50	EUR	1,949	(14,304)
Kingdee International Software Group Co., Ltd.	UBS AG	550,000	07/18/18	HKD	10.11	HKD	4,395	(5,031)
Xero Ltd.	Goldman Sachs International	42,000	07/18/18	AUD	44.70	AUD	1,888	(41,294)
ams AG	Goldman Sachs International	16,600	07/18/18	CHF	101.12	CHF	1,219	(179)
Aixtron SE	Morgan Stanley & Co. International PLC	31,500	07/25/18	EUR	13.23	EUR	347	(2,690)
Delivery Hero AG	Credit Suisse International	17,600	07/25/18	EUR	40.87	EUR	799	(93,900)
RIB Software SE Taiwan Semiconductor Manufacturing Co. Ltd.	Morgan Stanley & Co. International PLC	41,000	07/25/18	EUR	21.22	EUR	813	(22,573)
Altium Ltd.	UBS AG	108,000	07/25/18	USD	228.60	USD	23,382	(3,771)
GMO Payment Gateway, Inc.	Morgan Stanley & Co. International PLC	67,300	07/26/18	AUD	23.55	AUD	1,512	(23,165)
Kingdee International Software Group Co., Ltd.	JPMorgan Chase Bank N.A.	13,400	07/26/18	JPY	12,127.50	JPY	170,805	(111,904)
Tencent Holdings Ltd.	JPMorgan Chase Bank N.A.	550,000	07/26/18	HKD	9.45	HKD	4,395	(15,174)
InterXion Holding NV	Citibank N.A.	112,400	07/26/18	HKD	408.90	HKD	44,282	(75,939)
ON Semiconductor Corp.	Morgan Stanley & Co. International PLC	18,000	07/31/18	USD	66.48	USD	1,124	(6,223)
SOITEC	UBS AG	26,500	07/31/18	USD	26.22	USD	589	(4,220)
STMicroelectronics NV	Goldman Sachs International	17,800	08/07/18	EUR	78.93	EUR	1,278	(41,435)
	Goldman Sachs International	23,800	08/07/18	EUR	20.77	EUR	452	(9,819)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

UbiSoft									
Entertainment SA	Goldman Sachs International	11,400	08/07/18	EUR	93.55	EUR	1,067	(53,645)	
ASML Holding									
NV	UBS AG	12,000	08/08/18	EUR	175.02	EUR	2,033	(62,052)	
Altium Ltd.	Deutsche Bank AG	47,000	08/08/18	AUD	24.97	AUD	1,056	(10,293)	
Kingdee									
International									
Software Group									
Co., Ltd.	Morgan Stanley & Co. International PLC	154,000	08/08/18	HKD	8.46	HKD	1,230	(12,163)	
Smartsheet, Inc.,									
Class A	Barclays Bank PLC	14,200	08/08/18	USD	26.55	USD	369	(32,529)	

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>		<i>Exercise Price</i>		<i>Notional Amount (000)</i>		<i>Value</i>
Call (continued)									
UT Group Co., Ltd.	Societe Generale	31,500	08/08/18	JPY	4,433.00	JPY	130,257	\$	(38,889)
Carbon Black, Inc.	Deutsche Bank AG	8,400	08/09/18	USD	25.72	USD	218		(22,321)
Bandwidth, Inc., Class A	Barclays Bank PLC	17,000	08/10/18	USD	37.90	USD	646		(35,635)
Isra Vision AG	UBS AG	7,800	08/10/18	EUR	54.88	EUR	408		(28,472)
Carbon Black, Inc.	Deutsche Bank AG	8,400	08/14/18	USD	25.72	USD	218		(23,579)
Altair Engineering, Inc., Class A	Barclays Bank PLC	29,400	08/20/18	USD	34.73	USD	1,005		(46,467)
									\$ (1,205,483)

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Appreciation</i>	<i>Unrealized Depreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 2,999,050	\$ (1,545,291)	\$ (6,462,316)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

	<i>Commodity Contracts</i>	<i>Credit Contracts</i>	<i>Equity Contracts</i>	<i>Foreign Currency Exchange Contracts</i>	<i>Interest Rate Contracts</i>	<i>Other Contracts</i>	<i>Total</i>
Liabilities							
Derivative Financial Instruments							
Options written							
Options written, at value	\$	\$	\$ 6,462,316	\$	\$	\$	\$ 6,462,316

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

	<i>Commodity</i>	<i>Credit</i>	<i>Equity</i>	<i>Foreign</i>	<i>Interest</i>	<i>Other</i>	<i>Total</i>
	<i>Contracts</i>	<i>Contracts</i>	<i>Contracts</i>	<i>Exchange</i>	<i>Rate</i>	<i>Contracts</i>	
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (5,100)	\$	\$	\$	\$ (5,100)
Options written			(10,692,313)				(10,692,313)
	\$	\$	\$ (10,697,413)	\$	\$	\$	\$ (10,697,413)

^(a) Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation (Depreciation) on:

Options written	\$	\$	\$ (793,166)	\$	\$	\$	\$ (793,166)
-----------------	----	----	--------------	----	----	----	--------------

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased	\$	^(a)
Average value of option contracts written	\$	6,094,471

^(a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

Derivative Financial Instruments Offsetting as of Period End

The Trust's derivative assets and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Options	\$	\$ 6,462,316
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(5,256,833)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,205,483

The following table presents the Trust's derivative assets (and liabilities) by counterparty net of amounts available for offset under an MNA and net of the related collateral received (and pledged) by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to an MNA by Counterparty</i>	<i>Derivatives Available for Offset</i>	<i>Non-cash Collateral Pledged</i>	<i>Cash Collateral Pledged^(a)</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Barclays Bank PLC	\$ 142,641	\$	\$	\$ (142,641)	\$
Citibank N.A.	100,595			(100,595)	
Credit Suisse International	93,900			(30,000)	63,900
Deutsche Bank AG	56,193				56,193
Goldman Sachs International	236,492			(236,492)	
HSBC Bank PLC	14,304				14,304
JPMorgan Chase Bank N.A.	127,078			(90,000)	37,078
Morgan Stanley & Co. International PLC	273,271			(273,271)	
Societe Generale	38,889				38,889
UBS AG	122,120			(122,120)	
	\$ 1,205,483	\$	\$	\$ (995,119)	\$ 210,364

(a) Excess of collateral received from the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Automobiles	\$ 5,658,675	\$	\$	\$ 5,658,675
Consumer Finance	991,964			991,964
Diversified Consumer Services	1,584,082			1,584,082
Electronic Equipment, Instruments & Components		9,777,535		9,777,535
Health Care Technology	3,583,014			3,583,014
Household Durables	4,313,016			4,313,016
Internet & Direct Marketing Retail	53,326,347			53,326,347
Internet Software & Services	143,380,643	37,834,210		181,214,853
IT Services	79,124,395	4,409,488		83,533,883
Media		8,345,959		8,345,959
Professional Services		3,368,913		3,368,913
Semiconductors & Semiconductor Equipment	53,028,319	40,803,035		93,831,354
Software	169,690,761	36,711,743		206,402,504
Technology Hardware, Storage & Peripherals	26,266,369			26,266,369
Preferred Stocks			16,217,751	16,217,751
Short-Term Securities	5,803,333			5,803,333
Subtotal	\$ 546,750,919	\$ 141,250,882	\$ 16,217,751	\$ 704,219,552
Investments valued at NAV ^(a)				277,007
				\$ 704,496,559

Schedule of Investments (unaudited) (continued)

BlackRock Science and Technology Trust (BST)

June 30, 2018

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Derivative Financial Instruments ^(b)				
Liabilities:				
Equity contracts	\$ (5,201,275)	\$ (1,261,041)	\$	\$ (6,462,316)

(a) As of June 30, 2018, certain of the Trust's Investments were fair valued using net asset value (NAV) per share and have been excluded from the fair value hierarchy.

(b) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 10,286,668	\$ 10,286,668	\$

(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	<i>Common Stocks</i>	<i>Preferred Stocks</i>	<i>Total</i>
Assets:			
Opening Balance, as of December 31, 2017	\$ 4,971,557	\$ 9,033,909	\$ 14,005,466
Transfers into Level 3			
Transfers out of Level 3			
Accrued discounts/premiums			
Net realized gain (loss)			
Net change in unrealized appreciation (depreciation) ^{(a)(b)}	(1,077,034)	690,979	(386,055)
Purchases		6,492,863	6,492,863

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Sales		(3,894,523)	(3,894,523)
Closing Balance, as of June 30, 2018	\$	\$ 16,217,751	\$ 16,217,751
Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2018 ^(b)	\$	\$ 690,979	\$ 690,979

(a) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at June 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) to determine the value of certain of the Trust's Level 3 investments as of period end.

	Valuation Approach	Unobservable Inputs	Range of unobservable Inputs Utilized
Assets:			
Preferred Stocks	\$ 16,217,751	Market	
		Revenue Multiple ^(a)	7.50x
		Time to Exit ^(b)	2.5 years
		Volatility ^(b)	35%
		Recent Transactions ^(a)	
	\$ 16,217,751		

(a) Increase in unobservable input may result in a significant increase to value, while a decrease in the unobservable input may result in a significant decrease to value.

(b) Decrease in unobservable input may result in a significant increase to value, while an increase in the unobservable input may result in a significant decrease to value.

See notes to financial statements.

Schedule of Investments (unaudited) **BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)**

June 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 99.1%		
Auto Components 1.9%		
Continental AG	14,450	\$ 3,288,498
Valeo SA	58,550	3,192,355
		6,480,853
Building Products 1.1%		
Kingspan Group PLC	71,966	3,603,716
Chemicals 4.0%		
Air Liquide SA	53,100	6,655,830
Linde AG	28,950	6,877,907
		13,533,737
Electric Utilities 35.7%		
American Electric Power Co., Inc. ^(a)	96,220	6,663,235
Duke Energy Corp. ^(a)	155,468	12,294,410
Edison International	91,290	5,775,918
Enel SpA	3,107,517	17,219,313
Eversource Energy ^(a)	80,420	4,713,416
Exelon Corp. ^{(a)(b)}	269,310	11,472,606
FirstEnergy Corp. ^(a)	202,980	7,289,012
Fortis, Inc.	144,250	4,598,690
Iberdrola SA	205,992	1,588,559
NextEra Energy, Inc. ^{(a)(b)}	220,300	36,796,709
PG&E Corp.	80,000	3,404,800
Pinnacle West Capital Corp.	46,720	3,763,763
PPL Corp. ^(a)	114,710	3,274,971
Xcel Energy, Inc.	71,400	3,261,552
		122,116,954
Electrical Equipment 3.9%		
OSRAM Licht AG	27,050	1,101,607
Schneider Electric SE	76,750	6,383,047
Vestas Wind Systems A/S	94,150	5,812,475
		13,297,129
Independent Power and Renewable Electricity Producers 8.0%		
China Longyuan Power Group Corp. Ltd., Class H	10,218,000	8,208,229
EDP Renovaveis SA	1,566,700	16,338,259
NRG Yield, Inc., Class C	172,160	2,961,152
		27,507,640

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Multi-Utilities 19.3%

CMS Energy Corp. ^(a)	127,700	6,037,656
Dominion Energy, Inc. ^(a)	180,060	12,276,491
DTE Energy Co. ^(a)	46,620	4,831,231
National Grid PLC	1,241,374	13,718,507
NiSource, Inc. ^(a)	133,100	3,497,868
Public Service Enterprise Group, Inc. ^(a)	239,616	12,972,810
Sempra Energy ^(a)	70,350	8,168,338
WEC Energy Group, Inc. ^(a)	70,180	4,537,137

66,040,038

Security

Shares Value

Oil, Gas & Consumable Fuels 12.2%

Enbridge, Inc. ^(a)	252,040	\$ 8,995,308
Energy Transfer Partners LP ^(a)	139,769	2,661,202
Enterprise Products Partners LP ^(a)	94,614	2,617,969
MPLX LP	74,489	2,543,054
ONEOK, Inc. ^(a)	59,551	4,158,446
Targa Resources Corp. ^(a)	33,630	1,664,349
TransCanada Corp.	241,750	10,459,620
Williams Cos., Inc. ^(a)	323,650	8,774,152

41,874,100

Semiconductors & Semiconductor Equipment 1.0%

Infineon Technologies AG	133,000	3,378,373
--------------------------	---------	-----------

Transportation Infrastructure 11.2%

Aeroports de Paris	20,170	4,556,206
Atlantia SpA	397,024	11,705,144
Flughafen Zuerich AG	11,710	2,382,576
Fraport AG Frankfurt Airport Services Worldwide	22,880	2,201,159
Getlink SE, Registered Shares	287,850	3,946,383
Sydney Airport	677,826	3,588,371
Transurban Group	1,112,890	9,854,982

38,234,821

Water Utilities 0.8%

American Water Works Co., Inc. ^(a)	32,220	2,750,944
---	--------	-----------

Total Long-Term Investments 99.1%

(Cost \$270,725,073) 338,818,305

Short-Term Securities 2.0%

BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.80% ^{(c)(d)}	6,672,678	6,672,678
---	-----------	-----------

Total Short-Term Securities 2.0%

(Cost \$6,672,678) 6,672,678

Total Investments Before Options Written 101.6%

(Cost \$277,397,751) 345,490,983

Options Written (1.0)%	
(Premiums Received \$2,010,942)	(3,592,911)
Total Investments, Net of Options Written 99.6%	
(Cost \$275,386,809)	341,898,072
Other Assets Less Liabilities 0.4%	1,517,159
Net Assets 0.0%	\$ 343,415,231

- (a) All or a portion of security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (b) All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.
- (c) Annualized 7-day yield as of period end.
- (d) During the period ended June 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 06/30/18</i>	<i>Value at 06/30/18</i>	<i>Income</i>	<i>Change in Net Unrealized Realized Appreciation (Loss/Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	6,376,831	295,847	6,672,678	\$ 6,672,678	\$ 31,776	\$

(a) Includes net capital gain distributions, if applicable.

Schedule of Investments (unaudited) (continued)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

For Trust compliance purposes, the sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Derivative Financial Instruments Outstanding as of Period End**Exchange-Traded Options Written**

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call					
Enterprise Products Partners LP	55	07/06/18	USD 29.00	USD 152	\$ (275)
Williams Cos., Inc.	168	07/06/18	USD 27.50	USD 455	(2,100)
FirstEnergy Corp.	110	07/11/18	USD 34.01	USD 395	(21,810)
FirstEnergy Corp.	73	07/13/18	USD 34.50	USD 262	(11,602)
Williams Cos., Inc.	236	07/13/18	USD 27.00	USD 640	(11,918)
Dominion Energy, Inc.	630	07/19/18	USD 66.00	USD 4,295	(167,988)
American Electric Power Co., Inc.	336	07/20/18	USD 65.00	USD 2,327	(152,880)
American Water Works Co., Inc.	112	07/20/18	USD 85.00	USD 956	(15,960)
DTE Energy Co.	163	07/20/18	USD 100.00	USD 1,689	(70,090)
Duke Energy Corp.	272	07/20/18	USD 80.00	USD 2,151	(19,040)
Enbridge, Inc.	618	07/20/18	USD 35.00	USD 2,206	(80,340)
Enbridge, Inc.	264	07/20/18	USD 32.50	USD 942	(89,760)
Enterprise Products Partners LP	46	07/20/18	USD 29.00	USD 127	(460)
Eversource Energy	157	07/20/18	USD 60.00	USD 920	(2,748)
Eversource Energy	124	07/20/18	USD 55.00	USD 727	(48,980)
Exelon Corp.	471	07/20/18	USD 41.00	USD 2,006	(84,780)
FirstEnergy Corp.	96	07/20/18	USD 35.00	USD 345	(11,760)
NextEra Energy, Inc.	292	07/20/18	USD 166.25	USD 4,877	(84,028)
NextEra Energy, Inc.	186	07/20/18	USD 165.00	USD 3,107	(66,960)
NiSource, Inc.	370	07/20/18	USD 25.00	USD 972	(51,800)
ONEOK, Inc.	124	07/20/18	USD 60.00	USD 866	(125,240)
Targa Resources Corp.	59	07/20/18	USD 50.00	USD 292	(5,753)
Targa Resources Corp.	58	07/20/18	USD 49.00	USD 287	(8,845)
WEC Energy Group, Inc.	106	07/20/18	USD 60.00	USD 685	(51,410)
WEC Energy Group, Inc.	139	07/20/18	USD 61.90	USD 899	(40,934)
Williams Cos., Inc.	226	07/20/18	USD 28.00	USD 613	(4,859)
FirstEnergy Corp.	74	07/24/18	USD 34.75	USD 266	(11,685)
Public Service Enterprise Group, Inc.	363	07/24/18	USD 52.01	USD 1,965	(84,677)
NextEra Energy, Inc.	293	07/25/18	USD 156.00	USD 4,894	(332,440)
Enterprise Products Partners LP	46	07/27/18	USD 29.00	USD 127	(575)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Williams Cos., Inc.	158	07/27/18	USD	28.50	USD	428	(2,686)
Williams Cos., Inc.	172	07/27/18	USD	28.00	USD	466	(4,988)
FirstEnergy Corp.	111	07/31/18	USD	34.75	USD	399	(18,680)
NiSource, Inc.	95	07/31/18	USD	24.50	USD	250	(16,055)
PPL Corp.	401	07/31/18	USD	27.50	USD	1,145	(55,927)
Duke Energy Corp.	272	08/01/18	USD	73.75	USD	2,151	(151,037)
Enterprise Products Partners LP	138	08/10/18	USD	28.00	USD	382	(6,555)
FirstEnergy Corp.	111	08/10/18	USD	33.75	USD	399	(26,288)
Energy Transfer Partners LP	489	08/17/18	USD	20.00	USD	931	(14,670)
Enterprise Products Partners LP	46	08/17/18	USD	29.00	USD	127	(920)
ONEOK, Inc.	84	08/17/18	USD	70.00	USD	587	(16,590)
TransCanada Corp.	846	08/17/18	CAD	58.00	CAD	4,812	(54,377)
Williams Cos., Inc.	172	08/17/18	USD	28.00	USD	466	(9,116)
Public Service Enterprise Group, Inc.	251	08/22/18	USD	54.05	USD	1,359	(38,877)
Sempra Energy	101	08/27/18	USD	116.00	USD	1,173	(40,346)
							\$ (2,118,809)

OTC Options Written

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call						
Getlink SE, Registered Shares	Morgan Stanley & Co. International PLC	53,300	07/10/18	EUR 12.13	EUR 626	\$(879)
Valeo SA	UBS AG	16,600	07/10/18	EUR 58.32	EUR 775	(3)

Schedule of Investments (unaudited) (continued)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

June 30, 2018

OTC Options Written (continued)

<i>Description</i>	<i>Counterparty</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
Call (continued)						
Xcel Energy, Inc.	Bank of America N.A.	24,900	07/10/18	USD 43.65	USD 1,137	\$ (51,866)
China Longyuan Power Group Corp. Ltd., Class H	Morgan Stanley & Co. International PLC	1,000,000	07/11/18	HKD 7.53	HKD 6,300	(733)
Pinnacle West Capital Corp.	Credit Suisse International	16,300	07/11/18	USD 77.12	USD 1,313	(58,267)
EDP Renovaveis SA	UBS AG	50,000	07/12/18	EUR 8.23	EUR 447	(41,078)
Enel SpA	UBS AG	514,600	07/12/18	EUR 4.92	EUR 2,439	(12,560)
Iberdrola SA	UBS AG	36,000	07/12/18	EUR 6.55	EUR 238	(2,388)
Kingspan Group PLC	Morgan Stanley & Co. International PLC	28,200	07/12/18	EUR 40.11	EUR 1,209	(92,580)
Linde AG	Morgan Stanley & Co. International PLC	10,100	07/12/18	EUR 197.09	EUR 2,055	(95,544)
National Grid PLC	Morgan Stanley & Co. International PLC	97,000	07/12/18	GBP 8.94	GBP 812	(30)
OSRAM Licht AG	Deutsche Bank AG	8,400	07/12/18	EUR 54.41	EUR 293	(4)
Sydney Airport	Morgan Stanley & Co. International PLC	131,900	07/12/18	AUD 7.30	AUD 943	(4,355)
Transurban Group	UBS AG	145,200	07/12/18	AUD 11.90	AUD 1,738	(20,308)
Air Liquide SA	Morgan Stanley & Co. International PLC	3,300	07/13/18	EUR 112.62	EUR 354	(475)
Public Service Enterprise Group, Inc.	Bank of America N.A.	22,400	07/16/18	USD 53.44	USD 1,213	(24,618)
NRG Yield, Inc., Class C	Bank of America N.A.	16,800	07/17/18	USD 17.78	USD 289	(1,678)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Aeroports de Paris	Goldman Sachs International	7,100	07/18/18	EUR	178.96	EUR	1,373	(121,329)
Atlantia SpA	Bank of America N.A.	17,300	07/18/18	EUR	24.90	EUR	437	(13,425)
China Longyuan Power Group Corp. Ltd., Class H	Citibank N.A.	1,267,000	07/18/18	HKD	7.03	HKD	7,982	(7,575)
EDP Renovaveis SA	Credit Suisse International	50,000	07/18/18	EUR	8.25	EUR	447	(39,985)
Enel SpA	UBS AG	200,000	07/18/18	EUR	4.80	EUR	948	(15,396)
Iberdrola SA	Goldman Sachs International	36,000	07/18/18	EUR	6.40	EUR	238	(8,912)
Schneider Electric SE	Barclays Bank PLC	15,100	07/18/18	EUR	76.74	EUR	1,075	(1,242)
Transurban Group	Morgan Stanley & Co. International PLC	98,974	07/18/18	AUD	11.89	AUD	1,185	(16,685)
Vestas Wind Systems A/S	Goldman Sachs International	33,000	07/19/18	DKK	423.68	DKK	12,998	(14,232)
Fraport AG Frankfurt Airport Services Worldwide	Goldman Sachs International	8,100	07/24/18	EUR	81.62	EUR	667	(21,672)
Getlink SE, Registered Shares	Deutsche Bank AG	47,500	07/25/18	EUR	11.76	EUR	558	(11,937)
National Grid PLC	Citibank N.A.	9,100	07/25/18	GBP	8.42	GBP	76	(1,588)
Air Liquide SA	Citibank N.A.	15,300	07/26/18	EUR	111.75	EUR	1,642	(9,374)
Atlantia SpA	Credit Suisse International	43,200	07/26/18	EUR	25.01	EUR	1,091	(34,477)
China Longyuan Power Group Corp. Ltd., Class H	Citibank N.A.	1,310,000	07/26/18	HKD	7.13	HKD	8,253	(10,505)
EDP Renovaveis SA	Morgan Stanley & Co. International PLC	50,000	07/26/18	EUR	8.05	EUR	447	(51,357)
Infineon Technologies AG	Goldman Sachs International	23,100	07/26/18	EUR	24.08	EUR	502	(4,664)
National Grid PLC	Goldman Sachs International	106,100	07/26/18	GBP	8.83	GBP	888	(2,840)
Transurban Group	Morgan Stanley & Co. International PLC	145,300	07/26/18	AUD	12.00	AUD	1,739	(20,989)
Sempra Energy	Morgan Stanley & Co. International PLC	14,500	07/27/18	USD	116.68	USD	1,684	(33,325)
Atlantia SpA	UBS AG	78,500	08/01/18	EUR	24.72	EUR	1,982	(87,060)
EDP Renovaveis SA	UBS AG	30,000	08/01/18	EUR	8.21	EUR	268	(25,656)
Enel SpA		317,000	08/01/18	EUR	4.87	EUR	1,503	(11,666)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Exelon Corp.	Credit Suisse International JPMorgan Chase Bank N.A.	47,100	08/01/18	USD	41.18	USD	2,006	(85,020)
Fortis, Inc.	UBS AG	25,400	08/01/18	USD	32.50	USD	810	(22,181)
National Grid PLC	Credit Suisse International	193,900	08/01/18	GBP	8.46	GBP	1,623	(32,779)
Flughafen Zuerich AG	Citibank N.A.	4,169	08/02/18	CHF	216.75	CHF	840	(2,065)
CMS Energy Corp.	UBS AG	44,600	08/07/18	USD	43.45	USD	2,109	(184,041)
Continental AG	UBS AG	4,500	08/07/18	EUR	227.24	EUR	877	(916)
EDP Renovaveis SA	UBS AG	30,000	08/08/18	EUR	8.21	EUR	268	(25,950)
Schneider Electric SE	Morgan Stanley & Co. International PLC	11,800	08/08/18	EUR	71.59	EUR	840	(26,235)
EDP Renovaveis SA	UBS AG	30,000	08/14/18	EUR	8.21	EUR	268	(26,183)
Sydney Airport	JPMorgan Chase Bank N.A.	105,400	08/16/18	AUD	7.60	AUD	754	(3,687)
NRG Yield, Inc., Class C	Barclays Bank PLC	43,400	08/20/18	USD	17.75	USD	746	(14,794)
EDP Renovaveis SA	Morgan Stanley & Co. International PLC	40,000	08/21/18	EUR	8.49	EUR	357	(24,902)
EDP Renovaveis SA	Goldman Sachs International	40,000	08/29/18	EUR	8.93	EUR	357	(12,875)
FirstEnergy Corp.	JPMorgan Chase Bank N.A.	13,500	08/29/18	USD	36.65	USD	485	(9,574)
Fortis, Inc.	Bank of America N.A.	25,000	09/04/18	USD	31.72	USD	797	(16,050)
EDP Renovaveis SA	Goldman Sachs International	40,000	09/05/18	EUR	8.93	EUR	357	(13,593)
								\$ (1,474,102)

Schedule of Investments (unaudited) (continued) **BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)**
 June 30, 2018

Balances Reported in the Statements of Assets and Liabilities for OTC Derivatives

	<i>Swap Premium Paid</i>	<i>Swap Premium Received</i>	<i>Unrealized Depreciation</i>	<i>Unrealized Appreciation</i>	<i>Value</i>
Options Written	N/A	N/A	\$ 415,293	\$ (1,997,262)	\$ (3,592,911)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

Liabilities	Commodity Contracts	Credit Contracts	Equity Contracts	Foreign Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total
Derivative Financial Instruments							
Options written							
Options written, at value	\$	\$	\$ 3,592,911	\$	\$	\$	\$ 3,592,911

For the period ended June 30, 2018, the effect of derivative financial instruments in the Statements of Operations was as follows:

	Commodity Contracts	Credit Contracts	Equity Contracts	Foreign Currency Exchange Contracts	Interest Rate Contracts	Other Contracts	Total
Net Realized Gain (Loss) from:							
Options purchased ^(a)	\$	\$	\$ (713)	\$	\$	\$	\$ (713)
Options written			185,899				185,899
	\$	\$	\$ 185,186	\$	\$	\$	\$ 185,186

^(a) Options purchased are included in net realized gain (loss) from investments.

Net Change in Unrealized Appreciation (Depreciation) on:

Options purchased ^(a)	\$	\$	\$ (547)	\$	\$	\$	\$ (547)
Options written			(2,314,197)				(2,314,197)

\$ \$ \$ (2,314,744) \$ \$ \$ \$ (2,314,744)

(a) Includes options purchased at value as reported in the Schedule of Investments.

Average Quarterly Balances of Outstanding Derivative Financial Instruments

Options:

Average value of option contracts purchased	\$	(a)
Average value of option contracts written	\$	3,257,934

(a) Derivative not held at quarter-end. The amount shown in the Statements of Operations reflect the results of activity during the period.

For more information about the Trust's investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments Offsetting as of Period End

The Trust's derivative asset and liabilities (by type) are as follows:

	<i>Assets</i>	<i>Liabilities</i>
Derivative Financial Instruments		
Options	\$	\$ 3,592,911
Derivatives not subject to a Master Netting Agreement or similar agreement (MNA)		(2,118,809)
Total derivative assets and liabilities subject to an MNA	\$	\$ 1,474,102

Schedule of Investments (unaudited) (continued) **BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)**

June 30, 2018

The following table presents the Trust's derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral and pledged by the Trust:

<i>Counterparty</i>	<i>Derivative Liabilities Subject to Derivatives an MNA by Counterparty Available for Offset</i>		<i>Non-cash Collateral Pledged^(a)</i>	<i>Cash Collateral Pledged</i>	<i>Net Amount of Derivative Liabilities^(b)</i>
Bank of America N.A.	\$ 107,637	\$	\$	\$	\$ 107,637
Barclays Bank PLC	16,036		(2,495)		13,541
Citibank N.A.	31,107		(31,107)		
Credit Suisse International	177,174		(177,174)		
Deutsche Bank AG	11,941		(11,941)		
Goldman Sachs International	200,117			(130,000)	70,117
JPMorgan Chase Bank N.A.	98,281				98,281
Morgan Stanley & Co. International PLC	368,089		(368,089)		
UBS AG	463,720		(208,012)		255,708
	\$ 1,474,102	\$	\$ (798,818)	\$ (130,000)	\$ 545,284

(a) Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

(b) Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Notes to Financial Statements.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Auto Components	\$	\$ 6,480,853	\$	\$ 6,480,853
Building Products	3,603,716			3,603,716

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Chemicals		13,533,737		13,533,737
Electric Utilities	103,309,082	18,807,872		122,116,954
Electrical Equipment		13,297,129		13,297,129
Independent Power and Renewable Electricity Producers	19,299,411	8,208,229		27,507,640
Multi-Utilities	52,321,531	13,718,507		66,040,038
Oil, Gas & Consumable Fuels	41,874,100			41,874,100
Semiconductors & Semiconductor Equipment		3,378,373		3,378,373
Transportation Infrastructure		38,234,821		38,234,821
Water Utilities	2,750,944			2,750,944
Short-Term Securities	6,672,678			6,672,678
	\$ 229,831,462	\$ 115,659,521	\$	\$ 345,490,983
Derivative Financial Instruments ^(a)				
Liabilities:				
Equity contracts	\$ (1,016,434)	\$ (2,576,477)	\$	\$ (3,592,911)

^(a) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1</i>	<i>Transfers out of Level 1^(a)</i>	<i>Transfers Into Level 2^(a)</i>	<i>Transfers out of Level 2</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 3,858,072	\$ 3,858,072	\$

^(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

See notes to financial statements.

Statements of Assets and Liabilities (unaudited)

June 30, 2018

	BGR	CII	BDJ	BOE	BGY
ASSETS					
Investments at value unaffiliated ^{(a)(b)}	\$ 475,625,445	\$ 749,989,101	\$ 1,807,388,599	\$ 819,443,881	\$ 689,283,953
Investments at value affiliated ^(c)	4,599,459	4,630,300	13,805,466		943,659
Due to broker					1,553,352
Cash pledged:					
Collateral OTC derivatives			16,000		803,000
Collateral options written				3,225,000	5,170,000
Foreign currency at value ^(d)	290,569		1,117	351,455	438,298
Receivables:					
Investments sold	6,732,791	263,300	572,831	1,863,536	3,242,645
Dividends unaffiliated	382,970	864,966	2,431,189	3,752,713	3,771,338
Options written	139,844	601,703	1,378,909	400,215	590,394
Dividends affiliated	6,781	6,269	18,286	7,123	
Securities lending income affiliated			7		
Prepaid expenses	13,098	28,676	65,627	28,615	33,183
Total assets	487,790,957	756,384,315	1,825,678,031	829,072,538	705,829,822
LIABILITIES					
Cash collateral on securities loaned at value			12,294		
Bank overdraft			51,239	380,331	
Options written at value ^(e)	3,538,539	6,477,238	15,288,978	6,213,872	5,608,380
Payables:					
Investments purchased	6,552,884	372,603	3,065,960	184	5,116,017
Trustees and Officer s fees	485,529	200,707	961,873	711,177	218,602
Investment advisory fees	406,738	529,408	1,198,528	611,512	516,588
Options written	222,218	271,757	498,252	106,610	92,396
Income dividend distributions	159,320	212,598	298,756	191,684	614,474
Other accrued expenses	120,681	196,303	333,681	249,578	227,267
Total liabilities	11,485,909	8,260,614	21,709,561	8,464,948	12,393,724
NET ASSETS	\$ 476,305,048	\$ 748,123,701	\$ 1,803,968,470	\$ 820,607,590	\$ 693,436,098

NET ASSETS CONSIST OF:

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Paid-in capital	\$ 599,545,557	\$ 601,583,666	\$ 1,320,628,954	\$ 831,421,885	\$ 680,249,058
Distributions in excess of net investment income	(10,562,679)	(18,476,686)	(37,685,311)	(19,351,880)	(11,950,317)
Accumulated net realized gain (loss)	(183,729,721)	(2,501,419)	111,709,900	37,262,216	58,068,210
Net unrealized appreciation (depreciation)	71,051,891	167,518,140	409,314,927	(28,724,631)	(32,930,853)
NET ASSETS	\$ 476,305,048	\$ 748,123,701	\$ 1,803,968,470	\$ 820,607,590	\$ 693,436,098
Net asset value ^{(f)(g)}	\$ 15.97	\$ 16.96	\$ 9.62	\$ 11.91	\$ 6.36

(a) Investments at cost unaffiliated	\$ 404,613,943	\$ 584,061,337	\$ 1,400,290,492	\$ 848,155,824	\$ 721,868,971
(b) Securities loaned at value	\$	\$	\$ 11,215	\$	\$
(c) Investments at cost affiliated	\$ 4,599,459	\$ 4,630,300	\$ 13,805,466	\$	\$ 943,659
(d) Foreign currency at cost	\$ 287,746	\$	\$ 1,193	\$ 357,292	\$ 438,364
(e) Premiums received	\$ 3,574,813	\$ 8,067,614	\$ 17,508,135	\$ 6,227,625	\$ 5,304,238
(f) Shares outstanding, unlimited number of shares authorized, par value \$0.001 per share	29,825,326		187,542,405	68,911,795	109,049,017
(g) Shares outstanding, 200 million shares authorized, par value \$0.10 per share		44,121,400			

See notes to financial statements.

Statements of Assets and Liabilities (unaudited) (continued)

June 30, 2018

	BME	BCX ^(a)	BST	BUI
ASSETS				
Investments at value unaffiliated ^{(b)(c)}	\$ 337,614,893	\$ 988,025,166	\$ 698,416,219	\$ 338,818,305
Investments at value affiliated ^(d)	7,272,162	7,923,934	6,080,340	6,672,678
Cash	422,843			
Cash pledge as collateral for OTC derivatives			2,310,000	130,000
Foreign currency at value ^(e)	970	533,983	101,678	61
Receivables:				
Investments sold	2,025,642	15,398,531	4,268,837	1,417,520
Capital shares sold	352,211			
Dividends unaffiliated	195,412	1,756,944	290,645	1,267,488
Dividends affiliated	12,385	11,894	6,171	9,342
Options written	236,581	393,259	870,279	12,444
Securities lending income affiliated		102	1,906	
Offering costs	78,142			
Prepaid expenses	11,170	34,583	14,876	16,662
Total assets	348,222,411	1,014,078,396	712,360,951	348,344,500
LIABILITIES				
Cash collateral on securities loaned at value		27,985	277,000	
Bank overdraft		246,682		46,601
Options written at value ^(f)	2,688,836	7,080,083	6,462,316	3,592,911
Payables:				
Investments purchased	2,119,009	16,536,174	5,236,399	710,152
Income dividend distributions		212,092		130,617
Investment advisory fees	281,322	819,901	469,831	271,115
Offering costs	24,000			
Trustees and Officers fees	27,805	332,218	14,346	7,775
Options written	212,308	396,152	922,674	33,479
Other accrued expenses	139,700	251,680	179,165	136,619
Total liabilities	5,492,980	25,902,967	13,561,731	4,929,269
NET ASSETS	\$ 342,729,431	\$ 988,175,429	\$ 698,799,220	\$ 343,415,231

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

NET ASSETS CONSIST OF

Paid-in capital	\$ 235,049,601	\$ 1,274,977,072	\$ 348,761,569	\$ 281,896,948
Distributions in excess of net investment income	(10,780,214)	(22,907,120)	(20,223,997)	(4,028,661)
Accumulated net realized gain (loss)	7,206,834	(433,014,400)	31,109,433	(963,829)
Net unrealized appreciation (depreciation)	111,253,210	169,119,877	339,152,215	66,510,773
NET ASSETS	\$ 342,729,431	\$ 988,175,429	\$ 698,799,220	\$ 343,415,231
Net asset value ^(g)	\$ 36.54	\$ 10.30	\$ 31.20	\$ 20.26

(a) Consolidated Statement of Assets and Liabilities

(b) Investments at cost unaffiliated	\$ 226,572,848	\$ 820,877,390	\$ 360,716,431	\$ 270,725,073
(c) Securities loaned at value	\$	\$ 20	\$ 258,390	\$
(d) Investments at cost affiliated	\$ 7,272,162	\$ 7,923,928	\$ 6,080,330	\$ 6,672,678
(e) Foreign currency at cost	\$ 963	\$ 533,922	\$ 101,798	\$ 77
(f) Premiums received	\$ 2,899,524	\$ 9,065,805	\$ 7,916,075	\$ 2,010,942
(g) Shares outstanding, unlimited number of shares authorized, par value \$0.001 per share	9,380,449	95,908,874	22,395,449	16,953,526

See notes to financial statements.

Statements of Operations (unaudited)

Six Months Ended June 30, 2018

	BGR	CII	BDJ	BOE	BGY
INVESTMENT INCOME					
Dividends unaffiliated	\$ 7,085,380	\$ 7,035,737	\$ 24,335,838	\$ 18,998,651	\$ 18,760,836
Dividends affiliated	28,875	29,997	67,095	56,205	53,789
Securities lending income affiliated net			7		
Foreign taxes withheld	(451,705)	(69,908)	(776,065)	(1,196,883)	(1,636,342)
Total investment income	6,662,550	6,995,826	23,626,875	17,857,973	17,178,283
EXPENSES					
Investment advisory	2,742,268	3,180,371	7,304,337	4,297,630	3,643,847
Professional	44,322	49,685	92,717	73,041	63,257
Transfer agent	42,679	30,428	96,989	61,734	56,454
Custodian	25,697	12,207	81,925	56,480	64,888
Accounting services	17,408	14,923	42,200	24,842	19,900
Trustees and Officer	12,734	34,201	71,898	35,119	34,480
Printing	6,684	4,759	10,349	8,368	8,494
Registration	5,713	8,453	35,926	13,242	20,931
Miscellaneous	55,841	29,844	59,364	88,609	77,829
Total expenses	2,953,346	3,364,871	7,795,705	4,659,065	3,990,080
Less fees waived and/or reimbursed by the Manager	(344,178)	(1,442)	(3,186)	(432,678)	(367,212)
Total expenses after fees waived and/or reimbursed	2,609,168	3,363,429	7,792,519	4,226,387	3,622,868
Net investment income (loss)	4,053,382	3,632,397	15,834,356	13,631,586	13,555,415
REALIZED AND UNREALIZED GAIN (LOSS)					
Net realized gain (loss) from:					
Investments	3,787,294	28,001,029	75,000,639	3,550,649	93,880,466 ^(a)
Payments by affiliates ^(b)					243,859
Foreign currency transactions	11,596	95,365	38,465	140,397	(174,449)
Options written	(14,337,904)	(4,323,450)	(9,659,803)	2,305,969	3,505,781
	(10,539,014)	23,772,944	65,379,301	5,997,015	97,455,657
Net change in unrealized appreciation (depreciation) on:					

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Investments	21,231,224	(19,378,866)	(99,473,803)	(77,873,927)	(160,402,903)
Foreign currency translations	(1,996)		(2,412)	(60,005)	(98,503)
Options written	4,386,198	3,616,469	6,323,305	(63,217)	(1,888,476)
	25,615,426	(15,762,397)	(93,152,910)	(77,997,149)	(162,389,882)
Net realized and unrealized gain (loss)	15,076,412	8,010,547	(27,773,609)	(72,000,134)	(64,934,225)
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$ 19,129,794	\$ 11,642,944	\$ (11,939,253)	\$ (58,368,548)	\$ (51,378,810)

(a) Including \$(211,516) realized foreign capital gain tax.

(b) See Note 6 of the Notes to Financial Statements.

See notes to financial statements.

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2018

	BME	BCX ^(a)	BST	BUI
INVESTMENT INCOME				
Dividends unaffiliated	\$ 2,295,732	\$ 16,735,533	\$ 2,046,613	\$ 7,403,454
Dividends affiliated	83,489	73,740	32,717	31,776
Securities lending income affiliated net	1,241	2,510	123,932	
Foreign taxes withheld	(65,244)	(975,872)	(140,143)	(388,091)
Total investment income	2,315,218	15,835,911	2,063,119	7,047,139
EXPENSES				
Investment advisory	1,667,258	4,933,186	3,351,219	1,710,322
Professional	74,999	73,683	58,648	49,543
Transfer agent	24,563	61,372	32,913	30,272
Custodian	49,895	53,159	89,536	26,227
Accounting services	9,975	24,842	19,900	19,900
Trustees and Officer	14,631	40,980	30,227	15,626
Printing	7,418	8,492	8,105	6,832
Registration	5,838	18,509	4,672	5,980
Miscellaneous	20,545	121,010	55,317	49,422
Total expenses	1,875,122	5,335,233	3,650,537	1,914,124
Less fees waived and/or reimbursed by the Manager	(4,091)	(3,732)	(671,816)	(44,315)
Total expenses after fees waived and/or reimbursed	1,871,031	5,331,501	2,978,721	1,869,809
Net investment income (loss)	444,187	10,504,410	(915,602)	5,177,330
REALIZED AND UNREALIZED GAIN (LOSS)				
Net realized gain (loss) from:				
Investments unaffiliated	12,777,732	45,478,107	47,251,198	1,260,532
Investments affiliated	13	2	(464)	
Foreign currency transactions	5,323	371,864	(48,482)	(17,034)
Options written	(2,080,545)	(19,278,563)	(10,692,313)	185,899
	10,702,523	26,571,410	36,509,939	1,429,397
Net change in unrealized appreciation (depreciation) on:				

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Investments unaffiliated	7,749,006	(50,501,437)	60,415,871	(6,608,666)
Investments affiliated	7	45	179	
Foreign currency translations	(1,049)	(21,802)	(1,953)	(5,287)
Options written	6,401	10,195,573	(793,166)	(2,314,197)
	7,754,365	(40,327,621)	59,620,931	(8,928,150)
Net realized and unrealized gain (loss)	18,456,888	(13,756,211)	96,130,870	(7,498,753)
NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS	\$ 18,901,075	\$ (3,251,801)	\$ 95,215,268	\$ (2,321,423)

(a) Consolidated Statement of Operations.

See notes to financial statements.

Statements of Changes in Net Assets

	BGR		CII	
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
<i>INCREASE (DECREASE) IN NET ASSETS</i>				
OPERATIONS				
Net investment income	\$ 4,053,382	\$ 12,016,029	\$ 3,632,397	\$ 6,643,909
Net realized gain (loss)	(10,539,014)	240,009	23,772,944	10,582,824
Net change in unrealized appreciation (depreciation)	25,615,426	(484,738)	(15,762,397)	119,853,112
Net increase in net assets resulting from operations	19,129,794	11,771,300	11,642,944	137,079,845
DISTRIBUTIONS TO SHAREHOLDERS				
From net investment income	(13,886,672) ^(a)	(12,093,542) ^(b)	(21,919,512) ^(a)	(6,682,172) ^(b)
From return of capital		(15,679,802) ^(b)		(37,156,851) ^(b)
Decrease in net assets resulting from distributions to shareholders	(13,886,672)	(27,773,344)	(21,919,512)	(43,839,023)
NET ASSETS				
Total increase (decrease) in net assets	5,243,122	(16,002,044)	(10,276,568)	93,240,822
Beginning of period	471,061,926	487,063,970	758,400,269	665,159,447
End of period	\$ 476,305,048	\$ 471,061,926	\$ 748,123,701	\$ 758,400,269
Distributions in excess of net investment income, end of period	\$ (10,562,679)	\$ (729,389)	\$ (18,476,686)	\$ (189,571)

^(a) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

^(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations. See notes to financial statements.

Statements of Changes in Net Assets (continued)

	BDJ		BOE	
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
<i>INCREASE (DECREASE) IN NET ASSETS</i>				
OPERATIONS				
Net investment income	\$ 15,834,356	\$ 30,942,206	\$ 13,631,586	\$ 11,728,245
Net realized gain	65,379,301	191,391,199	5,997,015	188,939,188
Net change in unrealized appreciation (depreciation)	(93,152,910)	22,107,356	(77,997,149)	(54,178,546)
Net increase (decrease) in net assets resulting from operations	(11,939,253)	244,440,761	(58,368,548)	146,488,887
DISTRIBUTIONS TO SHAREHOLDERS				
From net investment income	(52,549,382) ^(a)	(31,328,211) ^(b)	(32,250,719) ^(a)	(12,416,010) ^(b)
From net realized gain		(74,032,175) ^(b)		(145,314,426) ^(b)
Decrease in net assets resulting from distributions to shareholders	(52,549,382)	(105,360,386)	(32,250,719)	(157,730,436)
CAPITAL SHARE TRANSACTIONS				
Redemption of shares resulting from share repurchase program (including transaction costs)		(12,272,105)		(7,428,758)
<i>NET ASSETS APPLICABLE TO COMMON SHAREHOLDERS</i>				
Total increase (decrease) in net assets	(64,488,635)	126,808,270	(90,619,267)	(18,670,307)
Beginning of period	1,868,457,105	1,741,648,835	911,226,857	929,897,164
End of period	\$ 1,803,968,470	\$ 1,868,457,105	\$ 820,607,590	\$ 911,226,857

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Distributions in excess of net
investment income, end of period \$ (37,685,311) \$ (970,285) \$ (19,351,880) \$ (732,747)

(a) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

Statements of Changes in Net Assets (continued)

	BGY		BME	
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
<i>INCREASE (DECREASE) IN NET ASSETS</i>				
OPERATIONS				
Net investment income	\$ 13,555,415	\$ 9,657,720	\$ 444,187	\$ 184,052
Net realized gain	97,455,657	20,853,143	10,702,523	16,290,255
Net change in unrealized appreciation (depreciation)	(162,389,882)	104,149,768	7,754,365	43,865,227
Net increase (decrease) in net assets resulting from operations	(51,378,810)	134,660,631	18,901,075	60,339,534
DISTRIBUTIONS				
From net investment income	(24,863,178) ^(a)	(9,780,974) ^(b)	(11,163,071) ^(a)	(355,707) ^(b)
From net realized gain				(19,026,099) ^(b)
From return of capital		(40,102,438) ^(b)		(2,234,310) ^(b)
Decrease in net assets resulting from distributions to shareholders	(24,863,178)	(49,883,412)	(11,163,071)	(21,616,116)
CAPITAL SHARE TRANSACTIONS				
Proceeds from the issuance of shares (including deferred offering costs)			2,867,059	20,787,792
Reinvestment of distributions			265,971	1,653,765
Redemption of shares resulting from share repurchase program (including transaction costs)		(5,726,813)		
Net increase in net assets derived from capital share transactions		(5,726,813)	3,133,030	22,441,557
<i>NET ASSETS</i>				
Total increase (decrease) in net assets	(76,241,988)	79,050,406	10,871,034	61,164,975
Beginning of period	769,678,086	690,627,680	331,858,397	270,693,422

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

End of period	\$ 693,436,098	\$ 769,678,086	\$ 342,729,431	\$ 331,858,397
Distributions in excess of net investment income, end of period	\$ (11,950,317)	\$ (642,554)	\$ (10,780,214)	\$ (61,330)

(a) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

Statements of Changes in Net Assets (continued)

	BCX ^(a)		BST	
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
<i>INCREASE (DECREASE) IN NET ASSETS</i>				
OPERATIONS				
Net investment income (loss)	\$ 10,504,410	\$ 19,831,605	\$ (915,602)	\$ (1,073,646)
Net realized gain	26,571,410	40,599,529	36,509,939	18,280,612
Net change in unrealized appreciation (depreciation)	(40,327,621)	71,294,123	59,620,931	182,129,520
Net increase (decrease) in net assets resulting from operations	(3,251,801)	131,725,257	95,215,268	199,336,486
DISTRIBUTIONS				
From net investment income	(29,737,204) ^(b)	(23,004,937) ^(c)	(17,456,110) ^(b)	(1,173,241) ^(c)
From net realized gain				(4,969,225) ^(c)
From return of capital		(36,309,489) ^(c)		(22,536,962) ^(c)
Decrease in net assets resulting from distributions to shareholders	(29,737,204)	(59,314,426)	(17,456,110)	(28,679,428)
CAPITAL SHARE TRANSACTIONS				
Reinvestment of common distributions			739,593	
Redemption of shares resulting from share repurchase program (including transaction costs)	(6,307,631)	(21,837,878)		(2,799,570)
Net increase (decrease) in net assets derived from capital share transactions	(6,307,631)	(21,837,878)	739,593	(2,799,570)
<i>NET ASSETS</i>				
Total increase (decrease) in net assets	(39,296,636)	50,572,953	78,498,751	167,857,488

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Beginning of period	1,027,472,065	976,899,112	620,300,469	452,442,981
End of period	\$ 988,175,429	\$ 1,027,472,065	\$ 698,799,220	\$ 620,300,469
Distributions in excess of net investment income, end of period	\$ (22,907,120)	\$ (3,674,326)	\$ (20,223,997)	\$ (1,852,285)

(a) Consolidated Statement of Changes in Net Assets.

(b) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

Statements of Changes in Net Assets (continued)

	BUI	
	Six Months Ended 06/30/18 (unaudited)	Year Ended 12/31/17
<i>INCREASE (DECREASE) IN NET ASSETS</i>		
OPERATIONS		
Net investment income	\$ 5,177,330	\$ 9,484,921
Net realized gain	1,429,397	20,594,890
Net change in unrealized appreciation (depreciation)	(8,928,150)	23,259,316
Net increase (decrease) in net assets resulting from operations	(2,321,423)	53,339,127
DISTRIBUTIONS		
From net investment income	(12,303,649) ^(a)	(7,954,054) ^(b)
From net realized gain		(16,614,050) ^(b)
Decrease in net assets resulting from distributions to shareholders	(12,303,649)	(24,568,104)
CAPITAL SHARE TRANSACTIONS		
Reinvestment of common distributions	263,846	708,672
<i>NET ASSETS</i>		
Total increase (decrease) in net assets	(14,361,226)	29,479,695
Beginning of period	357,776,457	328,296,762
End of period	\$ 343,415,231	\$ 357,776,457
Undistributed (distributions in excess of) net investment income, end of period	\$ (4,028,661)	\$ 3,097,658

^(a) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

^(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

Statements of Cash Flows (unaudited)

Six Months Ended June 30, 2018

	BGR	CII	BDJ	BOE	BGY
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES					
Net increase in net assets resulting from operations	\$ 19,129,794	\$ 11,642,944	\$ (11,939,253)	\$ (58,368,548)	\$ (51,378,810)
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities:					
Proceeds from sales of long-term investments and principal paydowns	114,571,364	116,237,176	363,606,803	155,101,865	350,498,589
Purchases of long-term investments	(89,564,193)	(92,071,676)	(305,526,879)	(147,814,279)	(338,849,992)
Net (purchases) sales of short-term securities	(728,615)	(1,487,326)	(8,838,277)	13,118,524	4,130,041
Premiums received from options written	14,800,983	33,060,594	75,228,716	25,885,437	20,158,527
Premiums paid on closing options written	(28,920,943)	(37,339,445)	(87,400,772)	(24,781,616)	(17,978,422)
Net realized (gain) loss on investments and options written	10,517,637	(23,677,336)	(65,340,836)	(5,551,856)	(97,967,425)
Net unrealized gain (loss) on investments, options written and foreign currency translations	(25,617,422)	15,792,997	93,086,688	77,937,145	160,708,193
(Increase) Decrease in Assets:					
Receivables:					
Dividends affiliated	(2,717)	(2,066)	(13,080)	29,896	(2,971)
Dividends unaffiliated	4,877	(245,091)	(257,382)	(570,075)	(1,392,057)
Securities lending income affiliated			(7)		
Prepaid expenses	1,031	3,618	(8,530)	2,221	(9,385)
Increase (Decrease) in Liabilities:					
Collateral on securities loaned at value			12,294		
Payables:					
Investment advisory fees	(1,717)	(17,256)	(68,866)	(112,801)	(65,830)
Trustees and Officers fees	(30,381)	1,302	(33,146)	(36,293)	(30,803)
				(12,332)	(116,814)

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Deferred foreign capital gain tax					
Other affiliates		(76,934)			
Other accrued expenses	18,245	43,045	22,293	6,455	2,534
Net cash provided by (used for) operating activities	14,177,943	21,864,546	52,529,766	34,833,743	26,200,375

CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES

Cash dividends paid to Shareholders	(13,892,273)	(21,939,546)	(52,582,273)	(35,324,522)	(24,873,009)
Increase (decrease) in bank overdraft	(11,776)		51,239	380,331	
Net cash used for financing activities	(13,904,049)	(21,939,546)	(52,531,034)	(34,944,191)	(24,873,009)

CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS

Cash impact from foreign exchange fluctuations	\$ 2,822	\$	\$ (56)	\$ (4,478)	\$ (2,199)
--	----------	----	---------	------------	------------

CASH

Net increase (decrease) in restricted and unrestricted cash and foreign currency	276,716	(75,000)	(1,324)	(114,926)	2,830,167
Restricted and unrestricted cash and foreign currency at beginning of period	13,853	75,000	18,441	3,691,381	5,134,483
Restricted and unrestricted cash and foreign currency at end of period	\$ 290,569	\$	\$ 17,117	\$ 3,576,455	\$ 7,964,650

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:

Due from Broker	\$	\$	\$	\$	\$ 1,553,352
Cash pledged:					
Collateral for OTC derivatives			16,000		803,000
Collateral for options written				3,225,000	5,170,000
Foreign currency at value	290,569		1,117	35,455	438,298
	\$ 290,569	\$	\$ 17,117	\$ 3,576,455	\$ 7,964,650

**RECONCILIATION OF
RESTRICTED AND
UNRESTRICTED CASH
AT VALUE AT THE
BEGINNING OF PERIOD
TO THE STATEMENTS
OF ASSETS AND
LIABILITIES:**

Cash	\$		\$		\$		\$	20,583
Cash pledged:								
Collateral for OTC derivatives			75,000		16,000		20,000	2,118,000
Collateral for options written							2,970,000	2,350,000
Foreign currency at value		13,853			2,441		701,381	645,900
	\$	13,853	\$	75,000	\$	18,441	\$	3,691,381
							\$	5,134,483

See notes to financial statements.

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2018

	BME	BCX	BST	BUI
CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES				
Net increase in net assets resulting from operations	\$ 18,901,075	\$ (3,251,801)	\$ 95,215,268	\$ (2,321,423)
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used for) operating activities:				
Proceeds from sales of long-term investments	63,002,792	403,155,155	192,064,386	63,993,278
Purchases of long-term investments	(60,570,975)	(367,331,390)	(164,526,263)	(56,800,800)
Net (purchases) sales of short-term securities	7,150,150	8,720,851	2,112,661	(295,847)
Premiums received from options written	11,409,301	34,674,571	31,496,701	7,793,703
Premiums paid on closing options written	(12,917,161)	(52,771,784)	(40,088,866)	(7,472,059)
Net realized (gain) on investments and options written	(10,665,080)	(26,199,546)	(36,580,903)	(1,406,572)
Net unrealized gain (loss) on investments, options written and foreign currency translations	(7,451,568)	40,242,904	(59,622,884)	8,922,863
(Increase) Decrease in Assets:				
Receivables:				
Dividends affiliated	1,015	3,618	(1,361)	(4,149)
Dividends unaffiliated	46,482	186,767	(180,125)	(392,511)
Securities lending income affiliated	617	183	35,687	
Prepaid expenses	(993)	(3,799)	4,390	1,982
Other assets				
Increase (Decrease) in Liabilities:				
Collateral on securities loaned at value	(120,900)	(457,358)	(3,220,229)	
Payables:				
Investment advisory fees	362	(26,708)	49,010	(26,560)
Trustees and Officer s fees	(405)	(26,231)	970	(398)
Other accrued expenses	(15,169)	16,817	(5,388)	1,182
Net cash provided by (used for) operating activities	8,769,543	36,932,249	16,753,054	11,992,689
CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES				
Cash dividends paid to Shareholders	(10,897,100)	(29,732,298)	(16,861,897)	(11,909,186)
Proceeds from issuance of Shares	2,560,422			
Payments on redemption of Shares		(7,018,860)		
Increase (decrease) in bank overdraft	(10,013)	246,682		46,497
Net cash provided by (used for) financing activities	(8,346,691)	(36,504,476)	(16,861,897)	(11,862,689)

CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS

Cash impact from foreign exchange fluctuations	\$	2	\$	61	\$	(130)	\$	1
--	----	---	----	----	----	-------	----	---

CASH

Net increase (decrease) in restricted and unrestricted cash and foreign currency		422,854		427,834		(108,973)		130,001
Restricted and unrestricted cash and foreign currency at beginning of period		959		106,149		2,520,651		60
Restricted and unrestricted cash and foreign currency at end of period	\$	423,813	\$	533,983	\$	2,411,678	\$	130,061

NON-CASH FINANCING ACTIVITIES

Capital shares issued in reinvestment of distributions paid to Shareholders	\$	265,971	\$		\$	739,593	\$	263,846
---	----	---------	----	--	----	---------	----	---------

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:

Cash pledged:								
Collateral for OTC derivatives	\$	422,843	\$		\$	2,310,000	\$	130,000
Foreign currency at value		970		533,983		101,678		61
	\$	423,813	\$	533,983	\$	2,411,678	\$	130,061

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT VALUE AT THE BEGINNING OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES:

Cash	\$		\$	94,925	\$		\$	
Cash pledged:								
Collateral for OTC derivatives						2,520,000		
Foreign currency at value		959		11,224		651		60
	\$	959	\$	106,149	\$	2,520,651	\$	60

See notes to financial statements.

Financial Highlights

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BGR			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		2017	2016	2015		2014	2013
Net asset value, beginning of period	\$ 15.79	\$ 16.33	\$ 14.05	\$ 21.15	\$ 24.90	\$ 30.12	\$ 25.95
Net investment income ^(a)	0.14	0.40 ^(b)	0.27	0.29	0.07	0.25	0.12
Net realized and unrealized gain (loss)	0.51	(0.01)	3.01	(5.89)	(2.41)	(1.21)	5.67
Net increase (decrease) from investment operations	0.65	0.39	3.28	(5.60)	(2.34)	(0.96)	5.79
Distributions^(c)							
From net investment income	(0.47) ^(d)	(0.40)	(0.27)	(0.29)	(0.47)	(0.44)	
From net realized gain					(0.94)	(3.82)	(1.62)
From return of capital		(0.53)	(0.73)	(1.21)			
Total distributions	(0.47)	(0.93)	(1.00)	(1.50)	(1.41)	(4.26)	(1.62)
Net asset value, end of period	\$ 15.97	\$ 15.79	\$ 16.33	\$ 14.05	\$ 21.15	\$ 24.90	\$ 30.12
Market price, end of period	\$ 15.22	\$ 14.18	\$ 14.44	\$ 12.53	\$ 19.95	\$ 23.78	\$ 26.82
Total Return^(e)							
Based on net asset value	4.49% ^(f)	3.49%	25.07%	(27.47)%	(9.06)% ^(f)	(2.36)%	23.68%
Based on market price	10.89% ^(f)	5.11%	24.01%	(31.42)%	(10.18)% ^(f)	4.73%	17.70%

**Ratios to
Average Net
Assets**

Total expenses	1.29% ^(g)	1.31%	1.31%	1.29%	1.30% ^(g)	1.26%	1.26%
Total expenses after fees waived and/or reimbursed	1.14% ^(g)	1.18%	1.24%	1.26%	1.26% ^(g)	1.26%	1.25%
Net investment income	1.77% ^(g)	2.69% ^(b)	1.80%	1.60%	1.82% ^(g)	0.89%	0.42%

**Supplemental
Data**

Net assets, end of period (000)	\$ 476,305	\$ 471,062	\$ 487,064	\$ 418,981	\$ 629,603	\$ 741,109	896,635
Portfolio turnover rate	21%	24%	33%	56%	4%	85%	132%

(a) Based on average shares outstanding.

(b) Net investment income per share and the ratio of net investment income to average net assets include \$0.15 per share and 0.99%, respectively, resulting from a special dividend.

(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(e) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) Aggregate total return.

(g) Annualized.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	CII			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		Year Ended December 31, 2017	2016	2015		2014	2013
Net asset value, beginning of period	\$ 17.19	\$ 15.08	\$ 15.11	\$ 15.67	\$ 15.47	\$ 15.31	\$ 14.11
Net investment income ^(a)	0.08	0.15	0.13	0.11	0.04	0.55	0.31
Net realized and unrealized gain (loss)	0.19	2.95	0.99	0.53	0.36	0.91	2.09
	0.27	3.10	1.12	0.64	0.40	1.46	2.40
Distributions^(b)							
From net investment income	(0.50) ^(c)	(0.15)	(0.13)	(0.14)	(0.10)	(0.65)	(0.32)
From net realized gain			(0.04)	(1.06)			
From return of capital		(0.84)	(0.98)		(0.10)	(0.65)	(0.88)
Total distributions	(0.50)	(0.99)	(1.15)	(1.20)	(0.20)	(1.30)	(1.20)
Net asset value, end of period	\$ 16.96	\$ 17.19	\$ 15.08	\$ 15.11	\$ 15.67	\$ 15.47	\$ 15.31
Market price, end of period	\$ 16.22	\$ 16.38	\$ 13.71	\$ 14.14	\$ 13.97	\$ 14.89	\$ 13.52
Total Return^(d)							
Based on net asset value	1.76% ^(e)	21.69%	8.66%	4.66%	2.69% ^(e)	10.49%	18.97%
Based on market price	2.13% ^(e)	27.54%	5.56%	9.86%	(4.88)% ^(e)	20.43%	14.11%

**Ratios to
Average Net
Assets**

Total expenses	0.90% ^(f)	0.93%	0.95%	0.94%	0.99% ^(f)	0.93%	0.93%
Total expenses after fees waived and paid indirectly	0.90% ^(f)	0.93%	0.95%	0.94%	0.95% ^(f)	0.93%	0.93%
Net investment income	0.97% ^(f)	0.94%	0.89%	0.71%	1.42% ^(f)	3.56%	2.15%

**Supplemental
Data**

Net assets, end of period (000)	\$ 748,124	\$ 758,400	\$ 665,159	\$ 666,492	\$ 691,380	\$ 682,485	675,472
Portfolio turnover rate	12%	32%	54%	133%	2%	80%	218%

(a) Based on average shares outstanding.

(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(d) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(e) Aggregate total return.

(f) Annualized.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BDJ			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		Year Ended December 31,		2014		2013	
		2017	2016	2015		2014	2013
Total asset value, beginning of period	\$ 9.96	\$ 9.22	\$ 8.70	\$ 9.24	\$ 9.19	\$ 8.88	\$ 8.30
Net investment income ^(a)	0.08	0.16	0.17	0.17	0.04	0.16	0.18
Net realized and unrealized gain (loss)	(0.14)	1.14	0.91	(0.15)	0.10	0.76	0.96
Net increase from investment operations	(0.06)	1.30	1.08	0.02	0.14	0.92	1.14
Distributions^(b)							
From net investment income	(0.28) ^(c)	(0.17)	(0.17)	(0.17)	(0.03)	(0.17)	(0.18)
From excess of net investment income ^(d)							(0.20)
From net realized gain from return of capital		(0.39)	(0.39)	(0.39)	(0.06)	(0.44)	(0.18)
Total distributions	(0.28)	(0.56)	(0.56)	(0.56)	(0.09)	(0.61)	(0.56)
Total asset value, end of period	\$ 9.62	\$ 9.96	\$ 9.22	\$ 8.70	\$ 9.24	\$ 9.19	\$ 8.88
Market price, end of period	\$ 9.18	\$ 9.23	\$ 8.15	\$ 7.61	\$ 8.12	\$ 8.35	\$ 7.72
Total Return^(e) based on net asset value	(0.38)% ^(f)	15.06%	13.90%	1.10%	1.69% ^(f)	11.40%	15.11%

Based on market price	2.59% ^(f)	20.63%	15.11%	0.63%	(1.65)% ^(f)	16.42%	12.09%
Ratio to Average Net Assets							
Total expenses	0.85% ^(g)	0.86%	0.87%	0.86%	0.87% ^(g)	0.87% ^(h)	0.87%
Total expenses after fees waived and/or reimbursed	0.85% ^(g)	0.86%	0.85%	0.85%	0.84% ^(g)	0.86% ^(h)	0.87%
Net investment income	1.73% ^(g)	1.73%	1.91%	1.85%	2.30% ^(g)	1.81%	2.13%
Supplemental Data							
Net assets, end of period (000)	\$ 1,803,968	\$ 1,868,457	\$ 1,741,649	\$ 1,643,508	\$ 1,747,070	\$ 1,648,683	1,594,223
Portfolio turnover rate	17%	42%	33%	26%	0% ⁽ⁱ⁾	63%	180%

(a) Based on average shares outstanding.

(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(d) Taxable distribution.

(e) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) Aggregate total return.

(g) Annualized.

(h) Includes reorganization costs associated with the Trust's merger. Without these costs, total expenses and total expenses after fees waived and/or reimbursed would have been 0.86% and 0.86%, respectively.

(i) Amount is less than 0.5%

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	Year Ended December 31,			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		2017	2016	BOE 2015		2014	2013
Net asset value, beginning of period	\$ 13.22	\$ 13.38	\$ 14.25	\$ 15.27	\$ 15.54	\$ 16.68	\$ 14.99
Net investment income ^(a)	0.20	0.17	0.15	0.11	0.00 ^(b)	0.14	0.12
Net realized and unrealized gain (loss)	(1.04)	1.96	0.03	0.03	(0.07)	0.07	2.82
Net increase (decrease) from investment operations	(0.84)	2.13	0.18	0.14	(0.07)	0.21	2.94
Distributions^(b)							
From net investment income	(0.47) ^(e)	(0.19)	(0.10)	(0.17)		(0.17)	(0.17)
In excess of net investment income ^(d)				(0.10)		(0.28)	(0.91)
From net realized gain		(2.10)					
From return of capital			(0.95)	(0.89)	(0.20)	(0.90)	(0.17)
Total distributions	(0.47)	(2.29)	(1.05)	(1.16)	(0.20)	(1.35)	(1.25)
Net asset value, end of period	\$ 11.91	13.22	\$ 13.38	\$ 14.25	\$ 15.27	\$ 15.54	\$ 16.68
Market price, end of period	\$ 11.12	12.51	\$ 11.57	\$ 12.76	\$ 13.13	\$ 14.00	\$ 14.74
Total Return^(f)							
Based on net asset value	(6.19)% ^(g)	17.22% ^(h)	2.62%	1.81%	(0.27)% ^(g)	2.10%	21.93%

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Based on market price	(7.44)% ^(g)	28.28%	(0.90)%	6.03%	(4.82)% ^(g)	4.09%	21.99%
Ratios to Average Net Assets							
Total expenses	1.08% ⁽ⁱ⁾	1.09% ⁽ⁱ⁾	1.10%	1.08%	1.10% ^(j)	1.08%	1.08%
Total expenses after fees waived and paid indirectly	0.98% ⁽ⁱ⁾	1.02% ⁽ⁱ⁾	1.05%	1.05%	1.07% ^(j)	1.08%	1.08%
Net investment income	3.17% ⁽ⁱ⁾	1.20% ⁽ⁱ⁾	1.15%	0.73%	0.00% ^{(j) (k)}	0.83%	0.77%
Supplemental Data							
Net assets, end of period (000)	\$ 820,608	\$ 911,227	\$ 929,897	\$ 990,318	\$ 1,060,687	\$ 1,079,862	1,159,072
Portfolio turnover rate	17%	133%	64%	72%	16%	150%	279%

(a) Based on average shares outstanding

(b) Amount is less than \$0.005 per share

(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) Taxable distribution.

(e) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(f) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(g) Aggregate total return.

(h) Includes payment received from an affiliate, which had no impact on the Trust's total return.

(i) Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

(j) Annualized.

(k) Amount is less than 0.005%

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BGY			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		2017	2016	2015		2014	2013
Net asset value, beginning of period	\$ 7.06	\$ 6.28	\$ 6.95	\$ 7.61	\$ 7.89	\$ 9.05	\$ 8.28
Net investment income ^(a)	0.13	0.09	0.09	0.08	(0.00) ^(b)	0.10	0.13
Net realized and unrealized gain (loss)	(0.60)	1.15	(0.24)	(0.15)	(0.17)	(0.53)	1.31
Net increase (decrease) from investment operations	(0.47)	1.24	(0.15)	(0.07)	(0.17)	(0.43)	1.44
Distributions^(c)							
From net investment income	(0.23) ^(d)	(0.09)	(0.07)	(0.11)		(0.13)	(0.17)
In excess of net investment income ^(e)						(0.08)	
From return of capital		(0.37)	(0.45)	(0.48)	(0.11)	(0.52)	(0.50)
Total distributions	(0.23)	(0.46)	(0.52)	(0.59)	(0.11)	(0.73)	(0.67)
Net asset value, end of period	\$ 6.36	\$ 7.06	\$ 6.28	\$ 6.95	\$ 7.61	\$ 7.89	\$ 9.05
Market price, end of period	\$ 5.74	\$ 6.52	\$ 5.51	\$ 6.24	\$ 6.74	\$ 7.26	\$ 8.14
Total Return^(f)							
Based on net asset value	(6.49)% ^{(g)(h)}	20.88% ^(h)	(1.12)%	(0.47)%	(2.10)% ^(g)	(4.49)%	19.25%
	(8.61)% ^(g)	27.23%	(3.37)%	0.90%	(5.77)% ^(g)	(2.29)%	19.86%

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Based on
market price

**Ratios to
Average Net
Assets**

Total expenses ⁽ⁱ⁾	1.10% ⁽ⁱ⁾	1.12%	1.12%	1.09%	1.12% ⁽ⁱ⁾	1.10%	1.09%
Total expenses after fees waived and paid indirectly ⁽ⁱ⁾	0.99% ⁽ⁱ⁾	1.02%	1.02%	1.01%	1.03% ⁽ⁱ⁾	1.05%	1.07%
Net investment income	3.78% ⁽ⁱ⁾	1.31%	1.41%	1.09%	(0.13)% ⁽ⁱ⁾	1.17%	1.49%

**Supplemental
Data**

Net assets, end of period (000)	\$ 693,436	\$ 769,678	\$ 690,628	\$ 764,154	\$ 836,552	\$ 867,986	\$ 995,736
Portfolio turnover rate	48%	90%	74%	67%	14%	195%	266%

- (a) Based on average shares outstanding.
- (b) Amount is greater than \$(0.005) per share.
- (c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
- (d) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- (e) Taxable distribution.
- (f) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
- (g) Aggregate total return.
- (h) Includes payment received from an affiliate, which had no impact on the Trust's total return.
- (i) Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

	Year Ended December 31				Period	Year Ended	
					November 1, 2014	October 31,	
Six Months Ended 06/30/18 (Unaudited)	2017	2016	2015	2014	2014	2012	
0.01%	0.02%	0.01%	0.01%				

Investments in
underlying funds

(i) Annualized.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BME			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		Year Ended December 31, 2017	2016	2015		2014	2013
Net asset value, beginning of period .	\$ 35.69	\$ 31.30	\$ 36.19	\$ 38.61	\$ 40.22	\$ 34.92	\$ 28.34
Net investment income ^(a)	0.05	0.02	0.02	(0.06)	(0.01)	(0.00) ^(b)	0.12
Net realized and unrealized gain (loss)	2.00	6.77	(1.91)	4.34	1.10	9.14	8.85
	2.05	6.79	(1.89)	4.28	1.09	9.14	8.97
Distributions^(c)							
From net investment income	(1.20) ^(d)	(0.04)	(0.03)	(0.63)	(0.01)	(0.10)	(0.06)
From net realized gain		(2.11)	(2.97)	(6.07)	(2.69)	(3.74)	(2.33)
From return of capital		(0.25)					
Total distributions	(1.20)	(2.40)	(3.00)	(6.70)	(2.70)	(3.84)	(2.39)
Net asset value, end of period	\$ 36.54	\$ 35.69	\$ 31.30	\$ 36.19	\$ 38.61	\$ 40.22	\$ 34.92
Market price, end of period	\$ 38.58	\$ 36.50	\$ 31.75	\$ 39.35	\$ 42.70	\$ 41.37	\$ 33.56
Total Return^(e)							
Based on net asset value	5.90% ^(f)	22.17%	(5.36)%	10.70%	2.38% ^(f)	28.00%	33.37%
Based on market price	9.33% ^(f)	23.17%	(11.71)%	8.87%	10.07% ^(f)	36.99%	30.38%

**Ratios to
Average Net
Assets**

Total expenses	1.12% ^{(g)(h)}	1.12% ^(h)	1.15% ⁽ⁱ⁾	1.13%	1.16% ⁽ⁱ⁾	1.11%	1.12%
Total expenses after fees waived and/or reimbursed and excluding amortization of offering costs	1.12% ^{(g)(h)}	1.12% ^(h)	1.14%	1.12%	1.11% ⁽ⁱ⁾	1.11%	1.12%
Net investment income	0.27% ^{(g)(h)}	0.06% ^(h)	0.07%	(0.14)%	(0.10)% ⁽ⁱ⁾	(0.01)%	0.38%

**Supplemental
Data**

Net assets, end of period (000)	\$ 342,729	\$ 331,858	\$ 270,693	\$ 297,530	\$ 303,103	\$ 313,933	270,161
Portfolio turnover rate	19%	38%	59%	68%	6%	74%	155%

(a) Based on average shares outstanding

(b) Amount is greater than \$(0.005) per share

(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(e) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) Aggregate total return.

(g) Annualized.

(h) Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

(i) Offering costs were not annualized in the calculation of the expense ratios. If these expenses were annualized, the total expenses would have been 1.16%.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BCX			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		Year Ended December 31, 2017	2016	2015		2014	2013
Net asset value, beginning of period	\$ 10.64	\$ 9.86	\$ 8.35	\$ 11.67	\$ 12.50	\$ 13.54	\$ 15.42
Net investment income ^(a)	0.11	0.20 ^(b)	0.14	0.25	0.04	0.23	0.25
Net realized and unrealized gain (loss)	(0.14)	1.19	1.95	(2.76)	(0.72)	(0.27)	(0.97)
Net increase (decrease) from investment operations	(0.03)	1.39	2.09	(2.51)	(0.68)	(0.04)	(0.72)
Distributions^(c)							
From net investment income	(0.31) ^(d)	(0.24)	(0.15)	(0.25)	(0.02)	(0.31)	(0.14)
From return of capital		(0.37)	(0.43)	(0.56)	(0.13)	(0.69)	(1.02)
Total distributions	(0.31)	(0.61)	(0.58)	(0.81)	(0.15)	(1.00)	(1.16)
Net asset value, end of period	\$ 10.30	\$ 10.64	\$ 9.86	\$ 8.35	\$ 11.67	\$ 12.50	\$ 13.54
Market price, end of period	\$ 9.29	\$ 9.77	\$ 8.27	\$ 7.11	\$ 9.71	\$ 10.78	\$ 11.68
Total Return^(e)							
Based on net asset value	0.07% ^(f)	15.60%	27.41%	(21.31)%	(5.20)% ^(f)	0.61%	(3.61)% ^(f)
Based on market price	(1.71)% ^(f)	26.55%	25.50%	(19.47)%	(8.53)% ^(f)	0.58%	(9.19)% ^(f)

ratios to							
verage Net							
sets							
Total expenses	1.08% ^(h)	1.08%	1.08%	1.07%	1.15% ^(h)	1.35% ⁽ⁱ⁾	1.27%
Total expenses after fees waived and paid directly	1.08% ^(h)	1.08%	1.08%	1.07%	1.04% ^(h)	1.06% ⁽ⁱ⁾	1.07%
Net investment income	2.13% ^(h)	2.06% ^(b)	1.61%	2.43%	2.01% ^(h)	1.70%	1.76%
Supplemental							
data							
Net assets, end of period (000)	\$ 988,175	\$ 1,027,472	\$ 976,899	\$ 827,040	\$ 1,156,499	\$ 582,220	\$ 630,617
Portfolio turnover rate	39%	73%	101%	74%	2%	62%	156%

(a) Based on average shares outstanding.

(b) Net investment income per share and the ratio of net investment income to average net assets include less than \$0.04 per share and 0.39% respectively, resulting from a special dividend from Baker Hughes Inc. in July 2017.

(c) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(e) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) Aggregate total return.

(g) Includes a payment from an affiliate to compensate for foregone securities lending revenue which impacted the Trust's total return. Not including this payment the Trust's return would have been (3.68)%.

(h) Annualized.

(i) Includes reorganization costs associated with the Trust's merger. Without these costs, total expenses and total expenses after fees waived and/or reimbursed would have been 1.26% and 1.06%, respectively.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BST Year Ended December 31,			Period Ended 10/31/14 ^(a)
		2017	2016	2015	to 12/31/14
Net asset value, beginning of period	\$ 27.73	\$ 20.10	\$ 19.70	\$ 19.43	\$ 19.10 ^(b)
Net investment income (loss) ^(c)	(0.04)	(0.05)	0.00 ^(d)	0.03	(0.01)
Net realized and unrealized gain	4.29	8.96	1.60	1.44	0.48
	4.25	8.91	1.60	1.47	0.47
Distributions^(e)					
From net investment income	(0.78) ^(g)	(0.05)		(0.03)	(0.00) ^(f)
From net realized gain		(0.22)		(0.01)	
From return of capital		(1.01)	(1.20)	(1.16)	(0.10)
Total distributions	(0.78)	(1.28)	(1.20)	(1.20)	(0.10)
Capital changes with respect to issuance of Preferred Shares					(0.04)
Net asset value, end of period	\$ 31.20	\$ 27.73	\$ 20.10	\$ 19.70	\$ 19.43
Market price, end of period	\$ 33.65	\$ 26.69	\$ 17.94	\$ 17.31	\$ 17.59
Total Return^(h)					
Based on net asset value	15.46% ⁽ⁱ⁾	45.73%	9.36%	8.61%	2.31% ⁽ⁱ⁾
Based on market price	29.37% ⁽ⁱ⁾	57.15%	11.08%	5.36%	(11.55)% ⁽ⁱ⁾
Ratios to Average Net Assets					
Total expenses	1.09% ^(j)	1.09%	1.10%	1.12%	1.19% ^(j)
Total expenses after fees waived and paid indirectly	0.89% ^(j)	0.89%	0.90%	0.92%	0.97% ^(j)
Net investment income (loss)	(0.27)% ^(j)	(0.19)%	0.02%	0.15%	(0.24)% ^(j)

Supplemental Data

Net assets, end of period (000)	\$ 698,799	\$ 620,300	\$ 452,443	\$ 443,477	\$ 437,380
Portfolio turnover rate	25%	41%	74%	91%	7%

- (a) Commencement of operations. This information includes the initial investment by BlackRock HoldCo2, Inc.
- (b) Net asset value, beginning of period, reflects a deduction of \$0.8975 per share sales charge from initial offering price of \$20.00 per share.
- (c) Based on average shares outstanding.
- (d) Amount is less than \$0.005 per share
- (e) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.
- (f) Amount is greater than \$(0.005) per share.
- (g) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.
- (h) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.
- (i) Aggregate total return.
- (j) Annualized.

See notes to financial statements.

Financial Highlights (continued)

(For a share outstanding throughout each period)

	Six Months Ended 06/30/18 (Unaudited)	BUI			Period from 11/01/14 to 12/31/14	Year Ended October 31,	
		Year Ended December 31, 2017	2016	2015		2014	2013
Net asset value, beginning of period	\$ 21.12	\$ 19.42	\$ 19.50	\$ 22.47	\$ 22.40	\$ 20.78	\$ 20.22
Net investment income ^(a)	0.31	0.56	0.56	0.47	0.11	0.51	0.57
Net realized and unrealized gain (loss)	(0.44)	2.59	0.81	(1.99)	0.20	2.68	1.44
	(0.13)	3.15	1.37	(1.52)	0.31	3.19	2.01
Distributions^(b)							
From net investment income	(0.73) ^(c)	(0.47)	(0.49)	(0.42)	(0.10)	(0.51)	(0.52)
From net realized gain		(0.98)	(0.53)	(0.54)		(0.37)	(0.42)
From return of capital			(0.43)	(0.49)	(0.14)	(0.69)	(0.51)
Total distributions	(0.73)	(1.45)	(1.45)	(1.45)	(0.24)	(1.57)	(1.45)
Net asset value, end of period	\$ 20.26	\$ 21.12	\$ 19.42	\$ 19.50	\$ 22.47	\$ 22.40	\$ 20.78
Market price, end of period	\$ 20.01	\$ 21.62	\$ 18.41	\$ 16.78	\$ 20.74	\$ 20.02	\$ 18.36
Total Return^(d)							
Based on net asset value	(0.56)% ^(e)	16.62%	7.57%	(6.09)%	1.50% ^(e)	16.94%	11.18%
Based on market price	(4.06)% ^(e)	25.93%	18.50%	(12.45)%	4.82% ^(e)	18.29%	4.37%

**Ratios to
Average Net
Assets**

Total expenses	1.12% ^(f)	1.11%	1.13%	1.11%	1.17% ^(f)	1.10%	1.11%
Total expenses after fees waived and paid indirectly	1.09% ^(f)	1.09%	1.13%	1.11%	1.11% ^(f)	1.10%	1.10%
Net investment income	3.03% ^(f)	2.70%	2.83%	2.24%	2.83% ^(f)	2.36%	2.83%

**Supplemental
Data**

Net assets, end of period (000)	\$ 343,415	\$ 357,776	\$ 328,297	\$ 329,747	\$ 379,830	\$ 378,762	351,325
Portfolio turnover rate	17%	31%	8%	20%	2%	41%	133%

(a) Based on average shares outstanding

(b) Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year end.

(d) Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(e) Aggregate total return.

(f) Annualized.

See notes to financial statements.

Notes to Financial Statements (unaudited)

1. ORGANIZATION

The following are registered under the Investment Company Act of 1940, as amended (the 1940 Act), as closed-end management investment companies and are referred to herein collectively as the Trusts , or individually as a Trust :

<i>Fund Name</i>	<i>Herein Referred To As</i>	<i>Organized</i>	<i>Diversification Classification</i>
BlackRock Energy and Resources Trust	BGR	Delaware	Non-diversified
BlackRock Enhanced Capital and Income Fund, Inc.	CII	Maryland	Diversified
BlackRock Enhanced Equity Dividend Trust	BDJ	Delaware	Diversified
BlackRock Enhanced Global Dividend Trust	BOE	Delaware	Diversified
BlackRock Enhanced International Dividend Trust	BGY	Delaware	Diversified
BlackRock Health Sciences Trust	BME	Delaware	Diversified
BlackRock Resources & Commodities Strategy Trust	BCX	Delaware	Non-diversified
BlackRock Science and Technology Trust	BST	Delaware	Non-diversified
BlackRock Utilities, Infrastructure & Power Opportunities Trust	BUI	Delaware	Diversified

The Board of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the Board of Trustees or the Board, and the directors/trustees thereof are collectively referred to throughout this report as Trustees . The Trusts determine and make available for publication the net asset values (NAVs) of their Common Shares on a daily basis.

The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the Manager) or its affiliates, are included in a complex of closed-end funds referred to as the Closed-End Complex.

Basis of Consolidation: The accompanying consolidated financial statements of BCX include the account of BlackRock Cayman Resources & Commodities Strategy Fund, Ltd. (the Subsidiary), which is a wholly-owned subsidiary of BCX and primarily invests in commodity-related instruments. The Subsidiary enables BCX to hold these commodity-related instruments and other derivatives and satisfy regulated investment company tax requirements. BCX may invest up to 25% of its total assets in the Subsidiary. Intercompany accounts and transactions, if any, have been eliminated. During the six months ended June 30, 2018, there were no transactions in the Subsidiary. The Subsidiary is subject to the same investment policies and restrictions that apply to BCX, except that the Subsidiary may invest without limitation in commodity-related instruments.

2. SIGNIFICANT ACCOUNTING POLICIES

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. Below is a summary of significant accounting policies:

Investment Transactions and Income Recognition: For financial reporting purposes, investment transactions are recorded on the dates the transactions are entered into (the trade dates). Realized gains and losses on investment transactions are determined on the identified cost basis. Dividend income is recorded on the ex-dividend date. Dividends from foreign securities where the ex-dividend date may have passed are subsequently recorded when the Trusts are informed of the ex-dividend date. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized on an accrual basis.

Foreign Currency Translation: Each Trust's books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (NYSE). Purchases and sales of investments are recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.

Each Trust does not isolate the portion of the results of operations arising as a result of changes in the exchange rates from the changes in the market prices of investments held or sold for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments, but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for U.S. federal income tax purposes.

Segregation and Collateralization: In cases where a Trust enters into certain investments (e.g., futures contracts, forward foreign currency exchange contracts and options written) that would be treated as senior securities for 1940 Act purposes, a Trust may segregate or designate on its books and records cash or liquid assets having a market value at least equal to the amount of its future obligations under such investments. Doing so allows the investment to be excluded from treatment as a senior security. Furthermore, if required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments or obligations.

Distributions: Distributions paid by the Trusts are recorded on the ex-dividend date. Subject to the Trusts' level distribution plan, the Trusts intend to make monthly cash distributions to shareholders, which may consist of net investment income, net options premium and net realized and unrealized gains on investments and/or return of capital.

Notes to Financial Statements (unaudited) (continued)

The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust's current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital.

Net income and realized gains from investments held by the Subsidiary are treated as ordinary income for tax purposes. If a net loss is realized by the Subsidiary in any taxable year, the loss will generally not be available to offset BCX's ordinary income and/or capital gains for that year.

Deferred Compensation Plan: Under the Deferred Compensation Plan (the Plan) approved by each Trust's Board, the independent Trustees (Independent Trustees) may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain other BlackRock Closed-End Funds selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain other BlackRock Closed-End Funds.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, if applicable. Deferred compensation liabilities are included in the Trustees' and Officer's fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan.

Recent Accounting Standards: In March 2017, the Financial Accounting Standards Board issued Accounting Standards Update Premium Amortization of Purchased Callable Debt Securities which amends the amortization period for certain purchased callable debt securities. Under the new guidance, the premium amortization of purchased callable debt securities that have explicit, non-contingent call features and are callable at fixed prices will be amortized to the earliest call date. The guidance will be applied on a modified retrospective basis and is effective for fiscal years, and their interim periods, beginning after December 15, 2018. Management is currently evaluating the impact of this guidance to the Funds.

Indemnifications: In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust's maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are prorated among those funds on the basis of relative net assets or other appropriate methods.

3. INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS

Investment Valuation Policies: The Trusts' investments are valued at fair value (also referred to as market value within the financial statements) as of the close of trading on the NYSE (generally 4:00 p.m., Eastern time) (or if the reporting date falls on a day the NYSE is closed, investments are valued at fair value as of the period end). U.S. GAAP defines fair value as the price the Trusts would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. The Trusts determine the fair values of their financial instruments using various independent dealers or pricing services under policies approved by the Board of Trustees of each Trust (the Board). The BlackRock Global Valuation Methodologies Committee (the Global

Valuation Committee) is the committee formed by management to develop global pricing policies and procedures and to oversee the pricing function for all financial instruments.

Fair Value Inputs and Methodologies: The following methods and inputs are used to establish the fair value of each Trust's assets and liabilities:

Equity investments traded on a recognized securities exchange are valued at the official closing price each day, if available. For equity investments traded on more than one exchange, the official closing price on the exchange where the stock is primarily traded is used. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price. Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Occasionally, events affecting the values of such instruments may occur between the foreign market close and the close of trading on the NYSE that may not be reflected in the computation of the Trusts' net assets. Each business day, the Trusts use a pricing service to assist with the valuation of certain foreign exchange-traded equity securities and foreign exchange-traded and over-the-counter (OTC) options (the Systematic Fair Value Price). Using current market factors, the Systematic Fair Value Price is designed to value such foreign securities and foreign options at fair value as of the close of trading on the NYSE, which follows the close of the local markets.

Fixed-income securities for which market quotations are readily available are generally valued using the last available bid prices or current market quotations provided by independent dealers or third party pricing services. Floating rate loan interests are valued at the mean of the bid prices from one or more independent brokers or dealers as obtained from a third party pricing service. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and offers), credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent fair value.

Investments in open-end U.S. mutual funds are valued at NAV each business day.

The Trusts value their investment in SL Liquidity Series, LLC, Money Market Series (the Money Market Series) at fair value, which is ordinarily based upon their pro rata ownership in the underlying fund's net assets. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments may follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act.

Futures contracts traded on exchanges are valued at their last sale price.

Notes to Financial Statements (unaudited) (continued)

Forward foreign currency exchange contracts are valued at the mean between the bid and ask prices and are determined as of the close of trading on the NYSE. Interpolated values are derived when the settlement date of the contract is an interim date for which quotations are not available.

Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day's price will be used, unless it is determined that the prior day's price no longer reflects the fair value of the option. OTC options and options on swaps (swaptions) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments.

If events (e.g., a company announcement, market volatility or a natural disaster) occur that are expected to materially affect the value of such investments, or in the event that the application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Global Valuation Committee, or its delegate, in accordance with a policy approved by the Board as reflecting fair value (Fair Valued Investments). The fair valuation approaches that may be used by the Global Valuation Committee will include market approach, income approach and cost approach. Valuation techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value. When determining the price for Fair Valued Investments, the Global Valuation Committee, or its delegate, seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm's-length transaction. Fair value determinations shall be based upon all available factors that the Global Valuation Committee, or its delegate, deems relevant and consistent with the principles of fair value measurement.

The Global Valuation Committee, or its delegate, employs various methods for calibrating valuation approaches for investments where an active market does not exist, including regular due diligence of each Trust's pricing vendors, regular reviews of key inputs and assumptions, transactional back-testing or disposition analysis to compare unrealized gains and losses to realized gains and losses, reviews of missing or stale prices and large movements in market values and reviews of any market related activity. The pricing of all Fair Valued Investments is subsequently reported to the Board or a committee thereof on a quarterly basis. As a result of the inherent uncertainty in valuation of these investments, the fair values may differ from the values that would have been used had an active market existed.

For investments in equity or debt issued by privately held companies or funds (Private Company or collectively, the Private Companies) and other Fair Valued Investments, the fair valuation approaches that are used by third party pricing services utilize one or a combination of, but not limited to, the following inputs.

Standard Inputs Generally Considered By Third Party Pricing Services

Market approach

(i) recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers;

- (ii) recapitalizations and other transactions across the capital structure; and
 - (iii) market multiples of comparable issuers.
- Income approach
- (i) future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks;
 - (ii) quoted prices for similar investments or assets in active markets; and
 - (iii) other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates.
- Cost approach
- (i) audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private Company;
 - (ii) changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company;
 - (iii) relevant news and other public sources; and
 - (iv) known secondary market transactions in the Private Company's interests and merger or acquisition activity in companies comparable to the Private Company.

Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Valuation techniques such as an option pricing model (OPM), a probability weighted expected return model (PWERM) or a hybrid of those techniques are used in allocating enterprise value of the company, as deemed appropriate under the circumstances. The use of OPM and PWERM techniques involve a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise value of the company among the various parts of its capital structure.

The Private Companies are not subject to the public company disclosure, timing, and reporting standards as other investments held by a Trust. Typically, the most recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the value of the investment and the price a Trust could receive upon the sale of the investment.

Fair Value Hierarchy: Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial statement purposes as follows:

Level 1 Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access

Level 2 Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market corroborated inputs)

Level 3 Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including each Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification

Notes to Financial Statements (unaudited) (continued)

is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies. There may not be a secondary market, and/or there are a limited number of investors. Level 3 investments may also be adjusted to reflect illiquidity and/or non-transferability, with the amount of such discount estimated by the Global Valuation Committee in the absence of market information.

Changes in valuation techniques may result in transfers into or out of an assigned level within the hierarchy. In accordance with each Trust's policy, transfers between different levels of the fair value hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investments and derivative financial instruments and is not necessarily an indication of the risks associated with investing in those securities.

As of June 30, 2018, certain investments of the BDJ, BCX and BST were valued using net asset value per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

4. SECURITIES AND OTHER INVESTMENTS

Preferred Stocks: Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer's board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Securities Lending: Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

The market value of any securities on loan, all of which were classified as common stocks in the Trusts' Schedules of Investments, and the value of any related collateral are shown separately in the Statements of Assets and Liabilities as a component of investments at value-unaffiliated, and collateral on securities loaned at value, respectively. As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

invested by the securities lending agent, BlackRock Investment Management, LLC (BIM), if any, is disclosed in the Schedules of Investments.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an MSLA), which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty s bankruptcy or insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and a Trust can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party s net payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.

As of period end, the following table is a summary of the Trusts securities lending agreements by counterparty which are subject to offset under an MSLA:

<i>Counterparty</i>	<i>Securities Loaned at Value</i>	<i>Cash Collateral Received^(a)</i>	<i>Net Amount</i>
BDJ			
Morgan Stanley & Co. LLC	\$ 11,215	\$ (11,215)	\$
BCX			
Goldman Sachs & Co.	\$ 5	\$ (5)	\$
Merrill Lynch, Pierce, Fenner & Smith Inc.	10	(10)	
Morgan Stanley & Co. LLC	5	(5)	
	\$ 20	\$ (20)	\$
BST			
Bank of Montreal	\$ 26,730	\$ (26,730)	\$
Deutsche Bank AG	98,010	(98,010)	
Merrill Lynch, Pierce, Fenner & Smith Inc.	133,650	(133,650)	
	\$ 258,390	\$ (258,390)	\$

^(a) Cash collateral with a value of \$12,294, \$27,985 and \$277,000 has been received in connection with securities lending agreements. Collateral received in excess of the value of securities loaned from the individual counterparty is not shown for financial reporting purposes in the table above.

Notes to Financial Statements (unaudited) (continued)

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM's indemnity allows for full replacement of the securities loaned if the collateral received does not cover the value on the securities loaned in the event of borrower default. Each Trust could incur a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received.

5. DERIVATIVE FINANCIAL INSTRUMENTS

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.

Futures Contracts: Futures contracts are purchased or sold to gain exposure to, or manage exposure to, changes in interest rates (interest rate risk), and changes in the value of equity securities (equity risk) or foreign currencies (foreign currency exchange rate risk).

Futures contracts are agreements between the Trusts and a counterparty to buy or sell a specific quantity of an underlying instrument at a specified price and on a specified date. Depending on the terms of a contract, it is settled either through physical delivery of the underlying instrument on the settlement date or by payment of a cash amount on the settlement date. Upon entering into a futures contract, the Trusts are required to deposit initial margin with the broker in the form of cash or securities in an amount that varies depending on a contract's size and risk profile. The initial margin deposit must then be maintained at an established level over the life of the contract. Amounts pledged, which are considered restricted, are included in cash pledged for futures contracts on the Statements of Assets and Liabilities.

Securities deposited as initial margin are designated in the Schedules of Investments and cash deposited, if any, is shown as cash pledged for futures contracts in the Statements of Assets and Liabilities. Pursuant to the contract, the Trusts agree to receive from or pay to the broker an amount of cash equal to the daily fluctuation in market value of the contract (variation margin). Variation margin is recorded as unrealized appreciation (depreciation) and, if any, shown as variation margin receivable (or payable) on futures contracts in the Statements of Assets and Liabilities. When the contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the notional amount of the contract at the time it was opened and the notional amount at the time it was closed. The use of futures contracts involves the risk of an imperfect correlation in the movements in the price of futures contracts and interest, foreign currency exchange rates or underlying assets.

Forward Foreign Currency Exchange Contracts: Forward foreign currency exchange contracts are entered into to gain or reduce exposure to foreign currencies (foreign currency exchange rate risk).

A forward foreign currency exchange contract is an agreement between two parties to buy and sell a currency at a set exchange rate on a specified date. These contracts help to manage the overall exposure to the currencies in which some of the investments held by the Trusts are denominated and in some cases, may be used to obtain exposure to a particular market.

The contract is marked-to-market daily and the change in market value is recorded as unrealized appreciation (depreciation) in the Statements of Assets and Liabilities. When a contract is closed, a realized gain or loss is recorded in the Statements of Operations equal to the difference between the value at the time it was opened and the value at the time it was closed. Non-deliverable forward foreign currency exchange contracts are settled with the counterparty in cash without the delivery of foreign currency. The use of forward foreign currency exchange contracts involves the risk that the value of a forward foreign currency exchange contract changes unfavorably due to movements in the value of the referenced foreign currencies. Cash amounts pledged for forward foreign currency contracts are considered restricted and are included in Cash pledged: Collateral OTC derivatives on the Statement of Assets and Liabilities.

Options: Certain Trusts purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.

A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.

Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically covered, meaning that they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, such option is covered by cash in an amount sufficient to cover the obligation. These amounts, which are considered restricted, are included in Cash pledged: Collateral option written on the Statement of Assets and Liabilities.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when it otherwise would not, or at a price different from the current market value.

Master Netting Arrangements: In order to define their contractual rights and to secure rights that will help them mitigate their counterparty risk, the Trusts may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (ISDA Master Agreement) or similar agreement with their counterparties. An ISDA Master Agreement is a bilateral agreement between each Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions in the event of a default and/or termination event. Under an ISDA Master Agreement, each Trust may, under certain circumstances,

Notes to Financial Statements (unaudited) (continued)

offset with the counterparty certain derivative financial instruments payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. Bankruptcy or insolvency laws of a particular jurisdiction may restrict or prohibit the right of offset in bankruptcy, insolvency or other events.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trusts and the counterparty.

Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately on the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from their counterparties are not fully collateralized, they bear the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, they bear the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

6. INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES

The PNC Financial Services Group, Inc. is the largest stockholder and an affiliate of BlackRock, Inc. (BlackRock) for 1940 Act purposes.

INVESTMENT ADVISORY: Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts' investment adviser, an indirect, wholly-owned subsidiary of BlackRock, to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust's portfolio and provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.

For such services, each Trust, except BCX and BST, pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust's net assets:
BGR

1.20%

BDJ	0.80
BOE	1.00
BME	1.00

Average daily value of each Trust's net assets:

CII	0.85%
BGY	1.00
BUI	1.00

For such services, BCX pays the Manager a monthly fee of 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the value of the Trust's interest in the Subsidiary) and the average daily value of the net assets of the Subsidiary, which fee is allocated pro rata between the Trust and the Subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Trust, the value of the Trust's interest in the Subsidiary).

For such services, BST pays the Manager a monthly fee at an annual rate equal to 1.00% of the average daily value of the Trust's managed assets. For purposes of calculating this fee, managed assets means the total assets of the Trust (including any assets attributable to money borrowed for investment purposes) minus the sum of its accrued liabilities (other than money borrowed for investment purposes).

With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (BIL), an affiliate of the Manager. The Manager pays BIL, for services it provides, a monthly fee that is a percentage of the investment advisory fees paid by each Trust to the Manager.

The Manager provides investment management and other services to BCX's Subsidiary. The Manager does not receive separate compensation from the Subsidiary for providing investment management or administrative services. However, BCX pays the Manager based on the Trust's net assets, which includes the assets of the Subsidiary.

Distribution Fees: BME has entered into a Distribution Agreement with BlackRock Investments, LLC (BRIL), an affiliate of the Manager, to provide for distribution of BME common shares on a reasonable best efforts basis through an equity shelf offering (a Shelf Offering) (the Distribution Agreement). Pursuant to the Distribution Agreement, BME will compensate BRIL with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BME's common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions retained by BRIL during the period ended June 30, 2018 amounted to \$2,683.

Notes to Financial Statements (unaudited) (continued)

Expense Limitations, Waivers and Reimbursements: The Manager has contractually agreed to waive a portion of the investment advisory fees on BST as a percentage of its average daily managed assets as follows:

		<i>Expiration Date</i>
BST	0.20%	December 31, 2018
	0.15	December 31, 2019
	0.10	December 31, 2020
	0.05	December 31, 2021

The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a percentage of their average weekly net assets, except BUI, which is average daily net assets, as follows:

BGR	0.150%
BOE	0.100
BUI	0.025

With respect to BGY, the Manager has voluntarily agreed to waive a portion of its investment advisory fees equal to the annual rate of 0.10% of BGY's average daily net assets.

These voluntary waivers may be reduced or discontinued at any time without notice.

For the period ended June 30, 2018, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of Operations, were as follows:

BGR	\$ 342,783
BOE	429,763
BGY	364,385
BST	670,244
BUI	42,758

With respect to each Trust, the Manager voluntarily agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds (the affiliated money market fund waiver). These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the period ended June 30, 2018, the amounts waived were as follows:

	<i>Amount Waived</i>
BGR	\$ 1,395
CII	1,442
BDJ	3,186
BOE	2,915
BGY	2,827

BME	4,091
BCX	3,732
BST	1,572
BUI	1,557

The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each Trust's assets invested in affiliated equity and fixed-income mutual funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2019. The agreement can be renewed for annual periods thereafter, and may be terminated on 90 days' notice, each subject to approval by a majority of the Trusts' Independent Trustees. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the period ended June 30, 2018, there were no investment advisory fees pursuant to these arrangements.

Securities Lending: The U.S. Securities and Exchange Commission (SEC) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the collateral investment expenses). The cash collateral is invested in a private investment company managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the private investment company to an annual rate of 0.04%. The investment adviser to the private investment company will not charge any advisory fees with respect to shares purchased by the Trusts. The private investment company in which the cash collateral has been invested may, under certain circumstances, impose a liquidity fee of up to 2% of the value withdrawn or temporarily restrict withdrawals for up to 10 business days during a 90 day period, in the event that the private investment company's weekly liquid assets fall below certain thresholds.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent. Pursuant to a securities lending agreement, BIM may lend securities only when the difference between the borrower rebate rate and the risk free rate exceeds a certain level (such securities, the specials only securities).

Notes to Financial Statements (unaudited) (continued)

Each Trust retains 80% of securities lending income. In addition, commencing the business day following the date that the aggregate securities lending income earned across the Closed-End Complex in a calendar year exceeds the breakpoint dollar threshold applicable in the given year as set forth in the securities lending agreement, each Trust, pursuant to the securities lending agreement, will retain for the remainder of the calendar year securities lending income in an amount equal to 85% of securities lending income.

The share of securities lending income earned by each Trust is shown as securities lending income affiliated net in the Statements of Operations. For the period ended June 30, 2018, each Trust paid BIM the following amounts for securities lending agent services:

BDJ	\$ 2
BME	310
BCX	628
BST	30,983

Trustees and Officers: Certain Trustees and/or officers of the Trusts are trustees and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.

Other Transactions: During the six months ended June 30, 2018, BGY received a reimbursement of \$243,859 from an affiliate, which is shown as payments by affiliates in the Statements of Operations, related to the reimbursement of transaction costs.

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the six months ended June 30, 2018, the purchase and sale transactions and any net realized gains (losses) with an affiliated fund in compliance with Rule 17a-7 under the 1940 Act were as follows:

	<i>Purchase</i>	<i>Sales</i>	<i>Net Realized Gain (Loss)</i>
BDJ	\$ 3,832,651		

7. PURCHASES AND SALES

For the six months ended June 30, 2018, purchases and sales of investments excluding short-term securities, were as follows:

	<i>Purchases</i>	<i>Sales</i>
BGR	\$ 96,116,237	\$ 121,304,155
CII	92,067,745	116,237,176

BDJ	308,006,919	363,941,063
BOE	147,813,777	156,965,401
BGY	346,240,233	353,741,234
BME	62,689,623	65,028,434
BCX	383,862,338	418,553,686
BST	169,757,561	196,333,223
BUI	57,510,952	65,410,798

8. INCOME TAX INFORMATION

It is each Trust's policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.

Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust's U.S. federal tax returns generally remains open for each of the three years ended December 31, 2017, the period ended December 31, 2014 and the year ended October 31, 2014 with the exception of BST. The statutes of limitations on BST's U.S. federal tax returns remains open for each of the three years ended December 31, 2017 and the period ended December 31, 2014. The statutes of limitations on each Trust's state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts as of June 30, 2018, inclusive of the open tax return years, and does not believe that there are any uncertain tax positions that require recognition of a tax liability in the Trusts' financial statements.

As of December 31, 2017, the Trusts had non-expiring capital loss carryforwards available to offset future realized capital gains as follows:

	<i>BGR</i>	<i>CII</i>	<i>BGY</i>	<i>BCX</i>
No expiration date	\$ 154,439,314	\$ 21,333,622	\$ 31,492,776	\$ 437,380,204

Notes to Financial Statements (unaudited) (continued)

As of June 30, 2018, gross unrealized appreciation and depreciation for investments and derivatives based on cost for U.S. federal income tax purposes were as follows:

	<i>BGR</i>	<i>CII</i>	<i>BDJ</i>	<i>BOE</i>	<i>BGY</i>
Tax cost	\$ 424,143,825	\$ 591,611,409	\$ 1,429,825,470	\$ 848,463,124	\$ 723,416,101
Gross unrealized appreciation	\$ 81,897,361	\$ 184,616,547	\$ 462,045,697	\$ 41,932,385	\$ 25,412,668
Gross unrealized depreciation	(25,780,008)	(20,018,179)	(68,457,946)	(70,937,899)	(58,905,300)
Net unrealized appreciation (depreciation)	\$ 56,117,353	\$ 164,598,368	\$ 393,587,751	\$ (29,005,514)	\$ (33,492,632)
		<i>BME</i>	<i>BCX</i>	<i>BST</i>	<i>BUI</i>
Tax cost		\$ 235,074,925	\$ 849,889,691	\$ 369,977,582	\$ 265,721,629
Gross unrealized appreciation		\$ 116,831,611	\$ 194,676,837	\$ 346,507,612	\$ 89,424,190
Gross unrealized depreciation		(6,808,793)	(46,631,714)	(10,534,876)	(11,236,806)
Net unrealized appreciation (depreciation)		\$ 110,022,818	\$ 148,045,123	\$ 335,972,736	\$ 78,187,384

The Tax Cuts and Jobs Act (the Act) was enacted on December 22, 2017. Certain provisions of the Act were effective upon enactment with the remainder becoming effective for tax years beginning after December 31, 2017. Although the Act does not amend any provisions directly related to the qualification or taxation of regulated investment companies (RICs), the Act does change the taxation of entities in which some RICs invest, the tax treatment of income derived from those entities and the taxation of RIC shareholders. While management does not anticipate significant impact to the Funds or to their shareholders, there is uncertainty in the application of certain provisions in the Act. Specifically, provisions in the Act may increase the amount of or accelerate the recognition of taxable income and may limit the deductibility of certain expenses by RICs. Until full clarity around these provisions is obtained, the impact on the Trusts' financial statements, if any, cannot be fully determined.

9. PRINCIPAL RISKS

In the normal course of business, certain Trusts invest in securities or other instruments and may enter into certain transactions, and such activities subject each Trust to various risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability; (iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations.

The Trusts may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of \$1.00 and which may be subject to redemption gates or liquidity fees under certain circumstances.

Valuation Risk: The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries. A Trust may invest in illiquid investments and may experience difficulty in selling those investments in a timely manner at the price that they believe the investments are worth. Prices may fluctuate widely over short or extended periods in response to company, market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each Trust's NAV to experience significant increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a Trust may lose value, regardless of the individual results of the securities and other instruments in which a Trust invests.

The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust's valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore a Trust's results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater than expected loss or lesser than expected gain upon the sale of the investment. A Trust's ability to value its investments may also be impacted by technological issues and/or errors by pricing services or other third party service providers.

Counterparty Credit Risk: The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trusts' exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.

A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

A Trust's risk of loss from counterparty credit risk on OTC derivatives is generally limited to the aggregate unrealized gain less the value of any collateral held by such Trust.

For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent the Trusts deposit collateral with its counterparty to a written option.

Notes to Financial Statements (unaudited) (continued)

With exchange-traded options purchased and futures, there is less counterparty credit risk to the Trusts since the exchange or clearinghouse, as counterparty to such instruments, guarantees against a possible default. The clearinghouse stands between the buyer and the seller of the contract; therefore, credit risk is limited to failure of the clearinghouse. While offset rights may exist under applicable law, a Trust does not have a contractual right of offset against a clearing broker or clearinghouse in the event of a default (including the bankruptcy or insolvency). Additionally, credit risk exists in exchange-traded futures with respect to initial and variation margin that is held in a clearing broker's customer accounts. While clearing brokers are required to segregate customer margin from their own assets, in the event that a clearing broker becomes insolvent or goes into bankruptcy and at that time there is a shortfall in the aggregate amount of margin held by the clearing broker for all its clients, typically the shortfall would be allocated on a pro rata basis across all the clearing broker's customers, potentially resulting in losses to the Trusts.

Concentration Risk: As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:

Energy . . .	BGR, BCX
Financials	BDJ, BGY
Health Care	BME
Information Technology	CII, BST
Materials	BCX
Utilities	BUI

Changes in economic conditions affecting such sectors would have a greater impact on the trusts and could affect the value, income and/or liquidity of positions in such securities.

BOE invests a substantial amount of its assets in issuers located in a single country or a limited number of countries. When a Trust concentrates its investments in this manner, it assumes the risk that economic, political and social conditions in those countries may have a significant impact on its investment performance. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the United States. Foreign securities markets may also be less liquid, more volatile, and less subject to governmental supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.

BOE, BGY and BCX invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts' investments.

The United Kingdom voted on June 23, 2016 to withdraw from the European Union, which may introduce significant new uncertainties and instability in the financial markets across Europe.

10. CAPITAL SHARE TRANSACTIONS

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

Each Trust is authorized to issue an unlimited numbers of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue 200 million Common Shares. The par value for each Trust's Common Shares is \$0.001, except for CII, which is \$0.10. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without the approval of Common Shareholders.

For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:

	<i>Six Months Ended</i>	<i>Year Ended</i>
	<i>06/30/18</i>	<i>12/31/17</i>
BME	75,574	601,804

For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:

	<i>Six Months Ended</i>	<i>Year Ended</i>
	<i>06/30/18</i>	<i>12/31/17</i>
BME	7,315	47,676
BST	24,224	
BUI	12,786	33,776

For the six months ended June 30, 2018, for BGR, CII, BDJ, BOE and BGY and year ended December 31, 2017, for BGR and CII shares issued and outstanding remained constant.

On June 9, 2016, BME filed a final prospectus with the SEC allowing it to issue an additional 2,500,000 Common Shares through a Shelf Offering. Under the Shelf Offering, BME, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above BME's NAV per Common Share (calculated within 48 hours of pricing). As of period end, 1,458,914 Common Shares remain available for issuance under the Shelf Offering. From August 12, 2015 to June 9, 2016, BME was authorized to issue 453,000 Common Shares under a previous Shelf Offering. See Additional Information - Shelf Offering Program for additional information about the Shelf Offering.

Initial costs incurred by BME in connection with its shelf offering are recorded - Deferred offering costs - on the Statements of Assets and Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the shelf offering period will be charged to expense. Any subsequent costs incurred to keep the filing active will be charged to expense as incurred.

Notes to Financial Statements (unaudited) (continued)

The Board previously approved each Trust's participation in an open market share repurchase program that allowed each Trust to purchase, at prevailing market prices, up to 5% of its common shares outstanding as of the close of business on October 28, 2016 through November 30, 2017, subject to certain conditions. On September 6, 2017, the Board approved a renewal of this program. Commencing December 1, 2017, each Trust may purchase through November 30, 2018, up to 5% of its common shares outstanding as of the close of business on November 30, 2017, subject to certain conditions. There is no assurance that the Trusts will purchase shares in any particular amounts. The shares repurchased during the six months ended June 30, 2018 are as follows:

	<i>Shares</i>	
	<i>Repurchased</i>	<i>Amount</i> ^(a)
BCX	636,819	\$ 6,307,631

^(a) Includes transaction costs.

The total amount of such repurchases is reflected in the Statements of Changes in Net Assets.

11. SUBSEQUENT EVENTS

Management's evaluation of the impact of all subsequent events on the Trusts' financial statements was completed through the date the financial statements were issued and the following items were noted:

	Common Dividend Per Share	
	<i>Paid</i> ^(a)	<i>Declared</i> ^(b)
BGR	\$ 0.0776	\$ 0.0776
CII	0.0828	0.0828
BDJ	0.0467	0.0467
BOE	0.0630	0.0630
BME	0.2000	0.2000
BGY	0.0380	0.0380
BCX	0.0516	0.0516
BST	0.1500	0.1500
BUI	0.1210	0.1210

^(a) Net investment income dividend paid on July 31, 2018 to shareholders of record on July 16, 2018.

^(b) Net investment income dividend declared on August 1, 2018, payable to shareholders of record on August 15, 2018.

Disclosure of Investment Advisory Agreement and Sub-Advisory Agreement

The Board of Directors or Trustees, as applicable (each, a Board, collectively, the Boards, and the members of which are referred to as Board Members), of BlackRock Energy and Resources Trust (BGR), BlackRock Enhanced Capital and Income Fund, Inc. (CII), BlackRock Enhanced Equity Dividend Trust (BDJ), BlackRock Enhanced Global Dividend Trust (BOE), BlackRock Health Sciences Trust (BME), BlackRock Enhanced International Dividend Trust (BGY), BlackRock Resources & Commodities Strategy Trust (BCX), BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) and BlackRock Science and Technology Trust (BST and together with BGR, CII, BDJ, BOE, BME, BGY, BCX and BUI, each a Fund, and, collectively, the Funds) met in person on April 24, 2018 (the April Meeting) and June 6-7, 2018 (the June Meeting) to consider the approval of the Fund's investment advisory agreement (the Advisory Agreement) with BlackRock Advisors, LLC (the Manager), each Fund's investment advisor. The Board of each of BGR, BCX, BOE, BGY and BUI also considered the approval of the sub-advisory agreement (the Sub-Advisory Agreement) among the Manager, BlackRock International Limited (the Sub-Advisor), and the Fund. The Manager and the Sub-Advisor are referred to herein as BlackRock. The Advisory Agreement and the Sub-Advisory Agreement are referred to herein as the Agreements.

Activities and Composition of the Board

On the date of the June Meeting, the Board of each Fund consisted of ten individuals, eight of whom were not interested persons of the Fund as defined in the Investment Company Act of 1940, as amended (the 1940 Act) (the Independent Board Members). The Board Members are responsible for the oversight of the operations of its Fund and perform the various duties imposed on the directors of investment companies by the 1940 Act. The Independent Board Members have retained independent legal counsel to assist them in connection with their duties. The Chair of each Board is an Independent Board Member. Each Board has established five standing committees: an Audit Committee, a Governance and Nominating Committee, a Compliance Committee, a Performance Oversight Committee, and an Executive Committee, each of which is chaired by an Independent Board Member and composed of Independent Board Members (except for the Executive Committee, which also has one interested Board Member).

The Agreements

Pursuant to the 1940 Act, each Board is required to consider the continuation of the Advisory Agreement for its Trust, and with respect to BGR, BCX, BOE, BGY and BUI, the Sub-Advisory Agreement, on an annual basis. Each Board has four quarterly meetings per year, each typically extending for two days, and additional in-person and telephonic meetings throughout the year, as needed. Each Board also has a fifth one-day meeting to consider specific information surrounding the consideration of renewing the Agreement(s) for its Fund. Each Board's consideration of the Agreement(s) for its Fund is a year-long deliberative process, during which the Board assessed, among other things, the nature, extent and quality of the services provided to its Fund by BlackRock, BlackRock's personnel and affiliates, including, as applicable; investment management, accounting, administrative, and shareholder services; oversight of the Fund's service providers; marketing; risk management and oversight; legal and compliance services; and ability to meet applicable legal and regulatory requirements.

Each Board, acting directly and through its committees, considers at each of its meetings, and from time to time as appropriate, factors that are relevant to its annual consideration of the renewal of the Agreement(s) for its Fund, including the services and support provided by BlackRock to the Fund and its shareholders. BlackRock also furnished additional information to each Board in response to specific questions from the Board. This additional information is discussed further below in the section titled Board Considerations in Approving the Agreements. Among the matters each Board considered were: (a) investment performance for one-year, three-year, five-year, ten-year, and/or since inception periods, as applicable, against peer funds, applicable benchmarks, and performance metrics, as applicable, as

well as senior management's and portfolio managers' analysis of the reasons for any over-performance or underperformance relative to its peers, benchmarks, and other performance metrics, as applicable; (b) leverage management, as applicable; (c) fees, including advisory, administration, if applicable, paid to BlackRock and its affiliates by the Fund for services; (d) Fund operating expenses and how BlackRock allocates expenses to the Fund; (e) the resources devoted to, risk oversight of, and compliance reports relating to, implementation of the Fund's investment objective(s), policies and restrictions, and meeting regulatory requirements; (f) the Fund's adherence to its compliance policies and procedures; (g) the nature, character and scope of non-investment management services provided by BlackRock and its affiliates and the estimated cost of such services; (h) BlackRock's and other service providers' internal controls and risk and compliance oversight mechanisms; (i) BlackRock's implementation of the proxy voting policies approved by the Board; (j) the use of brokerage commissions and execution quality of portfolio transactions; (k) BlackRock's implementation of the Fund's valuation and liquidity procedures; (l) an analysis of management fees for products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust, and institutional separate account product channels, as applicable, and the similarities and differences between these products and the services provided as compared to the Fund; (m) BlackRock's compensation methodology for its investment professionals and the incentives and accountability it creates, along with investment professionals' investments in the fund(s) they manage; and (n) periodic updates on BlackRock's business.

Board Considerations in Approving the Agreements

The Approval Process: Prior to the April Meeting, each Board requested and received materials specifically relating to the Agreement(s) for its Fund. Each Board is continuously engaged in a process with its independent legal counsel and BlackRock to review the nature and scope of the information provided to better assist its deliberations. The materials provided to the Board of each Fund in connection with the April Meeting included, among other things: (a) information independently compiled and prepared by Broadridge Financial Solutions, Inc. (Broadridge), based on Lipper classifications, regarding the Fund's fees and expenses as compared with a peer group of funds as determined by Broadridge (Expense Peers) and the investment performance of the Fund as compared with a peer group of funds (Performance Peers) and other metrics, as applicable; (b) information on the composition of the Expense Peers and Performance Peers, and a description of the Broadridge's methodology; (c) information on the estimated profits realized by BlackRock and its affiliates pursuant to the Fund's Agreement(s) and a discussion of fall-out benefits to BlackRock and its affiliates; (d) a general analysis provided by BlackRock concerning investment management fees received in connection with other types of investment products, such as institutional accounts, sub-advised mutual funds, closed-end funds, and open-end funds, under similar investment mandates, as applicable; (e) review of non-management fees; (f) the existence and impact and sharing of potential economies of scale, if any, and the sharing of potential economies of scale with the Fund; (g) a summary of aggregate amounts paid by the Fund to BlackRock; and (h) various additional information requested by the Board as appropriate regarding BlackRock's and the Fund's operations.

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

At the April Meeting, each Board reviewed materials relating to its consideration of the Agreement(s) for its Fund. As a result of the discussions that occurred during the April Meeting, and as a culmination of each Board's year-long deliberative process, each Board presented BlackRock with questions and requests for additional information. BlackRock responded to these requests with additional written information in advance of the June Meeting.

At the June Meeting, each Board considered, among other things: (a) the nature, extent and quality of the services provided by BlackRock; (b) the investment performance of the Fund as compared with Performance Peers and other metrics, as applicable; (c) the advisory fee and the estimated cost of the services and estimated profits realized by BlackRock and its affiliates from their relationship with the Fund; (d) the Fund's fees and expenses compared to Expense Peers; (e) the sharing of potential economies of scale; (f) fall-out benefits to BlackRock and its affiliates as a result of BlackRock's relationship with the Fund; and (g) other factors deemed relevant by the Board Members.

Each Board also considered other matters it deemed important to the approval process, such as other payments made to BlackRock or its affiliates relating to securities lending and cash management, services related to the valuation and pricing of Fund portfolio holdings, and advice from independent legal counsel with respect to the review process and materials submitted for the Board's review. Each Board noted the willingness of BlackRock personnel to engage in open, candid discussions with the Board. Each Board did not identify any particular information as determinative, and each Board Member may have attributed different weights to the various items considered.

A. Nature, Extent and Quality of the Services Provided by BlackRock: Each Board, including the Independent Board Members, reviewed the nature, extent and quality of services provided by BlackRock, including the investment advisory services and the resulting performance of its Fund. Throughout the year, each Board compared its Fund's performance to the performance of a comparable group of closed-end funds, relevant benchmark, and performance metrics, as applicable. Each Board met with BlackRock's senior management personnel responsible for investment activities, including the senior investment officers. Each Board also reviewed the materials provided by its Fund's portfolio management team discussing the Fund's performance and the Fund's investment objective(s), strategies and outlook.

Each Board considered, among other factors, with respect to BlackRock: the number, education and experience of investment personnel generally and its Fund's portfolio management team; BlackRock's research capabilities; investments by portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. Each Board also considered BlackRock's overall risk management program, including the continued efforts of BlackRock and its affiliates to address cybersecurity risks and the role of BlackRock's Risk & Quantitative Analysis Group. Each Board engaged in a review of BlackRock's compensation structure with respect to the Fund's portfolio management team and BlackRock's ability to attract and retain high-quality talent and create performance incentives.

In addition to investment advisory services, each Board considered the quality of the administrative and other non-investment advisory services provided to its Fund. BlackRock and its affiliates provide each Fund with certain administrative, shareholder, and other services (in addition to any such services provided to the Fund by third parties) and officers and other personnel as are necessary for the operations of the Fund. In particular, BlackRock and its affiliates provide each Fund with administrative services including, among others: (i) responsibility for disclosure documents, such as the prospectus and the statement of additional information in connection with the initial public offering, and, with respect to BME, registration statements in connection with BME's equity shelf program, and periodic shareholder reports; (ii) preparing communications with analysts to support secondary market trading of the

Fund; (iii) oversight of daily accounting and pricing; (iv) responsibility for periodic filings with regulators and stock exchanges; (v) overseeing and coordinating the activities of other service providers including, among others, the Fund's custodian, fund accountant, transfer agent, and auditor; (vi) organizing Board meetings and preparing the materials for such Board meetings; (vii) providing legal and compliance support; (viii) furnishing analytical and other support to assist the Board in its consideration of strategic issues such as the merger, consolidation or repurposing of certain closed-end funds; and (ix) performing administrative functions necessary for the operation of the Fund, such as tax reporting, expense management, fulfilling regulatory filing requirements, and shareholder call center and other services. Each Board reviewed the structure and duties of BlackRock's fund administration, shareholder services, and legal & compliance departments and considered BlackRock's policies and procedures for assuring compliance with applicable laws and regulations.

B. The Investment Performance of the Funds and BlackRock: Each Board, including the Independent Board Members, also reviewed and considered the performance history of its Fund. In preparation for the April Meeting, the Board of each Fund was provided with reports independently prepared by Broadridge, which included a comprehensive analysis of its Fund's performance as of December 31, 2017. The performance information is based on net asset value (NAV), and utilizes Lipper data. Lipper's methodology calculates a fund's total return assuming distributions are reinvested on the ex-date at a fund's ex-date NAV. Broadridge ranks funds in quartiles, ranging from first to fourth, where first is the most desirable quartile position and fourth is the least desirable. In connection with its review, the Board received and reviewed information regarding the investment performance of the Fund as compared to its Performance Peers and the performance of the Fund as compared with its custom benchmark. Each Board and its Performance Oversight Committee regularly review, and meet with Fund management to discuss, the performance of its Fund throughout the year.

In evaluating performance, each Board recognized that the performance data reflects a snapshot of a period as of a particular date and that selecting a different performance period could produce significantly different results. Further, each Board recognized that it is possible that long-term performance can be impacted by even one period of significant outperformance or underperformance, so that a single investment theme has the ability to affect long-term performance disproportionately.

The Board of BDJ noted that for the one-, three- and five-year periods reported, BDJ ranked in the third, second and second quartiles, respectively, against its Performance Peers. The Board noted BDJ's underperformance for the applicable period reported as compared to its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BDJ's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BDJ generally performed at or above expectations.

The Board of BGR noted that for the one-, three- and five-year periods reported, the Fund ranked in the second, second, and fourth quartiles, respectively, against its Performance Peers. The Board noted BGR's underperformance for the applicable period reported as compared to its Performance Peers.

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BGR's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BGR generally performed below expectations. The Board and BlackRock reviewed BGR's underperformance. The Board was informed that, among other things, BGR's overweight position in oil price sensitive stocks detracted from performance.

The Board and BlackRock discussed BlackRock's strategy for improving BGR's investment performance. Discussions covered topics such as performance attribution, BGR's investment personnel, and the resources appropriate to support BGR's investment processes. BlackRock and the Board previously had discussed changes within the portfolio management team. The Board will continue to monitor BGR's performance.

The Board of BOE noted that for the one-, three- and five-year periods reported, BOE ranked in the third, fourth, and fourth quartiles, respectively, against its Performance Peers. The Board noted BOE's underperformance for the applicable periods reported as compared to its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BOE's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BOE generally performed below expectations. The Board and BlackRock reviewed BOE's underperformance. The Board noted that effective June 12, 2017, BOE had undergone certain changes to its investment process and portfolio management team, and in connection with such changes, BOE changed its name from Global Opportunities Equity Trust to Enhanced Global Dividend Trust.

The Board and BlackRock discussed BlackRock's strategy for improving BOE's investment performance. Discussions covered topics such as performance attribution, BOE's investment personnel, and the resources appropriate to support BOE's investment processes.

The Board of BME noted that for each of the one-, three- and five-year periods reported, BME ranked in the first quartile against its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BME's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BME generally performed at or above expectations.

The Board of BGY noted that for the one-, three- and five-year periods reported, BGY ranked in the second, fourth, and fourth quartiles, respectively, against its Performance Peers. The Board noted BGY's underperformance for the applicable periods reported as compared to its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BGY's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BGY generally performed below expectations. The Board noted that effective June 12, 2017, BGY had undergone certain changes to its investment process and portfolio management team, and in connection with such changes, BGY changed its name from International Growth and Income Trust to Enhanced

International Dividend Trust.

The Board and BlackRock discussed BlackRock's strategy for improving BGY's investment performance. Discussions covered topics such as performance attribution, BGY's investment personnel, and the resources appropriate to support BGY's investment processes.

The Board of BCX noted that for the one-, three- and five-year periods reported, BCX ranked in first, first and third quartiles, respectively, against its Performance Peers. The Board noted BCX's underperformance for the applicable period reported as compared to its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BCX's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BCX generally performed near expectations.

The Board of BST noted that for each of the one-year, three-year and since-inception periods reported, BST ranked in the first quartile against its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BST's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BST generally performed at or above expectations.

The Board of CII noted that for the one-, three- and five-year periods reported, CII ranked in the second, first and first quartiles, respectively, against its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of CII's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, CII generally performed at or above expectations.

The Board of BUI noted that for the one-, three- and five-year periods reported, BUI ranked in the second, third and third quartiles, respectively, against its Performance Peers. The Board noted BUI's underperformance for the applicable periods reported as compared to its Performance Peers.

BlackRock believes that certain other performance metrics may be more appropriate than the Performance Peers, and the Board was provided with a comparison of BUI's performance relative to these metrics. These metrics include Fund return, Sharpe Ratio, stability of distribution and yield. Based on an overall rating relative to these metrics, as determined by BlackRock, BUI generally performed near expectations. The Board noted that effective November 27, 2017, BUI had undergone certain changes to its investment process, and in connection with such changes, BUI changed its name from Utility and Infrastructure Trust to Utilities, Infrastructure and Power Opportunities Trust.

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

C. Consideration of the Advisory/Management Fees and the Estimated Cost of the Services and Estimated Profits Realized by BlackRock and its Affiliates from their Relationship with the Funds: Each Board, including the Independent Board Members, reviewed its Fund's contractual management fee rate compared with those of its Expense Peers. The contractual management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. Each Board also compared its Fund's total expense ratio, as well as its actual management fee rate as a percentage of total assets, to those of its Expense Peers. The total expense ratio represents a fund's total net operating expenses, excluding any investment related expenses. The total expense ratio gives effect to any expense reimbursements or fee waivers that benefit a fund, and the actual management fee rate gives effect to any management fee reimbursements or waivers that benefit a fund. Each Board considered the services provided and the fees charged by BlackRock and its affiliates to other types of clients with similar investment mandates, as applicable, including institutional accounts and sub-advised mutual funds (including mutual funds sponsored by third parties).

Each Board received and reviewed statements relating to BlackRock's financial condition. Each Board reviewed BlackRock's profitability methodology and was also provided with an estimated profitability analysis that detailed the revenues earned and the expenses incurred by BlackRock for services provided to its Fund. Each Board reviewed BlackRock's estimated profitability with respect to the Fund and other funds the Board currently oversees for the year ended December 31, 2017 compared to available aggregate estimated profitability data provided for the prior two years. Each Board reviewed BlackRock's estimated profitability with respect to certain other U.S. fund complexes managed by the Manager and/or its affiliates. Each Board reviewed BlackRock's assumptions and methodology of allocating expenses in the estimated profitability analysis, noting the inherent limitations in allocating costs among various advisory products. Each Board recognized that profitability may be affected by numerous factors including, among other things, fee waivers and expense reimbursements by the Manager, the types of funds managed, precision of expense allocations and business mix. As a result, calculating and comparing profitability at individual fund levels is difficult.

Each Board noted that, in general, individual fund or product line profitability of other advisors is not publicly available. Each Board reviewed BlackRock's overall operating margin, in general, compared to that of certain other publicly-traded asset management firms. Each Board considered the differences between BlackRock and these other firms, including the contribution of technology at BlackRock, BlackRock's expense management, and the relative product mix.

In addition, each Board considered the estimated cost of the services provided to its Fund by BlackRock, and BlackRock's and its affiliates' estimated profits relating to the management of its Fund and the other funds advised by BlackRock and its affiliates. As part of its analysis, each Board reviewed BlackRock's methodology in allocating its costs of managing its Fund, to the Fund. Each Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations under its Fund's Agreement(s) and to continue to provide the high quality of services that is expected by the Board. Each Board further considered factors including but not limited to BlackRock's commitment of time, assumption of risk, and liability profile in servicing its Fund in contrast to what is required of BlackRock with respect to other products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust, and institutional separate account product channels, as applicable.

The Board of BDJ noted that BDJ's contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

The Board of BGR noted that BGR's contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BGR, which has been in effect since 2015. After discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of a 15bps voluntary advisory fee waiver.

The Board of BOE noted that BOE's contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BOE, which has been in effect since 2015. After discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to increase the voluntary advisory fee waiver from 10 basis points to 17.5 basis points. The waiver increase was implemented on July 1, 2018.

The Board of BME noted that BME's contractual management fee rate ranked first out of three funds, and that the actual management fee rate and total expense ratio ranked first out of four funds, and in the first quartile, respectively, relative to the Expense Peers.

The Board of BGY noted that BGY's contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. The Board also noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BGY, which has been in effect since 2013. After discussions between the Board, including Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of a 10 basis points voluntary advisory fee waiver.

The Board of BCX noted that BCX's contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board of BST noted that BST's contractual management fee rate ranked first out of three funds, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers. The Board also noted that, in connection with BST's launch, BlackRock has contractually agreed to waive a portion of the advisory fee payable by BST through December 31, 2021.

The Board of CII noted that CII's contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

The Board of BUI noted that BUI's contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. The Board also noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BUI, which has been in effect since 2017. After discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of a 2.5 basis points voluntary advisory fee waiver.

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

D. Economies of Scale: The Board of each Fund, including the Independent Board Members, considered the extent to which economies of scale might be realized as the assets of its Fund increase. Each Board also considered the extent to which its Fund benefits from such economies in a variety of ways, and whether there should be changes in the advisory fee rate or breakpoint structure in order to enable the Fund to more fully participate in these economies of scale. Each Board considered its Fund's asset levels and whether the current fee was appropriate.

Based on each Board's review and consideration of the issue, each Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds generally do not experience substantial growth after the initial public offering. They are typically priced at scale at a fund's inception. The Board of BME noted that although BME may from time-to-time make additional share offerings pursuant to its equity shelf program, the growth of BME's assets will occur primarily through the appreciation of its investment portfolio.

E. Other Factors Deemed Relevant by the Board Members: Each Board, including the Independent Board Members, also took into account other ancillary or "fall-out" benefits that BlackRock or its affiliates may derive from BlackRock's respective relationships with its Fund, both tangible and intangible, such as BlackRock's ability to leverage its investment professionals who manage other portfolios and risk management personnel, an increase in BlackRock's profile in the investment advisory community, and the engagement of BlackRock's affiliates as service providers to the Fund, including for administrative, securities lending and cash management services. Each Board also considered BlackRock's overall operations and its efforts to expand the scale of, and improve the quality of, its operations. Each Board also noted that, subject to applicable law, BlackRock may use and benefit from third party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client accounts.

In connection with its consideration of the Agreement(s) for its Fund, each Board also received information regarding BlackRock's brokerage and soft dollar practices. Each Board received reports from BlackRock which included information on brokerage commissions and trade execution practices throughout the year.

Each Board noted the competitive nature of the closed-end fund marketplace, and that shareholders are able to sell their Fund shares in the secondary market if they believe that the Fund's fees and expenses are too high or if they are dissatisfied with the performance of the Fund.

Each Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included the completion of the redemption of auction rate preferred securities for all of the BlackRock closed-end funds; developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic evaluation of share repurchases and other support initiatives for certain BlackRock funds; and continued communications efforts with shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members of each Fund noted BlackRock's continued commitment to supporting the secondary market for the common shares of its closed-end funds through a comprehensive secondary market communication program designed to raise investor and analyst awareness and understanding of closed-end funds. BlackRock's support services included, among other things: sponsoring and participating in conferences; communicating with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and enhancing its closed-end fund website.

Conclusion

Each Board, including the Independent Board Members, unanimously approved the continuation of the Advisory Agreement between the Manager and the Fund for a one-year term ending June 30, 2019. The Board of each of BGR, BCX, BOE, BGY and BUI, including the Independent Board Members, also unanimously approved the continuation of the Sub-Advisory Agreement between the Manager and the Sub-Advisor, with respect to its Fund, for a one-year term ending June 30, 2019. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, each Board, including the Independent Board Members, was satisfied that the terms of its Fund's Agreement(s) were fair and reasonable and in the best interest of the Fund and its shareholders. In arriving at its decision to approve the Agreement(s), each Board did not identify any single factor or group of factors as, all-important or controlling, but considered all factors together, and different Board Members may have attributed different weights to the various factors considered. The Independent Board Members of each Fund were also assisted by the advice of independent legal counsel in making this determination.

Trustee and Officer Information

Richard E. Cavanagh, Chair of the Board and Trustee

Karen P. Robards, Vice Chair of the Board and Trustee

Michael J. Castellano, Trustee

Cynthia L. Egan, Trustee

Frank J. Fabozzi, Trustee

R. Glenn Hubbard, Trustee

W. Carl Kester, Trustee

Catherine A. Lynch, Trustee

Robert Fairbairn, Trustee

John M. Perlowski, Trustee and President and Chief Executive Officer

Jonathan Diorio, Vice President

Neal J. Andrews, Chief Financial Officer

Jay M. Fife, Treasurer

Charles Park, Chief Compliance Officer

Janey Ahn, Secretary

Investment Adviser

BlackRock Advisors, LLC

Wilmington, DE 19809

Sub-Adviser

BlackRock International LTD.^(a)

Edinburgh, EH3 8BL

United Kingdom

Custodian and Accounting Agent

State Street Bank and Trust Company

Boston, MA 02111

Transfer Agent

Computershare Trust Company, N.A.

Canton, MA 02021

Independent Registered Public Accounting Firm

Deloitte & Touche LLP

Boston, MA 02116

Distributor

BlackRock Investments, LLC^(b)

New York, NY 10022

Legal Counsel

Skadden, Arps, Slate, Meagher & Flom LLP

Boston, MA 02116

Address of the Trusts

100 Bellevue Parkway

Wilmington, DE 19809

(a) For BGR, BOE, BGY, BCX and BUI.

(b) For BME.

Additional Information

Fund Certification

The Trusts are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE's listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by section 302 of the Sarbanes-Oxley Act.

General Information

The Trusts, other than BME, do not make available copies of their Statements of Additional Information because the Trusts' shares, except for BME, are not continuously offered, which means that the Statements of Additional Information of each Trust, other than BME, have not been updated after completion of the respective Trust's offerings and the information contained in each such Trust's Statement of Additional Information may have become outdated.

BME's Statement of Additional Information includes additional information about its Board and is available, without charge upon request by calling 1-800-882-0052.

During the period there were no material changes in the Trusts' investment objectives or policies or to the Trusts' charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders or in the principal risk factors associated with investment in the Trusts. There have been no changes in the persons who are primarily responsible for the day-to-day management of the Trusts' portfolios.

In accordance with Section 23(c) of the Investment Company Act of 1940, as amended, the Trusts from time to time may purchase its common shares in the open market or in private transactions.

Quarterly performance, semi-annual and annual reports and other information regarding the Trusts may be found on BlackRock's website, which can be accessed at <http://www.blackrock.com>. Any reference to BlackRock's website in this report is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock's website in this report.

Electronic Delivery

Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports by enrolling in the electronic delivery program. Electronic copies of shareholder reports are available on BlackRock's website.

To enroll in electronic delivery:

Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:

Please contact your financial advisor. Please note that not all investment advisers, banks or brokerages may offer this service.

Householding

The Trusts will mail only one copy of shareholder documents, annual and semi-annual reports and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called "householding" and is

intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts (800) 882-0052.

Availability of Quarterly Schedule of Investments

The Trusts file their complete schedule of portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-Q. The Trusts' Forms N-Q are available on the SEC's website at <http://www.sec.gov>, and may also be reviewed and copied at the SEC's Public Reference Room in Washington, D.C. Information on the operation of the Public Reference Room or how to access documents on the SEC's website without charge may be obtained by calling (800) SEC-0330. The Trusts' Forms N-Q may also be obtained upon request and without charge by calling (800) 882-0052.

Availability of Proxy Voting Policies and Procedures

A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities is available upon request and without charge (1) by calling (800) 882-0052; (2) at <http://www.blackrock.com>; and (3) on the SEC's website at <http://www.sec.gov>.

Availability of Proxy Voting Record

Information about how the Trusts voted proxies relating to securities held in the Trusts' portfolio during the most recent 12-month period ended June 30 is available upon request and without charge (1) at <http://www.blackrock.com> or by calling (800) 882-0052 and (2) on the SEC's website at <http://www.sec.gov>.

Availability of Trust Updates

BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the Closed-end Funds' section of <http://www.blackrock.com> as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock's website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock's website in this report.

Additional Information (continued)

Shelf Offering Program

From time-to-time, each Trust may seek to raise additional equity capital through an equity shelf program (a Shelf Offering). In a Shelf Offering, a Trust may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above the Trust's net asset value (NAV) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow a Trust to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.

BME has filed a final prospectus with the SEC in connection with its Shelf Offering. This report and the prospectus of BME are not offers to sell BME Common Shares or solicitations of an offer to buy BME Common Shares in any jurisdiction where such offers or sales are not permitted. The prospectus of BME contains important information about the Trust, including its investment objective, risks, charges and expenses. Investors are urged to read the prospectus of BME carefully and in its entirety before investing. Copies of the final prospectus for BME can be obtained from BlackRock at <http://www.blackrock.com>.

Dividend Policy

Each Trust's dividend policy is to distribute all or a portion of its net investment income to its shareholders on a monthly basis. In order to provide shareholders with a more stable level of dividend distributions, the distributions paid by the Trusts for any particular month may be more or less than the amount of net investment income earned by the Trusts during such month. The portion of distributions that exceeds a Trust's current and accumulated earnings and profits, which are measured on a tax basis, will constitute a nontaxable return of capital. Distributions in excess of a Trust's taxable income and net capital gains, but not in excess of a Trust's earnings and profits, will be taxable to shareholders as ordinary income and will not constitute a nontaxable return of capital. The Trusts' current accumulated but undistributed net investment income, if any, is disclosed in the Statements of Assets and Liabilities, which comprises part of the financial information included in this report.

BlackRock Privacy Principles

BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, Clients) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.

If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.

BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.

Edgar Filing: BlackRock Health Sciences Trust - Form N-CSRS

BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.

We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.

ADDITIONAL INFORMATION

129

Glossary of Terms Used in this Report

Currency

AUD	Australian Dollar
CAD	Canadian Dollar
CHF	Swiss Franc
DKK	Danish Krone
EUR	Euro
GBP	British Pound
HKD	Hong Kong Dollar
JPY	Japanese Yen
NOK	Norwegian Krone
NZD	New Zealand Dollar
SEK	Swedish Krona
SGD	Singapore Dollar
USD	U.S. Dollar
ZAR	South African Rand

Portfolio Abbreviations

ADR	American Depositary Receipts
REIT	Real Estate Investment Trust

This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.

CEF-BK9-6/18-SAR

Item 2 Code of Ethics Not Applicable to this semi-annual report

Item 3 Audit Committee Financial Expert Not Applicable to this semi-annual report

Item 4 Principal Accountant Fees and Services Not Applicable to this semi-annual report

Item 5 Audit Committee of Listed Registrants Not Applicable to this semi-annual report

Item 6 Investments

(a) The registrant's Schedule of Investments is included as part of the Report to Stockholders filed under Item 1 of this Form.

(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.

Item 7 Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies
Not Applicable to this semi-annual report

Item 8 Portfolio Managers of Closed-End Management Investment Companies

(a) Not Applicable to this semi-annual report

(b) As of the date of this filing, there have been no changes in any of the portfolio managers identified in the most recent annual report on Form N-CSR.

Item 9 Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers

<u>Period</u>	<u>(a) Total Number of Shares Purchased</u>	<u>(b) Average Price Paid per Share</u>	<u>(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</u>	<u>(d) Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs¹</u>
January 1 -31, 2018	0	0	0	463,672
February 1 - 28, 2018	0	0	0	463,672
March 1 - 31, 2018	0	0	0	463,672
April 1 - 30, 2018	0	0	0	463,672
May 1 - 31, 2018	0	0	0	463,672
June 1 - 30, 2018	0	0	0	463,672
Total:	0	0	0	463,672

¹ On September 6, 2017, the Fund announced a continuation of the open market share repurchase program, which commenced on December 1, 2017. The Fund may repurchase up to 5% of its outstanding shares based on common shares outstanding on November 30, 2017, in open market transactions, subject to certain conditions.

Item 10 Submission of Matters to a Vote of Security Holders There have been no material changes to these procedures.

Item 11 Controls and Procedures

(a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act")) are effective as of a date

within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the second fiscal quarter of the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 12 Disclosure of Securities Lending Activities for Closed-End Management Investment Companies Not applicable to this semi-annual report

Item 13 Exhibits attached hereto

(a)(1) Code of Ethics Not Applicable to this semi-annual report

(a)(2) Certifications Attached hereto

(a)(3) Not Applicable

(a)(4) Not Applicable

(b) Certifications Attached hereto

(c) Notices to the registrant's common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 2009¹

¹ The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund's common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Health Sciences Trust

By: /s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Health Sciences Trust

Date: September 4, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Health Sciences Trust

Date: September 4, 2018

By: /s/ Neal J. Andrews
Neal J. Andrews
Chief Financial Officer (principal financial officer) of
BlackRock Health Sciences Trust

Date: September 4, 2018